CN114026116A - Ras新抗原特异性结合蛋白及其用途 - Google Patents
Ras新抗原特异性结合蛋白及其用途 Download PDFInfo
- Publication number
- CN114026116A CN114026116A CN202080030201.XA CN202080030201A CN114026116A CN 114026116 A CN114026116 A CN 114026116A CN 202080030201 A CN202080030201 A CN 202080030201A CN 114026116 A CN114026116 A CN 114026116A
- Authority
- CN
- China
- Prior art keywords
- seq
- cell
- amino acid
- binding protein
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014914 Carrier Proteins Human genes 0.000 title claims abstract description 235
- 108091008324 binding proteins Proteins 0.000 title claims abstract description 235
- 230000009870 specific binding Effects 0.000 title description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 339
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 307
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 252
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 247
- 239000002157 polynucleotide Substances 0.000 claims abstract description 236
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 236
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 236
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 219
- 239000000203 mixture Substances 0.000 claims abstract description 131
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 129
- 230000027455 binding Effects 0.000 claims abstract description 102
- 229920001184 polypeptide Polymers 0.000 claims abstract description 102
- 238000000034 method Methods 0.000 claims abstract description 64
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 56
- 201000011510 cancer Diseases 0.000 claims abstract description 31
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 26
- 230000002163 immunogen Effects 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 203
- 108090000623 proteins and genes Proteins 0.000 claims description 176
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 122
- 241000282414 Homo sapiens Species 0.000 claims description 103
- 210000002865 immune cell Anatomy 0.000 claims description 92
- 239000013598 vector Substances 0.000 claims description 69
- 230000014509 gene expression Effects 0.000 claims description 68
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 64
- 238000006467 substitution reaction Methods 0.000 claims description 55
- 230000035772 mutation Effects 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 45
- 210000004881 tumor cell Anatomy 0.000 claims description 42
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 37
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 37
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 34
- 150000001576 beta-amino acids Chemical group 0.000 claims description 30
- 230000002759 chromosomal effect Effects 0.000 claims description 21
- 230000002147 killing effect Effects 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 19
- 210000000987 immune system Anatomy 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 19
- 238000012986 modification Methods 0.000 claims description 19
- 102200006655 rs104894230 Human genes 0.000 claims description 18
- 239000013604 expression vector Substances 0.000 claims description 17
- 239000013603 viral vector Substances 0.000 claims description 16
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 15
- 102200006616 rs104894230 Human genes 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 238000003209 gene knockout Methods 0.000 claims description 14
- 239000012636 effector Substances 0.000 claims description 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- 102200006531 rs121913529 Human genes 0.000 claims description 12
- 102200006539 rs121913529 Human genes 0.000 claims description 12
- 201000002510 thyroid cancer Diseases 0.000 claims description 12
- 108020004705 Codon Proteins 0.000 claims description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 10
- 210000004443 dendritic cell Anatomy 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 9
- 208000025113 myeloid leukemia Diseases 0.000 claims description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 206010014733 Endometrial cancer Diseases 0.000 claims description 8
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 210000002540 macrophage Anatomy 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 102100037850 Interferon gamma Human genes 0.000 claims description 7
- 108010074328 Interferon-gamma Proteins 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 108700026220 vif Genes Proteins 0.000 claims description 7
- LVFOCONPPZIORE-UHFFFAOYSA-N 2-[[2-[[2-[2-[[2-[[2-[[2-[[2-[[2-(2,6-diaminohexanoylamino)-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]propanoylamino]-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoic acid Chemical compound NCCCCC(N)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(C(C)C)C(O)=O LVFOCONPPZIORE-UHFFFAOYSA-N 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 102220011004 rs121913237 Human genes 0.000 claims description 6
- 210000001541 thymus gland Anatomy 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 5
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 102200124919 rs121913237 Human genes 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000017815 Dendritic cell tumor Diseases 0.000 claims description 4
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 4
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 4
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 4
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000005678 Rhabdomyoma Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 4
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 4
- 208000028436 anal melanoma Diseases 0.000 claims description 4
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 201000008275 breast carcinoma Diseases 0.000 claims description 4
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 4
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 4
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 4
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 4
- 230000003325 follicular Effects 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 4
- 201000011084 malignant anus melanoma Diseases 0.000 claims description 4
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 201000003731 mucosal melanoma Diseases 0.000 claims description 4
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 claims description 4
- 208000007538 neurilemmoma Diseases 0.000 claims description 4
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 206010039667 schwannoma Diseases 0.000 claims description 4
- 201000003708 skin melanoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 208000016595 therapy related acute myeloid leukemia and myelodysplastic syndrome Diseases 0.000 claims description 4
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 claims description 4
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims description 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 3
- 108010091268 alpha-Macroglobulins Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 claims description 3
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 3
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 2
- 108010004093 retinal S antigen peptide M Proteins 0.000 claims description 2
- 101150091887 Ctla4 gene Proteins 0.000 claims 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 1
- 101100369640 Homo sapiens TIGIT gene Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000009527 percussion Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 81
- 102000036639 antigens Human genes 0.000 abstract description 76
- 108091007433 antigens Proteins 0.000 abstract description 76
- 230000028993 immune response Effects 0.000 abstract description 11
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 100
- 102100030708 GTPase KRas Human genes 0.000 description 87
- 235000001014 amino acid Nutrition 0.000 description 71
- 150000007523 nucleic acids Chemical class 0.000 description 70
- 102000039446 nucleic acids Human genes 0.000 description 69
- 108020004707 nucleic acids Proteins 0.000 description 69
- 102000004169 proteins and genes Human genes 0.000 description 54
- 239000012634 fragment Substances 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 52
- 229940024606 amino acid Drugs 0.000 description 40
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 38
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 38
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 33
- 108010014186 ras Proteins Proteins 0.000 description 32
- 230000009258 tissue cross reactivity Effects 0.000 description 32
- 108010036972 HLA-A11 Antigen Proteins 0.000 description 31
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 29
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 28
- 102100039788 GTPase NRas Human genes 0.000 description 27
- 239000003112 inhibitor Substances 0.000 description 27
- 108020001507 fusion proteins Proteins 0.000 description 26
- 102000037865 fusion proteins Human genes 0.000 description 26
- 102000016914 ras Proteins Human genes 0.000 description 25
- 102100029974 GTPase HRas Human genes 0.000 description 24
- 230000000694 effects Effects 0.000 description 21
- 102000053602 DNA Human genes 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 19
- 108700019146 Transgenes Proteins 0.000 description 19
- -1 and c-Ki-RAS2) Proteins 0.000 description 18
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 17
- 238000012217 deletion Methods 0.000 description 17
- 230000037430 deletion Effects 0.000 description 17
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 17
- 102100031780 Endonuclease Human genes 0.000 description 14
- 108010042407 Endonucleases Proteins 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 13
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 108091028113 Trans-activating crRNA Proteins 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 101100405118 Mus musculus Nr4a1 gene Proteins 0.000 description 12
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 12
- 101100405120 Xenopus laevis nr4a1 gene Proteins 0.000 description 12
- 210000000822 natural killer cell Anatomy 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 10
- 101710163270 Nuclease Proteins 0.000 description 10
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 9
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 9
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000002372 labelling Methods 0.000 description 9
- 230000006780 non-homologous end joining Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
- 231100000491 EC50 Toxicity 0.000 description 7
- 102000017578 LAG3 Human genes 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 108010076667 Caspases Proteins 0.000 description 6
- 102000011727 Caspases Human genes 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 6
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 230000005782 double-strand break Effects 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 108010039471 Fas Ligand Protein Proteins 0.000 description 5
- 102000015212 Fas Ligand Protein Human genes 0.000 description 5
- 108020005004 Guide RNA Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- 238000010459 TALEN Methods 0.000 description 5
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000011651 chromium Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 101150030213 Lag3 gene Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 238000011469 lymphodepleting chemotherapy Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 3
- 102100038078 CD276 antigen Human genes 0.000 description 3
- 238000010453 CRISPR/Cas method Methods 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100031351 Galectin-9 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 3
- 102100022748 Wilms tumor protein Human genes 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 3
- 229950009791 durvalumab Drugs 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 231100000118 genetic alteration Toxicity 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 229940126546 immune checkpoint molecule Drugs 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 101150051188 Adora2a gene Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 101710185679 CD276 antigen Proteins 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 101710121810 Galectin-9 Proteins 0.000 description 2
- 241001663880 Gammaretrovirus Species 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 2
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 101150065403 NECTIN2 gene Proteins 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 102100035488 Nectin-2 Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101800001494 Protease 2A Proteins 0.000 description 2
- 101800001066 Protein 2A Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 101150028593 TRAV12-3 gene Proteins 0.000 description 2
- 101150061758 TRAV17 gene Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 241000703392 Tribec virus Species 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 230000001494 anti-thymocyte effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 238000012984 biological imaging Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- YQYGGOPUTPQHAY-KIQLFZLRSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[2-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(4S,7R)-7-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-carboxy-2-hydrazinylbutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-2-methyl-5,6-dioxooctan-4-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]hydrazinyl]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-hydroxy-3-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1ccccc1)NC(=O)C(CCCCNN[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)[C@H](C)O)C(C)C)[C@H](C)O YQYGGOPUTPQHAY-KIQLFZLRSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 229940080328 Arginase inhibitor Drugs 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108700016171 Aspartate ammonia-lyases Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102100035893 CD151 antigen Human genes 0.000 description 1
- 229940121697 CD27 agonist Drugs 0.000 description 1
- 229940123205 CD28 agonist Drugs 0.000 description 1
- 229940123189 CD40 agonist Drugs 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- HFOBENSCBRZVSP-LKXGYXEUSA-N C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O Chemical compound C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O HFOBENSCBRZVSP-LKXGYXEUSA-N 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100027668 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Human genes 0.000 description 1
- 101710134395 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Proteins 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100012466 Drosophila melanogaster Sras gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 101000889905 Enterobacteria phage RB3 Intron-associated endonuclease 3 Proteins 0.000 description 1
- 101000889904 Enterobacteria phage T4 Defective intron-associated endonuclease 3 Proteins 0.000 description 1
- 101000889900 Enterobacteria phage T4 Intron-associated endonuclease 1 Proteins 0.000 description 1
- 101000889899 Enterobacteria phage T4 Intron-associated endonuclease 2 Proteins 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102220502341 Golgin subfamily A member 1_F2A_mutation Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 102210024049 HLA-A*03:01 Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000946874 Homo sapiens CD151 antigen Proteins 0.000 description 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 description 1
- 101000997535 Homo sapiens Growth hormone-releasing hormone receptor Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101100086477 Homo sapiens KRAS gene Proteins 0.000 description 1
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 1
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000695187 Homo sapiens Protein patched homolog 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000714192 Human spumaretrovirus Species 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 229940125563 LAG3 inhibitor Drugs 0.000 description 1
- 101710084021 Large envelope protein Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940125568 MGD013 Drugs 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 101100047641 Mus musculus Txnrd3 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- FQWRAVYMZULPNK-BYPYZUCNSA-N N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NO FQWRAVYMZULPNK-BYPYZUCNSA-N 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- KOBHCUDVWOTEKO-VKHMYHEASA-N Nomega-hydroxy-nor-l-arginine Chemical compound OC(=O)[C@@H](N)CCNC(=N)NO KOBHCUDVWOTEKO-VKHMYHEASA-N 0.000 description 1
- 101710144111 Non-structural protein 3 Proteins 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 102100028680 Protein patched homolog 1 Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000034155 RAS-associated autoimmune leukoproliferative disease Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 229940125555 TIGIT inhibitor Drugs 0.000 description 1
- 101150053367 TRAV1-1 gene Proteins 0.000 description 1
- 101150077948 TRAV12-2 gene Proteins 0.000 description 1
- 101150112037 TRAV19 gene Proteins 0.000 description 1
- 101150053826 TRAV2 gene Proteins 0.000 description 1
- 101150078153 TRAV26-1 gene Proteins 0.000 description 1
- 101150103476 TRAV27 gene Proteins 0.000 description 1
- 101150104845 TRAV5 gene Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 108700020467 WT1 Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 102000018162 alpha-Macroglobulins Human genes 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000009200 autoimmune lymphoproliferative syndrome type 4 Diseases 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 102220354910 c.4C>G Human genes 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 229950004270 enoblituzumab Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- 102000043600 human HRAS Human genes 0.000 description 1
- 102000053563 human MYC Human genes 0.000 description 1
- 102000047526 human NRAS Human genes 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 101150035390 mag gene Proteins 0.000 description 1
- GRPSNTXTTSBKGW-BVGHQBMWSA-J magnesium;potassium;sodium;(3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;triacetate;chloride Chemical compound [Na+].[Mg+2].[Cl-].[K+].CC([O-])=O.CC([O-])=O.CC([O-])=O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O GRPSNTXTTSBKGW-BVGHQBMWSA-J 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- UCABRVRRPYJBHB-UHFFFAOYSA-N n-[bis(ethylamino)phosphinothioyl]ethanamine Chemical compound CCNP(=S)(NCC)NCC UCABRVRRPYJBHB-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 230000032965 negative regulation of cell volume Effects 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229960005492 pazopanib hydrochloride Drugs 0.000 description 1
- MQHIQUBXFFAOMK-UHFFFAOYSA-N pazopanib hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 MQHIQUBXFFAOMK-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 230000006555 post-translational control Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 208000012584 pre-descemet corneal dystrophy Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229940121484 relatlimab Drugs 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220101652 rs878854761 Human genes 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 229940121497 sintilimab Drugs 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 208000012498 virus associated tumor Diseases 0.000 description 1
- 229940121351 vopratelimab Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/60—Vectors comprising a special origin of replication system from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本公开提供了用于靶向Ras抗原以例如治疗或预防癌症的组合物和方法。公开的实施例包括与Ras抗原:HLA复合物结合的结合蛋白,例如T细胞受体或嵌合抗原受体。编码这种结合蛋白的多核苷酸可以引入宿主细胞,如T细胞,该细胞可用于治疗各种癌症的免疫疗法。还提供了免疫原性多肽,其可用于例如诱导针对突变的Ras的免疫应答或鉴定与Ras抗原结合的结合蛋白。
Description
关于序列表的声明
与本申请相关的序列表以文本格式代替纸质副本提供,并在此通过引用并入说明书。包含序列表的文本文件的名称是360056_469WO_SEQUENCE_LISTING.txt。该文本文件大小为653KB,创建于2020年2月17日,正在通过EFS-Web以电子方式提交。
背景技术
Ras家族蛋白是小GTPase,参与细胞内信号的传递,包括例如细胞增殖的转导。示例性RAS蛋白包括KRAS(也称为CK-RAS、CFC2、K-RAS2A、K-RAS2B、K-RAS4A、K-RAS4B、KI-RAS、KRAS1、KRAS2、NS、NS3、RALD、RASK2、K-ras、KRAS原癌基因、GTPase和c-Ki-ras2)、HRAS和NRAS。破坏负生长信号的RAS蛋白突变可导致细胞持续增殖。KRAS是多种人类癌症中最常见的突变原癌基因之一,包括黑色素瘤、子宫内膜癌、甲状腺癌、胰腺癌、结直肠癌、乳腺癌、卵巢癌和肺癌,以及一些髓系白血病(如AML)。需要针对突变RAS蛋白的新疗法。
附图说明
图1-8D涉及本公开的示例性HLA-A11/KRAS特异性TCR。
图1显示了通过功能筛选(示例性HLA-A11/KRAS特异性TCR的“排序1”)鉴定功能性HLA-A11/KRAS特异性T细胞系。
图2提供了来自富集方案的示例数据,其中示例性的HLA-A11/KRAS特异性TCR在混合突变KRAS肽刺激后在CD137(4-1BB)上分选。
图3显示本公开的示例性HLA-A11/KRAS特异性TCR在转导的宿主细胞中是有功能的。数据显示在与载有抗原的靶细胞孵育后转导细胞的活化(Nur77表达)和CD8表达。
图4A和4B显示示例性HLA-A11/KRAS特异性TCR识别不同的表位。(A)原代人CD8+T细胞被转导以表达HLA-A11/KRAS特异性TCR,用1μg/mL的混合KRAS肽刺激16小时,并使用PE-anti-CD137(4-1BB)mAb和anti-CD8 450mAb(赛默飞世尔)(Thermofisher)标记。(B)在高尔基体抑制剂存在的情况下,用1μg/mL的单个KRAS肽(见表左栏)脉冲的APC刺激转导的CD8+T细胞4小时。然后检查细胞的IFN-γ产生。“-”=没有可测量的IFN-γ。“+”=测得的IFN-γ水平低。“+++”=测得的IFN-γ水平高。
图5A-5D显示了示例性HLA-A11/KRAS-G12D特异性和-G12V特异性TCR的功能表征。(A)原代CD8+T细胞释放的IFN-γ,这些细胞被转导以表达指定的HLA-A11/KRAS-G12D特异性TCR,并用浓度增加的肽抗原刺激。(B)(A)中显示的TCR的功能亲合力(使用KRAS G12D的logEC50)值。(C)原代CD8+T细胞释放的IFN-γ,这些细胞被转导以表达指定的HLA-A11/KRAS-G12V特异性TCR,并用浓度增加的肽抗原刺激。(D)(C)中显示的TCR的功能亲合力(使用KRAS G12V的logEC50)值。
图6A-6G显示示例性HLA-A11 KRAS G12D突变特异性TCR对KRAS G12D+胰腺癌细胞系以及NRAS G12D+AML细胞系(THP-1)有反应。
图7A-7G显示了示例性HLA-A11 KRAS G12V突变特异性TCR对几种癌细胞系的反应性。TCR被证明对KRAS G12V+胰腺癌细胞系(Capan-2)以及NRAS G12V+伯基特淋巴瘤细胞系(GA-10.4)有反应。
图8A-8D显示了KRAS G12D+(A11/721.221靶细胞加载了100ng/ml突变肽);NRASG12D+(THP-1细胞);和NRAS G12V+(GA-10.4细胞)肿瘤系(流式细胞术效应物杀伤试验:指定比例的靶细胞),是由用本公开的示例性TCR转导的T细胞形成。
图9-11涉及示例性的HLA-A3相容的KRAS突变肽和反应性T细胞系。
图9显示了突变的KRAS G12V肽(10-mer(VVVGAVGVGK;SEQ ID NO:2);9-mer(VVGAVGVK;SEQ ID NO:3))对HLA-A*0301的预测HLA结合亲和力。使用NetMHC 3.4版(可在cbs.dtu.dk/services/NetMHC/在线获取)测量亲和力。
图10显示了在3轮肽刺激后通过四聚体标记检测HLA-A3/KRAS(G12V)特异性T细胞系。
图11提供了来自HLA-A3/KRAS(G12V)特异性T细胞富集方案的示例性数据,其中细胞用肽刺激并在CD137(4-1BB)或肽:HLA四聚体上评分。
图12-20C涉及与HLA-A2相容的KRAS突变肽和示例性T细胞系以及对其特异的TCR。
图12显示了KRAS序列的HLA-A*02:01MHC-I结合预测数据(使用IEDB),该序列跨越D-或V-突变的G12位置两侧的11aa。使用NetMHCpan、SYFPEITHI和BiMas也获得了类似的结果(数据未显示)。
图13A和13B显示本公开的分选的示例性HLA-A2/KRAS特异性T细胞响应肽刺激上调CD137。
图14A-14D显示本公开的示例性HLA-A2 KRAS特异性T细胞特异性响应KRAS突变肽,并且可以识别独特的抗原序列。HLA-A2 G12V和G12D特异性TCR使用已知技术进行测序。如本文所述,将TCR转导到Jurkat细胞和原代T细胞中,并测试对抗原的反应性,包括通过测量扩增、CD137表达、细胞因子产生和肽脉冲靶细胞的特异性杀伤。
图15A-16提供了来自四聚体标记实验的数据,证实了示例性HLA-A2/KRAS G12V特异性TCR的HLA和肽特异性,以及示例性TCR的相对亲和力读数和CD8非依赖性结合。图15A和15B显示了在指定浓度的野生型HLA-A2/KRAS(5-14_G12)-肽多聚体存在下表达指定HLA-A2特异性TCR的T细胞的平均荧光强度(MFI)。图16提供了流式细胞术数据,显示了转导以表达指定TCR的T细胞的标记,如通过使用HLA-A2(DM)/KRAS(514_G12V)-肽多聚体的功能测定所确定的。这种多聚体由修饰的HLA-A*02:01α-3域双突变(DM)单体组装而成,不能与CD8结合。
图17-18C显示了HLA-A2/KRAS G12V特异性TCR的功能亲合力等级(在用单个肽刺激4小时后通过肽剂量反应测试并用IFN-γ抗体标记)和对突变表位特异性的测定(通过用高剂量的野生型KRAS肽刺激T细胞并用IFN-γ抗体标记来测试)。图17显示了响应突变体与野生型肽的产生IFN-γ的T细胞的频率。图18A和18B显示了所示HLA-A2/KRAS特异性TCR的突变KRAS5-14_G12V肽亲合力曲线。图18C显示了本公开的某些示例性HLA-A2特异性TCR的KRAS5-14 G12V logEC50值。
图19提供了示例性HLA-A2/KRAS特异性TCR对内源性加工和呈递肽反应性的筛选结果(通过与CFPAC-1胰腺肿瘤细胞过夜孵育并用CD137/41-BB抗体标记来测试)。数据是流式细胞术图,显示与肿瘤细胞共孵育后HLA-A2/KRAS特异性T细胞上的CD137表达。
图20A-20C提供了杀伤测定的结果,显示表达本公开的示例性HLA-A2/KRAS特异性TCR的T细胞有效且特异性地杀伤CFPAC-1(A2+和KRAS G12V+)胰腺癌细胞系。在该测定中,测量了活化的半胱天冬酶和NucRed标记的肿瘤细胞重叠,其中增加的重叠面积等于细胞凋亡导致的肿瘤细胞死亡。显示的数据是A2/KRAS TCR的半胱天冬酶激活/杀伤曲线。每个图中都包含相同的对照组,为了便于阅读,实验组和对照组的数据显示在不同的图表上。
图21A-31B涉及本公开的示例性HLA-A11/KRAS特异性TCR。
图21A和21B显示了用指定的HLA-A11/KRAS特异性TCR转导的T细胞杀死具有内源性G12D突变和天然(A;Panc-1细胞系)或转导(B;AsPc-1细胞系)的HLA-A*11:01表达的RapidRed标记的胰腺肿瘤细胞系。数据来自杀伤试验。(A)使用了10:1的效应器:靶细胞比率。(B)使用了1:1的效应器:靶细胞比率。
图22A和22B显示了用指定的HLA-A11/KRAS特异性TCR转导的T细胞杀死具有内源性G12V突变和转导的HLA-A*11:01表达的RapidRed标记的胰腺肿瘤细胞系。数据来自杀伤试验。(A)使用CFPAC细胞系和10:1效应器:目标细胞比率。(B)使用Capan-2细胞系和1:1效应器:目标细胞比率。
图23A和23B提供了来自初始筛选(HLA-A11/KRAS特定TCR的“排序2a”)的流式细胞术数据,显示了在用1μg.mL野生型或突变型KRAS肽刺激过夜后,示例性HLA-A11/KRAS特异性TCR转导的CD8+T细胞的CD137标记。
图24A-24C提供的流式细胞术数据显示在用G12D-突变体KRAS肽((A)KRAS7-16G12D肽;(B)KRAS8-16 G12D肽;(C)用指定的TCR转导的T细胞的KRAS7-16 G12Dlog10EC50)的剂量滴定刺激4小时后,用于IFN-γ标记的示例性HLA-A11/KRAS TCR转导、分选和扩增的CD8+T细胞的log10EC50。
图25A-25D显示提供的流式细胞术数据显示在用G12V-突变体KRAS肽((A)KRAS7-16G12V肽;(B)KRAS8-16 G12V肽;(C)用指定的TCR转导的T细胞的KRAS7-16 G12V log10EC50;(D)用指定的TCR转导的T细胞的KRAS8-16 G12Vlog10EC50)的剂量滴定刺激4小时后,用于IFN-γ标记的示例性HLA-A11/KRAS TCR转导、分选和扩增的CD8+T细胞的log10EC50。
图26A和26B提供了流式细胞术数据,显示了在用野生型KRAS肽的剂量滴定刺激4小时后示例性A11/KRAS TCR转导、分选和扩增的CD8+T细胞的IFN-γ标记。
图27A和27B显示通过示例性HLA-A11/KRAS特异性TCR转导、分选和扩增的CD8+T细胞杀死(A)HLA-A11/AsPc-1(KRAS7-16 G12D+)和(B)HLA-A11/CFPAC-1(KRAS7/8-16G12V+)。数据来自杀伤试验。
图28A和28B提供了来自初始筛选(HLA-A11/KRAS特定TCR的“排序2b”)的流式细胞术数据,显示了在用1μg/mL野生型或突变型KRAS肽刺激过夜后,示例性HLA-A11/KRAS特异性TCR转导的CD8+T细胞的CD137(标记见图左边缘)。
图29A-29D提供了流式细胞术数据,显示了在用标记的G12D或G12V突变体KRAS肽的剂量滴定刺激4小时后示例性HLA-A11/KRAS TCR转导、分选和扩增的CD8+T细胞的IFN-γ标记。来自两(2)个不同CD8+T细胞供体的数据显示为转导的TCR 13和20。具体来说,如图所示,来自供体X或供体Y的CD8+T细胞用指定的TCR转导。
图30提供了流式细胞术数据,显示了在用WT KRAS肽的剂量滴定刺激4小时后示例性HLA-A11/KRAS TCR转导、分选和扩增的CD8+T细胞的IFN-γ标记。来自两个不同CD8+T细胞供体的数据显示为转导的TCR 13和20。如图所示,来自供体X或供体Y的CD8+T细胞用指定的TCR转导。
图31A和31B提供了流式细胞术数据,显示了用本公开的某些示例性KRAS G12D特异性TCR转导的CD8+T细胞的HLA-A11/KRAS7-16_G12D四聚体标记。
具体实施方式
本公开内容总体上涉及对Ras新抗原特异的结合蛋白、表达该结合蛋白的修饰的免疫细胞、编码结合蛋白的多核苷酸以及相关用途。突变的Ras蛋白(例如KRAS、NRAS、HRAS)可以产生新抗原,包括在全长KRAS蛋白(SEQ ID NO:1;UniProt KB P01116)的第12位或全长NRAS蛋白(SEQ ID NO:6;Uniprot KB P01111)的第12位或全长HRAS蛋白(SEQ ID NO:216;Uniprot KB P01112)的第12位的GàV突变或GàD突变。
在本公开中,提供了能够结合Ras新抗原的结合蛋白。在某些方面,提供了包含TCRVα结构域和TCR Vβ结构域的结合蛋白(和宿主细胞,例如免疫细胞,其包含编码本公开内容的Ras特异性结合蛋白的异源多核苷酸),其中结合蛋白能够与Ras肽抗原:HLA复合物特异性结合,其中Ras肽抗原包含SEQ ID NO:2-5或198-201中任一项所述的氨基酸序列或由其组成。在某些实施方案中,HLA包括HLA-A2、HLA-A11或HLA-A3。
在一些实施方案中,Ras肽抗原包含或由SEQ ID NO:2-5中任一项所列的氨基酸序列组成,并且HLA复合物包含HLA-A*11分子或HLA-A*03分子。在某些实施方案中,HLA-A*11分子包括HLA-A*11:01分子。在某些实施方案中,HLA-A*11分子包括HLA-A*11:01分子。
在一些实施方案中,Ras肽抗原包含或由SEQ ID NOs:198-201中任一项所列的氨基酸序列组成,并且HLA复合物包含HLA-A*02分子。在进一步的实施方案中,HLA-A*02分子包括HLA-A*02:01分子。
本文还提供了能够特异性结合Ras肽抗原(例如,在肽:HLA复合物的情况下)的融合蛋白,其中Ras肽抗原包含SEQ ID NO:2-5或198-201中任一项中所述的氨基酸序列或由其组成:其中融合蛋白包含:(i)可包含如本文公开的结合域(例如,Ras特异性结合蛋白(例如,TCR)的)的细胞外组分;(ii)细胞内成分;(iii)位于细胞外成分和细胞内成分之间的跨膜成分。
在本文公开的任何实施方案中,结合蛋白(或至少融合蛋白的结合域)可以是人的、人源化的或嵌合的。在某些实施方案中,结合蛋白或融合蛋白的结合域是人的。目前公开的结合蛋白、融合蛋白和宿主细胞(例如,T细胞、NK细胞、NK-T细胞)可用于治疗与KRAS新抗原相关的疾病或病症,例如癌症。前公开的结合蛋白还可以结合人NRAS(SEQ ID NO:6)或人HRAS(SEQ ID NO:216)中产生的G12V或G12D抗原,这些蛋白包含与在残基G12附近的区域中的KRAS相同的序列。因此,所公开的组合物可用于治疗与KRAS新抗原、包含G12V或G12D突变的NRAS新抗原、或包含G12V或G12D突变的HRAS新抗原或其任何组合相关的疾病或病症。
还提供了编码Ras特异性结合蛋白或融合蛋白、包含该多核苷酸的宿主细胞和相关组合物的多核苷酸。
在另一方面,提供了包含SEQ ID NO:198-201中任一所述的氨基酸序列或由其组成的免疫原性多肽,以及包含其的组合物。目前公开的免疫原性多肽,例如,可用于疫苗组合物中,以用于治疗或预防与Ras突变相关的疾病,用于在受试者中引发免疫应答,以及用于鉴定与Ras肽抗原特异性结合的结合蛋白(例如,TCR或CAR)。
还提供了本公开的结合蛋白、多核苷酸、载体、宿主细胞、免疫原性多肽和相关组合物的方法和用途,用于治疗与本文提供的KRAS、NRAS和/或HRAS突变相关的疾病或病症。
在更详细地阐述本公开之前,提供将在本文中使用的某些术语的定义可能有助于对其的理解。本公开通篇阐述了另外的定义。
在本说明书中,任何浓度范围、百分比范围、比率范围或整数范围应理解为包括所述范围内的任何整数的值,以及在适当时,其分数(例如整数的十分之一和百分之一),除非另有说明。此外,除非另有说明,否则本文所述的与任何物理特征(例如聚合物亚单元、尺寸或厚度)相关的任何数字范围应理解为包括所述范围内的任何整数。如本文所用,除非另有说明,否则术语“约”是指指示范围、值或结构的±20%。应当理解,本文所用的术语“一(a)”和“一(an)”是指列举的组分中的“一个或多个”。替代方案(例如,“或”)的使用应理解为表示替代方案中的任一个、两者或其任何组合。如本文所用,术语“包括”、“具有”和“包含”同义使用,这些术语及其变体旨在被解释为非限制性的。
另外,应该理解的是本申请公开了源自本文所述结构和取代基的各种组合的单个化合物或化合物组,其公开程度与每个化合物或化合物组被单独阐述的程度相同。因此,特定结构或特定取代基的选择在本公开的范围内。
术语“基本上由……组成”不等同于“包括”,而是指权利要求的特定材料或步骤,或者不实质上影响所要求保护主题的基本特征的那些材料或步骤。例如,蛋白质结构域、区域或模块(例如,结合域、铰链区、接头模块)或蛋白质(可能有一个或多个域、区域或模块)“基本上由”特定氨基酸序列组成,当结构域、区域、模块或蛋白质的氨基酸序列包括延伸、缺失、突变或它们的组合(例如,氨基末端或羧基末端或结构域之间的氨基酸)时,它们的组合最多占结构域、区域、模块或蛋白质长度的20%(例如,最多15%、10%、8%、6%、5%、4%、3%、2%或1%)并且不会显著影响(即减少活动量不超过50%,例如不超过40%、30%、25%、20%、15%、10%、5%或1%)域、区域、模块或蛋白质(例如,结合蛋白的目标结合亲和力或亲和力)的活性。
如本文所用,“造血祖细胞”是可以源自造血干细胞或胎儿组织并且能够进一步分化为成熟细胞类型的细胞(例如,免疫系统细胞)。示例性造血祖细胞包括具有CD24Lo Lin-CD117+表型的那些或在胸腺(称为祖胸腺细胞)中发现的那些。
如本文所用,“免疫系统细胞”是指源自骨髓中的造血干细胞的免疫系统的任何细胞,其产生两个主要谱系,髓样祖细胞(其产生髓样细胞,例如单核细胞、巨噬细胞、树突细胞、巨核细胞和粒细胞)和淋巴祖细胞(产生淋巴样细胞,如T细胞、B细胞和自然杀伤(NK)细胞)。示例性免疫系统细胞包括CD4+T细胞、CD8+T细胞、CD4-CD8-双阴性T细胞、γδT细胞、调节性T细胞、自然杀伤细胞、自然杀伤T细胞和树突状细胞。巨噬细胞和树突状细胞可以被称为“抗原呈递细胞”或“APC”,它们是特化的细胞,当与肽复合的APC表面上的主要组织相容性复合物(MHC)受体与T细胞表面上的TCR相互作用时,它可以激活T细胞。
“T细胞”或“T淋巴细胞”是在胸腺中成熟并产生T细胞受体(TCR)的免疫系统细胞。T细胞可以是幼稚的(“TN”;未暴露于抗原;与TCM(本文所述)相比,CD62L、CCR7、CD28、CD3、CD127和CD45RA表达增加,CD45RO表达减少或不表达)、记忆T细胞(TM)(有抗原经验且寿命长),其包括干细胞记忆T细胞和效应细胞(有抗原经验、细胞毒性)。TM可进一步分为中枢记忆T细胞亚群(TCM,表达CD62L、CCR7、CD28、CD95、CD45RO和CD127)和效应记忆T细胞(TEM,表达CD45RO,CD62L、CCR7、CD28和CD45RA)。效应T细胞(TE)是指存在抗原的CD8+细胞毒性T淋巴细胞,其表达CD45RA,具有与TCM相比,CD62L、CCR7和CD28的表达降低,并且颗粒酶和穿孔素呈阳性。辅助T细胞(TH)是CD4+细胞,通过释放细胞因子影响其他免疫细胞的活性。CD4+T细胞可以激活和抑制适应性免疫反应,这两种功能中的哪一种被诱导将取决于其他细胞和信号的存在。可以使用已知技术收集T细胞,并且可以通过已知技术例如通过与抗体的亲和结合、流式细胞术或免疫磁性选择来富集或去除各种亚群或其组合。其他示例性T细胞包括调节性T细胞,例如CD4+CD25+(Foxp3+)调节性T细胞和Treg17细胞,以及Tr1、Th3、CD8+CD28-和Qa-1限制性T细胞。
“T细胞受体”(TCR)是指具有可变结合域、恒定域、跨膜区和短胞质尾的免疫球蛋白超家族成员;(例如,参见Janeway et al.,Immunobiology:The Immune SysteminHealthand Disease,3rd Ed.,Current Biology Publications,p.433,1997)其能够特异性结合与MHC受体结合的抗原肽。TCR可以在细胞表面或以可溶形式存在,通常由具有α和β链(也分别称为TCRα和TCRβ)或γ和δ链(也分别称为TCRγ和TCRδ)的异二聚体组成。在某些实施方案中,可以对编码本公开内容的结合蛋白例如TCR的多核苷酸进行密码子优化以增强在特定宿主细胞中的表达,例如作为免疫系统的细胞、造血干细胞、T细胞、原代T细胞、T细胞系、NK细胞或自然杀伤T细胞(Scholten et al.,Clin.Immunol.119:135,2006)。可表达本公开内容的结合蛋白和TCR的示例性T细胞包括CD4+T细胞、CD8+T细胞及其相关亚群(例如,幼稚、中枢记忆、干细胞记忆、效应记忆)。
与其他免疫球蛋白(例如抗体)一样,TCR链(例如,α-链、β-链)的细胞外部分包含两个免疫球蛋白结构域,一个位于N端的可变结构域(例如,α-链可变域或Vα、b-链可变域或Vβ;通常是基于Kabat编号的氨基酸1至116(Kabat et al.,"Sequences ofProteinsofImmunological Interest,USDept.Health andHuman Services,Public HealthService National Institutes ofHealth,1991,5th ed.))和一个靠近细胞膜的恒定结构域(例如,α-链恒定域或Cα,通常基于Kabat的5个氨基酸117至259,β-链恒定域或Cβ,通常基于Kabat的氨基酸117至295)。此外,与免疫球蛋白一样,可变域包含由框架区(FR)分隔的互补决定区(CDR)(例如参见,Jores et al.,Proc.Nat'l Acad.Sci.USA87:9138,1990;Chothia et al.,EMBOJ.7:3745,1988;还参见Lefrancetal.,Dev.Comp.Immunol.27:55,2003)。本公开中使用的TCR的来源可以来自各种动物物种,例如人、小鼠、大鼠、兔或其他哺乳动物。
术语“可变区”或“可变域”是指参与免疫球蛋白超家族结合蛋白(例如,TCR)与抗原结合的免疫球蛋白超家族结合蛋白(例如,TCRα-链或β-链(或γδTCR的γ链和δ链))的域。天然TCR的α链和β链的可变域(分别为Vα和Vβ)通常具有相似的结构,每个域包含四个普遍保守的框架区(FR)和三个CDR。Vα结构域由两个独立的DNA片段编码,可变基因片段和连接基因片段(V-J);Vβ结构域由三个独立的DNA片段编码,即可变基因片段、多样性基因片段和连接基因片段(V-D-J)。单个Vα或Vβ结构域可能足以赋予抗原结合特异性。此外,可以使用来自结合抗原的TCR的Vα或Vβ域来分离结合特定抗原的TCR,以分别筛选互补Vα或Vβ域的文库。
术语“互补决定区”和“CDR”与“高变区”或“HVR”同义,并且在本领域中已知是指免疫球蛋白(例如,TCR)可变区内的氨基酸序列,其赋予抗原特异性和/或结合亲和力并且在一级氨基酸序列中被框架区彼此分开。一般来说,每个TCRα链可变区有3个CDR(αCDR1、αCDR2、αCDR3),每个TCRβ链可变区有3个CDR(βCDR1、βCDR2、βCDR3)。在TCR中,CDR3被认为是负责识别加工抗原的主要CDR。通常,CDR1和CDR2主要或专门与MHC相互作用。
CDR1和CDR2由TCR可变区编码序列的可变基因片段编码,而CDR3由跨越Vα可变和连接片段的区域,或跨越Vβ可变、多样性和连接片段的区域编码。因此,如果已知Vα或Vβ的可变基因片段的身份,就可以推导出它们相应的CDR1和CDR2的序列;例如,根据如本文所述的编号方案。与CDR1和CDR2相比,由于重组过程中核苷酸的添加和丢失,CDR3通常更加多样化。
TCR可变域序列可以与编号方案(例如Kabat、Chothia、EU、IMGT、EnhancedChothia和Aho)进行比对,从而允许注释等效的残基位置并使用例如ANARCI软件工具比较不同的分子(2016,Bioinformatics 15:298-300)。编号方案提供了TCR可变域中框架区和CDR的标准化描述。在某些实施例中,根据IMGT编号方案识别本公开的CDR(Lefranc etal.,Dev.Comp.Immunol.27:55,2003;imgt.org/IMGTindex/V-QUEST.php)。
如本文所用,术语“CD8共受体”或“CD8”是指细胞表面糖蛋白CD8,作为α-α同二聚体或α-β异二聚体。CD8共受体有助于细胞毒性T细胞(CD8+)的功能,并通过其细胞质酪氨酸磷酸化途径通过信号传导发挥作用(Gao and Jakobsen,Immunol.Today21:630-636,2000;Cole and Gao,Cell.Mol.Immunol.1:81-88,2004)。有五(5)种已知的人类CD8β链同种型(参见UniProtKB标识符P10966)和一种已知的人类CD8α链同种型(参见UniProtKB标识符P01732)。也参见SEQ ID NO:685-692。
“CD4”是一种免疫球蛋白共受体糖蛋白,其帮助TCR与抗原呈递细胞进行交流(参见Campbell&Reece,Biology 909(Benjamin Cummings,Sixth Ed.,2002))。CD4存在于免疫细胞(例如T辅助细胞、单核细胞、巨噬细胞和树突状细胞)的表面,并包括在细胞表面表达的四个免疫球蛋白结构域(D1至D4)。在抗原呈递过程中,CD4与TCR复合物一起被募集,以结合MHCII分子的不同区域(CD4结合MHCIIβ2,而TCR复合物结合MHCIIα1/β1)。不希望被理论束缚,据信靠近TCR复合物允许CD4相关激酶分子磷酸化CD3细胞质域上存在的免疫受体酪氨酸激活基序(ITAM)。这种活动被认为会放大由激活的TCR产生的信号,以产生或招募各种类型的免疫系统细胞(包括T辅助细胞)和免疫反应。
在某些实施方案中,TCR存在于T细胞(或T淋巴细胞)表面并与CD3复合物结合。“CD3”是六条链的多蛋白复合物(参见Abbas and Lichtman,2003;Janeway et al.,p.172and 178,1999),其与T细胞中的抗原信号传导有关。在哺乳动物中,该复合物包含一CD3γ链、一CD3δ链、两条CD3ε链和一CD3ζ链的同源二聚体。CD3γ、CD3β和CD3ε链是免疫球蛋白超家族的相关细胞表面蛋白,其含有单个免疫球蛋白结构域。CD3γ、CD3β和CD3ε链的跨膜区带负电荷,据信这使得这些链能够与T细胞受体链的带正电荷区域结合。CD3γ、CD3β和CD3ε链的细胞内尾部各包含一个保守基序,称为基于免疫受体酪氨酸的激活基序或ITAM,而每个CD3ζ链有三个。不希望受理论束缚,据信ITAM对于TCR复合物的信号传递能力是重要的。本公开中使用的CD3的来源可以来自各种动物物种,包括人、小鼠、大鼠或其他哺乳动物。
如本文所用,“TCR复合物”是指通过CD3与TCR结合形成的复合物。例如,TCR复合物可以包括一CD3γ链、一CD3β链、两条CD3ε链、一CD3ζ链的同源二聚体、一TCRα链和一TCRβ链。可选地,TCR复合物可以包括一CD3γ链、一CD3β链、两条CD3ε链、一CD3ζ链的同源二聚体、一TCRγ链和一TCRβ链。
如本文所用,“TCR复合物的组分”是指TCR链(即TCRα、TCRβ、TCRγ或TCRδ)、CD3链(即CD3γ、CD3δ、CD3ε或CD3ζ)或由两条或更多条TCR链或CD3链形成的复合物(例如,TCRα和TCRβ的复合物,TCRγ和TCRδ的复合物,CD3ε和CD3δ的复合物,CD3γ和CD3ε的复合物,或TCRα、TCRβ、CD3γ、CD3δ和两条CD3ε链的亚TCR复合物)。
“嵌合抗原受体”(CAR)是指融合蛋白,其是经工程改造以包含两个或多个天然存在的氨基酸序列、结构域或基序,以非天然存在或非天然存在于宿主细胞中的方式连接在一起,当存在于细胞表面时,融合蛋白可以作为受体发挥作用。CAR可以包括细胞外部分,该细胞外部分包含与跨膜结构域和一个或多个细胞内信号传导结构域(可选地包含共刺激域)连接的抗原结合结构域(例如,从免疫球蛋白或免疫球蛋白样分子获得或衍生,例如从对癌抗原特异的TCR衍生或获得的TCR结合域、从抗体衍生或获得的scFv、或来自NK细胞的杀伤性免疫受体的衍生或获得的抗原结合域)(参见,例如,Sadelain et al.,CancerDiscov.,3(4):388(2013);还参见Harris and Kranz,Trends Pharmacol.Sci.,37(3):220(2016),Stone et al.,Cancer Immunol.Immunother.,63(11):1163(2014),以及Walsenget al.,Scientific Reports7:10713(2017),其中CAR构建体及制造相同的方法通过引用并入本文)。与Ras抗原特异性结合的本公开的CAR(例如,在肽:HLA复合物的情况下)包含TCR Vα结构域和Vβ结构域。
本公开的任何多肽,如由多核苷酸序列编码的,可以包含“信号肽”(也称为前导序列、前导肽或转运肽)。信号肽将新合成的多肽靶向细胞内外的适当位置。在定位或分泌完成期间或一旦完成,可从多肽中去除信号肽。具有信号肽的多肽在本文中称为“前蛋白”,并且去除了它们的信号肽的多肽在本文中称为“成熟”蛋白质或多肽。在本文公开的任何实施方案中,结合蛋白或融合蛋白包含或是成熟蛋白,或者是或包含前蛋白。
“接头”是指连接两个蛋白质、多肽、肽、结构域、区域或基序的氨基酸序列,并且可以提供与两个亚结合结构域的相互作用相容的间隔区功能使得所得多肽保留对靶分子的特异性结合亲和力(例如,scTCR)或保留信号活性(例如,TCR复合物)。在某些实施方案中,接头由例如约2至约35个氨基酸或约4至约20个氨基酸或约8至约15个氨基酸或约15至约25个氨基酸组成。示例性接头包括甘氨酸-丝氨酸接头(例如,SEQ ID NO:214和215)。
如本文所用,“抗原”或“Ag”是指激发免疫反应的免疫原性分子。这种免疫反应可能涉及抗体产生、特定免疫活性细胞(例如T细胞)的激活,或两者都有。抗原(免疫原性分子)可以是例如肽、糖肽、多肽、糖多肽、多核苷酸、多糖、脂质等。很明显,抗原可以合成、重组生产或源自生物样品。可包含一种或多种抗原的示例性生物样品包括组织样品、肿瘤样品、细胞、生物流体或其组合。抗原可以由经过修饰或基因工程以表达抗原的细胞产生,或由内源性(例如,未经人为干预的修改或基因工程)表达具有免疫原性的突变或多态性的细胞产生。
如本文所用,“新抗原”是指包含产生新抗原或抗原表位的结构变化、改变或突变的宿主细胞产物,这种新抗原或抗原表位是先前未在受试者基因组(即,来自受试者的健康组织样本)中观察到或被宿主免疫系统“看到”或识别的,包括(a)由细胞的抗原加工和转运机制处理,并与MHC(例如HLA)分子一起呈递到细胞表面;(b)引发免疫反应(例如,细胞(T细胞)反应)。新抗原可源自例如具有导致改变或突变产物的改变(替换、添加、删除)的编码多核苷酸,或源自外源核酸分子或蛋白质的插入细胞,或源自暴露于导致基因改变环境因素(例如化学、放射学)。新抗原可能与肿瘤抗原分开产生,或可能来自肿瘤抗原或与肿瘤抗原相关。“肿瘤新抗原”(或“肿瘤特异性新抗原”)是指包含与肿瘤细胞(或肿瘤内的多个细胞)相关、源自或产生于肿瘤细胞(或肿瘤内的多个细胞)内的新抗原决定簇的蛋白质。肿瘤新抗原决定簇存在于例如包含一个或多个由肿瘤细胞(例如,宫颈癌、某些头颈癌)的DNA编码的体细胞突变或染色体重排的抗原性肿瘤蛋白质或肽,以及存在于来自与病毒相关肿瘤(例如,胰腺癌、肺癌、结肠直肠癌)相关的病毒开放阅读框的蛋白质或肽。当涉及包含本文公开的突变(G12D、G12V)的Ras抗原时,术语“抗原”和“新抗原”在本文中可互换使用。
术语“表位”或“抗原表位”包括任何分子、结构、氨基酸序列或蛋白质决定簇(被同源结合分子识别并特异性结合),例如免疫球蛋白、T细胞受体(TCR)、嵌合抗原受体,或其他结合分子、结构域或蛋白质。表位决定簇通常包含分子的化学活性表面基团,例如氨基酸或糖侧链,并且可以具有特定的三维结构特征以及特定的电荷特征。
如本文所用,术语“KRAS(或NRAS或HRAS)抗原(或新抗原)”或“KRAS(或NRAS或HRAS)肽抗原(或新抗原)”或“KRAS(NRAS或HRAS)肽”是指天然或合成产生的KRAS或NRAS或HRAS蛋白的肽部分,其长度范围为约7个氨基酸、约8个氨基酸、约9个氨基酸、约10个氨基酸、最多约20个氨基酸,并且包含至少一个氨基酸由G12V或G12D(其中第12位是指SEQ IDNO:1中列出的全长KRAS蛋白序列;并且也指SEQ ID NO:6和216中分别列出的全长NRAS和HRAS蛋白序列)突变引起的改变,肽可以与MHC(例如HLA)分子形成复合物,并且本公开的对KRAS或NRAS或HRAS肽:MHC(例如,HLA)复合物特异的结合蛋白可以特异性地结合到这样的复合物上。示例性的KRAS(或NRAS或HRAS)抗原包含具有SEQ ID NO:2-5或198-201中任一项的氨基酸序列的肽或由其组成。
“主要组织相容性复合体”(MHC)是指将肽抗原递送至所有有核细胞的细胞表面的糖蛋白。MHC I类分子是异源二聚体,具有跨膜α链(具有三个α结构域)和非共价结合的β2微球蛋白。MHC II类分子由两种跨膜糖蛋白α和β组成,它们都跨越膜。每条链包含两个域。MHCI类分子将源自胞质溶胶的肽递送至细胞表面,其中肽:MHC复合物被CD8+T细胞所识别。MHCII类分子将源自囊泡系统的肽递送到细胞表面,其中它们被CD4+T细胞识别。人类MHC被称为人类白细胞抗原(HLA)。对应于“I类”MHC的HLA从细胞内部呈递肽,包括例如HLA-A、HLA-B和HLA-C。等位基因包括,例如,HLA A*11:01;HLA-A*03:01;和HLA-A*02:01。对应于“II类”MHC的HLA呈递来自细胞外的肽,包括例如HLA-DP、HLA-DM、HLA-DOA、HLA-DOB、HLA-DQ和HLA-DR。
抗原呈递细胞(APC)(如树突细胞、巨噬细胞、淋巴细胞或其他细胞类型)处理抗原的原则以及APC将抗原呈递给T细胞的原理,包括免疫相容(例如,共享至少一种与抗原呈递相关的MHC基因的等位基因形式)APC和T细胞之间的主要组织相容性复合体(MHC)限制性呈递,均已确立(参见,例如,Murphy,Janeway’sImmunobiology(8th Ed.)2011GarlandScience,NY;chapters 6,9and 16)。例如,源自胞质溶胶(例如,肿瘤抗原、细胞内病原体)的加工抗原肽的长度通常为约7个氨基酸至约11个氨基酸,并将与I类MHC(HLA)分子结合,而在囊泡系统(例如细菌、病毒)中加工的肽的长度从约10个氨基酸到约25个氨基酸不等,并与II类MHC(HLA)分子结合。
如本文所用,术语“KRAS特异性结合蛋白”是涉及结合KRAS肽抗原或NRAS肽抗原或NRAS肽抗原(或针对aKRAS或NRAS或HRAS肽抗原:HLA复合物,例如,在细胞表面上)的蛋白质或多肽,例如TCR、scTCR或CAR,以及涉及不结合不含KRAS或NRAS或HRAS肽的肽,也不结合含有此类肽的HLA复合物。
本公开的结合蛋白,例如TCR、scTCR和CAR,将包含对靶标特异的结合域。如本文所用,“结合域”(也称为“结合区”或“结合部分”)是涉及具有与目标(例如,KRAS或NRAS或HRAS肽或KRAS或NRAS或HRAS肽:MHC复合物)特异性地和非共价结合、结合或结合的能力的分子或其部分(例如,肽、寡肽、多肽、蛋白质)。结合域包括生物分子、分子复合物(即包含两个或多个生物分子的复合物)或其他感兴趣的目标的任何天然存在的、合成的、半合成的或重组产生的结合配偶体。示例性的结合域包括免疫球蛋白可变区或包含它们的单链构建体(例如,单链TCR(scTCR))。
在某些实施方案中,Ras特异性结合蛋白以小于约10-8M、小于约10-9M、小于约10- 10M、小于约10-11M的Kd结合KRAS(或NRAS或HRAS)肽(或KRAS(或NRAS或HRAS):HLA复合体),小于约10-12M,或小于约10-13M,或以与本文提供的示例性SRas特异性结合蛋白的表现出的亲和力大约相同、至少大约相同或大于等于或大约为该亲和力的亲和力结合,例如本文提供的任何Ras特异性TCR,例如,如通过相同测定所测量的。在某些实施方案中,Ras特异性结合蛋白包含Ras特异性免疫球蛋白超家族结合蛋白或其结合部分。
如本文所用,“特异性结合”或“特异于”是指结合蛋白(例如,TCR受体)或结合域(或其融合蛋白)以等于或大于105M-1(它等于该缔合反应的接通率[kon]与解离率[koff]的比率)的亲和力或Ka(即,特定结合相互作用的平衡结合常数,单位为1/M)与靶分子的缔合或结合,同时不与样品中的任何其它分子或组分显着缔合或结合。结合蛋白或结合域(或其融合蛋白)可归类为“高亲和力”结合蛋白或结合域(或其融合蛋白)或“低亲和力”结合蛋白或结合域(或其融合蛋白)。“高亲和力”结合蛋白或结合域是指具有至少107M-1、至少108M-1、至少109M-1、至少1010M-1、至少1011M-1,至少1012M-1,或至少1013M-1。“低亲和力”结合蛋白或结合域是指具有高达107M-1、高达106M-1、高达105M-1的Ka的那些结合蛋白或结合域。或者,亲和力可以定义为与M单位(例如,10-5M至10-13M)的特定结合相互作用的平衡解离常数(Kd)。
在某些实施方案中,受体或结合域可具有“增强的亲和力”,它是指与野生型(或亲本)结合域相比,与靶抗原的结合更强的选定或工程化受体或结合域。例如,增强的亲和力可能是由于靶抗原的Ka(平衡缔合常数)高于野生型结合域,由于靶抗原的Kd(解离常数)小于野生型结合域的Kd(解离常数),由于靶抗原的解离率(koff)小于野生型结合域的解离率(koff),或其组合。
用于鉴定特异性结合特定靶标的本公开的结合域,以及确定结合域或融合蛋白亲和力的多种测定法是已知的,例如蛋白质印迹、ELISA、分析超速离心、光谱和表面等离子共振分析((参见,例如,Scatchard et al.,Ann.N.Y.Acad.Sci.51:660,1949;Wilson,Science 295:2103,2002;Wolff et al.,Cancer Res.53:2560,1993;andU.S.Patent Nos.5,283,173,5,468,614,或等同物)。
在某些实施方案中,单独的KRAS(或NRAS,或HRAS)特异性结合域(即,不含KRAS(或NRAS,或HRAS)特异性结合蛋白的任何其他部分)可以是可溶的并且可以以小于约10-8M、小于约10-9M、小于约10-10M,小于约10-11M,小于约10-12M,或小于约10-13M的Kd结合至KRAS(或NRAS,或HRAS)(或KRAS(或NRAS,或HRAS)肽,或KRAS(或NRAS,或HRAS)肽:HLA复合物)。在特定实施方案中,KRAS(或NRAS,或HRAS)特异性结合域包括KRAS(或NRAS,或HRAS)特异性scTCR(例如,单链αbTCR蛋白,例如Vα-L-Vb、Vb-L-Vα、Vα-Cα-L-Vα或Vα-L-Vb-Cb,其中Vα和Vb分别是TCRα和b可变域,Cα和Cb分别是TCRα和b恒定域,L是接头,例如本文所述的接头)。
如本文所用,术语“功能亲合力”是指体外免疫细胞(例如,T细胞、NK细胞、NK-T细胞)对给定浓度的配体反应的生物学量度或活化阈值,其中生物学测量可包括细胞因子产生(例如,IFN-γ产生、IL-2产生等)、细胞毒活性、活化标记物(例如,CD137、Nur77)和增殖。例如,通过例如产生细胞因子、表现出细胞毒性活性或增殖在体外对低抗原剂量作出生物学(免疫学)反应的T细胞被认为具有高功能性亲和力,而较低功能性亲和力的T细胞在引发类似于高亲和力T细胞的免疫反应之前需要更高量的抗原。应当理解,功能亲合力不同于亲合力(affinity)和亲合力(avidity)。亲和力是指结合蛋白与其抗原/配体之间任何给定键的强度。一些结合蛋白是多价的,可以与多种抗原结合——在这种情况下,整体连接的强度就是亲和力。
功能亲和力和免疫反应的有效性之间存在许多相关性。一些体外研究表明,不同的T细胞功能(例如增殖、细胞因子产生等)可以在不同的阈值下触发(参见,例如,Betts etal.,J.Immunol.172:6407,2004;Langenkamp et al.,Eur.J.Immunol.32:2046,2002)。影响功能亲合力的因素包括(a)TCR对pMHC复合物的亲和力,即TCR和pMHC之间相互作用的强度(Cawthonet al.,J.Immunol.167:2577,2001),(b)宿主细胞上TCR的表达水平,在一些实施方案中,CD4或CD8共受体的表达水平以及(c)信号分子的分布和组成(Viola andLanzavecchia,Science273:104,1996),以及减弱T细胞功能和TCR信号的分子的表达水平。
在指定的暴露时间后诱导基线和最大反应之间的半数最大反应(例如,细胞因子的产生;结合标记肽时的荧光强度:HLA多聚体)所需的抗原浓度称为“半数最大有效浓度”或“EC50”。EC50值通常表示为摩尔(摩尔/升)量,但它通常转换为对数值,如下所示–log10(EC50)。例如,如果EC50等于1μM(10-6M),则log10(EC50)值为–6。使用的另一个值是pEC50,它被定义为EC50的负对数(-log10(EC50))。在上面的示例中,EC50等于1μM,其pEC50值为6。在某些实施方案中,本公开的结合蛋白的功能亲合力将包括结合蛋白促进T细胞产生IFNγ的能力的量度,其可使用本领域已知和本文所述的测定法来测量。在某些实施例中,功能亲合力将包括结合蛋白在与抗原结合后激活宿主细胞(比如T细胞)的能力的量度。在某些情况下,“高功能亲合力”TCR或其结合域是指具有EC50为至少10-4M、至少约10-5M、或至少约10-6M、或至少约10-7M的那些TCR或其结合域。
还考虑了融合蛋白,其包含与抗体(例如,IgG(1、2、3、4)、IgE、IgD、IgA、IgM及其变体)或其片段(例如,在一些实施方案中,保持与一种或多种Fc受体、C1q、蛋白A、蛋白G或其任何组合的结合的片段)的恒定域连接的本公开的scTCR,并且包括免疫球蛋白重链单体和多聚体,例如Fc二聚体;参见,例如,Wong et al.,J.Immunol.198:1Supp.(2017)。包含增强、降低或消除与例如FcRn或其他Fc受体的结合或通过FcRn或其他Fc受体的结合的突变的变体Fc多肽是已知的,并且涵盖在本公开内容中。
在某些实施方案中,本公开的结合蛋白或融合蛋白(例如,TCR、scTCR、CAR)由宿主细胞(例如,通过异源表达结合蛋白或融合蛋白的T细胞、NK细胞或NK-T细胞)表达。可以通过以下方式确定这种宿主细胞对KRAS(或NRAS或HRAS)肽抗原或KRAS(或NRAS或HRAS)肽抗原:HLA复合物的亲和力:例如,通过将宿主细胞暴露于肽,或肽:HLA复合物(例如,组织为四聚体),或将肽呈递给宿主细胞的抗原呈递细胞(APC),任选地在肽:HLA复合物中,接着测量宿主细胞的活性,例如细胞因子的产生或分泌(例如,IFN-γ;TNFα);测量宿主细胞信号或活性成分(例如,CD137(4-1BB))的表达增加;宿主细胞的增殖;或通过杀死APC(例如,使用标记铬释放分析)。
如本文所用,“核酸”或“核酸分子”或“多核苷酸”是指脱氧核糖核酸(DNA)、核糖核酸(RNA)、寡核苷酸、多核苷酸、例如通过聚合酶链反应(PCR)或通过体外翻译生成的片段中任一个,并且也涉及由任何连接、断裂、核酸内切酶作用或核酸外切酶作用产生的片段。在某些实施方案中,本公开的核酸通过PCR产生。核酸可由单体组成,这些单体是天然存在的核苷酸(如脱氧核糖核苷酸和核糖核苷酸)、天然存在的核苷酸的类似物(例如,天然核苷酸的α-对映体形式)或两者的组合。修饰的核苷酸可以对糖部分或嘧啶或嘌呤碱基部分进行修饰或替换。核酸单体可通过磷酸二酯键或此类键的类似物连接。磷酸二酯键的类似物包括硫代磷酸酯、二硫代磷酸酯、硒代磷酸酯、二硒代磷酸酯、苯胺硫代磷酸酯、苯胺磷酸酯、氨基磷酸酯等。核酸分子可以是单链或双链的。
术语“隔离”是指材料从其原始环境中移除(例如,如果是自然发生的自然环境)。例如,存在于活体动物中的天然存在的核酸或多肽不是分离的,但是,从天然系统中的一些或全部共存物质中分离出来的相同核酸或多肽是分离的。这样的核酸可以是载体的一部分和/或这样的核酸或多肽可以是组合物(例如,细胞裂解物)的一部分,并且仍然是分离的,因为这样的载体或组合物不是核酸或多肽的自然环境的一部分。术语“基因”是指参与产生多肽链的DNA片段;它包括编码区之前和之后的区域(“前导和拖尾”)以及各个编码段(外显子)之间的插入序列(内含子)。
如本文所用,术语“重组的”、“工程化的”和“修饰的”是指通过引入外源核酸分子而修饰的细胞、微生物、核酸分子、多肽、蛋白质、质粒或载体,或指通过人为干预进行基因工程改造的细胞或微生物,即通过引入异源核酸分子进行修饰,或指已被改变使得内源核酸分子或基因的表达受到控制、解除调节或组成性的细胞或微生物,可以通过基因工程引入此类改变或修饰。人类产生的遗传改变可以包括,例如,引入编码一种或多种蛋白质或酶的核酸分子(可能包括表达控制元素,例如启动子)的修饰,或细胞遗传物质的其他核酸分子添加、缺失、替换或其他功能破坏或添加。示例性修饰包括来自参考或亲本分子的异源或同源多肽的编码区或其功能片段中的那些。
如本文所用,“突变”是指分别与参照或野生型核酸分子或多肽分子相比,核酸分子或多肽分子的序列发生变化。突变可导致多种不同类型的序列变化,包括核苷酸或氨基酸的取代、插入或缺失。在某些实施例中,突变是一个或三个密码子或氨基酸的取代,一到约5个密码子或氨基酸的缺失,或其组合。
在本领域中,“保守替换”被认为是一种氨基酸被另一种具有相似特性的氨基酸置换。示例性保守替换是本领域众所周知的(参见,例如,WO 97/09433第10页;Lehninger,Biochemistry,2nd Edition;Worth Publishers,Inc.NY,NY,pp.71-77,1975;Lewin,GenesIV,Oxford University Press,NY and Cell Press,Cambridge,MA,p.8,1990)。
在某些实施方案中,与参考序列相比,根据本公开的蛋白质(例如,结合蛋白、免疫原性肽)包含变体序列(例如,与本文公开的参考TCR CDR3β相比的变体TCR CDR3β)。如本文所用,“变体”氨基酸序列、肽或多肽是指与参考氨基酸序列(或肽或多肽)相比具有一或两个氨基酸取代、缺失或插入的氨基酸序列。在某些实施例中,变体氨基酸序列、肽或多肽保留与参考分子基本相同的功能性(例如,对肽:HLA复合物的结合特异性和亲和力);例如,与参考TCR结合片段相比,本文公开的变体TCR片段保留50%、约60%、约70%、约80%、约90%、约95%、约99%或100%的抗原结合特异性和亲和力。
“改变的域”或“改变的蛋白质”是指与野生型基序、区域、结构域、肽、多肽或蛋白质(例如,野生型TCRα链、TCRβ链、TCRα恒定域、TCRβ恒定域)具有至少85%(例如,86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、99.1%、99.2%、99.3%、99.4%、99.5%、99.6%、99.7%、99.8%、99.9%)的不同序列同一性的基序、区域、结构域、肽、多肽或蛋白质。
改变的结构域或改变的蛋白质或衍生物可以包括基于相同氨基酸的所有可能密码子选择的那些和基于保守氨基酸取代的密码子选择。例如,以下六组每组都包含彼此保守替换的氨基酸:1)丙氨酸(ala;A)、丝氨酸(ser;S)、苏氨酸(thr;T);2)天冬氨酸(asp;D)、谷氨酸(glu;E);3)天冬酰胺(asn;N)、谷氨酰胺(gln;Q);4)精氨酸(arg;R)、赖氨酸(lys;K);5)异亮氨酸(ile;I)、亮氨酸(L)、甲硫氨酸(met;M)、缬氨酸(val;V);和6)苯丙氨酸(phe;F)、酪氨酸(tyr;Y)、色氨酸(trp;W)。(也参见WO97/09433第10页,Lehninger,Biochemistry,2nd Edition,Worth Publishers,Inc.,NY,NY,pp.71-77,1975;Lewin GenesIV,Oxford University Press,NY and Cell Press,Cambridge,MA,p.8,1990;Creighton,Proteins,W.H.Freeman and Company 1984)。此外,改变、添加或删除编码序列中的单个氨基酸或一小部分氨基酸的个别替换、缺失或添加也是“保守替换”。
术语“构建体”是指包含重组核酸分子的任何多核苷酸。“转基因”或“转基因构建体”是指包含以自然界中未发现的排列可操作地连接的两个或更多个基因的构建体。术语“可操作地连接”(或本文中的“可操作地连接”)是指两个或更多个核酸分子在单个核酸片段上的缔合,使得一个的功能受另一个的影响。例如,当启动子可以影响编码序列的表达时,启动子与编码序列可操作地连接(即,编码序列在启动子的转录控制之下)。“无关联”是指相关的遗传元件彼此之间没有密切联系,一个的功能不影响另一个。在一些实施方案中,转基因中存在的基因与表达控制序列(例如,启动子)可操作地连接。
构建体(例如,转基因)可以存在于载体(例如,细菌载体、病毒载体)中或可以整合到基因组中。“载体”是能够运输另一种核酸分子的核酸分子。例如,载体可以是可以包括染色体、非染色体、半合成或合成核酸分子的质粒、粘粒、病毒、RNA载体或线性或环状DNA或RNA分子。示例性载体是能够自主复制(附加型载体)或表达与其连接的核酸分子的那些(表达载体)。可用于本公开的组合物和方法的载体在本文中进一步描述。
如本文所用,术语“表达”是指基于核酸分子(例如基因)的编码序列产生多肽的过程。该过程可以包括转录、转录后控制、转录后修饰、翻译、翻译后控制、翻译后修饰或其任何组合。
在将核酸分子插入细胞的上下文中,术语“引入”是指“转染”或“转化”或“转导”,并且术语包括提及将核酸分子并入真核或原核细胞其中核酸分子可以掺入细胞的基因组(例如,染色体、质粒、质体或线粒体DNA),转化为自主复制子,或瞬时表达(例如,转染的mRNA)。
如本文所用,“异源”或“外源”核酸分子、构建体序列是指非宿主细胞天然的核酸分子或核酸分子的一部分,但可以与来自宿主细胞的核酸分子或核酸分子的一部分同源。异源或外源核酸分子、构建体或序列的来源可以来自不同的属或种。在某些实施方案中,通过例如接合、转化、转染、转导、电穿孔等将异源或外源核酸分子添加(即,非内源性或原生性)到宿主细胞或宿主基因组中,其中添加的分子可以整合到宿主基因组中或作为染色体外遗传物质(例如,作为质粒或其他形式的自我复制载体)存在,并且可以以多个副本的形式存在。此外,“异源的”是指由引入宿主细胞的外源核酸分子编码的非天然酶、蛋白质或其他活性,即使宿主细胞编码同源蛋白质或活性。而且,包含“修饰”或“异源”多核苷酸或结合蛋白的细胞包括该细胞的后代,无论后代本身是否被转导、转染或以其他方式操纵或改变。
如本文所述,可以将多于一种异源或外源核酸分子作为单独的核酸分子、作为多个单独控制的基因、作为多顺反子核酸分子、作为编码融合蛋白的单个核酸分子或其任何组合引入宿主细胞。例如,如本文所公开的,可以修饰宿主细胞以表达一种或多种异源或外源核酸分子,异源或外源核酸分子编码对Ras抗原肽(例如,TCRα和TCRb)特异的所需TCR,并且任选地,如本文所公开的,还编码包含α链、β链或其部分,例如能够结合MHC的细胞外部分的CD8共受体多肽。当两个或多个外源核酸分子被引入宿主细胞时,应理解,两个或多个外源核酸分子可以作为单个核酸分子(例如,在单个向量上)在单独的载体上引入,在单个位点或多个位点整合到宿主染色体中,或其任何组合。提及的异源核酸分子或蛋白质活性的数量是指编码核酸分子的数量或蛋白质活性的数量,而不是引入宿主细胞的分离核酸分子的数量。
如本文所用,术语“内源的”或“天然的”是指通常存在于宿主细胞中的基因、蛋白质或活性。而且,与非亲本基因、蛋白质或活性相比发生突变、过度表达、改组、复制或以其他方式改变的基因、蛋白质或活性仍被认为是该特定宿主细胞的内源性或天然的。例如,来自第一个基因(例如,启动子、翻译衰减序列)的内源性控制序列可用于改变或调节第二个天然基因或核酸分子的表达,其中第二天然基因或核酸分子的表达或调控不同于亲代细胞中的正常表达或调控。
术语“同源”或“同源物”是指在宿主细胞、物种或菌株中发现的或衍生自宿主细胞、物种或菌株的分子或活性。例如,异源或外源核酸分子可以与原生宿主细胞基因同源,并且可以任选地具有改变的表达水平、不同的序列、改变的活性或其任何组合。
本文所述的“序列同一性”是指在比对序列并引入缺口后,一个序列中的氨基酸残基与另一参考多肽序列中的氨基酸残基相同的百分比,如有必要,以实现最大百分比的序列同一性,并且不考虑任何保守替换作为序列同一性的一部分。可以使用Altschul et al.(1997),Nucl.Acids Res.25:3389-3402定义的NCBI BLAST2.0软件生成百分比序列同一性值,其中参数设置为默认值。
结合蛋白
一方面,本公开提供了一种结合蛋白,其包含T细胞受体(TCR)α链可变(Vα)结构域和TCRβ链可变(Vβ)结构域,其中结合蛋白能够结合肽:HLA复合物,其中肽包含氨基酸序列KLVVVGAVGV(SEQ ID NO:198)或由其组成。在某些实施方案中,HLA包括HLA-A*02,任选地HLA-A*02:01。在任何目前公开的实施方案中,结合蛋白可由人免疫系统细胞(例如T细胞)异源表达。
在某些实施方案中,Vα结构域和/或Vβ结构域各自独立地是人的、人源化的或嵌合的,并且优选地各自是人。
目前公开的结合蛋白能够被宿主细胞(例如人类免疫细胞,例如T细胞)异源表达。此外,表目前公开的结合蛋白的表达可以赋予宿主细胞有利的特性;例如,具有对于本公开的Ras抗原:HLA复合物的结合特异性、改进的活性、增殖、或在存在Ras抗原:HLA呈递肿瘤细胞的杀伤活性或等同物。
例如,在某些实施方案中,当结合蛋白由免疫细胞(例如,人T细胞,任选CD8+和/或CD4+T细胞、NK细胞或NK-T细胞)表达时,免疫细胞能够特异性杀伤表达肽的HLA-A*02+肿瘤细胞,所述肽包含或由SEQID NO:198中所列的氨基酸序列组成。可以确定靶细胞的杀伤,例如,生物成像平台(Essen Bioscience)。在某些实施方案中,该平台使用活化的半胱天冬酶和标记的(例如,RapidRed或NucRed)肿瘤细胞信号,其中测量重叠并且增加的重叠面积等于细胞凋亡导致的肿瘤细胞死亡。杀死也可以使用4小时测定法确定,其中靶细胞加载有标记的铬(51Cr),并在与表达本公开内容的结合蛋白的免疫细胞共孵育4小时后测量上清液中的51Cr。在某些实施例中,可以使用效应器:靶细胞比率:1:1、2:1、3:1、4:1、5:1、6:1、7:1、8:1、9:1、10:1、20:1、25:1、50:1或100:1等进行杀伤试验。
在任何目前公开的实施例中,当结合蛋白由免疫细胞(例如,人类T细胞,可选的CD8+和/或CD4+T细胞、NK细胞或NK-T细胞)表达时,当存在HLA-A*02+肿瘤细胞时,任选地进一步存在外源性IFN-γ,免疫细胞具有升高的Nur77表达,其中HLA-A*02+肿瘤细胞表达包含SEQ ID NO:198中列出的氨基酸序列或由其组成的肽,其中Nur77表达与以下相比升高:(i)当参考免疫细胞存在肿瘤细胞时,不表达结合蛋白的参考免疫细胞(即,与表达结合蛋白的免疫细胞具有相同的细胞类型,并且在其他方面在表型和/或基因型上至少基本上相同或功能等效)表达Nur77;和/或(ii)当不存在肿瘤细胞和/或不存在表达肽:HLA复合物的抗原呈递细胞时,由表达结合蛋白的免疫细胞表达Nur77,其中肽包含SEQ ID NO:198中列出的氨基酸序列或由其组成,并且其中HLA任选地是HLA-A*02:01。例如,Nur77的表达可以使用包含与编码报告构建体的序列可操作地连接的Nur77基因座的转基因表达构建体来确定;例如,dTomato(参见Ahsouri和Weiss,J Immunol 198(2):657-668(2017))。
在任何目前公开的实施例中,当结合蛋白由免疫细胞(例如,人T细胞,任选CD8+和/或CD4+T细胞、NK细胞或NK-T细胞)表达时,当存在HLA-A*02+肿瘤细胞时,任选地进一步存在外源性IFN-γ,免疫细胞具有升高的CD137(也称为4-1BB)表达,其中,HLA-A*02+肿瘤细胞表达包含SEQ ID NO:198中列出的氨基酸序列或由其组成的肽,其中CD137表达与以下相比升高:(i)当参考免疫细胞存在肿瘤细胞时,不表达结合蛋白的参考免疫细胞表达CD137;和/或(ii)当不存在肿瘤细胞和/或不存在表达肽:HLA复合物的抗原呈递细胞时,表达结合蛋白的免疫细胞表达CD137,其中肽包含或由SEQ ID NO:198中列出的氨基酸序列组成,并且其中HLA任选地是HLA-A*02:01。例如,CD137表达可以使用标记的抗CD137抗体的流式细胞术来确定。在某些实施例中,CD137在16小时测定后测量,其中免疫细胞与肽或表达肽的靶细胞共孵育或刺激。
在任何目前公开的实施例中,当结合蛋白由免疫细胞(例如,人T细胞,任选CD8+和/或CD4+T细胞、NK细胞或NK-T细胞)表达时,当存在包含SEQ ID NO:198所示氨基酸序列或由其组成的肽时,当肽以至少约10-10M、至少约10-9M和/或至少约10-8M的浓度存在时,免疫细胞产生IFN-γ。IFN-γ的产生可以通过例如在用肽抗原、肽:HLA复合物或本文提供的肿瘤细胞刺激后使用标记的抗-IFN-γ抗体进行细胞内染色来确定。IFN-γ的产生可以在4小时测定后确定,其中免疫细胞与肽或表达肽的靶细胞共孵育或刺激。在某些实施例中,在表达结合蛋白的多个免疫细胞(例如,人T细胞、NK细胞、NK-T细胞或其任何组合)中,至少约10%、至少约15%、至少约20%或至少约25%的多个免疫细胞当存在10-9M肽时产生IFN-γ。
在某些实施例中,在表达结合蛋白的多个免疫细胞(例如,人T细胞,可选的CD8+和/或CD4+T细胞、NK细胞或NK-T细胞)中,当存在10-8M肽时,至少约25%、至少约30%或至少约35%的多个免疫细胞产生IFN-γ。在某些实施方案中,当存在0.1ng/mL或更多的包含氨基酸序列KLVVVGAVGV(SEQ ID NO:198)或由其组成的肽时,免疫细胞或多个免疫细胞产生IFN-γ,其中可选地,与当存在10,000ng/mL的包含SEQ ID NO:1的氨基酸5-14或由其组成的肽相比,当存在1ng/mL包含氨基酸序列KLVVVGAVGV(SEQ ID NO:198)或由其组成的肽时,免疫细胞或多个免疫细胞产生更多的IFN-γ。
在任何目前公开的实施例中,结合蛋白对于包含SEQ ID NO.:198中列出的氨基酸序列或由其组成的肽具有log10EC50,其中,SEQ ID NO:198具有小于-8.0,任选约-8.5或更小,进一步任选约-8.5、约-8.6、约-8.7、约-8.8、约-8.9、约-9、约-9.1或约-9.2。
在任何目前公开的实施方案中:(i)结合蛋白由与免疫细胞异源的多核苷酸编码;(ii)免疫细胞包括人CD8+T细胞、人CD4+T细胞或两者;(iii)表达包含SEQ ID NO.:198所示氨基酸序列或由其组成的肽的肿瘤细胞是HLA-A*02:01+;和/或(iv)肿瘤细胞包含CFPAC-1细胞。
在任何目前公开的实施方案中,结合蛋白能够独立于CD8或在不存在CD8的情况下结合肽:HLA复合物。例如,可以通过流式细胞术确定结合蛋白与A2(DM)/-肽多聚体的结合来确定CD8非依赖性结合。这种多聚体由修饰的HLA-A*02:01α3域双突变(DM)单体组装而成,其不能与CD8结合。CD8非依赖性结合也可以通过在CD8阴性细胞(例如,CD4+T细胞、Jurkat细胞等)中表达结合蛋白并鉴定细胞与靶标的结合来确定。
在某些实施例中:(i)Vα结构域包含根据SEQ ID NO.:351、343、359、367、375、383、391、399、407、415、423、431、439、447、455、463或471中任一项所述的Vα氨基酸序列的CDR1α、CDR2α和/或CDR3α氨基酸序列;和/或(ii)Vβ结构域包含根据SEQ ID NO:354、346、362、370、378、386、394、402、410、418、426、434、442、450、458、466、474、482或490中任一项所列的Vβ氨基酸序列的CDR1β、CDR2β和/或CDR3β氨基酸序列。在某些实施例中,使用IMGT、EU、Kabat、Chothia、Aho或增强型Chothia编号方案确定CDR。TCR可变域序列可以与编号方案(例如Kabat、Chothia、EU、IMGT、Enhanced Chothia和Aho)进行比对,从而允许注释等效的残基位置并使用例如ANARCI软件工具比较不同的分子(2016,Bioinformatics15:298-300)。
在进一步的实施例中,结合蛋白包含CDR1α、CDR2α、CDR3α和CDR1β、CDR2β和CDR3β氨基酸序列,其根据以下所列的Vα和Vβ氨基酸序列:(i)分别为SEQ ID NO:351和354;(ii)分别为SEQ ID NO:343和346;(iii)分别为SEQ ID NO:359和362;(iv)分别为SEQ ID NO:367和370;(v)分别为SEQ ID NO:375和378;(vi)分别为SEQ ID NO:383和386;(vii)分别为SEQ ID NO:391和394;(viii)分别为SEQ ID NO:399和402;(ix)分别为SEQ ID NO:407和410;(x)分别为SEQ ID NO:415和418;(xi)分别为SEQID NO:423和426;(xii)分别为SEQ IDNO:431和434;(xiii)分别为SEQ ID NO:439和442;(xiv)分别为SEQ ID NO:447和450;(xv)分别为SEQ ID NO:455和458;(xvi)分别为SEQ ID NO:463和466;(xvii)分别为SEQ ID NO:471和474;(xviii)分别为SEQ ID NO:479和482;或(xix)分别为SEQ ID NO:487和490。
在某些实施方案中,本公开的结合蛋白包含:(i)SEQ ID NO:228、222、234、240、246、252、258、264、270、276、282、288、294、300、306、312、318、324、或340中任一项所示的CDR3α氨基酸序列,或其变体,其中,变体包含一个、两个或三个氨基酸取代的变体,其中任何或所有的可包含保守氨基酸取代;和/或(ii)SEQ ID NO:225、219、231、237、243、249、255、261、267、273、279、285、291、297、303、309、315、321或327,或其变体中任一项所示的CDR3β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何或所有的可包含保守氨基酸取代;和/或(iii)SEQ ID NO:226、220、232、238、244、250、256、262、268、274、280、286、292、298、304、316、322或328或其变体中任一项所示的CDR1α氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何或所有的可包含保守氨基酸取代;和/或(iv)SEQ ID NO:223、217、229、235、241、247、253、259、265、271、277、283、289、295、301、307、313、319或325,或其变体中任一项所示的CDR1β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何或所有的可包含保守氨基酸取代;和/或(v)SEQ ID NO:227、221、233、239、245、251、257、263、269、275、281、287、293、299、305、311、317、323或329,或其变体中任一项所示的CDR2α氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何或所有的可包含保守氨基酸取代;和/或(vi)SEQ ID NO:224、218、230、236、242、248、254、260、266、272、278、284、290、296、302、308、314、320或326,或其变体中任一项所示的CDR2β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何或所有的可包含保守氨基酸取代。
在进一步的实施例中,本公开内容的结合蛋白包含以下所列的CDR1α、CDR2α、CDR3α、CDR1β、CDR2β和CDR3β氨基酸序列:(i)SEQ ID NO:分别为226、227、228、223、224和225;(ii)SEQ ID NO:分别为220、221、222、217、218和219;(iii)SEQ ID NO:分别为232、233、234、229、230和231;(iv)SEQ ID NO:分别为238、239、240、235、236和237;(v)SEQ ID NO:分别为244、245、246、241、242和243;(vi)SEQ ID NO:分别为250、251、252、247、248和249;(vii)SEQ ID NO:分别为256、257、258、253、254和255;(viii)SEQ ID NO:分别为262、263、264、259、260和261;(ix)SEQ ID NO:分别为268、269、270、265、266和267;(x)SEQ ID NO:分别为274、275、276、271、272和273;(xi)SEQ ID NO:分别为280、281、282、277、278和279;(xii)SEQ ID NO:分别为286、287、288、283、284和285;(xiii)SEQ ID NO:分别为292、293、294、289、290和291;(xiv)SEQ ID NO:分别为298、299、300、295、296和297;(xv)SEQ ID NO:分别为304、305、306、301、302和303;(xvi)SEQ ID NO:分别为310、311、312、307、308和309;(xvii)SEQ ID NO:分别为316、317、318、313、314和315;(xviii)SEQ ID NO:分别为322、323、324、319、320和321;或(xix)SEQ ID NO:分别为328、329、330、325、326和327。
在任何目前公开的实施例中,结合蛋白可包含分别与来自D_2_1.1、D_2_1.2、D_2_1.3、D_2_1.4、D_2_1.5、D_2_1.6、D_2_1.7、D_2_1.8、D_2_1.9、D_2_1.10、D_2_2.1、D_2_2.2、D_2_2.3、D_2_2.4、D_2_2.5、D_2_2.6、D_2_2.7、D_2_2.8、D_2_2.9或D_2_2.10的Vβ结构域或Vα结构域具有至少90%同一性的Vβ结构域和/或Vα结构域,前提是:(a)至少三个或四个CDR没有突变;(b)确实有突变的CDR仅具有最多两个氨基酸取代、最多五个连续的氨基酸缺失或其组合;和(c)编码的结合蛋白保留其结合肽:HLA-A*02:01复合物的能力,该复合物包含根据SEQ ID NO:198-201中任一项的KRAS肽。在进一步的实施方案中,结合域包括:(i)来自D_2_1.1、D_2_1.2、D_2_1.3、D_2_1.4、D_2_1.5、D_2_1.6、D_2_1.7、D_2_1.8、D_2_1.9、D_2_1.10、D_2_2.1的CDR3βD_2_2.2、D_2_2.3、D_2_2.4、D_2_2.5、D_2_2.6、D_2_2.7、D_2_2.8、D_2_2.9或D_2_2.10;和/或(ii)来自D_2_1.1、D_2_1.2、D_2_1.3、D_2_1.4、D_2_1.5、D_2_1.6、D_2_1.7、D_2_1.8、D_2_1.9、D_2_1.10、D_2_2.1、D_2_2.2、D_2_2.3、D_2_2.4、D_2_2.5、D_2_2.6、D_2_2.7、D_2_2.8、D_2_2.9或D_2_2.10的CDR3α。在一些实施例中,结合域包含来自D_2_1.1、D_2_1.2、D_2_1.3、D_2_1.4、D_2_1.5、D_2_1.6、D_2_1.7、D_2_1.8、D_2_1.9、D_2_1.10、D_2_2.1、D_2_2.2、D_2_2.3、D_2_2.4、D_2_2.5、D_2_2.6、D_2_2.7、D_2_2.8、D_2_2.9或D_2_2.10的CDR1β和CDR2β、CDR1α和/或CDR2α。
在特定实施方案中,结合域包含来自D_2_1.1、D_2_1.2、D_2_1.3、D_2_1.4、D_2_1.5、D_2_1.6、D_2_1.7、D_2_1.8、D_2_1.9、D_2_1.10、D_2_2.1、D_2_2.2、D_2_2.3、D_2_2.4、D_2_2.5、D_2_2.6、D_2_2.7、D_2_2.8、D_2_2.9或D_2_2.10的Vβ域和Vα域。
在任何目前公开的实施例中:(i)Vα结构域可包含与SEQ ID NO.351、343、359、367、375、383、391、399、407、415、423、431、439、447、455、463、471或479中任一项所述的氨基酸序列具有至少90%(即90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、99.5%或100%)同一性的氨基酸序列或由其组成;和/或(ii)Vβ结构域包含与SEQ IDNO.354、346、362、370、378、386、394、402、410、418、426、434、442、450、458、466、474、482或490中任一项所述的氨基酸序列具有至少90%(即90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、99.5%或100%)同一性的氨基酸序列或由其组成。在某些实施例中,与本文提供的参考可变域氨基酸序列相比的变异限于一个或多个框架序列,并且任选地包含一个或多个保守取代或由其组成。
在特定实施例中,Vα结构域和Vβ结构域包含或由以下氨基酸序列组成:(i)分别为SEQ ID NO:351和354;(ii)分别为SEQ ID NO:343和346;(iii)分别为SEQ ID NO:359和362;(iv)分别为SEQ ID NO:367和370;(v)分别为SEQ ID NO:375和378;(vi)分别为SEQ IDNO:383和386;(vii)分别为SEQ ID NO:391和394;(viii)分别为SEQ ID NO:399和402;(ix)分别为SEQ ID NO:407和410;(x)分别为SEQ ID NO:415和418;(xi)分别为SEQ ID NO:423和426;(xii)分别为SEQ ID NO:431和434;(xiii)分别为SEQ ID NO:439和442;(xiv)分别为SEQ ID NO:447和450;(xv)分别为SEQ ID NO:455和458;(xvi)分别为SEQ ID NO:463和466;(xvii)分别为SEQ ID NO:471和474;(xviii)分别为SEQ ID NO:479和482;或(xix)分别为SEQ ID NO:487和490。
在任何目前公开的实施例中,结合蛋白还可包含TCRα链恒定域(Cα)和/或TCRβ链恒定域(Cβ)。在某些实施方案中,Cα包含与SEQID NO.:85或86中列出的氨基酸序列具有至少90%(即90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、99.5%或100%)同一性的氨基酸序列或由其组成。在某些实施例中,Cβ包含与SEQ ID NO:87-99中的任一列出的氨基酸序列具有至少90%同一性的氨基酸序列或由其组成。
在一些实施例中,结合蛋白包含TCRα链和TCRβ链,其中TCRα链和TCRβ链包含与下述氨基酸序列具有至少90%同一性的氨基酸序列或由其组成:(i)分别为SEQ ID NO:350和353;(ii)分别为SEQ ID NO:342和345;(iii)分别为SEQ ID NO:358和361;(iv)分别为SEQID NO:366和369;(v)分别为SEQ ID NO:374和377;(vi)分别为SEQ ID NO:382和385;(vii)分别为SEQ ID NO:390和393;(viii)分别为SEQ ID NO:398和401;(ix)分别为SEQ ID NO:406和409;(x)分别为SEQ ID NO:414和417;(xi)分别为SEQ ID NO:422和425;(xii)分别为SEQ ID NO:430和433;(xiii)分别为SEQ ID NO:438和441;(xiv)分别为SEQ ID NO:446和449;(xv)分别为SEQ ID NO:454和457;(xvi)分别为SEQ ID NO:462和465;(xvii)分别为SEQ ID NO:470和473;(xviii)分别为SEQ ID NO:478和481;或(xix)分别为SEQ ID NO:486和489。
在任何目前公开的实施方案中,结合蛋白可包含TCR、单链TCR(scTCR)或嵌合抗原受体(CAR)。生产工程化TCR的方法描述于,例如,Bowerman et al.,Mol.Immunol.,46(15):3000(2009),其技术通过引用并入本文。制造CAR的方法是本领域已知的,并且描述于例如美国专利号6,410,319;美国专利号7,446,191;美国专利公开号2010/065818;美国专利号8,822,647;PCT公开号WO 2014/031687;美国专利号7,514,537;和Brentjens et al.,2007,Clin.Cancer Res.13:5426,其技术通过引用并入本文。
在另一方面,提供了包含T细胞受体(TCR)α链可变(Vα)结构域和TCRβ链可变(Vβ)结构域的结合蛋白,其中结合蛋白能够结合以下任何一种或多种:(i)肽:HLA复合物,其中所述肽包含氨基酸序列VVVGAVGVGK(SEQ ID NO:2)或由其组成;(ii)肽:HLA复合物,其中所述肽包含氨基酸序列VVGAVGVGK(SEQ ID NO:3)或由其组成;(iii)肽:HLA复合物,其中所述肽包含氨基酸序列VVGADGVGK(SEQ ID NO:4)或由其组成;或者(iv)肽:HLA复合物,其中所述肽包含氨基酸序列VVVGADGVGK(SEQ ID NO:5)或由其组成。
在某些实施方案中,Vα结构域和/或Vβ结构域各自独立地是人的、人源化的或嵌合的,并且优选地各自是人。
在任何当前公开的实施方案中,结合蛋白可以由免疫细胞(例如,T细胞、NK细胞、NK-T细胞等)异源表达。在某些实施方案中,免疫细胞包括人T细胞。
在某些实施方案中,HLA包括HLA-A*11,任选地HLA-A*11:01。
在任何目前公开的实施方案中,当结合蛋白由免疫细胞(例如,T细胞,例如人CD8+和/或CD4+T细胞、aNK细胞、NK-T细胞等)表达时,免疫细胞能够特异性(例如,仅或优先)杀死HLA-A*11+肿瘤细胞,该肿瘤细胞在其细胞表面表达或展示包含SEQ ID NO:2-5中的任何一个或多个所列氨基酸序列或由组成的肽,其中,任选地,表达的结合蛋白由与免疫细胞异源的多核苷酸编码。在任何目前公开的实施例中,肿瘤细胞包括Panc-1细胞、AsPc-1细胞、CFPAC-1细胞、Capan-2细胞、THP-1细胞、721.221细胞、GA-10.4细胞或其任何组合。可以确定靶细胞的杀伤,例如,生物成像平台(Essen Bioscience)。在某些实施方案中,该平台使用活化的半胱天冬酶和标记的(例如,RapidRed或NucRed)肿瘤细胞信号,其中测量重叠并且增加的重叠面积等于细胞凋亡导致的肿瘤细胞死亡。杀死也可以使用4小时测定法确定,其中靶细胞加载有标记的铬(51Cr),并在与表达本公开内容的结合蛋白的免疫细胞共孵育4小时后测量上清液中的游离51Cr。在某些实施例中,可以在效应器:靶细胞比率:1:1、2:1、3:1、4:1、5:1、6:1、7:1、8:1、9:1、10:1、20:1、25:1、50:1或100:1等进行杀伤试验。
在任何目前公开的实施例中,当结合蛋白由免疫细胞(例如,T细胞、NK细胞、NK-T细胞等)表达时,当存在以下情况时,免疫细胞的Nur77和/或CD137表达升高:(i)包含SEQID NO:2所列氨基酸序列或由其组成的肽;(ii)包含SEQ ID NO:3所列氨基酸序列或由其组成的肽;(iii)包含SEQ ID NO:4所列氨基酸序列或由其组成的肽;(iv)包含SEQ ID NO:5所列氨基酸序列或由其组成的肽;(v)包含SEQ ID NO:2所列氨基酸序列或由其组成的肽;和包含SEQ ID NO:3所列氨基酸序列或由其组成的肽;和/或(vi)包含或由SEQ ID NO:4中列出的氨基酸序列组成的肽和包含或由SEQ ID NO:5中列出的氨基酸序列组成的肽,其中当参考免疫细胞存在肽时,与不表达结合蛋白的参考免疫细胞的Nur77和/或CD137表达相比,Nur77和/或CD137表达升高,和/或与表达结合蛋白的人T细胞的Nur77和/或CD137表达相比,当存在包含SEQ ID NO:2或SEQ ID NO:3所示氨基酸序列或由其组成的肽时,Nur77和/或CD137表达升高,并且其中(i)-(vi)中任一项的肽任选地在免疫细胞存在下由肿瘤细胞表达。
在任何目前公开的实施例中,结合蛋白具有(i)包含SEQ ID NO:2或3中列出的氨基酸序列或由其组成的肽的log10EC50小于-6.5,任选约-7.0、约-7.5或约-8.0或小于-8.0,任选约-8.0、约-8.1、约-8.2、约-8.3、约-8.4、约-8.5;和/或(ii)包含SEQ ID NO:4或5中列出的氨基酸序列或由其组成的肽的log10EC50小于-7.0或小于-8.0,任选地约-7.5、约-7.6、约-7.7、约-7.8、约-8.0、约-8.1、约-8.2、约-8.3、约-8.4、约-8.5、约-8.6、约-8.7、约-8.8或大约-8.9。
在任何目前公开的实施例中,当结合蛋白由免疫细胞(例如,T细胞、NK细胞、NK-T细胞等)表达时,当存在以下物质时:(i)包含或由SEQ ID NO:2中列出的氨基酸序列组成的肽;和/或(ii)包含或由SEQ ID NO:3中列出的氨基酸序列组成的肽;和/或(iii)包含或由SEQ ID NO:4中列出的氨基酸序列组成的肽;和/或(v)包含或由SEQ ID NO:5中列出的氨基酸序列组成的肽,当肽以至少约10-11M、至少约10-10M、至少约10-9M和/或至少约10-8M的浓度存在时,免疫细胞产生IFN-γ。
在某些实施例中,表达结合蛋白的多个免疫细胞(例如,T细胞、NK细胞、NK-T细胞等)中,当存在10-8M肽、10-7M肽或10-6M肽时,至少约50%、至少约55%、至少约60%或更多的人T细胞产生IFN-γ。在进一步的实施例中,在表达结合蛋白的多个免疫细胞中:(i)当存在10ng/mL包含SEQ ID NO:4中所述氨基酸序列或由其组成的肽时,至少约10%、15%、20%或25%的多个免疫细胞产生IFN-γ;(ii)当存在100ng/mL的包含SEQ ID NO:4中列出的氨基酸序列或由其组成的肽时,至少约25%的多个免疫细胞产生IFN-γ;(iii)当存在10ng/mL的包含SEQ ID NO:3所述的氨基酸序列或由其组成的肽时,至少约10%、15%、20%或25%的多个免疫细胞产生IFN-γ;和/或(iv)当存在100ng/mL的包含SEQ ID NO:3中列出的氨基酸序列或由其组成肽时,至少约50%、至少约55%、至少约60%、至少约65%、至少约70%或至少约75%的多个免疫细胞生IFN-γ。
在任何目前公开的实施例中,当结合蛋白由免疫细胞(例如,T细胞、NK细胞或NK-T细胞)表达时,当存在包含SEQ ID NO:1的氨基酸7-16或8-16或由其组成的肽时,免疫细胞不产生或基本上不产生IFN-γ。
在任何目前公开的实施例中,(i)Vα结构域可包含根据SEQ ID NO:76、62、64、68、70、72、74、78、80、82、84、502、512、522、532、542、552、562、572、582、592、602或612中任一项所述的Vα氨基酸序列的CDR1α、CDR2α和/或CDR3α氨基酸序列;和/或(ii)Vβ结构域可包含根据SEQ ID NO:75、61、63、65、67、69、71、73、77、79、81、83、501、511、521、531、541、551、561、571、581、591、601或611中任一项所述的Vβ氨基酸序列的CDR1β、CDR2β和/或CDR3β氨基酸序列。TCR可变域序列可以与编号方案(例如Kabat、Chothia、EU、IMGT、Enhanced Chothia和Aho)进行比对,从而允许注释等效的残基位置并使用例如ANARCI软件工具比较不同的分子(2016,Bioinformatics 15:298-300)。
在某些实施例中,结合蛋白可以包含CDR1α、CDR2α、CDR3α和CDR1β、CDR2β和CDR3β氨基酸序列,其根据以下所列的Vα和Vβ氨基酸序列:(i)分别为SEQ ID NO:76和75;(ii)分别为SEQ ID NO:62和61;(iii)分别为SEQ ID NO:64和63;(iv)分别为SEQ ID NO:66和65;(v)分别为SEQ ID NO:68和67;(vi)分别为SEQ ID NO:70和69;(vii)分别为SEQ ID NO:72和71;(viii)分别为SEQ ID NO:74和73;(ix)分别为SEQ ID NO:78和77;(x)分别为SEQ IDNO:80和79;(xi)分别为SEQ ID NO:82和81;(xii)分别为SEQ ID NO:84和83;(xiii)分别为SEQ ID NO:522和521;(xiv)分别为SEQ ID NO:532和531;(xv)分别为SEQ ID NO:542和541;(xvi)分别为SEQ ID NO:552和551;(xvii)分别为SEQ ID NO:562和561;(xviii)分别为SEQ ID NO:572和571;(xix)分别为SEQ ID NO:582和581;(xx)分别为SEQ ID NO:592和591;(xxi)分别为SEQ ID NO:602和601;(xxii)分别为SEQ ID NO:612和611;(xxiii)分别为SEQ ID NO:502和501;(xxiv)分别为SEQ ID NO:512和511。
在特定实施方案中,结合蛋白包含:(i)SEQ ID NO:660、27、10、618、12、624、14、15、630、19、17、636、21、642、23、648、25、654、29、666、31、672、33、678、35、684、495、505、515、525、535、545、555、565、575、585、595、或605或其变体中任一项所示的CDR3α氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何一个或所有的可包含保守氨基酸取代;和/或(ii)SEQ ID NO:659、26、9、617、11、623、13、629、18、16、635、20、641、22、647、24、653、26、659、28、665、30、671、32、677、498、508、518、528、538、548、558、568、578、588、598或608或其变体中任一项所示的CDR3β氨基酸序列,其中变体包括一个、两个或三个氨基酸取代,其中任何或所有的可包含保守氨基酸取代;和/或(iii)SEQ ID NO:656、614、620、626、632、638、644、650、656、662、668、674、680、493、503、513、523、533、543、553、563、573、583、593、603或其变体中任一项所示的CDR1α氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何或所有的可包含保守氨基酸取代;和/或(iv)SEQ ID NO:655、613、619、625、631、637、643、649、661、667、673、679、496、506、516、526、536、546、556、566、576、586、596或606,或其变体中任一项所示的CDR1β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何或所有的可包含保守氨基酸取代;和/或(v)SEQ ID NO:658、616、622、628、634、640、646、652、664、670、676、682、494、504、514、524、534、544、554、564、574、584、594或604,或其变体中任一项所示的CDR2α氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何或所有可包含保守氨基酸取代;和/或(vi)SEQ ID NO:657、615、621、627、633、639、645、651、657、663、669、675、681、497、507、517、527、537、547、557、567、587、597、或607,或其变体中任一项所示的CDR2β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代,其中任何或所有的可包含保守氨基酸取代。
在一些实施方案中,结合蛋白包含(a)SEQ ID NO:19、35、10、12、14、15、17、21、23、25、27、29、31或33,或其变体中任一项的CDR3α氨基酸序列;(b)SEQ ID NO:18、34、9、11、13、16、18、20、22、24、26、28、30或32,或其变体中任一项的CDR3β氨基酸序列;或者(c)(a)和(b)。在一些实施方案中,结合蛋白包含(a)T细胞受体(TCR)α链可变(Vα)域和TCR Vβ结构域,其中,该T细胞受体(TCR)α链可变(Vα)域包含根据SEQ ID NO:19、35、10、12、14、15、17、21、23、25、27、29、31或33或其变体中任一项的CDR3氨基酸序列(CDR3α);或者(b)TCRVβ结构域和TCRVα结构域,其中TCRVβ结构域包含根据SEQ ID NO:18、34、9、11、13、16、18、20、22、24、26、28、30或32或其变体中任一项的CDR3氨基酸序列(CDR3β);或者(c)(a)的TCRVα结构域和(b)的TCRVβ结构域,其中编码的结合蛋白能够特异性结合KRAS肽:HLA复合物,其中KRAS肽包含或由以下组成:(i)氨基酸序列VVVGAVGVGK(SEQ ID NO:2)组成;或者(ii)氨基酸序列VVGAVGVGK(SEQ ID NO:3);或者(iii)氨基酸序列VVGADGVGK(SEQ ID NO:4);或者(viii)氨基酸序列VVVGADGVGK(SEQ ID NO:5)。
在进一步的实施例中,结合蛋白包含如下所列的CDR1α、CDR2α、CDR3α、CDR1β、CDR2β和CDR3β氨基酸序列:(i)SEQ ID NO:分别为656、658、660或27、655、657和659或26;(ii)SEQ ID NO:分别为614、616、618或10、613、615和617或9;(iii)SEQ ID NO:分别为620、622、624或12、619、621和629或13;(iv)SEQ ID NO:分别为626、628、630或14或15、625、627和629或13;(v)SEQ ID NO:分别为632、634、636或17或19、631、633和635或18或16;(vi)SEQ IDNO:分别为638、640、642或21或17、637、639和641或20或16;(vii)SEQ ID NO:分别为644、646、648或23、643、645和647或22;(viii)SEQ ID NO:分别为650、652、654或25、649、651和653或24;(ix)SEQ ID NO:分别为662、664、666或29、661、663和665或28;(x)SEQ ID NO:分别为668、670、672或31、667、669和671或30;(Xi)SEQ ID NO:分别为674、676、678或33、673、675和677或32;(Xii)SEQ ID NO:分别为680、682、684或35、679、681和683或34;(xiii)分别为SEQ ID NO:493-498;(xiv)分别为SEQ ID NO:503-508;(xv)分别为SEQ ID NO:513-518;(xvi)分别为SEQ ID NO:523-528;(xvii)分别为SEQ ID NO:533-538;(xviii)分别为SEQID NO:543-548;(xix)分别为SEQ ID NO:553-558;(xx)分别为SEQ ID NO:563-568;(xxi)分别为SEQ ID NO:573-578;(xxii)分别为SEQ ID NO:583-588;(xxii)分别为SEQ ID NO:593-598;或(xxiv)分别为SEQ ID NO:603-608。
在某些实施例中,(i)结合蛋白的Vα结构域包含与SEQ ID NO:76、62、64、68、70、72、74、78、80、82、84、502、512、522、532、542、552、562、572、582、592、602或612中的任一个所列氨基酸序列具有至少90%(即90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、99.5%或100%)同一性的氨基酸序列或由其组成;和/或(ii)Vβ结构域包含与SEQ IDNO:75、61、63、65、67、69、71、73、77、79、81、83、501、511、521、531、541、551、561、571、581、591、601或611中任一项所示的氨基酸序列具有至少90%同一性的氨基酸序列或由其组成。在某些实施例中,与本文提供的参考可变域氨基酸序列相比的变异限于一个或多个框架序列,并且任选地包含一个或多个保守取代或由其组成。在某些实施例中,结合蛋白包含与由本文表1中提供的TRBV、TRBD、TRBJ或TRAJ基因区段中的任一个编码的氨基酸序列具有至少90%同一性的氨基酸序列。由这些基因片段编码的氨基酸序列是已知的,可以使用例如IMGT数据库(imgt.org)访问。在某些实施方案中,(i)至少三个或四个CDR没有突变;(ii)确实有突变的CDR仅具有最多两个氨基酸取代、最多五个连续的氨基酸缺失或其组合;和(iii)编码的结合蛋白保留其结合肽:HLA-复合物的能力,其中肽:HLA-复合物包含根据SEQID NO:2-5中任一项的KRAS肽。
在特定实施例中,Vα结构域和Vβ结构域包含或由以下氨基酸序列组成:(i)分别为SEQ ID NO:76和75;(ii)分别为SEQ ID NO:62和61;(iii)分别为SEQ ID NO:64和63;(iv)分别为SEQ ID NO:66和65;(v)分别为SEQ ID NO:68和67;(vi)分别为SEQ ID NO:70和69;(vii)分别为SEQ ID NO:72和71;(viii)分别为SEQ ID NO:74和73;(ix)分别为SEQ ID NO:78和77;(x)分别为SEQ ID NO:80和79;(xi)分别为SEQ ID NO:82和81;(xii)分别为SEQ IDNO:84和83;(xiii)分别为SEQ ID NO:522和521;(xiv)分别为SEQ ID NO:532和531;(xv)分别为SEQ ID NO:542和541;(xvi)分别为SEQ ID NO:552和551;(xvii)分别为SEQ ID NO:562和561;(xviii)分别为SEQ ID NO:572和571;(xix)分别为SEQ ID NO:582和581;(xx)分别为SEQ ID NO:592和591;(xxi)分别为SEQ ID NO:602和601;(xxii)分别为SEQ ID NO:612和611;(xxiii)分别为SEQ ID NO:502和501;或(xix)分别为SEQ ID NO:512和511。
在任何目前公开的实施例中,结合蛋白还可包含TCRα链恒定域(Cα)和/或TCRβ链恒定域(Cβ)。在某些实施方案中,Cα包含与SEQ ID NO.:85或86中列出的氨基酸序列具有至少90%(即90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、99.5%或100%)同一性的氨基酸序列或由其组成。在某些实施例中,Cβ包含与SEQ ID NO.87-99中的任一列出的氨基酸序列具有至少90%同一性的氨基酸序列或由其组成。
在任何目前公开的实施例中,可以修改TCR恒定域以增强所需TCR链的配对。例如,由于修饰导致异源TCRα-链和异源TCRβ-链之间的宿主T细胞配对增强导致包含两条异源链TCR的优先组装,而不会异源TCR链与内源性TCR链的意外错配。(参见,例如,Govers etal.,Trends Mol.Med.16(2):77(2010),TCR修饰在此并入全文)。增强异源TCR链配对的示例性修饰包括在每个异源TCRα链和β链中引入互补的半胱氨酸残基。在一些实施例中,编码异源TCRα链的多核苷酸在氨基酸位置48(对应于全长、成熟的人类TCRα链序列)编码半胱氨酸,编码异源TCRβ链的多核苷酸在氨基酸位置57(对应于全长成熟人TCRβ链序列)编码半胱氨酸。
在特定实施例中,结合蛋白包含TCRα链和TCRβ链,其中TCRα链和TCRβ链包含氨基酸序列,所述氨基酸序列是与以下氨基酸序列具有至少90%同一性、包含以下氨基酸序列或由其组成:(i)分别为SEQ ID NO:115和114;(ii)分别为SEQ ID NO:101和100;(iii)分别为SEQ ID NO:103和102;(iv)分别为SEQ ID NO:105和104;(v)分别为SEQ ID NO:107和106;(vi)分别为SEQ ID NO:109和108;(vii)分别为SEQ ID NO:111和110;(viii)分别为SEQ ID NO:113和112;(ix)分别为SEQ ID NO:117和116;(x)分别为SEQ ID NO:119和118;(xi)分别为SEQ ID NO:121和120;或(xii)分别为SEQ ID NO:123和122。
在任何目前公开的实施方案中,结合蛋白可包含TCR、单链TCR(scTCR)或嵌合抗原受体(CAR)。
另一方面,提供了包含TCRVα结构域和TCRVβ结构域并且与KRAS肽:HLA复合物特异性结合的结合蛋白,其中KRAS肽包含SEQ ID NO:2-5中任一项所列的氨基酸序列或由其组成,并且其中所述和所述肽:HLA复合物包含HLA-A*03:01分子。在任何目前公开的实施方案中,结合蛋白可由人免疫系统细胞(例如T细胞)异源表达。在某些实施方案中,Vα结构域和/或Vβ结构域各自独立地是人的、人源化的或嵌合的,并且优选地各自是人。
在某些实施例中,(i)Vβ结构域包含来自D_3_4.3、D_3_4.6、D_3_4.9、D_3_1.7、D_3_2.10或D_3_3.6的CDR3氨基酸序列(CDR3β),和Vα结构域包含来自D_3_4.3、D_3_4.6、D_3_4.9、D_3_1.7、D_3_2.10或D_3_3.6的CDR3氨基酸序列(CDR3α);和/或(ii)结合域包含Vβ域和/或Vα域,其中Vβ域和/或Vα域分别与D_3_4.3、D_3_4.6、D_3_4.9、D_3_1.7、D_3_2.10或D_3_3.6的Vβ结构域或Vα结构域具有至少90%的同一性,前提是:(a)至少三个或四个CDR没有突变;(b)确实有突变的CDR仅具有最多两个氨基酸取代、最多五个连续的氨基酸缺失或其组合;和(c)结合蛋白保留其结合肽:HLA-A*03:01复合物的能力,该复合物包含根据SEQ IDNO:2-5中任一项的KRAS肽。在某些实施例中,结合域包含D_3_4.3、D_3_4.6、D_3_4.9、D_3_1.7、D_3_2.10或D_3_3.6的CDR1β,和CDR2β、CDR1α和/或CDR2α。在进一步的实施例中,结合域包括D_3_4.3、D_3_4.6、D_3_4.9、D_3_1.7、D_3_2.10或D_3_3.6的Vβ域和Vα域。
多核苷酸
在另一方面,本公开提供了编码任何一种或多种本公开的结合蛋白的分离的多核苷酸。
在某些实施例中,所述多核苷酸包含与如下的中的任一个所列的多核苷酸序列具有至少75%(即,在75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%)同一性的多核苷酸:SEQ IDNO.349、352、355、341、344、347、357、360、363、364、368、371、373、376、379、381、384、387、389、392、396、397、400、403、405、408、411、413、416、419、421、424、427、429、432、435、437、440、443、445、448、451、453、456、459、461、464、467、469、472、475、477、480、483、485、488、491、139、163、138、162、193、125、149、124、148、186、127、151、126、150、187、129、153、128、152、188、131、155、130、154、189、133、157、132、156、190、135、159、134、158、191、137、161、136、160、192、141、162、140、164、194、143、167、142、166、195、145、169、144、168、196、147、171、146、170、197、499、509、519、529、539、549、559、569、579、589、599或609或其任何组合。在某些实施方案中,多核苷酸包含具有SEQ ID NO:124-171中任一项中所列多核苷酸序列的至少75%的多核苷酸。在某些实施方案中,编码结合蛋白的多核苷酸包含(i)与SEQ IDNO:154中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:155中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(ii)与SEQ ID NO:170中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:171中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(iii)与SEQ ID NO:148中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:149中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(iv)与SEQ ID NO:150中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:151中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(v)与SEQ ID NO:152中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQID NO:153中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(vi)与SEQ ID NO:156中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:157中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(vii)与SEQ ID NO:158中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:159中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(viii)与SEQ ID NO:160中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:161中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(ix)与SEQ ID NO:162中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:163中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(x)与SEQ ID NO:164中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ IDNO:165中列出的多核苷酸序列具有至少75%同一性的多核苷酸;(xi)与SEQ ID NO:166中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:167中列出的多核苷酸序列具有至少75%同一性的多核苷酸;或者(xii)与SEQ ID NO:168中列出的多核苷酸序列具有至少75%同一性的多核苷酸,以及与SEQ ID NO:169中列出的多核苷酸序列具有至少75%同一性的多核苷酸。在一些实施例中,单个多核苷酸编码如本文所述的结合蛋白,或者,结合蛋白可以由多于一个多核苷酸编码。换言之,结合蛋白的组分或部分可由两个或更多个多核苷酸编码,其可包含在单个核酸分子中或可包含在两个或更多个核酸分子中。
还提供了一种分离的多核苷酸,其编码SEQ ID NO:356、348、364、372、380、388、396、404、412、420、428、436、444、452、460、468、476、484、492、500、510、520、530、540、550、560、570、580、590、600或610中的任一个氨基酸序列。在某些实施方案中,多核苷酸包含与SEQ ID NO.:355、347、363、371、379、387、395、403、411、419、427、435、443、451、459、467、475、483、491、186-197、499、509、519、529、539、549、559、569、579、589、599或609中任一个所示的多核苷酸序列具有至少75%(即,在75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%)同一性的多核苷酸。
在淋巴细胞发育过程中,Vα外显子由不同的可变和连接基因片段(V-J)组装而成,并且Vβ外显子由不同的可变、多样性和连接基因片段(V-D-J)组装而成。TCRα染色体基因座有70-80个可变基因片段和61个连接基因片段。TCRβ染色体基因座有52个可变基因片段,每个包含一个多样性基因片段的两个独立簇,以及六个或七个连接基因片段。功能性Vα和Vβ基因外显子是通过可变基因片段与Vα的连接基因片段、可变基因片段与多样性基因片段和Vβ的连接基因片段重组而产生的。
在某些实施方案中,编码结合蛋白的多核苷酸包含根据表1中所示的示例性结合蛋白中任一项的TRBV、TRBD、TRBJ、TRAV和/或TRAJ基因区段。
表1示例性结合蛋白的V-D-J基因使用
在某些实施例中,编码Vβ结构域的多核苷酸包含(i)TRBV25-01基因片段、TRBV12-04基因片段、TRBV28-01基因片段、TRBV09-01基因片段、TRBV11-02基因片段、TRBV07-09基因片段、TRBV10-01基因片段,或TRBV30-01基因片段;(ii)TRBD01-01基因片段、TRBD02-01基因片段或TRBD02-02基因片段;和(iii)TRBJ02-01基因片段、TRBJ01-06基因片段、TRBJ02-03基因片段、TRBJ02-07基因片段、TRBJ02-03基因片段、TRBJ02-04基因片段或TRBJ01-05基因片段。
在某些实施方案中,编码Vα结构域的多核苷酸包含:
(i)TRAV12-3基因片段、TRAV17基因片段、TRAV19基因片段、TRAV5基因片段、TRAV29DV05基因片段、TRAV2基因片段、TRAV26-1基因片段、TRAV1-1基因片段、TRAV27基因片段,或TRAV12-2基因片段;和(ii)TRAJ17基因片段、TRAJ45基因片段、TRAJ6基因片段、TRAJ13基因片段、TRAJ43基因片段、TRAJ30基因片段、TRAJ39基因片段、TRAJ12基因片段、TRAJ52基因片段。
在特定实施例中,(i)编码TCRVβ结构域的多核苷酸包含TRBV25-01基因片段、TRBD01-01基因片段或TRBD-02-01基因片段和TRBJ02-01基因片段;和(ii)编码TCRVα结构域的多核苷酸包含TRAV12-3基因片段和TRAJ17基因片段或TRAJ39基因片段。
在特定实施例中,(i)编码TCRVβ结构域的多核苷酸包含TRBV09-01基因片段、TRBD01-01基因片段或TRBD-02-01基因片段、TRBJ02-03基因片段或TRBJ02-07基因片段;和(ii)编码TCRVα结构域的多核苷酸包含TRAV17基因片段和TRAJ45基因片段或TRAJ13基因片段。
在任何目前公开的实施例中,编码结合蛋白的多核苷酸可进一步包含:(i)编码包含CD8共受体α链的胞外部分的多肽的多核苷酸,其中,任选地,编码的多肽是或包含CD8共受体α链;(ii)编码多肽的多核苷酸,所述多肽包含CD8共同受体β链的胞外部分,其中,任选地,所编码的多肽是或包含CD8共同受体β链;或者(iii)(i)的多核苷酸和(ii)的多核苷酸。不受理论束缚,在某些实施例中,与结合蛋白的单独表达相比,结合蛋白和具有结合HLA分子功能的CD8共受体蛋白或其部分的共表达或同时表达可以提高宿主细胞(例如,免疫细胞,例如T细胞,任选CD4+T细胞)的一种或多种所需活性。CD8共受体多肽的示例性氨基酸序列在SEQ ID NO:685-690中提供。将理解的是,编码结合蛋白的多核苷酸和编码CD8共受体多肽的多核苷酸可以存在于单个核酸分子上(例如,在同一表达载体中),或可以存在于宿主细胞中的不同核酸分子上。
在某些进一步的实施例中,多核苷酸包括:(a)编码包含CD8共受体α链的胞外部分的多肽的多核苷酸;(b)编码包含CD8共受体β链的胞外部分的多肽的多核苷酸;和(c)编码位于(a)的多核苷酸和(b)的多核苷酸之间的自切割肽的多核苷酸。在进一步的实施方案中,多核苷酸包含编码自切割肽且位于以下之间的多核苷酸:(1)编码结合蛋白的多核苷酸和编码包含CD8共受体α链胞外部分的多肽的多核苷酸;和/或(2)编码结合蛋白的多核苷酸和编码包含CD8共受体β链胞外部分的多肽的多核苷酸。
在更进一步的实施例中,多核苷酸可包含、可操作地框内连接:(i)(pnCD8α)-(pnSCP1)-(pnCD8β)-(pnSCP2)-(pnBP);(ii)(pnCD8β)-(pnSCP1)-(pnCD8α)-(pnSCP2)-(pnBP);(iii)(pnBP)-(pnSCP1)-(pnCD8α)-(pnSCP2)-(pnCD8β);(iv)(pnBP)-(pnSCP1)-(pnCD8β)-(pnSCP2)-(pnCD8α);(v)(pnCD8α)-(pnSCP1)-(pnBP)-(pnSCP2)-(pnCD8β);或者(vi)(pnCD8β)-(pnSCP1)-(pnBP)-(pnSCP2)-(pnCD8α),其中pnCD8α是编码包含CD8共受体α链的胞外部分的多肽的多核苷酸,其中pnCD8β是编码包含CD8共受体α链的胞外部分的多肽的多核苷酸,其中pnBP是编码结合蛋白的多核苷酸,并且其中pnSCP1和pnSCP2各自独立地是编码自切割肽的多核苷酸,其中多核苷酸和/或编码的自切割肽任选地相同或不同(例如,P2A、T2A、F2A、E2A;参见,例如,SEQ ID NO:172-185)。CD8共受体链的示例性多核苷酸序列在SEQ ID NO:691和692中提供。编码CD8共受体α链、自切割肽和CD8共受体β链的示例性多核苷酸序列在SEQ ID NO:693中提供。在一些实施方案中,本公开的多核苷酸包含与SEQ IDNO:691-693中任一项中列出的多核苷酸序列具有至少75%同一性的多核苷酸。
在某些实施例中,编码的结合蛋白包含TCRα链和TCRβ链,其中所述多核苷酸包含位于编码TCRα链的多核苷酸和编码TCRβ链的多核苷酸之间的编码自切割肽的多核苷酸。在进一步的实施方案中,多核苷酸包含可操作地框内连接的:(i)(pnCD8α)-(pnSCP1)-(pnCD8β)-(pnSCP2)-(pnTCRβ)-(pnSCP3)-(pnTCRα);(ii)(pnCD8β)-(pnSCP1)-(pnCD8α)-(pnSCP2)-(pnTCRβ)-(pnSCP3)-(pnTCRα);(iii)(pnCD8α)-(pnSCP1)-(pnCD8β)-(pnSCP2)-(pnTCRα)-(pnSCP3)-(pnTCRβ);(iv)(pnCD8β)-(pnSCP1)-(pnCD8α)-(pnSCP2)-(pnTCRα)-(pnSCP3)-(pnTCRβ);(v)(pnTCRβ)-(pnSCP1)-(pnTCRα)-(pnSCP2)-(pnCD8α)-(pnSCP3)-(pnCD8β);(vi)(pnTCRβ)-(pnSCP1)-(pnTCRα)-(pnSCP2)-(pnCD8β)-(pnSCP3)-(pnCD8α);(vii)(pnTCRα)-(pnSCP1)-(pnTCRβ)-(pnSCP2)-(pnCD8α)-(pnSCP3)-(pnCD8β);(viii)(pnTCRα)-(pnSCP1)-(pnTCRβ)-(pnSCP2)-(pnCD8β)-(pnSCP3)-(pnCD8α),其中pnCD8α是编码包含CD8共受体胞外部分的多肽的多核苷酸α链,
其中pnCD8β是编码包含CD8共受体α链的胞外部分的多肽的多核苷酸,其中pnTCRα是编码TCRα链的多核苷酸,其中pnTCRβ是编码TCRβ链的多核苷酸,其中pnSCP1、pnSCP2和pnSCP3各自独立地是编码自切割肽的多核苷酸,其中多核苷酸和/或编码的自切割肽任选地相同或不同。
在某些实施方案中,本公开内容的编码多肽包含一个或多个连接氨基酸。“连接氨基酸”或“连接氨基酸残基”是指多肽的两个相邻基序、区域或结构域之间的一个或多个(例如,2至约10个)氨基酸残基,例如在结合域和相邻的恒定域之间或在TCR链和相邻的自切割肽之间。连接氨基酸可源自编码融合蛋白(例如,在构建编码融合蛋白的核酸分子期间使用限制酶位点产生的氨基酸残基)的构建体的设计,或源自例如与本公开内容的编码结合蛋白(例如,位于TCRα链和TCRβ链之间的P2A肽,其自切割可在α链、TCRβ链或两者中留下一个或多个连接氨基酸)的一个或多个结构域相邻的自切割肽的切割。
在进一步的实施例中,结合蛋白表达为转基因构建体的一部分,其编码,和/或本公开的宿主细胞可以编码:一种或多种额外的辅助蛋白,例如安全开关蛋白;一个标签,一个选择标记;CD8共受体β链;CD8共受体α链或两者;或其任何组合。PCT申请PCT/US2017/053112中描述了用于编码和表达结合蛋白和辅助成分的多核苷酸和转基因构建体,多核苷酸、转基因构建体和辅助成分(例如,一种或多种安全开关蛋白、选择标记、CD8共同受体β链或CD8共同受体α链),包括核苷酸和氨基酸序列,其通过引用并入本文。将理解的是,本公开的任何或所有结合蛋白,安全开关蛋白、标签、选择标记、CD8共同受体β链或CD8共同受体α链可由单个核酸分子编码或可由多核苷酸序列编码,其中多核苷酸序列是或存在于单独的核酸分子。
示例性安全开关蛋白包括例如截短的EGF受体多肽(huEGFRt),其中截短的EGF受体多肽(huEGFRt)没有细胞外N端配体结合域和细胞内受体酪氨酸激酶活性,但保留其天然氨基酸序列,具有I型跨膜细胞表面定位,并具有用于药物级抗EGFR单克隆抗体的构象完整的结合表位抗体,西妥昔单抗(Erbitux)tEGF受体(tEGFr;Wang etal.,Blood 118:1255-1263,2011);半胱天冬酶多肽(例如,iCasp9;Straathof et al.,Blood105:4247-4254,2005;Di Stasi et al.,N.Engl.J.Med.365:1673-1683,2011;Zhou and Brenner,Exp.Hematol.pii:S0301-472X(16)30513-6.doi:10.1016/j.exphem.2016.07.011),RQR8(Philip et al.,Blood 124:1277-1287,2014);源自人c-myc蛋白质(Myc)的10氨基酸标记(Kieback et al.,Proc.Natl.Acad.Sci.USA 105:236-628,2008)和标记/安全开关多肽例如RQR(CD20+CD34;Philip et al.,2014)。
可用于本公开的修饰宿主细胞的其他辅助成分包括允许鉴定、分选、分离、富集或追踪细胞的标签或选择标记。例如,可以将具有所需特征(例如,抗原特异性TCR和安全开关蛋白)的标记宿主细胞与样品中的未标记细胞分选出来,并更有效地激活和扩增以包含在所需纯度的产品中。
如本文所用,术语“选择标记”包括核酸构建体(和编码的基因产物),其赋予细胞可识别的变化,以对使用包含选择标记的多核苷酸转导的免疫细胞进行允许检测和阳性选择。RQR是一种选择标记,其包含一个主要的CD20细胞外环和两个最小的CD34结合位点。在一些实施方案中,编码RQR的多核苷酸包含编码16-氨基酸的CD34最小表位的多核苷酸。在一些实施方案中,CD34最小表位并入CD8共受体茎结构域(Q8)的氨基末端位置。在进一步的实施方案中,CD34最小结合位点序列可以与CD20的靶表位组合以形成T细胞的紧密标记/自杀基因(RQR8)(Philip et al.,2014,通过引用并入本文)。该构建体允许选择表达构建体的宿主细胞,例如,CD34特异性抗体与磁珠(Miltenyi)结合,并利用临床接受的药物抗体利妥昔单抗,允许选择性删除表达转基因的工程T细胞(Philip et al.,2014)。
其他示例性选择标记还包括几种通常不在T细胞上表达的截短的I型跨膜蛋白:截短的低亲和力神经生长因子、截短的CD19和截短的CD34(例如,参见,Di Stasi et al.,N.Engl.J.Med.365:1673-1683,2011;Mavilio et al.,Blood 83:1988-1997,1994;Fehseet al.,Mol.Ther.1:448-456,2000;各自在此完整并入本文)。CD19和CD34的有用功能是现成的Miltenyi CliniMACsTM选择系统的可用性,该系统可以针对这些标志物进行临床级分类。然而,CD19和CD34是相对较大的表面蛋白,可能会影响整合载体的载体包装能力和转录效率。也可以使用包含细胞外、非信号结构域或各种蛋白质(例如,CD19、CD34、LNGFR)的表面标记。可以使用任何选择标记,并且应该是良好生产规范可接受的。在某些实施方案中,选择标记用编码感兴趣的基因产物(例如,本公开的结合蛋白,例如TCR或CAR)的多核苷酸表达。选择标记的其他实例包括,例如,报告基因,例如GFP、EGFP、β-gal或氯霉素乙酰转移酶(CAT)。在某些实施方案中,选择标记例如CD34由细胞表达并且CD34可用于选择富集或分离(例如,通过免疫磁性选择)感兴趣的转导细胞以用于本文所述的方法。如本文所用,CD34标记不同于抗CD34抗体,或例如scFv、TCR或结合CD34的其他抗原识别部分。
在某些实施例中,选择标记包括RQR多肽、截短的低亲和力神经生长因子(tNGFR)、截短的CD19(tCD19)、截短的CD34(tCD34)或其任何组合。
关于RQR多肽,不希望受理论束缚,据信距宿主细胞表面的距离对于RQR多肽作为选择标记/安全开关起作用是重要的(Philip et al.,2010(同上))。在一些实施方案中,编码的RQR多肽包含在编码的CD8共受体的β-链、α-链或两者,或任一者或两者的片段或变体中。在具体实施例中,修饰的宿主细胞包含编码iCasp9的异源多核苷酸和编码重组CD8共受体蛋白的异源多核苷酸,该蛋白包含含有RQR多肽的β链并进一步包含CD8α-链。
在一些实施方案中,编码的CD8共受体包括α-链或其片段或变体。人CD8共受体α链前体的氨基酸序列是已知的,并且提供于例如UniProtKB–P30433(另见UniProtKB–P31783;-P10732;和-P10731)。在一些实施方案中,编码的CD8共受体包括β-链或其片段或变体。人CD8共受体β链前体的氨基酸序列是已知的,例如在UniProtKB–P10966处提供(另见UniProtKB–Q9UQ56;-E9PD41;Q8TD28;和-P30434;和-P05541)。
本公开的分离的多核苷酸可以进一步包含编码如本文公开的安全开关蛋白、选择标记、CD8共同受体β链或CD8共同受体α链的多核苷酸,或可包含编码其任何组合的多核苷酸。
在任何目前公开的实施方案中,多核苷酸可以是密码子优化的以在宿主细胞中表达。在一些实施方案中,宿主细胞包括人免疫系统细胞,例如T细胞、NK细胞或NK-T细胞(Scholten et al.,Clin.Immunol.119:135,2006)。密码子优化可以使用已知的技术和工具进行,例如使用OptimumGeneTM工具或GeneArt(Life Technologies)。密码子优化的序列包括部分密码子优化(即,优化了一个或多个密码子以在宿主细胞中表达)的序列和完全密码子优化的序列。应当理解,在多核苷酸编码多于一种多肽(例如,TCRα链、TCRβ链、CD8共受体α链、CD8共受体β链和一种或多种自切割肽)的实施方案中,每个多肽可以独立地完全密码子优化、部分密码子优化或未密码子优化。
载体
在另一方面,本公开提供了一种表达载体,其包含与表达控制序列可操作地连接的如本文提供的任何多核苷酸。
本文还提供包含本公开内容的多核苷酸或转基因构建体的载体。载体的一些例子包括质粒、病毒载体、粘粒等。一些载体可能能够在它们被引入的宿主细胞中自主复制(例如,具有细菌复制起点的细菌载体和附加型哺乳动物载体),而其他载体可以整合到宿主细胞的基因组中,或在引入宿主细胞后促进多核苷酸插入物的整合,从而与宿主基因组一起复制(例如,慢病毒载体、逆转录病毒载体)。此外,一些载体能够指导与它们有效连接的基因的表达(这些载体可以称为“表达载体”)。根据相关实施例,还应理解,如果一种或多种药剂(例如,如本文所述的编码多肽的多核苷酸)被共同施用于受试者,则每种药剂可存在于单独或相同的载体中,以及多个载体(各自含有不同的药剂或相同的药剂)可被引入细胞或细胞群或施用于受试者。
在某些实施方案中,本公开的多核苷酸可以与载体的某些元件可操作地连接。例如,影响与其连接的编码序列的表达和加工所需的多核苷酸序列可以可操作地连接。表达控制序列可以包括适当的转录起始、终止、启动子和增强子序列;高效的RNA处理信号,如剪接和聚腺苷酸化信号;稳定细胞质mRNA的序列;提高翻译效率的序列(即Kozak共有序列);增强蛋白质稳定性的序列;以及可能增强蛋白质分泌的序列。如果表达控制序列与感兴趣的基因和在一定距离内进行转运以控制感兴趣的基因的表达控制序列连续,则它们可以可操作地连接。
在某些实施方案中,载体包括质粒载体或病毒载体(例如,选自慢病毒载体或γ-逆转录病毒载体的载体)。病毒载体包括逆转录病毒、腺病毒、细小病毒(例如,腺相关病毒)、冠状病毒、负链RNA病毒(如正粘病毒(例如流感病毒))、弹状病毒(例如,狂犬病和水泡性口炎病毒)、副粘病毒(例如,麻疹和仙台)、正链RNA病毒(如小核糖核酸病毒和甲病毒),以及双链DNA病毒(包括腺病毒、疱疹病毒(例如,单纯疱疹病毒1型和2型、爱泼斯坦-巴尔病毒、巨细胞病毒)和痘病毒(例如,牛痘、鸡痘和金丝雀痘))。例如,其他病毒包括诺沃克病毒、披膜病毒、黄病毒、呼肠孤病毒、乳多空病毒、肝炎病毒和肝炎病毒。逆转录病毒的实例包括禽白血病肉瘤、哺乳动物C型、B型病毒、D型病毒、HTLV-BLV组、慢病毒和泡沫病毒(Coffin,J.M.,Retroviridae:The viruses and their replication,In FundamentalVirology,Third Edition,B.N.Fields et al.,Eds.,Lippincott-Raven Publishers,Philadelphia,1996)。
“逆转录病毒”是具有RNA基因组的病毒,使用逆转录酶将其逆转录成DNA,然后将逆转录的DNA掺入宿主细胞基因组中。“逆转录病毒”是指逆转录病毒科的一个属。γ逆转录病毒的例子包括小鼠干细胞病毒、鼠白血病病毒、猫白血病病毒、猫肉瘤病毒和禽网状内皮增生病毒。如本文的“慢病毒载体”,是指用于基因递送的基于HIV的慢病毒载体,其可以是整合的或非整合的,具有较大的包装能力,并且可以转导一系列不同的细胞类型。慢病毒载体通常在三种(包装、包膜和转移)或更多质粒瞬时转染到生产细胞后产生。与HIV一样,慢病毒载体通过病毒表面糖蛋白与细胞表面受体的相互作用进入靶细胞。进入时,病毒RNA进行逆转录,这是由病毒逆转录酶复合物介导的。逆转录的产物是双链线性病毒DNA,它是病毒整合到受感染细胞DNA中的底物。
在某些实施方案中,病毒载体可以是γ逆转录病毒,例如莫洛尼鼠白血病病毒(MLV)衍生的载体。在其他实施方案中,病毒载体可以是更复杂的逆转录病毒衍生载体,例如慢病毒衍生载体。HIV-1衍生载体属于这一类。其他例子包括源自HIV-2、FIV、马传染性贫血病毒、SIV和Maedi-Visna病毒(绵羊慢病毒)的慢病毒载体。使用逆转录病毒和慢病毒载体和包装细胞通过含有TCR或CAR转基因的病毒颗粒来转导哺乳动物宿主细胞的方法是本领域已知的,并且之前已经描述过,例如,在:美国专利号8,119,772;Walchli et al.,PLoSOne 6:327930,2011;Zhao et al.,J.Immunol.174:4415,2005;Engels et al.,Hum.GeneTher.14:1155,2003;Frecha et al.,Mol.Ther.18:1748,2010;和Verhoeyen et al.,Methods Mol.Biol.506:97,2009。逆转录病毒和慢病毒载体构建体和表达系统也是可商购的。其他病毒载体也可用于多核苷酸递送,包括DNA病毒载体,包括例如基于腺病毒的载体和基于腺相关病毒(AAV)的载体;源自单纯疱疹病毒(HSV)的载体,包括扩增子载体、复制缺陷型HSV和减毒HSV((Krisky et al.,Gene Ther.5:1517,1998))。
开发用于基因治疗用途的其他载体也可以与本公开的组合物和方法一起使用。此类载体包括源自杆状病毒和α-病毒的载体。(Jolly,D J.1999.Emerging ViralVectors.pp 209-40 in Friedmann T.ed.The Development of Human Gene Therapy.NewYork:Cold Spring Harbor Lab),或质粒载体(如睡美人或其他转座子载体))。
当病毒载体基因组包含要在宿主细胞中作为单独转录本表达的多个多核苷酸时,病毒载体还可以在允许双顺反子或多顺反子表达的两个(或多个)转录物之间包含附加序列。用于病毒载体的此类序列的实例包括内部核糖体进入位点(IRES)、弗林蛋白酶切割位点、病毒2A肽或其任何组合。
在某些实施方案中,载体能够将多核苷酸或转基因构建体递送至宿主细胞(例如,造血祖细胞或人免疫系统细胞)。在具体实施方案中,载体能够将多核苷酸或转基因构建体递送至人免疫系统细胞,例如CD4+T细胞、CD8+T细胞、CD4-CD8-双阴性T细胞、干细胞记忆T细胞、γδT细胞、自然杀伤细胞、树突细胞或其任何组合。在进一步的实施方案中,载体能够将转基因构建体递送至幼稚T细胞、中央记忆T细胞、效应记忆T细胞或其任何组合。在一些实施例中,编码本公开的多核苷酸或转基因构建体的载体可以进一步包含编码核酸酶的多核苷酸,核酸酶可用于在宿主细胞中进行染色体敲除或可用于在基因治疗替代或基因修复治疗中将治疗性多核苷酸或转基因或其部分递送至宿主细胞(例如,如本文公开的CRISPR-Cas内切核酸酶或另一种内切核酸酶)。或者,用于染色体敲除或基因置换或基因修复疗法的核酸酶可以独立于编码本公开内容的多核苷酸或转基因构建体的载体递送至宿主细胞。
在某些实施方案中,载体能够将多核苷酸递送至宿主细胞。在进一步的实施方案中,宿主细胞是造血祖细胞或人免疫系统细胞。在更进一步的实施例中,人免疫系统细胞是CD4+T细胞、CD8+T细胞、CD4-CD8-双阴性T细胞、γδT细胞、自然杀伤细胞、自然杀伤T细胞、巨噬细胞、单核细胞、树突细胞或其任何组合。在更进一步的实施方案中,T细胞是幼稚T细胞、中央记忆T细胞、效应记忆T细胞或其任何组合。
在任何目前公开的实施方案中,载体是病毒载体。在某些实施方案中,病毒载体是慢病毒载体或γ-逆转录病毒载体。
宿主细胞
本文还提供了编码和/或表达结合蛋白(和任选地,一种或多种辅助蛋白,例如,如本文提供的转导标记物、CD8共受体多肽等)的宿主细胞。在某些实施例中,提供了宿主细胞,其被修饰以包含本公开的多核苷酸和/或表达载体,和/或表达本公开的结合蛋白。
可以修饰任何合适的宿主细胞以包括编码本公开内容的结合蛋白的异源多核苷酸,包括例如免疫细胞,例如T细胞、NK细胞或NK-T细胞。在一些实施方案中,修饰的免疫细胞包括CD4+T细胞、CD8+T细胞或两者。用所需核酸转染/转导T细胞的方法已被描述(例如,美国专利申请公布号US 2004/0087025)为具有使用所需靶标特异性T细胞的过继转移程序(例如,Schmitt et al.,Hum.Gen.20:1240,2009;Dossett et al.,Mol.Ther.17:742,2009;Till et al.,Blood 112:2261,2008;Wang et al.,Hum.Gene Ther.18:712,2007;Kuball et al.,Blood 109:2331,2007;US 2011/0243972;US 2011/0189141;Leen etal.,Ann.Rev.Immunol.25:243,2007),使得,基于本文的教导,可以考虑将这些方法适应当前公开的实施例。
可以使用任何合适的方法来转染或转导细胞(例如,T细胞),或施用本方法的多核苷酸或组合物。将多核苷酸递送至宿主细胞的已知方法包括例如使用阳离子聚合物、类脂分子和某些商业产品(例如,IN-VIVO-JET PEI)。其他方法包括离体转导、注射、电穿孔、DEAE-葡聚糖、超声加载、脂质体介导的转染、受体介导的转导、微粒轰击、转座子介导的转移等。转染或转导宿主细胞的更进一步的方法使用载体,本文进一步详细描述。
在某些实施方案中,修饰细胞包括造血祖细胞和/或人免疫细胞。在一些实施方案中,免疫细胞包括T细胞、NK细胞、NK-T细胞、树突细胞、巨噬细胞、单核细胞或其任何组合。在进一步的实施方案中,免疫细胞包括CD4+T细胞、CD8+T细胞、CD4-CD8-双阴性T细胞、γδT细胞或其任何组合。在某些进一步的实施方案中,免疫细胞包括CD4+T细胞和CD8+T细胞。在某些更进一步的实施方案中,CD4+T细胞、CD8+T细胞或两者都包含(i)编码多肽的多核苷酸,所述多肽包含CD8共同受体α链的胞外部分,其中,任选地,所编码的多肽是或包含CD8共同受体α链;(ii)编码多肽的多核苷酸,所述多肽包含CD8共同受体β链的胞外部分,其中,任选地,所编码的多肽是或包含CD8共同受体β链;或者(iii)(i)的多核苷酸和(ii)的多核苷酸。
在任何前述实施方案中,宿主细胞(例如,免疫细胞)可以被修饰以减少或消除一种或多种编码参与免疫信号传导或其他相关活性的多肽的内源基因的表达。示例性基因敲除包括编码PD-1、LAG-3、CTLA4、TIM3、TIGIT、FasL、HLA分子、TCR分子等的基因敲除。不希望被理论束缚,某些内源性表达的免疫细胞蛋白可能被接受修饰免疫细胞(例如,HLA等位基因)的同种异体宿主识别为外来的,这可能导致修饰免疫细胞的消除,或可能下调修饰免疫细胞(例如,PD-1、LAG-3、CTLA4、FasL、TIGIT、TIM3)的免疫活性,或可能干扰本公开的异源表达的结合蛋白的结合活性(例如,修饰的T细胞的内源性TCR结合非Ras抗原,从而干扰修饰的免疫细胞结合表达Ras抗原的细胞)。
因此,减少或消除此类内源基因或蛋白质的表达或活性可以提高修饰细胞在自体或同种异体宿主环境中的活性、耐受性或持久性,并且可以允许细胞的普遍施用(例如,对于任何接收者,无论HLA类型如何)。在某些实施方案中,修饰的细胞是供体细胞(例如,同种异体的)或自体细胞。在某些实施例中,本公开内容的修饰细胞包含编码PD-1、LAG-3、CTLA4、TIM3、TIGIT、FasL、HLA成分(例如,编码α1巨球蛋白、α2巨球蛋白、α3巨球蛋白、β1微球蛋白或β2微球蛋白的基因)或TCR成分(例如,编码TCR可变区或TCR恒定区的基因)中的一种或多种基因的染色体基因敲除(参见,例如Torikai et al.,Nature Sci.Rep.6:21757(2016);Torikai et al.,Blood119(24):5697(2012);and Torikai et al.,Blood 122(8):1341(2013),其基因编辑技术、组合物和过继细胞疗法通过引用整体并入本文)。
如本文所用,术语“染色体基因敲除”是指宿主细胞中的基因改变或引入抑制剂,其阻止(例如,减少、延迟、抑制或废除)宿主细胞产生功能活性内源多肽产物。导致染色体基因敲除的改变可以包括,例如,引入的无义突变(包括过早终止密码子的形成)、错义突变、基因缺失和链断裂,以及抑制宿主细胞中内源基因表达的抑制性核酸分子的异源表达。
在某些实施例中,染色体基因敲除或基因敲入是通过对宿主细胞进行染色体编辑而制成的。可以使用例如核酸内切酶进行染色体编辑。如本文所用,“核酸内切酶”是指能够催化切割多核苷酸链内的磷酸二酯键的酶。在某些实施方案中,核酸内切酶能够切割靶基因,从而灭活或“敲除”靶基因。核酸内切酶可以是天然存在的、重组的、遗传修饰的或融合核酸内切酶。由内切核酸酶引起的核酸链断裂通常通过同源重组或非同源末端连接(NHEJ)的不同机制进行修复。在同源重组期间,供体核酸分子可用于供体基因“敲入”、用于靶基因“敲除”,并且任选地通过供体基因敲入或靶基因敲除事件使靶基因失活。NHEJ是一种容易出错的修复过程,通常会导致切割位点的DNA序列发生变化,例如替换、删除或添加至少一个核苷酸。NHEJ可用于“敲除”目标基因。核酸内切酶的实例包括锌指核酸酶、TALE-核酸酶、CRISPR-Cas核酸酶、大范围核酸酶和megaTAL。
如本文所用,“锌指核酸酶”(ZFN)是指包含与非特异性DNA切割结构域融合的锌指DNA结合结构域的融合蛋白,例如Fokl核酸内切酶。每个约30个氨基酸的锌指基序与约3个DNA碱基对结合,并且可以改变某些残基的氨基酸以改变三联体序列的特异性(参见,例如Desjarlais et al.,Proc.Natl.Acad.Sci.90:2256-2260,1993;Wolfe et al.,J.Mol.Biol.285:1917-1934,1999)。多个锌指基序可串联连接以产生对所需DNA序列的结合特异性,例如长度范围为约9至约18个碱基对的区域。作为背景,ZFNs通过催化基因组中位点特异性DNA双链断裂(DSB)的形成来介导基因组编辑,同源定向修复促进了包含与DSB位点基因组同源的侧翼序列的转基因的靶向整合。或者,ZFN产生的DSB可以通过非同源末端连接(NHEJ)修复导致靶基因敲除,这是一种容易出错的细胞修复途径,其导致在切割位点插入或删除核苷酸。在某些实施方案中,基因敲除包括使用ZFN分子进行的插入、缺失、突变或其组合。
如本文所用,“转录激活因子样效应核酸酶”(TALEN)是指包含TALE DNA结合结构域和DNA切割结构域的融合蛋白,例如FokI核酸内切酶。“TALE DNA结合域”或“TALE”由一个或多个TALE重复域/单元组成,每个通常具有高度保守的33-35个氨基酸序列,其中第12个和第13个氨基酸不同。TALE重复结构域参与TALE与目标DNA序列的结合。不同的氨基酸残基,称为重复可变双残基(RVD),与特定的核苷酸识别相关。已经确定了这些TALEs的DNA识别的自然(典型)密码,使得TALE位置12和13处的HD(组氨酸-天冬氨酸)序列导致TALE与胞嘧啶(C)结合,NG(天冬酰胺-甘氨酸)与T核苷酸结合,NI(天冬酰胺-异亮氨酸)与A结合,NN(天冬酰胺-天冬酰胺)与G或A核苷酸结合,NG(天冬酰胺-甘氨酸)与T核苷酸结合。非典型(非典型)RVD也是已知的(参见,例如,美国专利公开号US 2011/0301073,该非典型RVD通过引用整体并入本文)。TALEN可用于指导T细胞基因组中的位点特异性双链断裂(DSB)。非同源末端连接(NHEJ)连接来自双链断裂两侧的DNA,其中几乎没有或没有序列重叠用于退火,从而引入了敲除基因表达的错误。或者,同源定向修复可以在DSB位点引入转基因,前提是转基因中存在同源侧翼序列。在某些实施方案中,基因敲除包括插入、缺失、突变或其组合,并且使用TALEN分子进行。
如本文所用,“成簇的规则间隔的短回文重复序列/Cas”(CRISPR/Cas)核酸酶系统是指系统,其采用CRISPR RNA(crRNA)引导的Cas核酸酶通过碱基配对互补性识别基因组(称为原型间隔器)内的靶位点,然后如果短的、保守的原型间隔区相关基序(PAM)紧跟在互补靶序列的3'端,则切割DNA。根据Cas核酸酶的序列和结构,CRISPR/Cas系统分为三种类型(即I型、II型和III型)。I型和III型中的crRNA引导的监视复合物需要多个Cas亚基。研究最多的II型系统至少包含三个组件:RNA引导的Cas9核酸酶、crRNA和反式作用crRNA(tracrRNA)。tracrRNA包含双链体形成区。crRNA和tracrRNA形成双链体,其能够与Cas9核酸酶相互作用,并通过crRNA上的间隔区和PAM上游的目标DNA上的原型间隔区之间的Watson-Crick碱基配对将Cas9/crRNA:tracrRNA复合物引导到目标DNA上的特定位点。Cas9核酸酶在由crRNA间隔区定义的区域内切割双链断裂。NHEJ修复会导致插入和/或缺失,从而破坏目标基因座的表达。或者,可以通过同源定向修复在DSB位点引入具有同源侧翼序列的转基因。crRNA和tracrRNA可以被设计成单个向导RNA(sgRNA或gRNA)(参见,例如Jineket al.,Science337:816-21,2012)。此外,可以改变或编程与靶位点互补的引导RNA区域以靶向所需序列(Xie et al.,PLOS One9:e100448,2014;美国专利申请公开号US 2014/0068797,美国专利申请公开号US 2014/0186843;美国专利号8,697,359,和PCT公开号WO2015/071474;每个都通过引用方式并入)。在某些实施方案中,基因敲除包括插入、缺失、突变或其组合,并且使用CRISPR/Cas核酸酶系统进行。
示例性gRNA序列和使用其敲除编码免疫细胞蛋白的内源基因的方法包括描述在Ren et al.,Clin.Cancer Res.23(9):2255-2266(2017)中的这些,gRNA、CAS9DNA、载体和基因敲除技术通过引用整体并入本文。
如本文所用,“大范围核酸酶”,也称为“归巢核酸内切酶”,是指以大识别位点(约12至约40个碱基对的双链DNA序列)为特征的脱氧核糖核酸内切酶。大范围核酸酶可根据序列和结构基序分为五个家族:LAGLIDADG、GIY-YIG、HNH、His-Cys盒和PD-(D/E)XK。示例性大范围核酸酶包括I-SceI、I-CeuI、PI-PspI、PI-Sce、I-SceIV、I-CsmI、I-PanI、I-SceII、I-PpoI、I-SceIII、I-CreI、I-TevI、I-TevII和I-TevIII,它们的识别序列是已知的(参见,例如,美国专利申请号5,420,032和6,833,252;Belfort et al.,Nucleic Acids Res.25:3379-3388,1997;Dujon et al.,Gene 82:115-118,1989;Perler et al.,Nucleic AcidsRes.22:1125-1127,1994;Jasin,Trends Genet.12:224-228,1996;Gimble et al.,J.Mol.Biol.263:163-180,1996;Argast et al.,J.Mol.Biol.280:345-353,1998)。
在某些实施例中,天然存在的大范围核酸酶可用于促进选自PD-1、LAG3、TIM3、CTLA4、TIGIT、FasL、HLA编码基因或TCR成分编码基因的靶标的位点特异性基因组修饰。在其他实施例中,对靶基因具有新结合特异性的工程化大范围核酸酶用于位点特异性基因组修饰(参见,例如Porteus et al.,Nat.Biotechnol.23:967-73,2005;Sussman et al.,J.Mol.Biol.342:31-41,2004;Epinat et al.,Nucleic Acids Res.31:2952-62,2003;Chevalier et al.,Molec.Cell 10:895-905,2002;Ashworth et al.,Nature 441:656-659,2006;Paques et al.,Curr.Gene Ther.7:49-66,2007;U.S.Patent PublicationNos.US 2007/0117128;US2006/0206949;US2006/0153826;US2006/0078552;和US 2004/0002092)。在进一步的实施例中,染色体基因敲除是使用归巢核酸内切酶产生的,该核酸内切酶已被TALEN的模块化DNA结合域修饰,以产生称为megaTAL的融合蛋白。MegaTALs不仅可用于敲除一个或多个靶基因,而且当与编码目标多肽的外源供体模板组合使用时,还可引入(敲入)异源或外源多核苷酸。
在某些实施例中,染色体基因敲除包含引入宿主细胞(例如,免疫细胞)的抑制性核酸分子,所述宿主细胞包含编码与肿瘤相关抗原特异性结合的抗原特异性受体的异源多核苷酸,其中抑制性核酸分子编码靶特异性抑制剂并且其中编码的靶特异性抑制剂抑制宿主细胞中的内源基因表达(例如,PD-1、TIM3、LAG3、CTLA4、TIGIT、FasL、HLA成分或TCR成分,或其任何组合)。
在使用敲除程序或试剂后,可以通过宿主免疫细胞的DNA测序直接确认染色体基因敲除。染色体基因敲除也可以从敲除后基因表达的缺失(例如,不存在基因编码的mRNA或多肽产物)来推断。
在某些实施方案中,染色体基因敲除包括选自α1巨球蛋白基因、α2巨球蛋白基因、α3巨球蛋白基因、β1微球蛋白基因或β2微球蛋白基因的HLA成分基因的基因敲除。
在某些实施方案中,染色体基因敲除包括选自TCRα可变区基因、TCRβ可变区基因、TCR恒定区基因或其组合的TCR组分基因的敲除。
宿主细胞组合物和单位剂量
在另一方面,本文提供了组合物和单位剂量,其包含本公开内容的修饰宿主细胞和药学上可接受的载体、稀释剂或赋形剂。
在某些实施例中,宿主细胞组合物或单位剂量包含(i)包含至少约30%、至少约40%、至少约50%、至少约60%、至少约70%、至少约80%、至少约85%、至少约90%,或至少约95%修饰的CD4+T细胞的组合物,以约1:1的比例结合(ii)包含至少约30%、至少约40%、至少约50%、至少约60%、至少约70%、至少约80%、至少约85%、至少约90%,或至少约95%修饰的CD8+T细胞的组合物,其中单位剂量含有减少量的或基本上不含幼稚T细胞(即,与具有相当数量的PBMC的患者样本相比,具有小于约50%、小于约40%、小于约30%、小于约20%、小于约10%、小于约5%或小于约1%的以单位剂量存在的幼稚T细胞群体)。
在一些实施例中,宿主细胞组合物或单位剂量包含(i)包含至少约50%修饰的CD4+T细胞的组合物,与约为1:1的比例结合(ii)包含至少约50%的改良CD8+T细胞的组合物,其中宿主细胞组合物或单位剂量含有减少量的或基本上不含幼稚T细胞。在进一步的实施例中,宿主细胞组合物或单位剂量包含(i)包含至少约60%修饰的CD4+T细胞的组合物,与约为1:1的比例结合(ii)包含至少约60%修饰的CD8+T细胞的组合物,其中单位剂量含有减少量的或基本上不含幼稚T细胞。在进一步的实施例中,宿主细胞组合物或单位剂量包含(i)包含至少约70%设计的CD4+T细胞的组合物,与约为1:1的比例结合(ii)包含至少约70%设计的CD8+T细胞的组合物,其中单位剂量含有减少量的或基本上不含幼稚T细胞。在一些实施例中,宿主细胞组合物或单位剂量包含(i)包含至少约80%修饰的CD4+T细胞的组合物,与约为1:1的比例结合(ii)包含至少约80%的修饰CD8+T细胞的组合物,其中宿主细胞组合物或单位剂量含有减少量的或基本上不含幼稚T细胞。在一些实施例中,宿主细胞组合物或单位剂量包含(i)包含至少约85%修饰的CD4+T细胞的组合物,与约为1:1的比例结合(ii)包含至少约85%的修饰CD8+T细胞的组合物,其中宿主细胞组合物或单位剂量含有减少量的或基本上不含幼稚T细胞。在一些实施例中,宿主细胞组合物或单位剂量包含(i)包含至少约90%修饰的CD4+T细胞的组合物,与约为1:1的比例结合(ii)包含至少约90%的修饰CD8+T细胞的组合物,其中宿主细胞组合物或单位剂量含有减少量的或基本上不含幼稚T细胞。
应理解,本公开的宿主细胞组合物或单位剂量可包含本文所述的任何宿主细胞,或宿主细胞的任何组合。在某些实施例中,例如,宿主细胞组合物或单位剂量包含修饰的CD8+T细胞、修饰的CD4+T细胞或两者,其中这些T细胞被修饰以编码对Ras肽:HLA-A*02:01复合物特异的结合蛋白,并且进一步包含修饰的CD8+T细胞、修饰的CD4+T细胞或两者,其中这些T细胞被修饰以编码对Ras肽:HLA-A*11:01复合物特异的结合蛋白。此外或可选地,本公开的宿主细胞组合物或单位剂量可包含如本文所述的任何宿主细胞或宿主细胞的组合,并且可进一步包含表达对不同抗原具有特异性的结合蛋白的修饰细胞(例如,免疫细胞,如T细胞)(例如,不同的Ras抗原,或来自不同蛋白质或靶标的抗原,例如,BCMA、CD3、CEACAM6、c-Met、EGFR、EGFRvIII、ErbB2、ErbB3、ErbB4、EphA2、IGF1R、GD2、O-乙酰基GD2、O-乙酰基GD3、GHRHR、GHR、FLT1、KDR、FLT4、CD44v6、CD151、CA125、CEA、CTLA-4、GITR、BTLA、TGFBR2、TGFBR1、IL6R、gp130、LewisA、LewisY、TNFR1、TNFR2、PD1、PD-L1、PD-L2、HVEM、MAGE-A(例如,包括MAGE-A1、MAGE-A3和MAGE-A4)、间皮素、NY-ESO-1、PSMA、RANK、ROR1、TNFRSF4、CD40、CD137、TWEAK-R、HLA、与HLA结合的肿瘤或病原体相关肽、与HLA结合的hTERT肽、与HLA结合的酪氨酸酶肽,结合HLA的WT-1肽、LTβR、LIFRβ、LRP5、MUC1、OSMRβ、TCRα、TCRβ、CD19、CD20、CD22、CD25、CD28、CD30、CD33、CD52、CD56、CD79a、CD79b、CD80、CD81、、CD123、CD171、CD276、B7H4、TLR7、TLR9、PTCH1、WT-1、HA1-H、Robo1、甲胎蛋白(AFP)、Frizzled、OX40、PRAME和SSX-2,或类似)。例如,单位剂量可包含表达特异性结合Ras-HLA复合物的结合蛋白的修饰CD8+T细胞和表达特异性结合PSMA抗原的结合蛋白(例如CAR)的修饰CD4+T细胞(和/或修饰的CD8+T细胞)。还应理解,本文公开的任何宿主细胞都可以在联合疗法中施用。
在本文所述的任何实施方案中,宿主细胞组合物或单位剂量包含相等或大致相等数量的工程化CD45RA-CD3+CD8+和修饰的CD45RA-CD3+CD4+TM细胞。
免疫原性肽
在另一方面,本公开提供了一种免疫原性多肽,其包含在SEQIDNO:198-201中的任何一个或多个中列出的氨基酸序列或由其组成。在某些实施方案中,多肽包含两个或更多个SEQIDNO:198-201。在某些实施方案中,免疫原性多肽包含在进一步包含药学上可接受的载体、赋形剂或稀释剂的组合物中。在进一步的实施方案中,组合物包含一种或多种额外的免疫原性多肽和/或佐剂。
用途
在其他方面,本公开提供了治疗或预防受试者中与KRAS G12D突变或KRAS G12V或NRAS G12D突变或NRAS G12V突变或HRAS G12V突变或HRAS G12D突变相关的疾病或病症复发的方法。此类疾病或病症包括例如癌症,例如实体癌和血液恶性肿瘤。在某些示例性实施例中,所述疾病或病症包括胰腺癌或癌,任选地胰腺导管腺癌(PDAC);结直肠癌或癌;肺癌,任选非小细胞肺癌;胆道癌;子宫内膜癌或癌;宫颈癌;卵巢癌;膀胱癌;肝癌;髓性白血病,可选的髓性白血病,例如急性髓性白血病;骨髓增生异常综合征;淋巴瘤,如非霍奇金淋巴瘤;慢性粒单核细胞白血病;急性淋巴细胞白血病(ALL);泌尿道癌;小肠癌;乳腺癌或癌;黑色素瘤(可选皮肤黑色素瘤、肛门黑色素瘤或粘膜黑色素瘤);胶质瘤;低分化甲状腺癌;神经母细胞瘤;组织细胞和树突细胞肿瘤;1型神经纤维瘤病;横纹肌肉瘤;软组织肉瘤;膀胱癌;肉瘤;胶质母细胞瘤;鳞状细胞肺癌;间变性星形细胞瘤;慢性粒细胞白血病;弥漫性大B细胞淋巴瘤;双重打击淋巴瘤;头颈癌;头颈部鳞状细胞癌;肝细胞癌;恶性周围神经鞘瘤;套细胞淋巴瘤;骨髓增生异常/骨髓增生性肿瘤,无法分类;外周T细胞淋巴瘤;前列腺癌;伴原始细胞过多的难治性贫血-2;肾细胞癌;横纹肌瘤;神经鞘瘤;继发性AML;小细胞肺癌;治疗相关的AML;胸腺癌;甲状腺滤泡癌;恶性甲状腺肿瘤;甲状腺癌;甲状腺腺癌;尿路上皮癌;或甲状腺乳头状癌。
“治疗”或“治疗”或“改善”是指对象(例如,人类或非人类哺乳动物,例如灵长类动物、马、猫、狗、山羊、小鼠或大鼠)的疾病、病症或病况的医学管理。一般而言,以足以引起治疗或预防益处的量施用包含本公开内容的组合物(例如,包含结合蛋白、多核苷酸、载体、宿主细胞、宿主细胞组合物、单位剂量和/或免疫原性多肽)的适当剂量或治疗方案。治疗性或预防性/预防性益处包括改善临床结果;减轻或减轻与疾病相关的症状;减少症状的发生;提高生活质量;更长的无病状态;疾病程度的减轻,疾病状态的稳定;延缓疾病进展;缓解;生存;延长生存期;或其任何组合。
如本文所用,“治疗有效量”或“有效量”,指足以产生包括改善的临床结果在内的治疗效果的组合物的量;减轻或减轻与疾病相关的症状;减少症状的发生;提高生活质量;更长的无病状态;疾病程度的减轻,疾病状态的稳定;延缓疾病进展;缓解;生存;或以统计学显着的方式延长生存期。当提及单独施用的单个活性成分或表达单一活性成分的细胞时,治疗有效量是指该成分或单独表达该成分的细胞的效果。当提及组合时,治疗有效量是指活性成分或组合的辅助活性成分与表达导致治疗效果的活性成分的细胞的组合量,无论是连续给药还是同时给药。组合也可以是表达多于一种活性成分的细胞。
术语“药学上可接受的赋形剂或载体”或“生理学上可接受的赋形剂或载体”是指生物相容的载体,例如生理盐水,其在本文中有更详细的描述,适合施用于人或其他非人哺乳动物受试者并且通常被认为是安全的或不会引起严重的不良事件。
如本文所用,“统计显着”是指使用学生t-test计算时的p值为0.050或更小,并表明所测量的特定事件或结果不太可能是偶然出现的。
本发明可以治疗的对象通常是人和其他灵长类对象,例如用于兽医目的的猴子和猿。在任何前述实施例中,受试者可以是人类受试者。受试者可以是男性或女性并且可以是任何合适的年龄,包括婴儿、少年、青少年、成人和老年受试者。根据本公开的组合物可以以适合于由医学领域技术人员确定的待治疗的疾病、病症或病症的方式施用。在上述任一实施例中,如本文所述的修饰的宿主细胞、宿主细胞组合物或单位剂量经静脉内、腹膜内、瘤内、骨髓、淋巴结或脑脊液施用,以便遇到靶细胞(例如,白血病细胞)。组合物的合适剂量、合适的持续时间和给药频率将取决于诸如患者状况等因素;疾病、病症或障碍的大小、类型和严重程度;活性成分的特定形式;和给药方法。
如本文所用,术语“过继免疫疗法”或“过继免疫疗法”是指施用天然存在的或基因工程的、疾病或抗原特异性免疫细胞(例如,T细胞)。过继细胞免疫疗法可以是自体的(免疫细胞来自受体)、同种异体的(免疫细胞来自同一物种的供体)或同基因的(免疫细胞来自与受体基因相同的供体)。
在一些实施例中,受试者表达包含或由SEQ ID NO:2-5和198-101中任一项所列的氨基酸序列组成的Rasantigen。
在一些实施方案中,受试者是HLA-A*11:01+;HLA-A*03:01+;或HLA-A*02:01+。
在某些实施方案中,方法包括在施用根据本公开的治疗之前确定受试者的一个或多个HLA类型和/或鉴定Ras抗原的存在。
在特定实施例中,一种方法包括给予(i)当受试者表达HLA-A*02:01时,包含修饰的CD8+和/或修饰的CD4+T细胞的组合物,所述修饰的CD8+和/或修饰的CD4+T细胞包含编码如本文提供的第一结合蛋白的异源多核苷酸;和/或(ii)当受试者表达HLA-A*11:01时,包含修饰的CD8+和/或修饰的CD4+T细胞的组合物,所述修饰的CD8+和/或修饰的CD4+T细胞包含编码如本文提供的第二结合蛋白的异源多核苷酸。在进一步的实施方案中,如果同时施用(i)的组合物和(ii)的组合物,则(i)的组合物和(ii)的组合物包含在相同的组合物中或作为单独的组合物施用。
在宿主细胞组合物或单位剂量的情况下,其中的细胞数量为至少一个细胞(例如,一种修饰的CD8+T细胞亚群(例如,可选地包含记忆和/或初始CD8+T细胞);一种修饰的CD4+T细胞亚群(例如,可选地包含记忆和/或初始CD4+T细胞))或更典型地大于102个细胞,例如最多104个、最多105个、最多106个、最多107个、最多108个、最多109个或超过1010个细胞。在某些实施例中,细胞以约104至约1010个细胞/m2的范围施用,优选在约105至约109个细胞/m2的范围内。在一些实施方案中,施用剂量包含高达约3.3x105个细胞/kg。在一些实施方案中,施用剂量包括高达约1×106个细胞/kg。在一些实施方案中,施用剂量包含高达约3.3x106个细胞/kg。在一些实施方案中,施用剂量包括高达约1×107个细胞/kg。在某些实施方案中,将修饰的免疫细胞以包含高达约5×104个细胞/kg、5×105个细胞/kg、5x106个细胞/kg或高达约5×107个细胞/kg。在某些实施例中,将修饰的免疫细胞以包含至少约5×104个细胞/kg、5×105个细胞/kg、5×106个细胞/kg或高达约5×107个细胞/kg的剂量施用于受试者。细胞的数量将取决于组合物的最终用途以及其中包含的细胞类型。例如,经修饰以含有结合蛋白的细胞将包含含有至少30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%或更多这样的细胞的细胞群。对于本文提供的用途,细胞的体积通常为一升或更少、500毫升或更少、250毫升或更少、或100毫升或更少。在实施例中,所需细胞的密度通常大于104个细胞/ml并且通常大于107个细胞/ml,通常为108个细胞/ml或更大。细胞可以作为单次输注或在一定时间范围内多次输注施用。临床相关数量的免疫细胞可以分配到累积等于或超过106、107、108、109、1010或1011个细胞的多次输注中。在某些实施例中,单位剂量的修饰免疫细胞可以与来自同种异体供体的造血干细胞共同给药(例如,同时或同时)。在一些实施方案中,单位剂量中包含的一种或多种修饰的免疫细胞对于受试者是自体的。
在一些实施方案中,接受修饰的免疫细胞的受试者之前已经接受过淋巴细胞清除化疗。在进一步的实施方案中,淋巴细胞清除化疗包括环磷酰胺、氟达拉滨、抗胸腺细胞球蛋白或其组合。
在一些实施方案中,该方法进一步包括向受试者施用如本文公开的免疫检查点分子的抑制剂。
还考虑了药物组合物(即,组合物),其包含如本文公开的组合物(结合蛋白、多核苷酸、载体、宿主细胞、宿主细胞组合物、单位剂量和/或免疫原性多肽)和药学上可接受的载体、稀释剂或赋形剂。合适的赋形剂包括水、盐水、葡萄糖、甘油等及其组合。在实施方案中,包含本文公开的融合蛋白或宿主细胞的组合物进一步包含合适的输注介质。合适的输注介质可以是任何等渗介质制剂,通常是生理盐水、Normosol R(Abbott)或Plasma-Lyte A(Baxter)、5%葡萄糖水溶液,可以使用林格乳酸盐。输注介质可以补充有人血清白蛋白或其他人血清成分。
如医学领域的技术人员所确定的,药物组合物可以以适合于待治疗(或预防)的疾病或病症的方式施用。组合物的合适剂量和合适的给药持续时间和频率将取决于以下因素:患者的健康状况、患者的体型(即重量、质量或身体面积)、患者状况的类型和严重程度、活性成分的特定形式、和给药方法。通常,合适的剂量和治疗方案以足以提供治疗和/或预防益处的量提供组合物(如本文所述,包括改善的临床结果,例如更频繁的完全或部分缓解,或更长的无病和/或总生存期,或症状严重程度的减轻)。
如本文所述,药物组合物的有效量是指在所需的剂量和时间段内足以实现期望的临床结果或有益治疗的量。可以在一次或多次给药中递送有效量。如果对已知或确认患有疾病或疾病状态的受试者给药,则术语“治疗量”可用于指代治疗,而“预防有效量”可用于描述将有效量施用于易感或有发展疾病或疾病状态(例如,复发)风险的受试者作为预防过程。
本文所述的药物组合物可以存在于单位剂量或多剂量容器中,例如密封的安瓿或小瓶。这种容器可以冷冻以保持制剂的稳定性直到输注到患者体内。剂量会有所不同,但用于施用如本文所述的经修饰的免疫细胞的优选剂量为约104个细胞/平方米、约5×104个细胞/平方米、约105个细胞/平方米、约5×105个细胞/平方米、约106个细胞/平方米、约5×106 个细胞/平方米,约107细胞/平方米,约5×107细胞/平方米,约108细胞/平方米,约5×108细胞/平方米,约109细胞/平方米,约5×109细胞/平方米,约1010细胞/平方米,约5×1010个细胞/平方米,或约1011个细胞/平方米。在某些实施方案中,单位剂量包含约104个细胞/平方米至约1011个细胞/平方米的剂量的如本文所述的修饰的免疫细胞。开发用于在各种治疗方案中使用本文所述的特定组合物的合适的给药和治疗方案,包括例如肠胃外或静脉内给药或制剂。
如果主题组合物肠胃外给药,则该组合物还可包括无菌水性或油性溶液或悬浮液。合适的无毒肠胃外可接受的稀释剂或溶剂包括水、林格氏溶液、等渗盐溶液、1,3-丁二醇、乙醇、丙二醇或与水混合的聚乙二醇。水溶液或悬浮液还可包含一种或多种缓冲剂,例如乙酸钠、柠檬酸钠、硼酸钠或酒石酸钠。当然,用于制备任何剂量单位制剂的任何材料应该是药学纯的并且在所使用的量中基本上是无毒的。此外,活性化合物可以加入缓释制剂和制剂中。如本文所用,剂量单位形式是指适合作为待治疗受试者的单位剂量的物理离散单位;每个单元可包含预定量的工程化免疫细胞或活性化合物,经计算可与适当的药物载体结合产生所需的效果。
通常,合适的剂量和治疗方案以足以提供益处的量提供活性分子或细胞。与未治疗的受试者相比,可以通过在治疗的受试者中建立改善的临床结果(例如,更频繁的缓解、完全或部分或更长的无病存活)来监测这种反应。对肿瘤蛋白的预先存在的免疫反应的增加通常与临床结果的改善相关。这种免疫反应通常可以使用标准的增殖、细胞毒性或细胞因子分析来评估,这些都是常规的。
预防性使用,剂量应足以预防、延迟与疾病或病症相关的疾病的发作或减轻其严重性。根据本文所述方法施用的免疫原性组合物的预防益处可以通过进行临床前(包括体外和体内动物研究)和临床研究并通过适当的统计、生物学和临床方法和技术分析从中获得的数据来确定,所有这些都可以由本领域技术人员容易地实践。
如本文所用,组合物的施用是指将其递送至受试者,而不管递送途径或方式。给药可以连续或间歇地进行,也可以胃肠外给药。给药可以用于治疗已经确认为具有公认病症、疾病或疾病状态的受试者,或用于治疗易患或有风险发展此类病症、疾病或疾病状态的受试者。与辅助疗法的共同给药可包括以任何顺序和以任何给药方案同时和/或顺序递送多种药剂(例如,具有一种或多种细胞因子的修饰免疫细胞;免疫抑制疗法,例如钙调神经磷酸酶抑制剂、皮质类固醇、微管抑制剂、低剂量的霉酚酸前药或其任何组合)。
在某些实施方案中,向受试者施用多剂量的本文所述组合物,其可以以约两周至约四周的施用间隔施用。
本公开的治疗或预防方法可以作为治疗过程或方案的一部分施用于受试者,其可包括在施用即刻公开的单位剂量、细胞或组合物之前或之后的额外治疗。例如,在某些实施方案中,接受单位剂量的修饰免疫细胞的受试者正在接受或之前接受过造血细胞移植(HCT;包括清髓性和非清髓性HCT)。进行HCT的技术和方案是本领域已知的并且可以包括移植任何合适的供体细胞,例如源自脐带血、骨髓或外周血的细胞、造血干细胞、动员的干细胞或来自羊水的细胞。因此,在某些实施方案中,本公开的修饰的免疫细胞可以在修饰的HCT疗法中与造血干细胞一起或在其之后不久施用。在一些实施方案中,HCT包含供体造血细胞,其包含编码HLA组分的基因的染色体敲除、编码TCR组分的基因的染色体敲除或两者。
在进一步的实施方案中,受试者在接受组合物或HCT之前先前已经接受了淋巴细胞清除化疗。在某些实施方案中,淋巴耗竭化疗包括包含环磷酰胺、氟达拉滨、抗胸腺细胞球蛋白或其组合的调理方案。
根据本公开的方法可以进一步包括施用一种或多种另外的药剂以在联合疗法中治疗疾病或病症。例如,在某些实施方案中,联合疗法包括将本公开的组合物与(同时、同时或依次)免疫检查点抑制剂一起施用。在一些实施方案中,联合疗法包括将本公开内容的组合物与刺激性免疫检查点试剂的激动剂一起施用。在进一步的实施方案中,联合疗法包括将本公开的组合物与二级疗法一起施用,例如化学治疗剂、放射疗法、手术、抗体或其任何组合。
如本文所用,术语“免疫抑制剂”或“免疫抑制剂”是指提供抑制信号以帮助控制或抑制免疫反应的一种或多种细胞、蛋白质、分子、化合物或复合物。例如,免疫抑制剂包括部分或完全阻断免疫刺激的那些分子;减少、阻止或延迟免疫激活;或增加、激活或上调免疫抑制。靶向(例如,使用免疫检查点抑制剂)的示例性免疫抑制剂包括PD-1、PD-L1、PD-L2、LAG3、CTLA4、B7-H3、B7-H4、CD244/2B4、HVEM、BTLA、CD160、TIM3、GAL9、KIR、PVR1G(CD112R)、PVRL2、腺苷、A2aR、免疫抑制性细胞因子(例如,IL-10、IL-4、IL-1RA、IL-35)、IDO、精氨酸酶、VISTA、TIGIT、LAIR1、CEACAM-1、CEACAM-3、CEACAM-5、Treg细胞或其任何组合。
免疫抑制剂抑制剂(也称为免疫检查点抑制剂)可以是化合物、抗体、抗体片段或融合多肽(例如Fc融合,如CTLA4-Fc或LAG3-Fc)、反义分子、核酶或RNAi分子,或低分子量有机分子。在本文公开的任何实施例中,一种方法可以包括本公开的组合物与一种或多种以下免疫抑制组分中的任何一种的抑制剂,单独或以任何组合。
在某些实施例中,本公开的组合物与PD-1抑制剂组合使用,例如PD-1特异性抗体或其结合片段,例如匹地珠单抗、纳武单抗、派姆单抗、MEDI0680(原AMP-514)、AMP-224、BMS-936558或其任意组合。在进一步的实施例中,本公开的组合物与PD-L1特异性抗体或其结合片段组合使用,例如BMS-936559、durvalumab(MEDI4736)、atezolizumab(RG7446)、avelumab(MSB0010718C)、MPDL3280A或其任何组合。还考虑的是cemiplimab;IBI-308;nivolumab+relatlimab;BCD-100;卡瑞珠单抗;JS-001;斯帕利珠单抗;替雷利珠单抗;AGEN-2034;BGBA-333+替雷利珠单抗;CBT-501;dostarlimab;durvalumab+MEDI-0680;JNJ-3283;盐酸帕唑帕尼+派姆单抗;匹地珠单抗;REGN-1979+cemiplimab;ABBV-181;ADUS-100+spartalizumab;AK-104;AK-105;AMP-224;BAT-1306;BI-754091;CC-90006;cemiplimab+REGN-3767;CS-1003;GLS-010;LZM-009;MEDI-5752;MGD-013;PF-06801591;Sym-021;替雷利珠单抗+帕米帕利;XmAb-20717;AK-112;ALPN-202;AM-0001;一种拮抗PD-1治疗阿尔茨海默病的抗体;BH-2922;BH-2941;BH-2950;BH-2954;拮抗CTLA-4和PD-1治疗实体瘤的生物制剂;靶向PD-1和LAG-3用于肿瘤学的双特异性单克隆抗体;BLSM-101;CB-201;CB-213;CBT-103;CBT-107;细胞免疫疗法+PD-1抑制剂;CX-188;HAB-21;HEISCOIII-003;IKT-202;JTX-4014;MCLA-134;MD-402;mDX-400;MGD-019;用于肿瘤学拮抗PDCD1的单克隆抗体;一种用于肿瘤学拮抗PD-1的单克隆抗体;一种抑制PD-1用于肿瘤学的溶瘤病毒;OT-2;PD-1拮抗剂+ropeginterferon alfa-2b;PEGMP-7;PRS-332;RXI-762;STIA-1110;TSR-075;一种针对HER2和PD-1用于肿瘤学的疫苗;一种针对PD-1治疗肿瘤和自身免疫性疾病的疫苗;XmAb-23104;一种用于肿瘤学抑制PD-1的反义寡核苷酸;AT-16201;一种用于肿瘤学抑制PD-1的双特异性单克隆抗体;IMM-1802;用于对抗实体瘤和血液肿瘤的PD-1和CTLA-4的单克隆抗体;纳武单抗生物仿制药;一种重组蛋白,用于激动CD278和CD28并拮抗PD-1,用于肿瘤学;一种在自身免疫性疾病和炎症性疾病中激动PD-1的重组蛋白;SNA-01;SSI-361;YBL-006;AK-103;JY-034;AUR-012;BGB-108;抑制实体瘤的PD-1、Gal-9和TIM-3的药物;ENUM-244C8;ENUM-388D4;MEDI-0680;用于对抗转移性黑色素瘤和转移性肺癌的PD-1的单克隆抗体;抑制肿瘤学PD-1的单克隆抗体;靶向CTLA-4和PD-1用于肿瘤学的单克隆抗体;一种用于拮抗NSCLC PD-1的单克隆抗体;用于肿瘤学抑制PD-1和TIM-3的单克隆抗体;抑制肿瘤学PD-1的单克隆抗体;一种抑制PD-1和VEGF-A的重组蛋白,用于治疗血液系统恶性肿瘤和实体瘤;一种对抗PD-1用于肿瘤学的小分子;Sym-016;inebilizumab+MEDI-0680;针对转移性黑色素瘤的PDL-1和IDO的疫苗;抗PD-1单克隆抗体加上胶质母细胞瘤的细胞免疫疗法;一种拮抗PD-1用于肿瘤学的抗体;抑制PD-1/PD-L1治疗血液系统恶性肿瘤和细菌感染的单克隆抗体;一种用于抑制HIV PD-1的单克隆抗体;或抑制实体瘤PD-1的小分子。
在某些实施例中,本公开的本公开的组合物与LAG3抑制剂例如LAG525、IMP321、IMP701、9H12、BMS-986016或其任意组合组合使用。
在某些实施方案中,本公开的组合物与CTLA4抑制剂组合使用。在特定实施例中,本公开的组合物与CTLA4特异性抗体或其结合片段组合使用,例如ipilimumab、tremelimumab、CTLA4-Ig融合蛋白(例如,abatacept、belatacept)或其任何组合。
在特定实施例中,在某些实施方案中,本公开的组合物与B7-H3特异性抗体或其结合片段组合使用,例如enoblituzumab(MGA271)、376.96或两者。B7-H4抗体结合片段可以是scFv或其融合蛋白,如Dangaj et al.,Cancer Res.73:4820,2013,还有在美国专利号9,574,000和PCT专利公开号WO/201640724A1和WO 2013/025779A1中描述的那些。
在某些实施方案中,本公开的组合物与CD244抑制剂组合使用。
在某些实施方案中,本公开的组合物与BLTA、HVEM、CD160或其任何组合的抑制剂组合使用。抗CD-160抗体描述于例如PCT公开号WO 2010/084158中。
在某些实施方案中,本公开细胞的组合物与TIM3抑制剂组合使用。
在某些实施方案中,本公开的组合物与Gal9抑制剂组合使用。
在某些实施方案中,本公开的组合物与腺苷信号传导抑制剂例如诱饵腺苷受体组合使用。
在某些实施方案中,本公开的组合物与A2aR抑制剂组合使用。
在某些实施方案中,本公开的组合物与KIR抑制剂例如lirilumab(BMS-986015)组合使用。
在某些实施例中,本公开内容的组合物与抑制性细胞因子(通常为除TGFβ之外的细胞因子)或Treg发育或活性的抑制剂组合使用。
在某些实施例中,本公开的组合物与IDO抑制剂组合使用,例如左旋-1-甲基色氨酸、依帕司他(INCB024360;Liu et al.,Blood 115:3520-30,2010)、依布硒啉(Terentiset al.,Biochem.49:591-600,2010)、吲哚昔莫德、NLG919(Mautino et al.,AmericanAssociation for Cancer Research 104th Annual Meeting 2013;Apr 6-10,2013)、1-甲基-色氨酸(1-MT)-tira-pazamine,或其任何组合。
在某些实施例中,本公开的组合物与精氨酸酶抑制剂组合使用,如N(omega)-硝基-L-精氨酸甲酯(L-NAME)、N-omega-羟基-nor-l-精氨酸(nor-NOHA)、L-NOHA、2(S)-amino-6-硼己酸(ABH)、S-(2-硼乙基)-L-半胱氨酸(BEC)或其任意组合。
在某些实施例中,本公开的组合物与VISTA抑制剂,例如CA-170(Curis,Lexington,Mass.)组合使用。
在某些实施例中,本公开的组合物与TIGIT抑制剂例如COM902(Compugen,Toronto,Ontario Canada)、CD155抑制剂例如COM701(Compugen)或两者组合使用。
在某些实施例中,本公开的组合物与PVRIG、PVRL2或两者的抑制剂组合使用。抗PVRIG抗体描述于例如PCT公开号WO 2016/134333中。抗-PVRL2抗体描述于例如PCT公开号WO 2017/021526中。
在某些实施方案中,本公开的组合物与LAIR1抑制剂组合使用。
在某些实施方案中,本公开的组合物与CEACAM-1、CEACAM-3、CEACAM-5或其任何组合的抑制剂组合使用。
在某些实施方案中,本公开的组合物与增加刺激性免疫检查点分子的活性(即,激动剂)的药剂组合使用。例如,本公开的组合物可以与CD137(4-1BB)激动剂(例如,urelumab)、CD134(OX-40)激动剂(例如,MEDI6469、MEDI6383或MEDI0562)、来那度胺、泊马度胺、CD27激动剂(例如,CDX-1127)、CD28激动剂(例如,TGN1412、CD80或CD86)、CD40激动剂(例如,CP-870,893、rhuCD40L或SGN-40)、CD122激动剂(例如,IL-2)、GITR激动剂(例如,PCT专利公开号WO 2016/054638中描述的人源化单克隆抗体)、ICOS(CD278)激动剂(例如,GSK3359609、mAb 88.2、JTX-2011、Icos 145-1、Icos 314-8或其任意组合)。在本文公开的任何实施例中,一种方法可以包括将本公开的组合物与一种或多种刺激性免疫检查点分子的激动剂一起给药,包括上述任何一种,单独或以任何组合。
在某些实施例中,组合疗法包含本公开的组合物和包含以下一种或多种的二级疗法:对由非炎症实体瘤、放射治疗、手术、化学治疗剂、细胞因子、RNAi或其任何组合表达的癌抗原具有特异性的抗体或其抗原结合片段。
在某些实施例中,联合治疗方法包括给予本公开的组合物并进一步给予放射治疗或手术。放射疗法在本领域中是众所周知的并且包括X射线疗法,例如γ-辐射和放射性药物疗法。适合治疗受试者的特定癌症的手术和手术技术是本领域普通技术人员众所周知的。
在某些实施方案中,联合治疗方法包括施用本公开的组合物并进一步施用化疗剂。化疗剂包括但不限于染色质功能抑制剂、拓扑异构酶抑制剂、微管抑制药、DNA损伤剂、抗代谢剂(如叶酸拮抗剂、嘧啶类似物、嘌呤类似物和糖修饰类似物)、DNA合成抑制剂、DNA相互作用剂(如嵌入剂)和DNA修复抑制剂。示例性化疗剂包括但不限于以下组:抗代谢物/抗癌剂,例如嘧啶类似物(5-氟尿嘧啶、氟尿苷、卡培他滨、吉西他滨和阿糖胞苷)和嘌呤类似物、叶酸拮抗剂和相关抑制剂(巯嘌呤、硫鸟嘌呤、喷司他丁和2-氯脱氧腺苷(克拉屈滨));抗增殖/抗有丝分裂剂,包括天然产物,如长春花生物碱(长春碱、长春新碱和长春瑞滨)、微管破坏剂如紫杉烷(紫杉醇、多西他赛)、长春新碱、长春花素、诺考达唑、埃坡霉素和navelbine、表鬼臼毒素(依托泊苷、替尼泊苷)、DNA损伤剂(放线菌素、安吖啶、蒽环类药物、博来霉素、白消安、喜树碱、卡铂、苯丁酸氮芥、顺铂、环磷酰胺、胞嘧啶、更生霉素、柔红霉素、多柔比星、表柔比星、六甲基三聚氰胺奥沙利铂、异磷酰胺原、三甲氨基甲酰胺脲、紫杉醇、泰索帝、替莫唑胺、替尼泊苷、三亚乙基硫代磷酰胺和依托泊苷(VP 16));抗生素如更生霉素(放线菌素D)、柔红霉素、多柔比星(阿霉素)、伊达比星、蒽环类、米托蒽醌、博来霉素、普卡霉素(光神霉素)和丝裂霉素;酶(L-天冬酰胺酶全身代谢L-天冬酰胺并剥夺没有能力合成自己天冬酰胺的细胞);抗血小板剂;抗增殖/抗有丝分裂烷化剂,例如氮芥(氯胺酮、环磷酰胺和类似物、美法仑、苯丁酸氮芥)、乙烯亚胺和甲基三聚氰胺(六甲基三聚氰胺和噻替哌)、烷基磺酸盐-白消安、亚硝基脲(卡莫司汀(BCNU)和类似物,链脲佐菌素)、茚-达卡巴嗪(DTIC);抗增殖/抗有丝分裂抗代谢物,如叶酸类似物(甲氨蝶呤);铂配位配合物(顺铂、卡铂)、丙卡巴肼、羟基脲、米托坦、氨基鲁米特;激素、激素类似物(雌激素、他莫昔芬、戈舍瑞林、比卡鲁胺、尼鲁米特)和芳香酶抑制剂(来曲唑、阿那曲唑);抗凝剂(肝素、合成肝素盐和其他凝血酶抑制剂);纤溶剂(如组织纤溶酶原激活剂、链激酶和尿激酶)、阿司匹林、双嘧达莫、噻氯匹定、氯吡格雷、阿昔单抗;抗迁移剂;抗分泌剂(breveldin);免疫抑制剂(环孢素、他克莫司(FK-506)、西罗莫司(雷帕霉素)、硫唑嘌呤、霉酚酸酯);抗血管生成化合物(TNP470、染料木黄酮)和生长因子抑制剂(血管内皮生长因子(VEGF)抑制剂、成纤维细胞生长因子(FGF)抑制剂);血管紧张素受体阻滞剂;一氧化氮供体;反义寡核苷酸;抗体(曲妥珠单抗、利妥昔单抗);嵌合抗原受体;细胞周期抑制剂和分化诱导剂(维甲酸);mTOR抑制剂、拓扑异构酶抑制剂(阿霉素(阿霉素)、安吖啶、喜树碱、柔红霉素、更生霉素、艾尼泊苷、表柔比星、依托泊苷、伊达比星、伊立替康(CPT-11)和米托蒽醌、拓扑替康、伊立替康)、皮质类固醇(可的松、地塞米松、氢化可的松、甲基潘尼松龙、泼尼松和泼尼松龙);生长因子信号转导激酶抑制剂;线粒体功能障碍诱导剂、霍乱毒素、蓖麻毒蛋白、假单胞菌外毒素、百日咳博德特氏菌腺苷酸环化酶毒素或白喉毒素等毒素和半胱天冬酶激活剂;和染色质干扰物。
细胞因子可用于操纵宿主对抗癌活性的免疫反应。参见,例如Floros&Tarhini,Semin.Oncol.42(4):539-548,2015。用于促进免疫抗癌或抗肿瘤反应的细胞因子包括,例如,IFN-α、IL-2、IL-3、IL-4、IL-10、IL-12、IL-13、IL-15、IL-16、IL-17、IL-18、IL-21、IL-24和GM-CSF,单独或与本公开的组合物的任何组合。
本文还提供了用于调节过继免疫疗法的方法,其中所述方法包括向受试者施用先前施用的修饰的宿主细胞,其中,受试者之前接受过本公开内容的修饰宿主细胞,其包含编码安全开关蛋白的异源多核苷酸、有效量的在受试者中消融的安全开关蛋白的同源化合物。
在某些实施例中,安全开关蛋白包含tEGFR并且关联化合物是西妥昔单抗,或者安全开关蛋白包含iCasp9并且关联化合物是AP1903(例如,二聚化AP1903),或安全开关蛋白包含RQR多肽并且同源化合物是利妥昔单抗,或者安全开关蛋白包含myc结合域并且同源化合物是对myc结合域特异的抗体。
在更进一步的方面,提供了用于制造本公开的组合物或单位剂量的方法。在某些实施例中,该方法包括将(i)用本公开的载体转导的宿主细胞的等分试样与(ii)药学上可接受的载体组合。在某些实施例中,本公开的载体用于转染/转导宿主细胞(例如,T细胞)以用于过继转移疗法(例如,靶向癌抗原)。
在一些实施例中,该方法进一步包括,在等分之前,培养转导的宿主细胞并选择已掺入(即表达)载体的转导细胞。在进一步的实施例中,该方法包括,在培养和选择之后和等分之前,扩增转导的宿主细胞。在本方法的任何实施例中,可以将制造的组合物或单位剂量冷冻以备后用。根据本发明的方法,任何合适的宿主细胞均可用于制造组合物或单位剂量,包括例如造血干细胞、T细胞、原代T细胞、T细胞系、NK细胞或NK-T细胞。在特定实施方案中,该方法包括宿主细胞,其为CD8+T细胞、CD4+T细胞或两者。
还提供了用于在受试者中诱导免疫应答的方法,该方法包括向受试者施用免疫原性多肽,该免疫原性多肽包含或由SEQ ID NO:198-201中任一项所列的氨基酸序列组成。
还提供了制备抗原脉冲的抗原呈递细胞的方法,所述方法包括:在足以发生抗原呈递细胞的抗原加工和呈递的条件和时间下在体外接触,(i)一群抗原呈递细胞,和(ii)本公开的Ras肽(例如,SEQ ID NO:198-201)或编码其的多核苷酸,从而获得能够引发针对Ras肽的抗原特异性T细胞反应的抗原脉冲抗原呈递细胞。在一些实施例中,该方法进一步包括在足以产生Ras肽特异性T细胞的条件和时间下将抗原脉冲的抗原呈递细胞与一种或多种免疫相容性T细胞接触。
还提供了任何结合蛋白、多核苷酸、表达载体、宿主细胞、宿主细胞组合物、单位剂量和免疫原性多肽,单独或以任何组合形式用于治疗与受试者的KRAS G12D突变或KRASG12V或NRAS G12D突变或NRAS G12V突变或HRAS G12V突变或HRAS G12D突变相关的疾病或病症。
还提供了任何结合蛋白、多核苷酸、表达载体、宿主细胞、宿主细胞组合物、单位剂量和免疫原性多肽,单独或以任何组合使用,用于制造用于治疗与受试者的KRAS G12D突变或KRAS G12V或NRAS G12D突变或NRAS G12V突变或HRAS G12V突变或HRAS G12D突变相关的疾病或障碍的药物。
在某些实施方案中,疾病或病症包括癌症。在一些实施方案中,癌症是实体癌或血液恶性肿瘤。在某些示例性实施例中,所述疾病或病症选自胰腺癌或癌,任选地胰腺导管腺癌(PDAC);结直肠癌或癌;肺癌,任选非小细胞肺癌;胆道癌;子宫内膜癌或癌;宫颈癌;卵巢癌;膀胱癌;肝癌;髓性白血病,可选的髓性白血病,例如急性髓性白血病;骨髓增生异常综合征;淋巴瘤,如非霍奇金淋巴瘤;慢性粒单核细胞白血病;急性淋巴细胞白血病(ALL);泌尿道癌;小肠癌;乳腺癌或癌;黑色素瘤(可选皮肤黑色素瘤、肛门黑色素瘤或粘膜黑色素瘤);胶质瘤;低分化甲状腺癌;神经母细胞瘤;组织细胞和树突细胞肿瘤;1型神经纤维瘤病;横纹肌肉瘤;软组织肉瘤;膀胱癌;肉瘤;胶质母细胞瘤;鳞状细胞肺癌;间变性星形细胞瘤;慢性粒细胞白血病;弥漫性大B细胞淋巴瘤;双重打击淋巴瘤;头颈癌;头颈部鳞状细胞癌;肝细胞癌;恶性周围神经鞘瘤;套细胞淋巴瘤;骨髓增生异常/骨髓增生性肿瘤,无法分类;外周T细胞淋巴瘤;前列腺癌;伴原始细胞过多的难治性贫血-2;肾细胞癌;横纹肌瘤;神经鞘瘤;继发性AML;小细胞肺癌;治疗相关的AML;胸腺癌;甲状腺滤泡癌;恶性甲状腺肿瘤;甲状腺癌;甲状腺腺癌;尿路上皮癌;或甲状腺乳头状癌。在一些实施例中,该方法包括受试者组合物的肠胃外或静脉内给药。在一些实施方案中,该方法包括向受试者施用多剂量的结合蛋白、多核苷酸、表达载体、宿主细胞、宿主细胞组合物、单位剂量和/或免疫原性多肽。
在某些实施方案中,以约两周至约四周的施用间隔施用多个剂量。
在某些实施方案中,组合物包含修饰的宿主细胞。在一些实施方案中,该方法包括以约104个细胞/kg至约1011个细胞/kg的剂量向受试者施用修饰的宿主细胞。
在特定实施例中,一种方法包括施用:(i)一组合物,其包含修饰的CD8+和/或修饰的CD4+T细胞,其包含编码根据权利要求1-26中任一项的结合蛋白的异源多核苷酸,当受试者表达HLA-A*02:01时;和/或(ii)一组合物,其包含修饰的CD8+和/或修饰的CD4+T细胞,其包含编码根据权利要求27-50中任一项的结合蛋白的异源多核苷酸,当受试者表达HLA-A*11:01时,其中如果同时施用(i)的组合物和(ii)的组合物,则(i)的组合物和(ii)的组合物包含在相同的组合物中或作为单独的组合物施用。
在某些实施方案中,其中该方法进一步包括向受试者施用细胞因子。在一些实施方案中,细胞因子包括IL-2、IL-15或IL-21。
在某些实施例中,受试者已经接受或正在接受免疫检查点抑制剂和/或刺激性免疫检查点试剂的激动剂。
示例
示例1
突变体KRAS:HLA-A*11:01特异性TCR的生成和表征
来自2个健康供体的T细胞系用混合的KRAS突变肽刺激3次,并在高尔基体抑制剂存在下与装载突变KRAS肽的抗原呈递细胞(APC)一起孵育4小时。通过流式细胞术测量细胞因子产生(IFN-γ和TNFα)。数据如图1所示。来自3个不同供体的30个HLA-A11/KRAS特异性T细胞系用100ng/ml的混合KRAS突变肽刺激16小时,然后汇集并根据CD137表达进行分类。数据如图2所示。对编码完整TCRβ链(Adaptive Biotechnologies,Seattle,WA)或配对的Vα和Vβ结构域(10x Genomics,Pleasanton,CA)的基因进行测序。
然后针对功能转导的宿主细胞测试TCR。用HLA-A11/KRAS特异性TCR转导表达Nur77-dtTomato报告基因(报告人类T细胞中抗原特异性信号;参见Ahsouri and Weiss,JImmunol 198(2):657-668(2017))的Jurkat细胞,并与装载有突变KRAS肽的APC孵育24小时。数据如图3所示,表明转导的细胞在载有抗原的APC存在下是有功能的。此外,如图4A和4B所示,用示例性TCR转导的T细胞识别不同的突变KRAS表位。
图5A-5D中提供了来自附加表征实验的数据;这些数据显示表达本公开的示例性TCR的原代CD8+T细胞在用抗原刺激后产生IFN-γ,并且具有高功能亲和力。
在表达抗原的肿瘤细胞系存在下测试TCR转导的T细胞的反应性。数据显示在图6A-7G中。当THP-1、Capan-2或GA-10.4细胞刺激时,几个TCR的CD137表达升高。
使用杀伤试验测试了TCR转导的T细胞杀伤肿瘤细胞系的能力。(外源表达抗原,或者在图8A中的721细胞的情况下,用抗原包被)数据显示在图8A-8D中。使用肿瘤细胞系进行额外的杀伤测定。如图21A-22B所示,TCR转导的T细胞有效杀死Panc-1、AsPc-1、CFPAC-1和/或Capan-2细胞。
示例2
突变体KRAS:HLA-A*03:01特异性TCR的生成和表征
使用NetMHC版本3.4(可在cbs.dtu.dk/services/NetMHC/在线获取)测量突变的KRAS G12V肽(10-mer(VVVGAVGVGK;SEQ ID NO:2);9-mer(VVGAVGVK;SEQ ID NO:3))对HLA-A*0301的预测HLA结合亲和力。结果如图9所示。在3轮肽刺激后,通过四聚体标记检测来自健康供体的HLA-A3/KRAS(G12V)特异性T细胞系(图10)。接下来,用肽刺激T细胞系并在CD137或四聚体上评分。
示例3
突变体KRAS:HLA-A*02:01特异性TCR的生成和表征
使用IEDB测量突变的KRAS G12V肽对HLA-A*02:01的预测HLA结合亲和力,并使用NetMHCpan、SYFPEITHI和BiMas(未显示)重复测量。IEDB预测的结果如图12所示。来自健康供体的T细胞系用肽抗原刺激并检查CD137表达(图13A和13B)。接着,测试T细胞响应肽抗原产生IFN-γ的能力。数据显示在图14A-14D中。示例性TCR的HLA和肽特异性通过四聚体标记实验(与标记四聚体结合时的平均荧光强度)以及相对亲和力读数和在不存在CD8的情况下与四聚体结合的能力来证实。四聚体标记MFI数据显示在图15A和15B中。细胞可以独立于CD8与四聚体结合,如图16所示的以下细胞计数数据所证明。
TCR转导的T细胞的功能亲合力和特异性在4小时试验中通过肽剂量反应进行测试。图17中的数据表明,与野生型肽相比,这些T细胞对突变KRAS肽具有高度特异性和反应性。图18A-18C中的数据显示了亲和力曲线证明T细胞在低肽刺激水平和高计算亲和力下产生IFN-γ。
通过与CFPAC-1胰腺肿瘤细胞孵育过夜并用CD137/41-BB抗体标记来测试了TCR转导的T细胞对内源性加工和呈递肽反应的能力。反应性如图19所示。
示例4
特异于突变KRAS:HLA-A*11:01的额外TCR的生成和表征
如实施例1中所述,对另外的A11/KRAS特异性供体T细胞系进行分选并且对TCR进行测序。如图23A和23B所示,TCR被转导到原代T细胞中,并测量CD137对抗原的表达。如图24A-26B所示,转导的T细胞响应肽抗原表达IFN-γ。包括来自实施例1的TCR13和20,以用于比较。
如图27A和27B所示,TCR转导的T细胞有效杀死表达KRAS突变肽的肿瘤细胞系。
如实施例1中所述,对另外的A11/KRAS特异性供体T细胞系进行分选并且对TCR进行测序。TCR被转导到原代T细胞中,并测量响应于抗原的CD137表达,如图28A和28B所示。如图29A所示,用这些TCR转导的T细胞响应突变的KRAS肽特异性地产生IFN-γ。测试了来自实施例1和4的A11/KRAS特异性TCR对肿瘤细胞系的杀伤活性。如图32A-32D所示,用这些TCR转导的T细胞对多种肿瘤细胞系具有杀伤活性。
可以组合上述各种实施例以提供进一步的实施例。本说明书中提及和/或申请数据表中列出的所有美国专利、美国专利申请出版物、美国专利申请、外国专利、外国专利申请和非专利出版物(包括于2019年2月20日提交的美国临时申请号62/808,248)的全部内容通过引用并入本文。如果需要采用各种专利、申请和出版物的概念来提供另外的实施例,则可以修改实施例的方面。
根据以上详细描述,可以对实施例进行这些和其他改变。通常,在以下权利要求中,所使用的术语不应被解释为将权利要求限于说明书和权利要求中公开的特定实施例,但应被解释为包括所有可能的实施例以及这些权利要求所授权的等效物的完整范围。因此,权利要求不受本公开的限制。
序列表
<110> 弗雷德哈钦森癌症研究中心
R·佩雷特
P·D·格林伯格
T·M·施米特
A·G·沙皮伊
I·M·斯特罗姆内斯
T·马丁诺夫
<120> RAS新抗原特异性结合蛋白及其用途
<130> 360056.469WO
<140> PCT
<141> 2020-02-19
<150> US 62/808,248
<151> 2019-02-20
<160> 693
<170> Windows版本4.0的FastSEQ
<210> 1
<211> 189
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 wt KRAS full (UniProt: P01116)
<400> 1
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1 5 10 15
Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
20 25 30
Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45
Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
50 55 60
Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80
Val Phe Ala Ile Asn Asn Thr Lys Ser Phe Glu Asp Ile His His Tyr
85 90 95
Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Glu Asp Val Pro Met Val
100 105 110
Leu Val Gly Asn Lys Cys Asp Leu Pro Ser Arg Thr Val Asp Thr Lys
115 120 125
Gln Ala Gln Asp Leu Ala Arg Ser Tyr Gly Ile Pro Phe Ile Glu Thr
130 135 140
Ser Ala Lys Thr Arg Gln Arg Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160
Arg Glu Ile Arg Gln Tyr Arg Leu Lys Lys Ile Ser Lys Glu Glu Lys
165 170 175
Thr Pro Gly Cys Val Lys Ile Lys Lys Cys Ile Ile Met
180 185
<210> 2
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 wt KRAS 7-16 G12V
<400> 2
Val Val Val Gly Ala Val Gly Val Gly Lys
1 5 10
<210> 3
<211> 9
<212> PRT
<213>人工序列
<220>
<223> 合成序列 wt KRAS 8-16 G12V
<400> 3
Val Val Gly Ala Val Gly Val Gly Lys
1 5
<210> 4
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 KRAS 7-16 G12D
<400> 4
Val Val Gly Ala Asp Gly Val Gly Lys
1 5
<210> 5
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 KRAS 8-16 G12D
<400> 5
Val Val Val Gly Ala Asp Gly Val Gly Lys
1 5 10
<210> 6
<211> 189
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 NRAS full (UniProt: P01111)
<400> 6
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1 5 10 15
Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
20 25 30
Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45
Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
50 55 60
Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80
Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
85 90 95
Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
100 105 110
Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
115 120 125
Gln Ala His Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
130 135 140
Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160
Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Ser Asp Asp
165 170 175
Gly Thr Gln Gly Cys Met Gly Leu Pro Cys Val Val Met
180 185
<210> 7
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 NRAS G12D (8-16)
<400> 7
Val Val Val Gly Ala Asp Gly Val Gly Lys
1 5 10
<210> 8
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 NRAS G12V (8-16)
<400> 8
Val Val Val Gly Ala Val Gly Val Gly Lys
1 5 10
<210> 9
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17_CDR3b
<400> 9
Cys Ala Ser Ser Leu Gly Ala Gly Gln His Asn Ser Pro Leu His Phe
1 5 10 15
<210> 10
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17_CDR3a
<400> 10
Cys Ala Leu Ser Glu Val His Ala Ser Gly Gly Ser Tyr Ile Pro Thr
1 5 10 15
Phe
<210> 11
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14_CDR3b
<400> 11
Cys Ala Ser Thr His Gly Arg Asp Ser Thr Asp Thr Gln Tyr Phe
1 5 10 15
<210> 12
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14_CDR3a
<400> 12
Cys Ala Thr Asp Glu Gly Gly Gly Ala Asp Gly Leu Thr Phe
1 5 10
<210> 13
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_CDR3b
<400> 13
Cys Ala Ser Ser Val Thr Trp Gly Pro Tyr Glu Gln Tyr Phe
1 5 10
<210> 14
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_CDR3a (1)
<400> 14
Cys Ala Thr Asp Glu Gly Gly Gly Ala Asp Gly Leu Thr Phe
1 5 10
<210> 15
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_CDR3a (2)
<400> 15
Cys Ala Glu Ser Pro Asn Ser Gly Gly Tyr Gln Lys Val Thr Phe
1 5 10 15
<210> 16
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 一致CDR3b (TCR 13/22)
<220>
<221> VARIANT
<222> 5
<223> Xaa = Glu or Gln
<400> 16
Cys Ala Ser Ser Xaa Gly Leu Tyr Asn Glu Gln Phe Phe
1 5 10
<210> 17
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 一致 CDR3a (TCR 13/22)
<220>
<221> VARIANT
<222> 6
<223> Xaa = Gly or Ser
<400> 17
Cys Ala Met Ser Ala Xaa Ala Ala Gly Asn Lys Leu Thr Phe
1 5 10
<210> 18
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR13_CDR3b
<400> 18
Cys Ala Ser Ser Glu Gly Leu Tyr Asn Glu Gln Phe Phe
1 5 10
<210> 19
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR13_CDR3a
<400> 19
Cys Ala Met Ser Ala Ser Ala Ala Gly Asn Lys Leu Thr Phe
1 5 10
<210> 20
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR22_CDR3b
<400> 20
Cys Ala Ser Ser Gln Gly Leu Tyr Asn Glu Gln Phe Phe
1 5 10
<210> 21
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR22_CDR3a
<400> 21
Cys Ala Met Ser Ala Gly Ala Ala Gly Asn Lys Leu Thr Phe
1 5 10
<210> 22
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19_CDR3b
<400> 22
Cys Ala Ser Ser Pro Thr Gly Gly Gly Met Leu Gly Gln Tyr Phe
1 5 10 15
<210> 23
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19_CDR3a
<400> 23
Cys Ala Ala Ser Ala Asn Asn Asn Asp Met Arg Phe
1 5 10
<210> 24
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16_CDR3b
<400> 24
Cys Ala Ser Ser Arg Leu Gly Pro Tyr Asn Glu Gln Phe Phe
1 5 10
<210> 25
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16_CDR3a
<400> 25
Cys Val Leu Asn Arg Asp Asp Lys Ile Ile Phe
1 5 10
<210> 26
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20_CDR3b
<400> 26
Cys Ala Ser Ser Pro Thr Phe Pro Ala Gly Asp Arg Asp Thr Gln Tyr
1 5 10 15
Phe
<210> 27
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20_CDR3a
<400> 27
Cys Ile Val Arg Leu Asn Ser Gly Asn Thr Pro Leu Val Phe
1 5 10
<210> 28
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21_CDR3b
<400> 28
Cys Ala Ser Ser Val Gly Leu Tyr Asn Glu Gln Phe Phe
1 5 10
<210> 29
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21_CDR3a
<400> 29
Cys Ala Met Ser Gly Gly Asn Ala Gly Asn Met Leu Thr Phe
1 5 10
<210> 30
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24_CDR3b
<400> 30
Cys Ala Ser Ser Pro Pro Gly Trp Glu Leu Ala Lys Asn Ile Gln Tyr
1 5 10 15
Phe
<210> 31
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24_CDR3a
<400> 31
Cys Ala Gly Gly Asp Ser Ser Tyr Lys Leu Ile Phe
1 5 10
<210> 32
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23_CDR3b
<400> 32
Cys Ala Ser Ser Glu Tyr Val Gly Ala His Glu Gln Tyr Phe
1 5 10
<210> 33
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23_CDR3a
<400> 33
Cys Ala Gly Val Arg Glu Ala Gly Gly Thr Ser Tyr Gly Lys Leu Thr
1 5 10 15
Phe
<210> 34
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15_CDR3b
<400> 34
Cys Ala Trp Thr Leu Thr Gly Phe Gly Gln Pro Gln His Phe
1 5 10
<210> 35
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15_CDR3a
<400> 35
Cys Ala Val Asn Ala Arg Gly Asn Met Leu Thr Phe
1 5 10
<210> 36
<211> 134
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17_Vb (具有前导序列)
<400> 36
Met Gly Ile Arg Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val
1 5 10 15
Gly Leu Val Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys
20 25 30
Arg Thr Gly Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His
35 40 45
Glu Asn Met Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu
50 55 60
Ile Tyr Phe Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro
65 70 75 80
Glu Gly Tyr Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile
85 90 95
Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser
100 105 110
Ser Leu Gly Ala Gly Gln His Asn Ser Pro Leu His Phe Gly Asn Gly
115 120 125
Thr Arg Leu Thr Val Thr
130
<210> 37
<211> 138
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17_Va (具有前导序列)
<400> 37
Met Leu Thr Ala Ser Leu Leu Arg Ala Val Ile Ala Ser Ile Cys Val
1 5 10 15
Val Ser Ser Met Ala Gln Lys Val Thr Gln Ala Gln Thr Glu Ile Ser
20 25 30
Val Val Glu Lys Glu Asp Val Thr Leu Asp Cys Val Tyr Glu Thr Arg
35 40 45
Asp Thr Thr Tyr Tyr Leu Phe Trp Tyr Lys Gln Pro Pro Ser Gly Glu
50 55 60
Leu Val Phe Leu Ile Arg Arg Asn Ser Phe Asp Glu Gln Asn Glu Ile
65 70 75 80
Ser Gly Arg Tyr Ser Trp Asn Phe Gln Lys Ser Thr Ser Ser Phe Asn
85 90 95
Phe Thr Ile Thr Ala Ser Gln Val Val Asp Ser Ala Val Tyr Phe Cys
100 105 110
Ala Leu Ser Glu Val His Ala Ser Gly Gly Ser Tyr Ile Pro Thr Phe
115 120 125
Gly Arg Gly Thr Ser Leu Ile Val His Pro
130 135
<210> 38
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14_Vb (具有前导序列)
<400> 38
Met Gly Phe Arg Leu Leu Cys Cys Val Ala Phe Cys Leu Leu Gly Ala
1 5 10 15
Gly Pro Val Asp Ser Gly Val Thr Gln Thr Pro Lys His Leu Ile Thr
20 25 30
Ala Thr Gly Gln Arg Val Thr Leu Arg Cys Ser Pro Arg Ser Gly Asp
35 40 45
Leu Ser Val Tyr Trp Tyr Gln Gln Ser Leu Asp Gln Gly Leu Gln Phe
50 55 60
Leu Ile Gln Tyr Tyr Asn Gly Glu Glu Arg Ala Lys Gly Asn Ile Leu
65 70 75 80
Glu Arg Phe Ser Ala Gln Gln Phe Pro Asp Leu His Ser Glu Leu Asn
85 90 95
Leu Ser Ser Leu Glu Leu Gly Asp Ser Ala Leu Tyr Phe Cys Ala Ser
100 105 110
Thr His Gly Arg Asp Ser Thr Asp Thr Gln Tyr Phe Gly Pro Gly Thr
115 120 125
Arg Leu Thr Val Leu
130
<210> 39
<211> 132
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14_Va (具有前导序列)
<400> 39
Met Glu Thr Leu Leu Gly Val Ser Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ala Arg Val Asn Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser
20 25 30
Ile Gln Glu Gly Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser
35 40 45
Ile Asn Asn Leu Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val
50 55 60
His Leu Ile Leu Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg
65 70 75 80
Leu Arg Val Thr Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile
85 90 95
Thr Ala Ser Arg Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp
100 105 110
Glu Gly Gly Gly Ala Asp Gly Leu Thr Phe Gly Lys Gly Thr His Leu
115 120 125
Ile Ile Gln Pro
130
<210> 40
<211> 132
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_Vb (具有前导序列)
<400> 40
Met Gly Phe Arg Leu Leu Cys Cys Val Ala Phe Cys Leu Leu Gly Ala
1 5 10 15
Gly Pro Val Asp Ser Gly Val Thr Gln Thr Pro Lys His Leu Ile Thr
20 25 30
Ala Thr Gly Gln Arg Val Thr Leu Arg Cys Ser Pro Arg Ser Gly Asp
35 40 45
Leu Ser Val Tyr Trp Tyr Gln Gln Ser Leu Asp Gln Gly Leu Gln Phe
50 55 60
Leu Ile Gln Tyr Tyr Asn Gly Glu Glu Arg Ala Lys Gly Asn Ile Leu
65 70 75 80
Glu Arg Phe Ser Ala Gln Gln Phe Pro Asp Leu His Ser Glu Leu Asn
85 90 95
Leu Ser Ser Leu Glu Leu Gly Asp Ser Ala Leu Tyr Phe Cys Ala Ser
100 105 110
Ser Val Thr Trp Gly Pro Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg
115 120 125
Leu Thr Val Thr
130
<210> 41
<211> 132
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_Va (具有前导序列)
<400> 41
Met Glu Thr Leu Leu Gly Val Ser Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ala Arg Val Asn Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser
20 25 30
Ile Gln Glu Gly Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser
35 40 45
Ile Asn Asn Leu Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val
50 55 60
His Leu Ile Leu Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg
65 70 75 80
Leu Arg Val Thr Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile
85 90 95
Thr Ala Ser Arg Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp
100 105 110
Glu Gly Gly Gly Ala Asp Gly Leu Thr Phe Gly Lys Gly Thr His Leu
115 120 125
Ile Ile Gln Pro
130
<210> 42
<211> 131
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR13_Vb (具有前导序列)
<400> 42
Met Thr Ile Arg Leu Leu Cys Tyr Met Gly Phe Tyr Phe Leu Gly Ala
1 5 10 15
Gly Leu Met Glu Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile
20 25 30
Gly Thr Gly Lys Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His
35 40 45
Asp Lys Met Tyr Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu
50 55 60
Ile His Tyr Ser Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser
65 70 75 80
Ser Glu Ser Thr Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr
85 90 95
Leu Glu Ser Ala Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser
100 105 110
Ser Glu Gly Leu Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu
115 120 125
Thr Val Leu
130
<210> 43
<211> 134
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR13_Va (具有前导序列)
<400> 43
Met Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ser Trp Val Trp Ser Gln Gln Lys Glu Val Glu Gln Asp Pro Gly Pro
20 25 30
Leu Ser Val Pro Glu Gly Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser
35 40 45
Asn Ser Ala Phe Gln Tyr Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys
50 55 60
Gly Pro Glu Leu Leu Met Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp
65 70 75 80
Gly Arg Phe Thr Ala Gln Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu
85 90 95
Phe Ile Arg Asp Ser Gln Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala
100 105 110
Met Ser Ala Ser Ala Ala Gly Asn Lys Leu Thr Phe Gly Gly Gly Thr
115 120 125
Arg Val Leu Val Lys Pro
130
<210> 44
<400> 44
000
<210> 45
<211> 131
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR22_Vb (具有前导序列)
<400> 45
Met Thr Ile Arg Leu Leu Cys Tyr Met Gly Phe Tyr Phe Leu Gly Ala
1 5 10 15
Gly Leu Met Glu Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile
20 25 30
Gly Thr Gly Lys Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His
35 40 45
Asp Lys Met Tyr Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu
50 55 60
Ile His Tyr Ser Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser
65 70 75 80
Ser Glu Ser Thr Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr
85 90 95
Leu Glu Ser Ala Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser
100 105 110
Ser Gln Gly Leu Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu
115 120 125
Thr Val Leu
130
<210> 46
<211> 134
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR22_Va (具有前导序列)
<400> 46
Met Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ser Trp Val Trp Ser Gln Gln Lys Glu Val Glu Gln Asp Pro Gly Pro
20 25 30
Leu Ser Val Pro Glu Gly Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser
35 40 45
Asn Ser Ala Phe Gln Tyr Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys
50 55 60
Gly Pro Glu Leu Leu Met Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp
65 70 75 80
Gly Arg Phe Thr Ala Gln Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu
85 90 95
Phe Ile Arg Asp Ser Gln Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala
100 105 110
Met Ser Ala Gly Ala Ala Gly Asn Lys Leu Thr Phe Gly Gly Gly Thr
115 120 125
Arg Val Leu Val Lys Pro
130
<210> 47
<211> 134
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19_Vb (具有前导序列)
<400> 47
Met Gly Ser Trp Thr Leu Cys Cys Val Ser Leu Cys Ile Leu Val Ala
1 5 10 15
Lys His Thr Asp Ala Gly Val Ile Gln Ser Pro Arg His Glu Val Thr
20 25 30
Glu Met Gly Gln Glu Val Thr Leu Arg Cys Lys Pro Ile Ser Gly His
35 40 45
Asp Tyr Leu Phe Trp Tyr Arg Gln Thr Met Met Arg Gly Leu Glu Leu
50 55 60
Leu Ile Tyr Phe Asn Asn Asn Val Pro Ile Asp Asp Ser Gly Met Pro
65 70 75 80
Glu Asp Arg Phe Ser Ala Lys Met Pro Asn Ala Ser Phe Ser Thr Leu
85 90 95
Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Phe Cys Ala
100 105 110
Ser Ser Pro Thr Gly Gly Gly Met Leu Gly Gln Tyr Phe Gly Pro Gly
115 120 125
Thr Arg Leu Thr Val Leu
130
<210> 48
<211> 137
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19_Va (具有前导序列)
<400> 48
Met Ala Met Leu Leu Gly Ala Ser Val Leu Ile Leu Trp Leu Gln Pro
1 5 10 15
Asp Trp Val Asn Ser Gln Gln Lys Asn Asp Asp Gln Gln Val Lys Gln
20 25 30
Asn Ser Pro Ser Leu Ser Val Gln Glu Gly Arg Ile Ser Ile Leu Asn
35 40 45
Cys Asp Tyr Thr Asn Ser Met Phe Asp Tyr Phe Leu Trp Tyr Lys Lys
50 55 60
Tyr Pro Ala Glu Gly Pro Thr Phe Leu Ile Ser Ile Ser Ser Ile Lys
65 70 75 80
Asp Lys Asn Glu Asp Gly Arg Phe Thr Val Phe Leu Asn Lys Ser Ala
85 90 95
Lys His Leu Ser Leu His Ile Val Pro Ser Gln Pro Gly Asp Ser Ala
100 105 110
Val Tyr Phe Cys Ala Ala Ser Ala Asn Asn Asn Asp Met Arg Phe Gly
115 120 125
Ala Gly Thr Arg Leu Thr Val Lys Pro
130 135
<210> 49
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16_Vb (具有前导序列)
<400> 49
Met Gly Ser Trp Thr Leu Cys Cys Val Ser Leu Cys Ile Leu Val Ala
1 5 10 15
Lys His Thr Asp Ala Gly Val Ile Gln Ser Pro Arg His Glu Val Thr
20 25 30
Glu Met Gly Gln Glu Val Thr Leu Arg Cys Lys Pro Ile Ser Gly His
35 40 45
Asp Tyr Leu Phe Trp Tyr Arg Gln Thr Met Met Arg Gly Leu Glu Leu
50 55 60
Leu Ile Tyr Phe Asn Asn Asn Val Pro Ile Asp Asp Ser Gly Met Pro
65 70 75 80
Glu Asp Arg Phe Ser Ala Lys Met Pro Asn Ala Ser Phe Ser Thr Leu
85 90 95
Lys Ile Gln Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Phe Cys Ala
100 105 110
Ser Ser Arg Leu Gly Pro Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr
115 120 125
Arg Leu Thr Val Leu
130
<210> 50
<211> 129
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16_Va (具有前导序列)
<400> 50
Met Ala Leu Gln Ser Thr Leu Gly Ala Val Trp Leu Gly Leu Leu Leu
1 5 10 15
Asn Ser Leu Trp Lys Val Ala Glu Ser Lys Asp Gln Val Phe Gln Pro
20 25 30
Ser Thr Val Ala Ser Ser Glu Gly Ala Val Val Glu Ile Phe Cys Asn
35 40 45
His Ser Val Ser Asn Ala Tyr Asn Phe Phe Trp Tyr Leu His Phe Pro
50 55 60
Gly Cys Ala Pro Arg Leu Leu Val Lys Gly Ser Lys Pro Ser Gln Gln
65 70 75 80
Gly Arg Tyr Asn Met Thr Tyr Glu Arg Phe Ser Ser Ser Leu Leu Ile
85 90 95
Leu Gln Val Arg Glu Ala Asp Ala Ala Val Tyr Tyr Cys Val Leu Asn
100 105 110
Arg Asp Asp Lys Ile Ile Phe Gly Lys Gly Thr Arg Leu His Ile Leu
115 120 125
Pro
<210> 51
<211> 137
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20_Vb (具有前导序列)
<400> 51
Met Gly Thr Arg Leu Leu Cys Trp Ala Ala Leu Cys Leu Leu Gly Ala
1 5 10 15
Glu Leu Leu Thr Glu Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile
20 25 30
Ile Glu Lys Arg Gln Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly
35 40 45
His Ala Thr Leu Tyr Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys
50 55 60
Leu Leu Ile Gln Phe Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu
65 70 75 80
Pro Lys Asp Arg Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr
85 90 95
Leu Lys Ile Gln Pro Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys
100 105 110
Ala Ser Ser Pro Thr Phe Pro Ala Gly Asp Arg Asp Thr Gln Tyr Phe
115 120 125
Gly Pro Gly Thr Arg Leu Thr Val Leu
130 135
<210> 52
<211> 128
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20_Va (具有前导序列)
<400> 52
Met Arg Leu Val Ala Arg Val Thr Val Phe Leu Thr Phe Gly Thr Ile
1 5 10 15
Ile Asp Ala Lys Thr Thr Gln Pro Pro Ser Met Asp Cys Ala Glu Gly
20 25 30
Arg Ala Ala Asn Leu Pro Cys Asn His Ser Thr Ile Ser Gly Asn Glu
35 40 45
Tyr Val Tyr Trp Tyr Arg Gln Ile His Ser Gln Gly Pro Gln Tyr Ile
50 55 60
Ile His Gly Leu Lys Asn Asn Glu Thr Asn Glu Met Ala Ser Leu Ile
65 70 75 80
Ile Thr Glu Asp Arg Lys Ser Ser Thr Leu Ile Leu Pro His Ala Thr
85 90 95
Leu Arg Asp Thr Ala Val Tyr Tyr Cys Ile Val Arg Leu Asn Ser Gly
100 105 110
Asn Thr Pro Leu Val Phe Gly Lys Gly Thr Arg Leu Ser Val Ile Ala
115 120 125
<210> 53
<211> 131
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21_Vb (具有前导序列)
<400> 53
Met Thr Ile Arg Leu Leu Cys Tyr Met Gly Phe Tyr Phe Leu Gly Ala
1 5 10 15
Gly Leu Met Glu Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile
20 25 30
Gly Thr Gly Lys Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His
35 40 45
Asp Lys Met Tyr Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu
50 55 60
Ile His Tyr Ser Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser
65 70 75 80
Ser Glu Ser Thr Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr
85 90 95
Leu Glu Ser Ala Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser
100 105 110
Ser Val Gly Leu Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu
115 120 125
Thr Val Leu
130
<210> 54
<211> 134
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21_Va (具有前导序列)
<400> 54
Met Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ser Trp Val Trp Ser Gln Gln Lys Glu Val Glu Gln Asp Pro Gly Pro
20 25 30
Leu Ser Val Pro Glu Gly Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser
35 40 45
Asn Ser Ala Phe Gln Tyr Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys
50 55 60
Gly Pro Glu Leu Leu Met Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp
65 70 75 80
Gly Arg Phe Thr Ala Gln Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu
85 90 95
Phe Ile Arg Asp Ser Gln Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala
100 105 110
Met Ser Gly Gly Asn Ala Gly Asn Met Leu Thr Phe Gly Gly Gly Thr
115 120 125
Arg Leu Met Val Lys Pro
130
<210> 55
<211> 136
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24_Vb (具有前导序列)
<400> 55
Met Gly Thr Ser Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala
1 5 10 15
Asp His Ala Asp Thr Gly Val Ser Gln Asn Pro Arg His Lys Ile Thr
20 25 30
Lys Arg Gly Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His
35 40 45
Asn Arg Leu Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe
50 55 60
Leu Thr Tyr Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu
65 70 75 80
Ser Asp Arg Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu
85 90 95
Glu Ile Gln Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala
100 105 110
Ser Ser Pro Pro Gly Trp Glu Leu Ala Lys Asn Ile Gln Tyr Phe Gly
115 120 125
Ala Gly Thr Arg Leu Ser Val Leu
130 135
<210> 56
<211> 126
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24_Va (具有前导序列)
<400> 56
Met Trp Gly Ala Phe Leu Leu Tyr Val Ser Met Lys Met Gly Gly Thr
1 5 10 15
Ala Gly Gln Ser Leu Glu Gln Pro Ser Glu Val Thr Ala Val Glu Gly
20 25 30
Ala Ile Val Gln Ile Asn Cys Thr Tyr Gln Thr Ser Gly Phe Tyr Gly
35 40 45
Leu Ser Trp Tyr Gln Gln His Asp Gly Gly Ala Pro Thr Phe Leu Ser
50 55 60
Tyr Asn Ala Leu Asp Gly Leu Glu Glu Thr Gly Arg Phe Ser Ser Phe
65 70 75 80
Leu Ser Arg Ser Asp Ser Tyr Gly Tyr Leu Leu Leu Gln Glu Leu Gln
85 90 95
Met Lys Asp Ser Ala Ser Tyr Phe Cys Ala Gly Gly Asp Ser Ser Tyr
100 105 110
Lys Leu Ile Phe Gly Ser Gly Thr Arg Leu Leu Val Arg Pro
115 120 125
<210> 57
<211> 132
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23_Vb (具有前导序列)
<400> 57
Met Gly Thr Arg Leu Phe Phe Tyr Val Ala Leu Cys Leu Leu Trp Ala
1 5 10 15
Gly His Arg Asp Ala Glu Ile Thr Gln Ser Pro Arg His Lys Ile Thr
20 25 30
Glu Thr Gly Arg Gln Val Thr Leu Ala Cys His Gln Thr Trp Asn His
35 40 45
Asn Asn Met Phe Trp Tyr Arg Gln Asp Leu Gly His Gly Leu Arg Leu
50 55 60
Ile His Tyr Ser Tyr Gly Val Gln Asp Thr Asn Lys Gly Glu Val Ser
65 70 75 80
Asp Gly Tyr Ser Val Ser Arg Ser Asn Thr Glu Asp Leu Pro Leu Thr
85 90 95
Leu Glu Ser Ala Ala Ser Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser
100 105 110
Ser Glu Tyr Val Gly Ala His Glu Gln Tyr Phe Gly Pro Gly Thr Arg
115 120 125
Leu Thr Val Thr
130
<210> 58
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23_Va (具有前导序列)
<400> 58
Met Val Leu Lys Phe Ser Val Ser Ile Leu Trp Ile Gln Leu Ala Trp
1 5 10 15
Val Ser Thr Gln Leu Leu Glu Gln Ser Pro Gln Phe Leu Ser Ile Gln
20 25 30
Glu Gly Glu Asn Leu Thr Val Tyr Cys Asn Ser Ser Ser Val Phe Ser
35 40 45
Ser Leu Gln Trp Tyr Arg Gln Glu Pro Gly Glu Gly Pro Val Leu Leu
50 55 60
Val Thr Val Val Thr Gly Gly Glu Val Lys Lys Leu Lys Arg Leu Thr
65 70 75 80
Phe Gln Phe Gly Asp Ala Arg Lys Asp Ser Ser Leu His Ile Thr Ala
85 90 95
Ala Gln Pro Gly Asp Thr Gly Leu Tyr Leu Cys Ala Gly Val Arg Glu
100 105 110
Ala Gly Gly Thr Ser Tyr Gly Lys Leu Thr Phe Gly Gln Gly Thr Ile
115 120 125
Leu Thr Val His Pro
130
<210> 59
<211> 131
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15_Vb (具有前导序列)
<400> 59
Met Met Leu Cys Ser Leu Leu Ala Leu Leu Leu Gly Thr Phe Phe Gly
1 5 10 15
Val Arg Ser Gln Thr Ile His Gln Trp Pro Ala Thr Leu Val Gln Pro
20 25 30
Val Gly Ser Pro Leu Ser Leu Glu Cys Thr Val Glu Gly Thr Ser Asn
35 40 45
Pro Asn Leu Tyr Trp Tyr Arg Gln Ala Ala Gly Arg Gly Leu Gln Leu
50 55 60
Leu Phe Tyr Ser Val Gly Ile Gly Gln Ile Ser Ser Glu Val Pro Gln
65 70 75 80
Asn Leu Ser Ala Ser Arg Pro Gln Asp Arg Gln Phe Ile Leu Ser Ser
85 90 95
Lys Lys Leu Leu Leu Ser Asp Ser Gly Phe Tyr Leu Cys Ala Trp Thr
100 105 110
Leu Thr Gly Phe Gly Gln Pro Gln His Phe Gly Asp Gly Thr Arg Leu
115 120 125
Ser Ile Leu
130
<210> 60
<211> 130
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15_Va (具有前导序列)
<400> 60
Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu Ser
1 5 10 15
Trp Val Trp Ser Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser
20 25 30
Val Pro Glu Gly Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg
35 40 45
Gly Ser Gln Ser Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro
50 55 60
Glu Leu Ile Met Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg
65 70 75 80
Phe Thr Ala Gln Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile
85 90 95
Arg Asp Ser Gln Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Asn
100 105 110
Ala Arg Gly Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val
115 120 125
Lys Pro
130
<210> 61
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17_Vb (移除前导序列)
<400> 61
Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly
1 5 10 15
Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe
35 40 45
Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr
50 55 60
Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser
65 70 75 80
Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ser Leu Gly
85 90 95
Ala Gly Gln His Asn Ser Pro Leu His Phe Gly Asn Gly Thr Arg Leu
100 105 110
Thr Val Thr
115
<210> 62
<211> 116
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17_Va (移除前导序列)
<400> 62
Lys Val Thr Gln Ala Gln Thr Glu Ile Ser Val Val Glu Lys Glu Asp
1 5 10 15
Val Thr Leu Asp Cys Val Tyr Glu Thr Arg Asp Thr Thr Tyr Tyr Leu
20 25 30
Phe Trp Tyr Lys Gln Pro Pro Ser Gly Glu Leu Val Phe Leu Ile Arg
35 40 45
Arg Asn Ser Phe Asp Glu Gln Asn Glu Ile Ser Gly Arg Tyr Ser Trp
50 55 60
Asn Phe Gln Lys Ser Thr Ser Ser Phe Asn Phe Thr Ile Thr Ala Ser
65 70 75 80
Gln Val Val Asp Ser Ala Val Tyr Phe Cys Ala Leu Ser Glu Val His
85 90 95
Ala Ser Gly Gly Ser Tyr Ile Pro Thr Phe Gly Arg Gly Thr Ser Leu
100 105 110
Ile Val His Pro
115
<210> 63
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14_Vb (移除前导序列)
<400> 63
Asp Ser Gly Val Thr Gln Thr Pro Lys His Leu Ile Thr Ala Thr Gly
1 5 10 15
Gln Arg Val Thr Leu Arg Cys Ser Pro Arg Ser Gly Asp Leu Ser Val
20 25 30
Tyr Trp Tyr Gln Gln Ser Leu Asp Gln Gly Leu Gln Phe Leu Ile Gln
35 40 45
Tyr Tyr Asn Gly Glu Glu Arg Ala Lys Gly Asn Ile Leu Glu Arg Phe
50 55 60
Ser Ala Gln Gln Phe Pro Asp Leu His Ser Glu Leu Asn Leu Ser Ser
65 70 75 80
Leu Glu Leu Gly Asp Ser Ala Leu Tyr Phe Cys Ala Ser Thr His Gly
85 90 95
Arg Asp Ser Thr Asp Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr
100 105 110
Val Leu
<210> 64
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14_Va (移除前导序列)
<400> 64
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Glu Gly Gly Gly
85 90 95
Ala Asp Gly Leu Thr Phe Gly Lys Gly Thr His Leu Ile Ile Gln Pro
100 105 110
<210> 65
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_Vb (移除前导序列)
<400> 65
Asp Ser Gly Val Thr Gln Thr Pro Lys His Leu Ile Thr Ala Thr Gly
1 5 10 15
Gln Arg Val Thr Leu Arg Cys Ser Pro Arg Ser Gly Asp Leu Ser Val
20 25 30
Tyr Trp Tyr Gln Gln Ser Leu Asp Gln Gly Leu Gln Phe Leu Ile Gln
35 40 45
Tyr Tyr Asn Gly Glu Glu Arg Ala Lys Gly Asn Ile Leu Glu Arg Phe
50 55 60
Ser Ala Gln Gln Phe Pro Asp Leu His Ser Glu Leu Asn Leu Ser Ser
65 70 75 80
Leu Glu Leu Gly Asp Ser Ala Leu Tyr Phe Cys Ala Ser Ser Val Thr
85 90 95
Trp Gly Pro Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr
<210> 66
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_Va (移除前导序列)
<400> 66
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Glu Gly Gly Gly
85 90 95
Ala Asp Gly Leu Thr Phe Gly Lys Gly Thr His Leu Ile Ile Gln Pro
100 105 110
<210> 67
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR13_Vb (移除前导序列)
<400> 67
Glu Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile Gly Thr Gly
1 5 10 15
Lys Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His Asp Lys Met
20 25 30
Tyr Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu Ile His Tyr
35 40 45
Ser Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser Ser Glu Ser
50 55 60
Thr Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr Leu Glu Ser
65 70 75 80
Ala Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser Ser Glu Gly
85 90 95
Leu Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
<210> 68
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR13_Va (移除前导序列)
<400> 68
Gln Lys Glu Val Glu Gln Asp Pro Gly Pro Leu Ser Val Pro Glu Gly
1 5 10 15
Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser Asn Ser Ala Phe Gln Tyr
20 25 30
Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys Gly Pro Glu Leu Leu Met
35 40 45
Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp Gly Arg Phe Thr Ala Gln
50 55 60
Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu Phe Ile Arg Asp Ser Gln
65 70 75 80
Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Met Ser Ala Ser Ala Ala
85 90 95
Gly Asn Lys Leu Thr Phe Gly Gly Gly Thr Arg Val Leu Val Lys Pro
100 105 110
<210> 69
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR22_Vb (移除前导序列)
<400> 69
Glu Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile Gly Thr Gly
1 5 10 15
Lys Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His Asp Lys Met
20 25 30
Tyr Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu Ile His Tyr
35 40 45
Ser Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser Ser Glu Ser
50 55 60
Thr Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr Leu Glu Ser
65 70 75 80
Ala Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser Ser Gln Gly
85 90 95
Leu Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
<210> 70
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR22_Va (移除前导序列)
<400> 70
Gln Lys Glu Val Glu Gln Asp Pro Gly Pro Leu Ser Val Pro Glu Gly
1 5 10 15
Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser Asn Ser Ala Phe Gln Tyr
20 25 30
Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys Gly Pro Glu Leu Leu Met
35 40 45
Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp Gly Arg Phe Thr Ala Gln
50 55 60
Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu Phe Ile Arg Asp Ser Gln
65 70 75 80
Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Met Ser Ala Gly Ala Ala
85 90 95
Gly Asn Lys Leu Thr Phe Gly Gly Gly Thr Arg Val Leu Val Lys Pro
100 105 110
<210> 71
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19_Vb (移除前导序列)
<400> 71
Asp Ala Gly Val Ile Gln Ser Pro Arg His Glu Val Thr Glu Met Gly
1 5 10 15
Gln Glu Val Thr Leu Arg Cys Lys Pro Ile Ser Gly His Asp Tyr Leu
20 25 30
Phe Trp Tyr Arg Gln Thr Met Met Arg Gly Leu Glu Leu Leu Ile Tyr
35 40 45
Phe Asn Asn Asn Val Pro Ile Asp Asp Ser Gly Met Pro Glu Asp Arg
50 55 60
Phe Ser Ala Lys Met Pro Asn Ala Ser Phe Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Pro
85 90 95
Thr Gly Gly Gly Met Leu Gly Gln Tyr Phe Gly Pro Gly Thr Arg Leu
100 105 110
Thr Val Leu
115
<210> 72
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19_Va (移除前导序列)
<400> 72
Asp Gln Gln Val Lys Gln Asn Ser Pro Ser Leu Ser Val Gln Glu Gly
1 5 10 15
Arg Ile Ser Ile Leu Asn Cys Asp Tyr Thr Asn Ser Met Phe Asp Tyr
20 25 30
Phe Leu Trp Tyr Lys Lys Tyr Pro Ala Glu Gly Pro Thr Phe Leu Ile
35 40 45
Ser Ile Ser Ser Ile Lys Asp Lys Asn Glu Asp Gly Arg Phe Thr Val
50 55 60
Phe Leu Asn Lys Ser Ala Lys His Leu Ser Leu His Ile Val Pro Ser
65 70 75 80
Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Ala Ser Ala Asn Asn
85 90 95
Asn Asp Met Arg Phe Gly Ala Gly Thr Arg Leu Thr Val Lys Pro
100 105 110
<210> 73
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16_Vb (移除前导序列)
<400> 73
Asp Ala Gly Val Ile Gln Ser Pro Arg His Glu Val Thr Glu Met Gly
1 5 10 15
Gln Glu Val Thr Leu Arg Cys Lys Pro Ile Ser Gly His Asp Tyr Leu
20 25 30
Phe Trp Tyr Arg Gln Thr Met Met Arg Gly Leu Glu Leu Leu Ile Tyr
35 40 45
Phe Asn Asn Asn Val Pro Ile Asp Asp Ser Gly Met Pro Glu Asp Arg
50 55 60
Phe Ser Ala Lys Met Pro Asn Ala Ser Phe Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Arg
85 90 95
Leu Gly Pro Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr
100 105 110
Val Leu
<210> 74
<211> 104
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16_Va (移除前导序列)
<400> 74
Lys Asp Gln Val Phe Gln Pro Ser Thr Val Ala Ser Ser Glu Gly Ala
1 5 10 15
Val Val Glu Ile Phe Cys Asn His Ser Val Ser Asn Ala Tyr Asn Phe
20 25 30
Phe Trp Tyr Leu His Phe Pro Gly Cys Ala Pro Arg Leu Leu Val Lys
35 40 45
Gly Ser Lys Pro Ser Gln Gln Gly Arg Tyr Asn Met Thr Tyr Glu Arg
50 55 60
Phe Ser Ser Ser Leu Leu Ile Leu Gln Val Arg Glu Ala Asp Ala Ala
65 70 75 80
Val Tyr Tyr Cys Val Leu Asn Arg Asp Asp Lys Ile Ile Phe Gly Lys
85 90 95
Gly Thr Arg Leu His Ile Leu Pro
100
<210> 75
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20_Vb (移除前导序列)
<400> 75
Glu Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile Ile Glu Lys Arg
1 5 10 15
Gln Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly His Ala Thr Leu
20 25 30
Tyr Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys Leu Leu Ile Gln
35 40 45
Phe Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg
50 55 60
Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Pro
85 90 95
Thr Phe Pro Ala Gly Asp Arg Asp Thr Gln Tyr Phe Gly Pro Gly Thr
100 105 110
Arg Leu Thr Val Leu Glu
115
<210> 76
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20_Va (移除前导序列)
<400> 76
Asp Ala Lys Thr Thr Gln Pro Pro Ser Met Asp Cys Ala Glu Gly Arg
1 5 10 15
Ala Ala Asn Leu Pro Cys Asn His Ser Thr Ile Ser Gly Asn Glu Tyr
20 25 30
Val Tyr Trp Tyr Arg Gln Ile His Ser Gln Gly Pro Gln Tyr Ile Ile
35 40 45
His Gly Leu Lys Asn Asn Glu Thr Asn Glu Met Ala Ser Leu Ile Ile
50 55 60
Thr Glu Asp Arg Lys Ser Ser Thr Leu Ile Leu Pro His Ala Thr Leu
65 70 75 80
Arg Asp Thr Ala Val Tyr Tyr Cys Ile Val Arg Leu Asn Ser Gly Asn
85 90 95
Thr Pro Leu Val Phe Gly Lys Gly Thr Arg Leu Ser Val Ile Ala
100 105 110
<210> 77
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21_Vb (移除前导序列)
<400> 77
Glu Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile Gly Thr Gly
1 5 10 15
Lys Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His Asp Lys Met
20 25 30
Tyr Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu Ile His Tyr
35 40 45
Ser Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser Ser Glu Ser
50 55 60
Thr Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr Leu Glu Ser
65 70 75 80
Ala Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser Ser Val Gly
85 90 95
Leu Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
<210> 78
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21_Va (移除前导序列)
<400> 78
Gln Lys Glu Val Glu Gln Asp Pro Gly Pro Leu Ser Val Pro Glu Gly
1 5 10 15
Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser Asn Ser Ala Phe Gln Tyr
20 25 30
Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys Gly Pro Glu Leu Leu Met
35 40 45
Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp Gly Arg Phe Thr Ala Gln
50 55 60
Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu Phe Ile Arg Asp Ser Gln
65 70 75 80
Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Met Ser Gly Gly Asn Ala
85 90 95
Gly Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro
100 105 110
<210> 79
<211> 117
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24_Vb (移除前导序列)
<400> 79
Asp Thr Gly Val Ser Gln Asn Pro Arg His Lys Ile Thr Lys Arg Gly
1 5 10 15
Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His Asn Arg Leu
20 25 30
Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr
35 40 45
Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg
50 55 60
Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln
65 70 75 80
Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Pro
85 90 95
Pro Gly Trp Glu Leu Ala Lys Asn Ile Gln Tyr Phe Gly Ala Gly Thr
100 105 110
Arg Leu Ser Val Leu
115
<210> 80
<211> 109
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24_Va (移除前导序列)
<400> 80
Gly Gln Ser Leu Glu Gln Pro Ser Glu Val Thr Ala Val Glu Gly Ala
1 5 10 15
Ile Val Gln Ile Asn Cys Thr Tyr Gln Thr Ser Gly Phe Tyr Gly Leu
20 25 30
Ser Trp Tyr Gln Gln His Asp Gly Gly Ala Pro Thr Phe Leu Ser Tyr
35 40 45
Asn Ala Leu Asp Gly Leu Glu Glu Thr Gly Arg Phe Ser Ser Phe Leu
50 55 60
Ser Arg Ser Asp Ser Tyr Gly Tyr Leu Leu Leu Gln Glu Leu Gln Met
65 70 75 80
Lys Asp Ser Ala Ser Tyr Phe Cys Ala Gly Gly Asp Ser Ser Tyr Lys
85 90 95
Leu Ile Phe Gly Ser Gly Thr Arg Leu Leu Val Arg Pro
100 105
<210> 81
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23_Vb (移除前导序列)
<400> 81
Asp Ala Glu Ile Thr Gln Ser Pro Arg His Lys Ile Thr Glu Thr Gly
1 5 10 15
Arg Gln Val Thr Leu Ala Cys His Gln Thr Trp Asn His Asn Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Leu Gly His Gly Leu Arg Leu Ile His Tyr
35 40 45
Ser Tyr Gly Val Gln Asp Thr Asn Lys Gly Glu Val Ser Asp Gly Tyr
50 55 60
Ser Val Ser Arg Ser Asn Thr Glu Asp Leu Pro Leu Thr Leu Glu Ser
65 70 75 80
Ala Ala Ser Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser Ser Glu Tyr
85 90 95
Val Gly Ala His Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr
<210> 82
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23_Va (移除前导序列)
<400> 82
Thr Gln Leu Leu Glu Gln Ser Pro Gln Phe Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Leu Thr Val Tyr Cys Asn Ser Ser Ser Val Phe Ser Ser Leu
20 25 30
Gln Trp Tyr Arg Gln Glu Pro Gly Glu Gly Pro Val Leu Leu Val Thr
35 40 45
Val Val Thr Gly Gly Glu Val Lys Lys Leu Lys Arg Leu Thr Phe Gln
50 55 60
Phe Gly Asp Ala Arg Lys Asp Ser Ser Leu His Ile Thr Ala Ala Gln
65 70 75 80
Pro Gly Asp Thr Gly Leu Tyr Leu Cys Ala Gly Val Arg Glu Ala Gly
85 90 95
Gly Thr Ser Tyr Gly Lys Leu Thr Phe Gly Gln Gly Thr Ile Leu Thr
100 105 110
Val His Pro
115
<210> 83
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15_Vb (移除前导序列)
<400> 83
Ser Gln Thr Ile His Gln Trp Pro Ala Thr Leu Val Gln Pro Val Gly
1 5 10 15
Ser Pro Leu Ser Leu Glu Cys Thr Val Glu Gly Thr Ser Asn Pro Asn
20 25 30
Leu Tyr Trp Tyr Arg Gln Ala Ala Gly Arg Gly Leu Gln Leu Leu Phe
35 40 45
Tyr Ser Val Gly Ile Gly Gln Ile Ser Ser Glu Val Pro Gln Asn Leu
50 55 60
Ser Ala Ser Arg Pro Gln Asp Arg Gln Phe Ile Leu Ser Ser Lys Lys
65 70 75 80
Leu Leu Leu Ser Asp Ser Gly Phe Tyr Leu Cys Ala Trp Thr Leu Thr
85 90 95
Gly Phe Gly Gln Pro Gln His Phe Gly Asp Gly Thr Arg Leu Ser Ile
100 105 110
Leu
<210> 84
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15_Va (移除前导序列)
<400> 84
Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly
1 5 10 15
Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser
20 25 30
Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met
35 40 45
Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln
50 55 60
Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln
65 70 75 80
Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Asn Ala Arg Gly Asn
85 90 95
Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro
100 105 110
<210> 85
<211> 140
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 人TRAC基因产物
(Uniprot P01848)
<400> 85
Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser
1 5 10 15
Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn
20 25 30
Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Thr Val
35 40 45
Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp
50 55 60
Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile
65 70 75 80
Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val
85 90 95
Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe Gln
100 105 110
Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala Gly
115 120 125
Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
130 135 140
<210> 86
<211> 140
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 人TRAC基因产物
(Uniprot P01848)具有T47C mod
<400> 86
Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser
1 5 10 15
Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn
20 25 30
Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys Val
35 40 45
Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp
50 55 60
Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile
65 70 75 80
Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val
85 90 95
Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe Gln
100 105 110
Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala Gly
115 120 125
Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
130 135 140
<210> 87
<211> 176
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 人TRBC1基因产物
(Uniprot P01848)
<400> 87
Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser
1 5 10 15
Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala
20 25 30
Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
35 40 45
Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro Leu Lys Glu
50 55 60
Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg
65 70 75 80
Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln
85 90 95
Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg
100 105 110
Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala
115 120 125
Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly Val Leu Ser Ala
130 135 140
Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val
145 150 155 160
Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Phe
165 170 175
<210> 88
<211> 177
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17_Cb (S57C mod)
<400> 88
Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Phe
<210> 89
<211> 179
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14_Cb (S57C mod)
<400> 89
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 90
<211> 179
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_Cb (S57C mod)
<400> 90
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 91
<211> 179
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 91 - TCR13_Cb (S57C mod)
<400> 91
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 92
<211> 179
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 A11_TCR22_Cb (S57C mod)
<400> 92
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 93
<211> 179
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19_Cb (S57C mod)
<400> 93
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 94
<211> 179
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16_Cb (S57C mod)
<400> 94
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 95
<211> 178
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20_Cb (S57C mod)
<400> 95
Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser
1 5 10 15
Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala
20 25 30
Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
35 40 45
Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu
50 55 60
Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg
65 70 75 80
Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln
85 90 95
Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg
100 105 110
Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala
115 120 125
Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser Ala
130 135 140
Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val
145 150 155 160
Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Ser
165 170 175
Arg Gly
<210> 96
<211> 179
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21_Cb (S57C mod)
<400> 96
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 97
<211> 179
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24_Cb (S57C mod)
<400> 97
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 98
<211> 179
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23_Cb (S57C mod)
<400> 98
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Ser Arg Gly
<210> 99
<211> 177
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15_Cb (S57C mod)
<400> 99
Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
1 5 10 15
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
20 25 30
Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
35 40 45
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
50 55 60
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
65 70 75 80
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
85 90 95
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
100 105 110
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
115 120 125
Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly Val Leu Ser
130 135 140
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
145 150 155 160
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
165 170 175
Phe
<210> 100
<211> 292
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17_B-链 (Cys-mod) (移除前导序列)
<400> 100
Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly
1 5 10 15
Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe
35 40 45
Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr
50 55 60
Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser
65 70 75 80
Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ser Leu Gly
85 90 95
Ala Gly Gln His Asn Ser Pro Leu His Phe Gly Asn Gly Thr Arg Leu
100 105 110
Thr Val Thr Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val
115 120 125
Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu
130 135 140
Val Cys Leu Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp
145 150 155 160
Trp Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln
165 170 175
Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser
180 185 190
Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His
195 200 205
Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp
210 215 220
Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala
225 230 235 240
Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly
245 250 255
Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr
260 265 270
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys
275 280 285
Arg Lys Asp Phe
290
<210> 101
<211> 259
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17_A-链 (Cys-mod) (移除前导序列)
<400> 101
Ala Gln Lys Val Thr Gln Ala Gln Thr Glu Ile Ser Val Val Glu Lys
1 5 10 15
Glu Asp Val Thr Leu Asp Cys Val Tyr Glu Thr Arg Asp Thr Thr Tyr
20 25 30
Tyr Leu Phe Trp Tyr Lys Gln Pro Pro Ser Gly Glu Leu Val Phe Leu
35 40 45
Ile Arg Arg Asn Ser Phe Asp Glu Gln Asn Glu Ile Ser Gly Arg Tyr
50 55 60
Ser Trp Asn Phe Gln Lys Ser Thr Ser Ser Phe Asn Phe Thr Ile Thr
65 70 75 80
Ala Ser Gln Val Val Asp Ser Ala Val Tyr Phe Cys Ala Leu Ser Glu
85 90 95
Val His Ala Ser Gly Gly Ser Tyr Ile Pro Thr Phe Gly Arg Gly Thr
100 105 110
Ser Leu Ile Val His Pro Tyr Ile Gln Asn Pro Asp Pro Ala Val Tyr
115 120 125
Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr
130 135 140
Asp Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val
145 150 155 160
Tyr Ile Thr Asp Lys Cys Val Leu Asp Met Arg Ser Met Asp Phe Lys
165 170 175
Ser Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala
180 185 190
Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser
195 200 205
Pro Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr
210 215 220
Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile
225 230 235 240
Leu Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu
245 250 255
Trp Ser Ser
<210> 102
<211> 293
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14_B-链 (Cys-mod) (移除前导序列)
<400> 102
Asp Ser Gly Val Thr Gln Thr Pro Lys His Leu Ile Thr Ala Thr Gly
1 5 10 15
Gln Arg Val Thr Leu Arg Cys Ser Pro Arg Ser Gly Asp Leu Ser Val
20 25 30
Tyr Trp Tyr Gln Gln Ser Leu Asp Gln Gly Leu Gln Phe Leu Ile Gln
35 40 45
Tyr Tyr Asn Gly Glu Glu Arg Ala Lys Gly Asn Ile Leu Glu Arg Phe
50 55 60
Ser Ala Gln Gln Phe Pro Asp Leu His Ser Glu Leu Asn Leu Ser Ser
65 70 75 80
Leu Glu Leu Gly Asp Ser Ala Leu Tyr Phe Cys Ala Ser Thr His Gly
85 90 95
Arg Asp Ser Thr Asp Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr
100 105 110
Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe
115 120 125
Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val
130 135 140
Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp
145 150 155 160
Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro
165 170 175
Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser
180 185 190
Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe
195 200 205
Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr
210 215 220
Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp
225 230 235 240
Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val
245 250 255
Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu
260 265 270
Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg
275 280 285
Lys Asp Ser Arg Gly
290
<210> 103
<211> 253
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14_A-链 (Cys-mod) (移除前导序列)
<400> 103
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Glu Gly Gly Gly
85 90 95
Ala Asp Gly Leu Thr Phe Gly Lys Gly Thr His Leu Ile Ile Gln Pro
100 105 110
Tyr Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys
115 120 125
Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr
130 135 140
Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys
145 150 155 160
Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala
165 170 175
Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser
180 185 190
Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp
195 200 205
Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe
210 215 220
Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala
225 230 235 240
Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 104
<211> 292
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_B-链 (Cys-mod) (移除前导序列)
<400> 104
Asp Ser Gly Val Thr Gln Thr Pro Lys His Leu Ile Thr Ala Thr Gly
1 5 10 15
Gln Arg Val Thr Leu Arg Cys Ser Pro Arg Ser Gly Asp Leu Ser Val
20 25 30
Tyr Trp Tyr Gln Gln Ser Leu Asp Gln Gly Leu Gln Phe Leu Ile Gln
35 40 45
Tyr Tyr Asn Gly Glu Glu Arg Ala Lys Gly Asn Ile Leu Glu Arg Phe
50 55 60
Ser Ala Gln Gln Phe Pro Asp Leu His Ser Glu Leu Asn Leu Ser Ser
65 70 75 80
Leu Glu Leu Gly Asp Ser Ala Leu Tyr Phe Cys Ala Ser Ser Val Thr
85 90 95
Trp Gly Pro Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu
115 120 125
Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys
130 135 140
Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val
145 150 155 160
Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu
165 170 175
Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg
180 185 190
Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg
195 200 205
Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln
210 215 220
Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly
225 230 235 240
Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu
245 250 255
Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr
260 265 270
Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys
275 280 285
Asp Ser Arg Gly
290
<210> 105
<211> 253
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18_A-链 (Cys-mod) (移除前导序列)
<400> 105
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Glu Gly Gly Gly
85 90 95
Ala Asp Gly Leu Thr Phe Gly Lys Gly Thr His Leu Ile Ile Gln Pro
100 105 110
Tyr Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys
115 120 125
Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr
130 135 140
Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys
145 150 155 160
Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala
165 170 175
Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser
180 185 190
Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp
195 200 205
Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe
210 215 220
Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala
225 230 235 240
Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 106
<211> 291
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR13_B-链 (Cys-mod) (移除前导序列)
<400> 106
Glu Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile Gly Thr Gly
1 5 10 15
Lys Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His Asp Lys Met
20 25 30
Tyr Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu Ile His Tyr
35 40 45
Ser Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser Ser Glu Ser
50 55 60
Thr Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr Leu Glu Ser
65 70 75 80
Ala Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser Ser Glu Gly
85 90 95
Leu Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
115 120 125
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
130 135 140
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
145 150 155 160
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
165 170 175
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
180 185 190
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
195 200 205
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
210 215 220
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
225 230 235 240
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
245 250 255
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
260 265 270
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
275 280 285
Ser Arg Gly
290
<210> 107
<211> 253
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR13_A-链 (Cys-mod) (移除前导序列)
<400> 107
Gln Lys Glu Val Glu Gln Asp Pro Gly Pro Leu Ser Val Pro Glu Gly
1 5 10 15
Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser Asn Ser Ala Phe Gln Tyr
20 25 30
Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys Gly Pro Glu Leu Leu Met
35 40 45
Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp Gly Arg Phe Thr Ala Gln
50 55 60
Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu Phe Ile Arg Asp Ser Gln
65 70 75 80
Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Met Ser Ala Ser Ala Ala
85 90 95
Gly Asn Lys Leu Thr Phe Gly Gly Gly Thr Arg Val Leu Val Lys Pro
100 105 110
Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys
115 120 125
Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr
130 135 140
Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys
145 150 155 160
Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala
165 170 175
Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser
180 185 190
Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp
195 200 205
Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe
210 215 220
Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala
225 230 235 240
Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 108
<211> 291
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR22_B-链 (Cys-mod) (移除前导序列)
<400> 108
Glu Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile Gly Thr Gly
1 5 10 15
Lys Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His Asp Lys Met
20 25 30
Tyr Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu Ile His Tyr
35 40 45
Ser Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser Ser Glu Ser
50 55 60
Thr Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr Leu Glu Ser
65 70 75 80
Ala Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser Ser Gln Gly
85 90 95
Leu Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
115 120 125
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
130 135 140
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
145 150 155 160
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
165 170 175
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
180 185 190
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
195 200 205
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
210 215 220
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
225 230 235 240
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
245 250 255
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
260 265 270
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
275 280 285
Ser Arg Gly
290
<210> 109
<211> 253
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR22_A-链 (Cys-mod) (移除前导序列)
<400> 109
Gln Lys Glu Val Glu Gln Asp Pro Gly Pro Leu Ser Val Pro Glu Gly
1 5 10 15
Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser Asn Ser Ala Phe Gln Tyr
20 25 30
Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys Gly Pro Glu Leu Leu Met
35 40 45
Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp Gly Arg Phe Thr Ala Gln
50 55 60
Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu Phe Ile Arg Asp Ser Gln
65 70 75 80
Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Met Ser Ala Gly Ala Ala
85 90 95
Gly Asn Lys Leu Thr Phe Gly Gly Gly Thr Arg Val Leu Val Lys Pro
100 105 110
Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys
115 120 125
Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr
130 135 140
Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys
145 150 155 160
Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala
165 170 175
Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser
180 185 190
Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp
195 200 205
Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe
210 215 220
Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala
225 230 235 240
Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 110
<211> 294
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19_B-链 (Cys-mod) (移除前导序列)
<400> 110
Asp Ala Gly Val Ile Gln Ser Pro Arg His Glu Val Thr Glu Met Gly
1 5 10 15
Gln Glu Val Thr Leu Arg Cys Lys Pro Ile Ser Gly His Asp Tyr Leu
20 25 30
Phe Trp Tyr Arg Gln Thr Met Met Arg Gly Leu Glu Leu Leu Ile Tyr
35 40 45
Phe Asn Asn Asn Val Pro Ile Asp Asp Ser Gly Met Pro Glu Asp Arg
50 55 60
Phe Ser Ala Lys Met Pro Asn Ala Ser Phe Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Pro
85 90 95
Thr Gly Gly Gly Met Leu Gly Gln Tyr Phe Gly Pro Gly Thr Arg Leu
100 105 110
Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val
115 120 125
Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu
130 135 140
Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp
145 150 155 160
Trp Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln
165 170 175
Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser
180 185 190
Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His
195 200 205
Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp
210 215 220
Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala
225 230 235 240
Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly
245 250 255
Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr
260 265 270
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys
275 280 285
Arg Lys Asp Ser Arg Gly
290
<210> 111
<211> 252
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19_A-链 (Cys-mod) (移除前导序列)
<400> 111
Asp Gln Gln Val Lys Gln Asn Ser Pro Ser Leu Ser Val Gln Glu Gly
1 5 10 15
Arg Ile Ser Ile Leu Asn Cys Asp Tyr Thr Asn Ser Met Phe Asp Tyr
20 25 30
Phe Leu Trp Tyr Lys Lys Tyr Pro Ala Glu Gly Pro Thr Phe Leu Ile
35 40 45
Ser Ile Ser Ser Ile Lys Asp Lys Asn Glu Asp Gly Arg Phe Thr Val
50 55 60
Phe Leu Asn Lys Ser Ala Lys His Leu Ser Leu His Ile Val Pro Ser
65 70 75 80
Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Ala Ser Ala Asn Asn
85 90 95
Asn Asp Met Arg Phe Gly Ala Gly Thr Arg Leu Thr Val Lys Pro Asn
100 105 110
Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser
115 120 125
Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn
130 135 140
Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys Val
145 150 155 160
Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp
165 170 175
Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile
180 185 190
Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val
195 200 205
Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe Gln
210 215 220
Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala Gly
225 230 235 240
Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 112
<211> 293
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16_B-链 (Cys-mod) (移除前导序列)
<400> 112
Asp Ala Gly Val Ile Gln Ser Pro Arg His Glu Val Thr Glu Met Gly
1 5 10 15
Gln Glu Val Thr Leu Arg Cys Lys Pro Ile Ser Gly His Asp Tyr Leu
20 25 30
Phe Trp Tyr Arg Gln Thr Met Met Arg Gly Leu Glu Leu Leu Ile Tyr
35 40 45
Phe Asn Asn Asn Val Pro Ile Asp Asp Ser Gly Met Pro Glu Asp Arg
50 55 60
Phe Ser Ala Lys Met Pro Asn Ala Ser Phe Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Arg
85 90 95
Leu Gly Pro Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr
100 105 110
Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe
115 120 125
Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val
130 135 140
Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp
145 150 155 160
Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro
165 170 175
Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser
180 185 190
Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe
195 200 205
Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr
210 215 220
Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp
225 230 235 240
Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val
245 250 255
Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu
260 265 270
Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg
275 280 285
Lys Asp Ser Arg Gly
290
<210> 113
<211> 245
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16_A-链 (Cys-mod) (移除前导序列)
<400> 113
Lys Asp Gln Val Phe Gln Pro Ser Thr Val Ala Ser Ser Glu Gly Ala
1 5 10 15
Val Val Glu Ile Phe Cys Asn His Ser Val Ser Asn Ala Tyr Asn Phe
20 25 30
Phe Trp Tyr Leu His Phe Pro Gly Cys Ala Pro Arg Leu Leu Val Lys
35 40 45
Gly Ser Lys Pro Ser Gln Gln Gly Arg Tyr Asn Met Thr Tyr Glu Arg
50 55 60
Phe Ser Ser Ser Leu Leu Ile Leu Gln Val Arg Glu Ala Asp Ala Ala
65 70 75 80
Val Tyr Tyr Cys Val Leu Asn Arg Asp Asp Lys Ile Ile Phe Gly Lys
85 90 95
Gly Thr Arg Leu His Ile Leu Pro Asn Ile Gln Asn Pro Asp Pro Ala
100 105 110
Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu
115 120 125
Phe Thr Asp Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser
130 135 140
Asp Val Tyr Ile Thr Asp Lys Cys Val Leu Asp Met Arg Ser Met Asp
145 150 155 160
Phe Lys Ser Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala
165 170 175
Cys Ala Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe
180 185 190
Pro Ser Pro Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe
195 200 205
Glu Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe
210 215 220
Arg Ile Leu Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu
225 230 235 240
Arg Leu Trp Ser Ser
245
<210> 114
<211> 296
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20_B-链 (Cys-mod) (移除前导序列)
<400> 114
Glu Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile Ile Glu Lys Arg
1 5 10 15
Gln Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly His Ala Thr Leu
20 25 30
Tyr Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys Leu Leu Ile Gln
35 40 45
Phe Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg
50 55 60
Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Pro
85 90 95
Thr Phe Pro Ala Gly Asp Arg Asp Thr Gln Tyr Phe Gly Pro Gly Thr
100 105 110
Arg Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val
115 120 125
Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala
130 135 140
Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu
145 150 155 160
Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp
165 170 175
Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys
180 185 190
Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg
195 200 205
Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp
210 215 220
Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala
225 230 235 240
Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln
245 250 255
Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys
260 265 270
Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met
275 280 285
Val Lys Arg Lys Asp Ser Arg Gly
290 295
<210> 115
<211> 252
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20_A-链 (Cys-mod) (移除前导序列)
<400> 115
Asp Ala Lys Thr Thr Gln Pro Pro Ser Met Asp Cys Ala Glu Gly Arg
1 5 10 15
Ala Ala Asn Leu Pro Cys Asn His Ser Thr Ile Ser Gly Asn Glu Tyr
20 25 30
Val Tyr Trp Tyr Arg Gln Ile His Ser Gln Gly Pro Gln Tyr Ile Ile
35 40 45
His Gly Leu Lys Asn Asn Glu Thr Asn Glu Met Ala Ser Leu Ile Ile
50 55 60
Thr Glu Asp Arg Lys Ser Ser Thr Leu Ile Leu Pro His Ala Thr Leu
65 70 75 80
Arg Asp Thr Ala Val Tyr Tyr Cys Ile Val Arg Leu Asn Ser Gly Asn
85 90 95
Thr Pro Leu Val Phe Gly Lys Gly Thr Arg Leu Ser Val Ile Ala Asn
100 105 110
Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser
115 120 125
Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn
130 135 140
Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys Val
145 150 155 160
Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp
165 170 175
Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile
180 185 190
Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val
195 200 205
Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe Gln
210 215 220
Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala Gly
225 230 235 240
Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 116
<211> 291
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21_B-链 (Cys-mod) (移除前导序列)
<400> 116
Glu Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile Gly Thr Gly
1 5 10 15
Lys Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His Asp Lys Met
20 25 30
Tyr Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu Ile His Tyr
35 40 45
Ser Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser Ser Glu Ser
50 55 60
Thr Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr Leu Glu Ser
65 70 75 80
Ala Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser Ser Val Gly
85 90 95
Leu Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
115 120 125
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
130 135 140
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
145 150 155 160
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
165 170 175
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
180 185 190
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
195 200 205
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
210 215 220
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
225 230 235 240
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
245 250 255
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
260 265 270
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
275 280 285
Ser Arg Gly
290
<210> 117
<211> 253
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21_A-链 (Cys-mod) (移除前导序列)
<400> 117
Gln Lys Glu Val Glu Gln Asp Pro Gly Pro Leu Ser Val Pro Glu Gly
1 5 10 15
Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser Asn Ser Ala Phe Gln Tyr
20 25 30
Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys Gly Pro Glu Leu Leu Met
35 40 45
Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp Gly Arg Phe Thr Ala Gln
50 55 60
Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu Phe Ile Arg Asp Ser Gln
65 70 75 80
Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Met Ser Gly Gly Asn Ala
85 90 95
Gly Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro
100 105 110
His Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys
115 120 125
Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr
130 135 140
Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys
145 150 155 160
Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala
165 170 175
Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser
180 185 190
Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp
195 200 205
Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe
210 215 220
Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala
225 230 235 240
Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 118
<211> 296
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24_B-链 (Cys-mod) (移除前导序列)
<400> 118
Asp Thr Gly Val Ser Gln Asn Pro Arg His Lys Ile Thr Lys Arg Gly
1 5 10 15
Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His Asn Arg Leu
20 25 30
Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr
35 40 45
Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg
50 55 60
Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln
65 70 75 80
Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Pro
85 90 95
Pro Gly Trp Glu Leu Ala Lys Asn Ile Gln Tyr Phe Gly Ala Gly Thr
100 105 110
Arg Leu Ser Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val
115 120 125
Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala
130 135 140
Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu
145 150 155 160
Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp
165 170 175
Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys
180 185 190
Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg
195 200 205
Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp
210 215 220
Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala
225 230 235 240
Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln
245 250 255
Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys
260 265 270
Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met
275 280 285
Val Lys Arg Lys Asp Ser Arg Gly
290 295
<210> 119
<211> 250
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24_A-链 (Cys-mod) (移除前导序列)
<400> 119
Gly Gln Ser Leu Glu Gln Pro Ser Glu Val Thr Ala Val Glu Gly Ala
1 5 10 15
Ile Val Gln Ile Asn Cys Thr Tyr Gln Thr Ser Gly Phe Tyr Gly Leu
20 25 30
Ser Trp Tyr Gln Gln His Asp Gly Gly Ala Pro Thr Phe Leu Ser Tyr
35 40 45
Asn Ala Leu Asp Gly Leu Glu Glu Thr Gly Arg Phe Ser Ser Phe Leu
50 55 60
Ser Arg Ser Asp Ser Tyr Gly Tyr Leu Leu Leu Gln Glu Leu Gln Met
65 70 75 80
Lys Asp Ser Ala Ser Tyr Phe Cys Ala Gly Gly Asp Ser Ser Tyr Lys
85 90 95
Leu Ile Phe Gly Ser Gly Thr Arg Leu Leu Val Arg Pro Asp Ile Gln
100 105 110
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
115 120 125
Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn Val Ser
130 135 140
Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys Val Leu Asp
145 150 155 160
Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp Ser Asn
165 170 175
Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile Ile Pro
180 185 190
Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val Lys Leu
195 200 205
Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu
210 215 220
Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala Gly Phe Asn
225 230 235 240
Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 120
<211> 292
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23_B-链 (Cys-mod) (移除前导序列)
<400> 120
Asp Ala Glu Ile Thr Gln Ser Pro Arg His Lys Ile Thr Glu Thr Gly
1 5 10 15
Arg Gln Val Thr Leu Ala Cys His Gln Thr Trp Asn His Asn Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Leu Gly His Gly Leu Arg Leu Ile His Tyr
35 40 45
Ser Tyr Gly Val Gln Asp Thr Asn Lys Gly Glu Val Ser Asp Gly Tyr
50 55 60
Ser Val Ser Arg Ser Asn Thr Glu Asp Leu Pro Leu Thr Leu Glu Ser
65 70 75 80
Ala Ala Ser Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser Ser Glu Tyr
85 90 95
Val Gly Ala His Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu
115 120 125
Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys
130 135 140
Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val
145 150 155 160
Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu
165 170 175
Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg
180 185 190
Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg
195 200 205
Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln
210 215 220
Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly
225 230 235 240
Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu
245 250 255
Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr
260 265 270
Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys
275 280 285
Asp Ser Arg Gly
290
<210> 121
<211> 256
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23_A-链 (Cys-mod) (移除前导序列)
<400> 121
Thr Gln Leu Leu Glu Gln Ser Pro Gln Phe Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Leu Thr Val Tyr Cys Asn Ser Ser Ser Val Phe Ser Ser Leu
20 25 30
Gln Trp Tyr Arg Gln Glu Pro Gly Glu Gly Pro Val Leu Leu Val Thr
35 40 45
Val Val Thr Gly Gly Glu Val Lys Lys Leu Lys Arg Leu Thr Phe Gln
50 55 60
Phe Gly Asp Ala Arg Lys Asp Ser Ser Leu His Ile Thr Ala Ala Gln
65 70 75 80
Pro Gly Asp Thr Gly Leu Tyr Leu Cys Ala Gly Val Arg Glu Ala Gly
85 90 95
Gly Thr Ser Tyr Gly Lys Leu Thr Phe Gly Gln Gly Thr Ile Leu Thr
100 105 110
Val His Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg
115 120 125
Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp
130 135 140
Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr
145 150 155 160
Asp Lys Cys Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser
165 170 175
Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe
180 185 190
Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser
195 200 205
Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn
210 215 220
Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu
225 230 235 240
Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250 255
<210> 122
<211> 290
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15_B-链 (Cys-mod) (移除前导序列)
<400> 122
Ser Gln Thr Ile His Gln Trp Pro Ala Thr Leu Val Gln Pro Val Gly
1 5 10 15
Ser Pro Leu Ser Leu Glu Cys Thr Val Glu Gly Thr Ser Asn Pro Asn
20 25 30
Leu Tyr Trp Tyr Arg Gln Ala Ala Gly Arg Gly Leu Gln Leu Leu Phe
35 40 45
Tyr Ser Val Gly Ile Gly Gln Ile Ser Ser Glu Val Pro Gln Asn Leu
50 55 60
Ser Ala Ser Arg Pro Gln Asp Arg Gln Phe Ile Leu Ser Ser Lys Lys
65 70 75 80
Leu Leu Leu Ser Asp Ser Gly Phe Tyr Leu Cys Ala Trp Thr Leu Thr
85 90 95
Gly Phe Gly Gln Pro Gln His Phe Gly Asp Gly Thr Arg Leu Ser Ile
100 105 110
Leu Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe Glu
115 120 125
Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys
130 135 140
Leu Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val
145 150 155 160
Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu
165 170 175
Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg
180 185 190
Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg
195 200 205
Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln
210 215 220
Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly
225 230 235 240
Arg Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly Val Leu
245 250 255
Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr
260 265 270
Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys
275 280 285
Asp Phe
290
<210> 123
<211> 251
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15_A-链 (Cys-mod) (移除前导序列)
<400> 123
Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu Ser Val Pro Glu Gly
1 5 10 15
Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp Arg Gly Ser Gln Ser
20 25 30
Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser Pro Glu Leu Ile Met
35 40 45
Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly Arg Phe Thr Ala Gln
50 55 60
Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu Ile Arg Asp Ser Gln
65 70 75 80
Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val Asn Ala Arg Gly Asn
85 90 95
Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met Val Lys Pro His Ile
100 105 110
Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser
115 120 125
Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn Val
130 135 140
Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Cys Val Leu
145 150 155 160
Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp Ser
165 170 175
Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile Ile
180 185 190
Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val Lys
195 200 205
Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe Gln Asn
210 215 220
Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala Gly Phe
225 230 235 240
Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 124
<211> 405
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR17_TCRb基因片段
<400> 124
atgggaatca ggctcctgtg tcgtgtggcc ttttgtttcc tggctgtagg cctcgtagat 60
gtgaaagtaa cccagagctc gagatatcta gtcaaaagga cgggagagaa agtttttctg 120
gaatgtgtcc aggatatgga ccatgaaaat atgttctggt atcgacaaga cccaggtctg 180
gggctacggc tgatctattt ctcatatgat gttaaaatga aagaaaaagg agatattcct 240
gaggggtaca gtgtctctag agagaagaag gagcgcttct ccctgattct ggagtccgcc 300
agcaccaacc agacatctat gtacctctgt gccagcagcc tgggcgcggg acagcataat 360
tcacccctcc actttgggaa tgggaccagg ctcactgtga cagag 405
<210> 125
<211> 438
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR17_TCRa基因片段
<400> 125
atgctgactg ccagcctgtt gagggcagtc atagcctcca tctgtgttgt atccagcatg 60
gctcagaagg taactcaagc gcagactgaa atttctgtgg tggagaagga ggatgtgacc 120
ttggactgtg tgtatgaaac ccgtgatact acttattact tattctggta caagcaacca 180
ccaagtggag aattggtttt ccttattcgt cggaactctt ttgatgagca aaatgaaata 240
agtggtcggt attcttggaa cttccagaaa tccaccagtt ccttcaactt caccatcaca 300
gcctcacaag tcgtggactc agcagtatac ttctgtgctc tgagtgaggt tcatgcatca 360
ggaggaagct acatacctac atttggaaga ggaaccagcc ttattgttca tccgtatatc 420
cagaaccctg accctgcc 438
<210> 126
<211> 402
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR14_TCRb基因片段
<400> 126
atgggcttca ggctcctctg ctgtgtggcc ttttgtctcc tgggagcagg cccagtggat 60
tctggagtca cacaaacccc aaagcacctg atcacagcaa ctggacagcg agtgacgctg 120
agatgctccc ctaggtctgg agacctctct gtgtactggt accaacagag cctggaccag 180
ggcctccagt tcctcattca gtattataat ggagaagaga gagcaaaagg aaacattctt 240
gaacgattct ccgcacaaca gttccctgac ttgcactctg aactaaacct gagctctctg 300
gagctggggg actcagcttt gtatttctgt gccagcaccc acgggaggga cagcacagat 360
acgcagtatt ttggcccagg cacccggctg acagtgctcg ag 402
<210> 127
<211> 420
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR14_TCRa基因片段
<400> 127
atggaaactc tcctgggagt gtctttggtg attctatggc ttcaactggc tagggtgaac 60
agtcaacagg gagaagagga tcctcaggcc ttgagcatcc aggagggtga aaatgccacc 120
atgaactgca gttacaaaac tagtataaac aatttacagt ggtatagaca aaattcaggt 180
agaggccttg tccacctaat tttaatacgt tcaaatgaaa gagagaaaca cagtggaaga 240
ttaagagtca cgcttgacac ttccaagaaa agcagttcct tgttgatcac ggcttcccgg 300
gcagcagaca ctgcttctta cttctgtgct acggacgaag gaggaggtgc tgacggactc 360
acctttggca aagggactca tctaatcatc cagccctata tccagaaccc tgaccctgcc 420
<210> 128
<211> 399
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR18_TCRb基因片段
<400> 128
atgggcttca ggctcctctg ctgtgtggcc ttttgtctcc tgggagcagg cccagtggat 60
tctggagtca cacaaacccc aaagcacctg atcacagcaa ctggacagcg agtgacgctg 120
agatgctccc ctaggtctgg agacctctct gtgtactggt accaacagag cctggaccag 180
ggcctccagt tcctcattca gtattataat ggagaagaga gagcaaaagg aaacattctt 240
gaacgattct ccgcacaaca gttccctgac ttgcactctg aactaaacct gagctctctg 300
gagctggggg actcagcttt gtatttctgt gccagcagcg tcacttgggg gccctacgag 360
cagtacttcg ggccgggcac caggctcacg gtcacagag 399
<210> 129
<211> 420
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR18_TCRa基因片段
<400> 129
atggaaactc tcctgggagt gtctttggtg attctatggc ttcaactggc tagggtgaac 60
agtcaacagg gagaagagga tcctcaggcc ttgagcatcc aggagggtga aaatgccacc 120
atgaactgca gttacaaaac tagtataaac aatttacagt ggtatagaca aaattcaggt 180
agaggccttg tccacctaat tttaatacgt tcaaatgaaa gagagaaaca cagtggaaga 240
ttaagagtca cgcttgacac ttccaagaaa agcagttcct tgttgatcac ggcttcccgg 300
gcagcagaca ctgcttctta cttctgtgct acggacgaag gaggaggtgc tgacggactc 360
acctttggca aagggactca tctaatcatc cagccctata tccagaaccc tgaccctgcc 420
<210> 130
<211> 396
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR13_TCRb基因片段
<400> 130
atgactatca ggctcctctg ctacatgggc ttttattttc tgggggcagg cctcatggaa 60
gctgacatct accagacccc aagatacctt gttataggga caggaaagaa gatcactctg 120
gaatgttctc aaaccatggg ccatgacaaa atgtactggt atcaacaaga tccaggaatg 180
gaactacacc tcatccacta ttcctatgga gttaattcca cagagaaggg agatctttcc 240
tctgagtcaa cagtctccag aataaggacg gagcattttc ccctgaccct ggagtctgcc 300
aggccctcac atacctctca gtacctctgt gccagcagtg aagggcttta caatgagcag 360
ttcttcgggc cagggacacg gctcaccgtg ctagag 396
<210> 131
<211> 426
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR13_ TCRa基因片段
<400> 131
atgatgaaat ccttgagagt tttactggtg atcctgtggc ttcagttaag ctgggtttgg 60
agccaacaga aggaggtgga gcaggatcct ggaccactca gtgttccaga gggagccatt 120
gtttctctca actgcactta cagcaacagt gcttttcaat acttcatgtg gtacagacag 180
tattccagaa aaggccctga gttgctgatg tacacatact ccagtggtaa caaagaagat 240
ggaaggttta cagcacaggt cgataaatcc agcaagtata tctccttgtt catcagagac 300
tcacagccca gtgattcagc cacctacctc tgtgcaatga gcgcaagcgc tgcaggcaac 360
aagctaactt ttggaggagg aaccagggtg ctagttaaac caaatatcca gaaccctgac 420
cctgcc 426
<210> 132
<211> 396
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR22_TCRb基因片段
<400> 132
atgactatca ggctcctctg ctacatgggc ttttattttc tgggggcagg cctcatggaa 60
gctgacatct accagacccc aagatacctt gttataggga caggaaagaa gatcactctg 120
gaatgttctc aaaccatggg ccatgacaaa atgtactggt atcaacaaga tccaggaatg 180
gaactacacc tcatccacta ttcctatgga gttaattcca cagagaaggg agatctttcc 240
tctgagtcaa cagtctccag aataaggacg gagcattttc ccctgaccct ggagtctgcc 300
aggccctcac atacctctca gtacctctgt gccagcagtc agggactgta caatgagcag 360
ttcttcgggc cagggacacg gctcaccgtg ctagag 396
<210> 133
<211> 426
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR22_TCRa基因片段
<400> 133
atgatgaaat ccttgagagt tttactggtg atcctgtggc ttcagttaag ctgggtttgg 60
agccaacaga aggaggtgga gcaggatcct ggaccactca gtgttccaga gggagccatt 120
gtttctctca actgcactta cagcaacagt gcttttcaat acttcatgtg gtacagacag 180
tattccagaa aaggccctga gttgctgatg tacacatact ccagtggtaa caaagaagat 240
ggaaggttta cagcacaggt cgataaatcc agcaagtata tctccttgtt catcagagac 300
tcacagccca gtgattcagc cacctacctc tgtgcaatga gcgcaggagc tgcaggcaac 360
aagctaactt ttggaggagg aaccagggtg ctagttaaac caaatatcca gaaccctgac 420
cctgcc 426
<210> 134
<211> 405
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR19_TCRb基因片段
<400> 134
atgggctcct ggaccctctg ctgtgtgtcc ctttgcatcc tggtagcaaa gcacacagat 60
gctggagtta tccagtcacc ccggcacgag gtgacagaga tgggacaaga agtgactctg 120
agatgtaaac caatttcagg acacgactac cttttctggt acagacagac catgatgcgg 180
ggactggagt tgctcattta ctttaacaac aacgttccga tagatgattc agggatgccc 240
gaggatcgat tctcagctaa gatgcctaat gcatcattct ccactctgaa gatccagccc 300
tcagaaccca gggactcagc tgtgtacttc tgtgccagca gcccgacagg gggcggtatg 360
cttgggcagt attttggccc aggcacccgg ctgacagtgc tcgag 405
<210> 135
<211> 435
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR19_TCRa基因片段
<400> 135
atggccatgc tcctgggggc atcagtgctg attctgtggc ttcagccaga ctgggtaaac 60
agtcaacaga agaatgatga ccagcaagtt aagcaaaatt caccatccct gagcgtccag 120
gaaggaagaa tttctattct gaactgtgac tatactaaca gcatgtttga ttatttccta 180
tggtacaaaa aataccctgc tgaaggtcct acattcctga tatctataag ttccattaag 240
gataaaaatg aagatggaag attcactgtc ttcttaaaca aaagtgccaa gcacctctct 300
ctgcacattg tgccctccca gcctggagac tctgcagtgt acttctgtgc agcaagcgcg 360
aataacaatg acatgcgctt tggagcaggg accagactga cagtaaaacc aaatatccag 420
aaccctgacc ctgcc 435
<210> 136
<211> 402
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 A11_TCR16_TCRb基因片段
<400> 136
atgggctcct ggaccctctg ctgtgtgtcc ctttgcatcc tggtagcaaa gcacacagat 60
gctggagtta tccagtcacc ccggcacgag gtgacagaga tgggacaaga agtgactctg 120
agatgtaaac caatttcagg acatgactac cttttctggt acagacagac catgatgcgg 180
ggactggagt tgctcattta ctttaacaac aacgttccga tagatgattc agggatgccc 240
gaggatcgat tctcagctaa gatgcctaat gcatcattct ccactctgaa gatccagccc 300
tcagaaccca gggactcagc tgtgtacttc tgtgccagca gccgtttggg accgtacaat 360
gagcagttct tcgggccagg gacacggctc accgtgctag ag 402
<210> 137
<211> 411
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR16_TCRa基因片段
<400> 137
atggctttgc agagcactct gggggcggtg tggctagggc ttctcctcaa ctctctctgg 60
aaggttgcag aaagcaagga ccaagtgttt cagccttcca cagtggcatc ttcagaggga 120
gctgtggtgg aaatcttctg taatcactct gtgtccaatg cttacaactt cttctggtac 180
cttcacttcc cgggatgtgc accaagactc cttgttaaag gctcaaagcc ttctcagcag 240
ggacgataca acatgaccta tgaacggttc tcttcatcgc tgctcatcct ccaggtgcgg 300
gaggcagatg ctgctgttta ctactgtgtt ttgaacagag atgacaagat catctttgga 360
aaagggacac gacttcatat tctccccaat atccagaacc ctgaccctgc c 411
<210> 138
<211> 411
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR20_TCRb基因片段
<400> 138
atgggcacca ggctcctctg ctgggcggcc ctctgtctcc tgggagcaga actcacagaa 60
gctggagttg cccagtctcc cagatataag attatagaga aaaggcagag tgtggctttt 120
tggtgcaatc ctatatctgg ccatgctacc ctttactggt accagcagat cctgggacag 180
ggcccaaagc ttctgattca gtttcagaat aacggtgtag tggatgattc acagttgcct 240
aaggatcgat tttctgcaga gaggctcaaa ggagtagact ccactctcaa gatccagcct 300
gcaaagcttg aggactcggc cgtgtatctc tgtgccagca gccccacgtt cccagcggga 360
gatagagata cgcagtattt tggcccaggc acccggctga cagtgctcga g 411
<210> 139
<211> 408
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR20_ TCRa基因片段
<400> 139
atgaggctgg tggcaagagt aactgtgttt ctgacctttg gaactataat tgatgctaag 60
accacccagc ccccctccat ggattgcgct gaaggaagag ctgcaaacct gccttgtaat 120
cactctacca tcagtggaaa tgagtatgtg tattggtatc gacagattca ctcccagggg 180
ccacagtata tcattcatgg tctaaaaaac aatgaaacca atgaaatggc ctctctgatc 240
atcacagaag acagaaagtc cagcaccttg atcctgcccc acgctacgct gagagacact 300
gctgtgtact attgcatcgt cagattaaat tcaggaaaca cacctcttgt ctttggaaag 360
ggcacaagac tttctgtgat tgcaaatatc cagaaccctg accctgcc 408
<210> 140
<211> 396
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR21_TCRb基因片段
<400> 140
atgactatca ggctcctctg ctacatgggc ttttattttc tgggggcagg cctcatggaa 60
gctgacatct accagacccc aagatacctt gttataggga caggaaagaa gatcactctg 120
gaatgttctc aaaccatggg ccatgacaaa atgtactggt atcaacaaga tccaggaatg 180
gaactacacc tcatccacta ttcctatgga gttaattcca cagagaaggg agatctttcc 240
tctgagtcaa cagtctccag aataaggacg gagcattttc ccctgaccct ggagtctgcc 300
aggccctcac atacctctca gtacctctgt gccagcagtg tgggcttgta caatgagcag 360
ttcttcgggc cagggacacg gctcaccgtg ctagag 396
<210> 141
<211> 426
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR21_TCRa基因片段
<400> 141
atgatgaaat ccttgagagt tttactggtg atcctgtggc ttcagttaag ctgggtttgg 60
agccaacaga aggaggtgga gcaggatcct ggaccactca gtgttccaga gggagccatt 120
gtttctctca actgcactta cagcaacagt gcttttcaat acttcatgtg gtacagacag 180
tattccagaa aaggccctga gttgctgatg tacacatact ccagtggtaa caaagaagat 240
ggaaggttta cagcacaggt cgataaatcc agcaagtata tctccttgtt catcagagac 300
tcacagccca gtgattcagc cacctacctc tgtgcaatga gcgggggtaa tgcaggcaac 360
atgctcacct ttggaggggg aacaaggtta atggtcaaac cccatatcca gaaccctgac 420
cctgcc 426
<210> 142
<211> 411
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR24_TCRb基因片段
<400> 142
atgggcacca gcctcctctg ctggatggcc ctgtgtctcc tgggggcaga tcacgcagat 60
actggagtct cccagaaccc cagacacaag atcacaaaga ggggacagaa tgtaactttc 120
aggtgtgatc caatttctga acacaaccgc ctttattggt accgacagac cctggggcag 180
ggcccagagt ttctgactta cttccagaat gaagctcaac tagaaaaatc aaggctgctc 240
agtgatcggt tctctgcaga gaggcctaag ggatctttct ccaccttgga gatccagcgc 300
acagagcagg gggactcggc catgtatctc tgtgccagca gcccccctgg gtgggagcta 360
gccaaaaaca ttcagtactt cggcgccggg acccggctct cagtgctgga g 411
<210> 143
<211> 402
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR24_TCRa基因片段
<400> 143
atgtggggag ctttccttct ctatgtttcc atgaagatgg gaggcactgc aggacaaagc 60
cttgagcagc cctctgaagt gacagctgtg gaaggagcca ttgtccagat aaactgcacg 120
taccagacat ctgggtttta tgggctgtcc tggtaccagc aacatgatgg cggagcaccc 180
acatttcttt cttacaatgc tctggatggt ttggaggaga caggtcgttt ttcttcattc 240
cttagtcgct ctgatagtta tggttacctc cttctacagg agctccagat gaaagactct 300
gcctcttact tctgcgctgg gggggatagc agctataaat tgatcttcgg gagtgggacc 360
agactgctgg tcaggcctga tatccagaac cctgaccctg cc 402
<210> 144
<211> 399
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR23_TCRb基因片段
<400> 144
atgggcacga ggctcttctt ctatgtggcc ctttgtctgc tgtgggcagg acacagggat 60
gctgaaatca cccagagccc aagacacaag atcacagaga caggaaggca ggtgaccttg 120
gcgtgtcacc agacttggaa ccacaacaat atgttctggt atcgacaaga cctgggacat 180
gggctgaggc tgatccatta ctcatatggt gttcaagaca ctaacaaagg agaagtctca 240
gatggctaca gtgtctctag atcaaacaca gaggacctcc ccctcactct ggagtctgct 300
gcctcctccc agacatctgt atatttctgc gccagcagtg agtatgtggg ggcccacgag 360
cagtacttcg ggccgggcac caggctcacg gtcacagag 399
<210> 145
<211> 423
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR23_TCRa基因片段
<400> 145
atggtcctga aattctccgt gtccattctt tggattcagt tggcatgggt gagcacccag 60
ctgctggagc agagccctca gtttctaagc atccaagagg gagaaaatct cactgtgtac 120
tgcaactcct caagtgtttt ttccagctta caatggtaca gacaggagcc tggggaaggt 180
cctgtcctcc tggtgacagt agttacgggt ggagaagtga agaagctgaa gagactaacc 240
tttcagtttg gtgatgcaag aaaggacagt tctctccaca tcactgcagc ccagcctggt 300
gatacaggcc tctacctctg tgcaggagtg agagaagctg gtggtactag ctatggaaag 360
ctgacatttg gacaagggac catcttgact gtccatccaa atatccagaa ccctgaccct 420
gcc 423
<210> 146
<211> 393
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR15_TCRb基因片段
<400> 146
atgctctgct ctctccttgc ccttctcctg ggcactttct ttggggtcag atctcagact 60
attcatcaat ggccagcgac cctggtgcag cctgtgggca gcccgctctc tctggagtgc 120
actgtggagg gaacatcaaa ccccaaccta tactggtacc gacaggctgc aggcaggggc 180
ctccagctgc tcttctactc cgttggtatt ggccagatca gctctgaggt gccccagaat 240
ctctcagcct ccagacccca ggaccggcag ttcatcctga gttctaagaa gctcctcctc 300
agtgactctg gcttctatct ctgtgcctgg actctgacag ggtttggtca gccccagcat 360
tttggtgatg ggactcgact ctccatccta gag 393
<210> 147
<211> 417
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR15_TCRa基因片段
<400> 147
atgaaatcct tgagagtttt actagtgatc ctgtggcttc agttgagctg ggtttggagc 60
caacagaagg aggtggagca gaattctgga cccctcagtg ttccagaggg agccattgcc 120
tctctcaact gcacttacag tgaccgaggt tcccagtcct tcttctggta cagacaatat 180
tctgggaaaa gccctgagtt gataatgttc atatactcca atggtgacaa agaagatgga 240
aggtttacag cacagctcaa taaagccagc cagtatgttt ctctgctcat cagagactcc 300
cagcccagtg attcagccac ctacctctgt gccgtgaacg ctaggggcaa catgctcacc 360
tttggagggg gaacaaggtt aatggtcaaa ccccatatcc agaaccctga ccctgcc 417
<210> 148
<211> 405
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR17_TCRb基因片段 (nt -密码子优化)
<400> 148
atgggcatca gactcctttg cagggtggcc ttttgctttc tggctgtggg attagtggac 60
gtgaaggtta cccagagcag cagatatctg gtgaagagaa ccggcgagaa ggtgttcctg 120
gaatgtgtgc aggatatgga ccacgagaac atgttctggt acagacagga ccctggactg 180
ggactgagac tgatctactt cagctacgac gtgaagatga aggagaaggg cgatatccct 240
gagggctaca gcgtgagcag agagaaaaag gagaggttca gcctgattct ggaaagcgcc 300
agcacaaatc agaccagcat gtacctgtgc gcctcttctc ttggagctgg acagcacaat 360
tctcctctgc actttggaaa tggcaccaga ctgaccgtga cagag 405
<210> 149
<211> 439
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR17_TCRa基因片段 (nt -密码子优化)
<400> 149
atgttgaccg cttctctctt acgtgccgtg attgccagca tctgtgtggt gtcttctatg 60
gcccagaagg ttacacaggc tcagacagag atcagcgttg tggagaagga ggatgtgacc 120
ctggattgcg tgtacgagac aagagatacc acctactacc tgttctggta caagcagcct 180
ccttctggcg aactggtgtt cctgatccgg agaaacagct ttgatgagca gaacgagatt 240
agcggcaggt atagctggaa cttccagaag agcaccagca gcttcaactt caccatcaca 300
gcctctcagg tggtggattc tgccgtgtac ttttgtgccc tgtctgaggt gcatgcttct 360
ggaggaagct atatccccac ctttggaaga ggcacctctc tgattgtgca cccctacatc 420
cagaatcctg atcctgctt 439
<210> 150
<211> 402
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR14_TCRb基因片段 (nt -密码子优化)
<400> 150
atgggcttca gactcttatg ctgcgtggcc ttttgtctgc ttggagctgg acctgtggat 60
tctggagtta cccagacacc taaacacctg atcaccgcta caggacagag agtgaccctg 120
agatgtagcc ctagaagcgg agatctgtct gtgtactggt atcagcagag cctggatcaa 180
ggactgcagt tcctgatcca gtactacaac ggcgaggaaa gagccaaagg caacatcctg 240
gagagattta gcgcccagca gttccctgat ctgcattctg agctgaatct gagcagcctg 300
gaactgggag attctgctct gtacttctgt gccagcacac atggcagaga ttctaccgat 360
acccagtact ttggccctgg cacaagactg acagttctgg ag 402
<210> 151
<211> 420
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR14_TCRa基因片段 (nt -密码子优化)
<400> 151
atggagacac tgcttggcgt atcactggtg attctgtggc tgcaactggc tagagtgaac 60
tctcagcagg gagaagagga tcctcaagct ctgagcattc aggaaggcga aaatgccacc 120
atgaactgca gctacaagac cagcatcaac aacctgcagt ggtaccggca gaatagcgga 180
agaggactgg ttcacctgat cctgatcagg agcaatgaaa gggagaagca cagcggcaga 240
ctgagagtta ccctggatac cagcaagaag tctagcagcc tgctgattac agcctctaga 300
gccgccgata cagccagcta cttttgtgcc acagatgaag gaggaggagc tgatggactg 360
acatttggaa agggcacaca cctgatcatc cagccctaca tccagaatcc tgatcctgcc 420
<210> 152
<211> 399
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR18_TCRb基因片段 (nt -密码子优化)
<400> 152
atgggcttca gactcttatg ctgcgtggcc ttttgtctgc ttggagctgg acctgtggat 60
tctggagtta cccagacacc taaacacctg atcaccgcta caggacagag agtgaccctg 120
agatgtagcc ctagaagcgg agatctgtct gtgtactggt atcagcagag cctggatcaa 180
ggactgcagt tcctgatcca gtactacaac ggcgaggaaa gagccaaagg caacatcctg 240
gagagattta gcgcccagca gttccctgat ctgcattctg agctgaatct gagcagcctg 300
gaactgggag attctgctct gtacttctgt gcctctagcg tgacatgggg cccttatgag 360
cagtactttg gacctggcac aagactgaca gtgacagag 399
<210> 153
<211> 420
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR18_TCRa基因片段 (nt -密码子优化)
<400> 153
atggagacac tgcttggcgt atcactggtg attctgtggc tgcaactggc tagagtgaac 60
tctcagcagg gagaagagga tcctcaagct ctgagcattc aggaaggcga aaatgccacc 120
atgaactgca gctacaagac cagcatcaac aacctgcagt ggtaccggca gaatagcgga 180
agaggactgg ttcacctgat cctgatcagg agcaatgaaa gggagaagca cagcggcaga 240
ctgagagtta ccctggatac cagcaagaag tctagcagcc tgctgattac agcctctaga 300
gccgccgata cagccagcta cttttgtgcc acagatgaag gaggaggagc tgatggactg 360
acatttggaa agggcacaca cctgatcatc cagccctaca tccagaatcc tgatcctgcc 420
<210> 154
<211> 396
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR13_TCRb基因片段 (nt -密码子优化)
<400> 154
atgaccattc gactgctgtg ctacatgggc ttctacttcc tgggagctgg actgatggaa 60
gccgacattt accaaacccc cagatacctg gtgatcggaa caggcaagaa gatcaccctg 120
gagtgtagcc agacaatggg acacgacaag atgtactggt accagcagga tcctggaatg 180
gaactgcacc tgatccacta cagctatggc gtgaacagca cagagaaagg cgatctgagc 240
tctgagtcta cagtgagcag aatcaggacc gagcacttcc cactgacact ggaatctgct 300
agacctagcc acacaagcca gtacctttgt gcctcttctg aaggcctgta caacgagcag 360
ttctttggac ctggcaccag actgacagtg cttgaa 396
<210> 155
<211> 426
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR13_ TCRa基因片段 (nt -密码子优化)
<400> 155
atgatgaaga gcctgcgagt cctcctggtg attctgtggt tacagctgtc ttgggtgtgg 60
tctcagcaga aagaagtgga gcaggatcct ggacctctgt ctgtgcctga aggagctatt 120
gtgagcctga attgcaccta cagcaatagc gccttccagt acttcatgtg gtaccggcag 180
tacagcagaa agggccctga actgctgatg tacacctact ctagcggcaa taaggaagat 240
ggccggttta cagctcaggt ggacaagagc agcaagtaca tcagcctgtt catcagggat 300
tctcagccta gcgattctgc cacctacctg tgtgccatgt ctgcttctgc tgccggcaat 360
aaactgacat ttggaggagg cacaagagtg ctggtgaagc ccaacatcca gaatcctgat 420
cccgcc 426
<210> 156
<211> 396
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR22_TCRb基因片段 (nt -密码子优化)
<400> 156
atgaccattc gactgctgtg ctacatgggc ttctacttcc tgggagctgg actgatggaa 60
gccgacattt accaaacccc cagatacctg gtgatcggaa caggcaagaa gatcaccctg 120
gagtgtagcc agacaatggg acacgacaag atgtactggt accagcagga tcctggaatg 180
gaactgcacc tgatccacta cagctatggc gtgaacagca cagagaaagg cgatctgagc 240
tctgagtcta cagtgagcag aatcaggacc gagcacttcc cactgacact ggaatctgct 300
agacctagcc acacaagcca gtacctttgt gcctcttctc agggcctgta caatgagcag 360
tttttcggac ctggcaccag actgacagtg cttgaa 396
<210> 157
<211> 426
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR22_TCRa基因片段 (nt -密码子优化)
<400> 157
atgatgaaga gcctgcgagt cctcctggtg attctgtggt tacagctgtc ttgggtgtgg 60
tctcagcaga aagaagtgga gcaggatcct ggacctctgt ctgtgcctga aggagctatt 120
gtgagcctga attgcaccta cagcaatagc gccttccagt acttcatgtg gtaccggcag 180
tacagcagaa agggccctga actgctgatg tacacctact ctagcggcaa taaggaagat 240
ggccggttta cagctcaggt ggacaagagc agcaagtaca tcagcctgtt catcagggat 300
tctcagccta gcgattctgc cacctacctg tgtgccatgt ctgctggagc tgctggcaat 360
aaactgacat ttggaggagg cacaagagtg ctggtgaagc ccaacatcca gaatcccgat 420
cccgct 426
<210> 158
<211> 405
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR19_TCRb基因片段 (nt -密码子优化)
<400> 158
atgggaagct ggacactgtg ttgcgttagc ctgtgtatcc tggtggccaa acacacagat 60
gctggagtga ttcagagccc tagacacgag gtgacagaga tgggacagga agtgacactg 120
agatgtaagc ccattagcgg acacgactac ctgttctggt acaggcagac catgatgaga 180
ggactggaac tgctgatcta cttcaacaac aacgtgccca tcgacgatag cggcatgcct 240
gaggacagat ttagcgccaa gatgcctaat gccagctttt ctaccctgaa gatccagccc 300
tctgagccca gagattctgc cgtgtacttt tgtgcctcta gccctacagg aggaggaatg 360
ttaggccagt acttcggacc tggaaccaga ctgacagtgc ttgaa 405
<210> 159
<211> 435
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR19_TCRa基因片段 (nt -密码子优化)
<400> 159
atggccatgt tactaggagc gagcgtgctg attctgtggt tacagcctga ttgggtgaac 60
tctcagcaga agaacgatga tcagcaggtg aagcagaaca gcccctctct gtctgtgcag 120
gaaggcagaa tcagcatcct gaattgcgat tacaccaaca gcatgttcga ctacttcctg 180
tggtacaaga agtaccccgc cgagggccct acctttctga tcagcatctc tagcatcaag 240
gacaagaacg aagatggcag attcaccgtg ttcctgaaca agagcgccaa gcacctgagc 300
ctgcacattg tgccttctca acctggagat tctgccgtgt acttttgtgc tgcctctgcc 360
aacaacaacg acatgaggtt tggagccgga accagactga ccgtgaagcc taatatccag 420
aatcccgatc ctgct 435
<210> 160
<211> 402
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR16_TCRb基因片段 (nt -密码子优化)
<400> 160
atgggaagct ggacactgtg ttgcgttagc ctgtgtatcc tggtggccaa acacacagat 60
gctggagtga ttcagagccc tagacacgag gtgacagaga tgggacagga agtgacactg 120
agatgtaagc ccattagcgg acacgactac ctgttctggt acaggcagac catgatgaga 180
ggactggaac tgctgatcta cttcaacaac aacgtgccca tcgacgatag cggcatgcct 240
gaggacagat ttagcgccaa gatgcctaat gccagctttt ctaccctgaa gatccagccc 300
tctgagccca gagattctgc cgtgtacttt tgtgccagca gcagattagg cccctataat 360
gagcagttct tcggccctgg cacaagactg acagttcttg ag 402
<210> 161
<211> 411
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR16_TCRa基因片段 (nt -密码子优化)
<400> 161
atggctctgc aatctacact tggcgctgtt tggcttggac ttctgctgaa ctctctgtgg 60
aaagtggccg agagcaagga tcaggttttc cagccttcta cagtggcctc ttctgaagga 120
gctgtggtgg agatcttctg caaccactct gtgtctaacg cctacaactt cttctggtac 180
ctgcacttcc ctggctgtgc ccctagactg ctggttaagg gatctaagcc ttctcaacaa 240
ggcagataca acatgaccta cgagcgcttc agcagcagcc tgctgatcct gcaggtgaga 300
gaagctgatg ctgctgtgta ttattgtgtg ctgaacaggg acgacaagat catcttcggc 360
aagggcacca ggctgcacat cctgcctaat atccagaatc ctgatcctgc c 411
<210> 162
<211> 411
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR20_TCRb基因片段 (nt -密码子优化)
<400> 162
atgggcacaa gacttctctg ttgggctgct ctttgtctgc ttggagctga actgacagaa 60
gctggagttg cccagtctcc taggtacaag atcatcgaga agaggcagtc tgtggccttt 120
tggtgcaatc ccattagcgg acacgccacc ctgtactggt atcagcaaat tctgggacaa 180
ggccctaaac tgctgatcca gttccagaac aacggcgtgg tggacgattc tcaactgcct 240
aaggacaggt tttctgccga gagactgaaa ggcgtggata gcaccctgaa gatccaacca 300
gccaaactgg aggattctgc tgtgtacctg tgtgcttcta gccctacctt tcctgccgga 360
gatagagaca cccagtactt tggacctggc acaagactga cagttctgga g 411
<210> 163
<211> 408
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR20_ TCRa基因片段 (nt -密码子优化)
<400> 163
atgagactgg tggcacgcgt aactgtgttt ctgacctttg gcaccatcat cgatgccaag 60
acaacccaac ctcctagcat ggactgtgcc gagggaagag ctgctaatct gccttgtaat 120
cacagcacaa tcagcggcaa cgagtacgtg tactggtacc ggcagatcca ctctcaagga 180
cctcagtaca tcattcatgg cctgaagaac aacgagacca acgagatggc cagcctgatc 240
atcaccgagg acaggaagtc ttctaccctg attctgcctc atgctacact gagagatacc 300
gccgtgtact actgcatcgt gcggctgaat agcggcaata caccactggt gtttggaaaa 360
ggcacaaggc tgagcgtgat cgccaatatc cagaaccctg accctgct 408
<210> 164
<211> 396
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR21_TCRb基因片段 (nt -密码子优化)
<400> 164
atgaccattc gactgctgtg ctacatgggc ttctacttcc tgggagctgg actgatggaa 60
gccgacattt accaaacccc cagatacctg gtgatcggaa caggcaagaa gatcaccctg 120
gagtgtagcc agacaatggg acacgacaag atgtactggt accagcagga tcctggaatg 180
gaactgcacc tgatccacta cagctatggc gtgaacagca cagagaaagg cgatctgagc 240
tctgagtcta cagtgagcag aatcaggacc gagcacttcc cactgacact ggaatctgct 300
agacctagcc acacaagcca gtacctttgt gcctcttctg tgggcctgta caatgagcag 360
tttttcggac ctggcaccag actgacagtg cttgaa 396
<210> 165
<211> 426
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR21_TCRa基因片段 (nt -密码子优化)
<400> 165
atgatgaaga gcctgcgagt cctcctggtg attctgtggt tacagctgtc ttgggtgtgg 60
tctcagcaga aagaagtgga gcaggatcct ggacctctgt ctgtgcctga aggagctatt 120
gtgagcctga attgcaccta cagcaatagc gccttccagt acttcatgtg gtaccggcag 180
tacagcagaa agggccctga actgctgatg tacacctact ctagcggcaa taaggaagat 240
ggccggttta cagctcaggt ggacaagagc agcaagtaca tcagcctgtt catcagggat 300
tctcagccta gcgattctgc cacctacctg tgtgccatgt ctggcggaaa tgccggaaat 360
atgctgacat ttggaggagg cacaaggctg atggtgaaac cccacatcca gaaccctgat 420
cctgct 426
<210> 166
<211> 411
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR24_TCRb基因片段 (nt -密码子优化)
<400> 166
atgggcacat ctcttctctg ctggatggct ctttgtctgc ttggagccga tcatgccgat 60
acaggagtta gccagaaccc tagacacaag atcaccaaga gaggccagaa tgtgaccttc 120
cggtgcgatc ctattagcga gcacaacagg ctgtactggt acagacaaac actgggacaa 180
ggacctgagt tcctgaccta cttccagaac gaagcccagc tggagaagag tcgactcctg 240
agcgacagat ttagcgccga gagacctaaa ggcagcttta gcaccctgga gatccagaga 300
acagaacagg gcgattctgc catgtacctg tgtgcttcta gccctcctgg atgggaactg 360
gccaagaata tccagtactt tggagccggc acaagactgt ctgttctgga g 411
<210> 167
<211> 402
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR24_TCRa基因片段 (nt -密码子优化)
<400> 167
atgtggggcg cttttcttct gtatgtgagc atgaagatgg gcggaacagc tggacagtct 60
ctggaacagc ctagcgaggt tacagctgtt gaaggagcta ttgtgcagat caactgcacc 120
taccagacaa gcggcttcta cggcctgagc tggtatcaac agcacgatgg aggagctcct 180
acatttctga gctataatgc cctggatggc ctggaggaga caggcagatt tagcagcttc 240
ctgagcagat ctgactctta cggatatctg ctgctgcagg agctgcagat gaaggatagc 300
gccagctact tttgtgctgg aggagatagc tcttacaagc tgatcttcgg cagcggcaca 360
agactgctgg tgagacctga tatccagaat cctgatcctg ct 402
<210> 168
<211> 399
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR23_TCRb基因片段 (nt -密码子优化)
<400> 168
atgggcacac ggctgttttt ctacgttgcc ctttgtctgc tttgggctgg ccatagagat 60
gccgagatta cccagagccc cagacacaaa attaccgaga caggaagaca ggtgacactg 120
gcctgtcacc agacatggaa ccacaacaac atgttctggt acaggcagga tctgggacat 180
ggactgcggc tgatccacta ctcttatggc gtgcaggata ccaataaagg cgaagtgtct 240
gacggctaca gcgtgagcag gagcaatacc gaagatctgc ctctgacact ggaatctgct 300
gcttcttctc agacaagcgt gtacttctgc gcctctagcg agtatgtggg agcccatgaa 360
cagtactttg gacctggcac aagactgaca gtgacagag 399
<210> 169
<211> 423
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR23_TCRa基因片段 (nt -密码子优化)
<400> 169
atggtgctga agttctctgt ctcgatcctg tggatccagc ttgcttgggt gtctacacag 60
ctgctggaac agtctcctca gtttctgagc attcaggaag gcgagaatct gaccgtgtac 120
tgcaacagca gcagcgtgtt tagcagctta cagtggtaca gacaggagcc tggagaagga 180
ccagtgttac tggtgacagt ggtgacagga ggagaagtga agaagctgaa gagactgacc 240
ttccagttcg gcgatgccag aaaggatagc tctctgcaca tcacagctgc tcaacctgga 300
gacacaggcc tgtatctgtg tgccggagtg agagaagctg gaggaacatc ttatggcaag 360
ctgacctttg gacagggcac aatcctgaca gtgcacccca atatccagaa ccctgatcct 420
gct 423
<210> 170
<211> 393
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR15_TCRb基因片段 (nt -密码子优化)
<400> 170
atgctgtgct ctcttcttgc ccttctgctg ggcacctttt ttggcgtgag atctcagacc 60
attcaccaat ggcctgctac attagtgcag cctgtgggca gccctctttc tctggagtgt 120
acagtggaag gaacaagcaa tcccaacctt tactggtaca gacaggccgc cggaagagga 180
ctgcagctgc tgttttactc tgtgggaatt ggacagatta gctctgaagt tccccagaac 240
ctgtccgcct ccagacccca ggatagacag ttcattctga gctctaagaa acttctgctg 300
agcgatagcg gcttctacct gtgcgcctgg accctgacag gatttggaca acctcaacat 360
tttggagatg gcacaaggct gagcattctg gag 393
<210> 171
<211> 417
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR15_TCRa基因片段 (nt -密码子优化)
<400> 171
atgaagagcc tgagagtcct gctggtgatt ttgtggctgc agctgtcttg ggtttggtct 60
cagcagaaag aagtggagca gaatagcggc cctctgtctg ttcctgaagg cgctattgct 120
agcctgaatt gcacatacag cgatagagga tctcagagct tcttctggta ccggcagtac 180
agcggcaaga gcccagaact gatcatgttc atctacagca atggcgacaa ggaggatggc 240
aggtttacag cccagctgaa caaggccagc cagtatgttt ctctgctgat cagagatagc 300
cagcctagcg attctgccac ctacctgtgt gccgtgaacg ctagaggaaa tatgctgaca 360
tttggaggcg gcacaagact gatggtgaag ccccatatcc agaaccccga tcctgct 417
<210> 172
<211> 66
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 P2A-1 (密码子优化)
<400> 172
ggaagtggag ctacgaattt ttctttatta aaacaagcag gagatgttga ggagaatccc 60
ggtcca 66
<210> 173
<211> 63
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 P2A-2 (密码子优化)
<400> 173
agcggcgcca ccaacttcag cctgctgaaa caggccggcg acgtggaaga gaaccctggc 60
cct 63
<210> 174
<211> 65
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 P2A-3 (密码子优化)
<400> 174
gaagcggcgc cacaaatttc agcctgctga agcaggccgg cgacgtggaa gagaaccctg 60
gccct 65
<210> 175
<211> 66
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 P2A-4 (密码子优化)
<400> 175
ggctccggcg ccaccaactt ttcactgctg aaacaggctg gggatgtgga agaaaatccc 60
ggccca 66
<210> 176
<211> 66
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 P2A-5
<400> 176
ggcagcggcg ccaccaactt tagcctgctg aaacaggctg gcgacgtgga agagaacccc 60
ggacct 66
<210> 177
<211> 66
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 P2A-6
<400> 177
ggctctggcg ccaccaactt tagcctgctg aaacaggctg gcgacgtgga agagaacccc 60
ggacct 66
<210> 178
<211> 63
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 T2A
<400> 178
ggaagcggag agggcagagg aagtctgcta acatgcggtg acgtcgagga gaatcctgga 60
cct 63
<210> 179
<211> 69
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 E2A
<400> 179
ggaagcggac agtgtactaa ttatgctctc ttgaaattgg ctggagatgt tgagagcaac 60
cctggacct 69
<210> 180
<211> 75
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 F2A
<400> 180
ggaagcggag tgaaacagac tttgaatttt gaccttctca agttggcggg agacgtggag 60
tccaaccctg gacct 75
<210> 181
<211> 22
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 P2A-1
<400> 181
Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val
1 5 10 15
Glu Glu Asn Pro Gly Pro
20
<210> 182
<211> 21
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 P2A-2
<400> 182
Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu
1 5 10 15
Glu Asn Pro Gly Pro
20
<210> 183
<211> 21
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 T2A
<400> 183
Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu
1 5 10 15
Glu Asn Pro Gly Pro
20
<210> 184
<211> 23
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 E2A
<400> 184
Gly Ser Gly Gln Cys Thr Asn Tyr Ala Leu Leu Lys Leu Ala Gly Asp
1 5 10 15
Val Glu Ser Asn Pro Gly Pro
20
<210> 185
<211> 25
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 F2A
<400> 185
Gly Ser Gly Val Lys Gln Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala
1 5 10 15
Gly Asp Val Glu Ser Asn Pro Gly Pro
20 25
<210> 186
<211> 1511
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR17_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 186
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcatc agactccttt 60
gcagggtggc cttttgcttt ctggctgtgg gattagtgga cgtgaaggtt acccagagca 120
gcagatatct ggtgaagaga accggcgaga aggtgttcct ggaatgtgtg caggatatgg 180
accacgagaa catgttctgg tacagacagg accctggact gggactgaga ctgatctact 240
tcagctacga cgtgaagatg aaggagaagg gcgatatccc tgagggctac agcgtgagca 300
gagagaaaaa ggagaggttc agcctgattc tggaaagcgc cagcacaaat cagaccagca 360
tgtacctgtg cgcctcttct cttggagctg gacagcacaa ttctcctctg cactttggaa 420
atggcaccag actgaccgtg acagaggatc tgaacaaggt gttcccccca gaggtggccg 480
tgttcgagcc ttctgaggcc gagatctccc acacccagaa agccaccctc gtgtgcctgg 540
ccaccggctt tttccccgac cacgtggaac tgtcttggtg ggtcaacggc aaagaggtgc 600
actccggcgt gtgcaccgat ccccagcctc tgaaagaaca gcccgccctg aacgacagcc 660
ggtactgcct gagcagcaga ctgagagtgt ccgccacctt ctggcagaac ccccggaacc 720
acttcagatg ccaggtgcag ttctacggcc tgagcgagaa cgacgagtgg acccaggaca 780
gagccaagcc cgtgacacag atcgtgtctg ccgaagcctg gggcagagcc gattgcggct 840
ttacctccgt gtcctatcag cagggcgtgc tgagcgccac aatcctgtac gagatcctgc 900
tgggcaaggc caccctgtac gccgtgctgg tgtctgccct ggtgctgatg gccatggtca 960
agcggaagga cttcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atgttgaccg cttctctctt acgtgccgtg attgccagca 1080
tctgtgtggt gtcttctatg gcccagaagg ttacacaggc tcagacagag atcagcgttg 1140
tggagaagga ggatgtgacc ctggattgcg tgtacgagac aagagatacc acctactacc 1200
tgttctggta caagcagcct ccttctggcg aactggtgtt cctgatccgg agaaacagct 1260
ttgatgagca gaacgagatt agcggcaggt atagctggaa cttccagaag agcaccagca 1320
gcttcaactt caccatcaca gcctctcagg tggtggattc tgccgtgtac ttttgtgccc 1380
tgtctgaggt gcatgcttct ggaggaagct atatccccac ctttggaaga ggcacctctc 1440
tgattgtgca cccctacatc cagaatcctg atcctgctgt gtaccagctg cgggacagca 1500
agagcagcga c 1511
<210> 187
<211> 1496
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR14_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 187
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcttc agactcttat 60
gctgcgtggc cttttgtctg cttggagctg gacctgtgga ttctggagtt acccagacac 120
ctaaacacct gatcaccgct acaggacaga gagtgaccct gagatgtagc cctagaagcg 180
gagatctgtc tgtgtactgg tatcagcaga gcctggatca aggactgcag ttcctgatcc 240
agtactacaa cggcgaggaa agagccaaag gcaacatcct ggagagattt agcgcccagc 300
agttccctga tctgcattct gagctgaatc tgagcagcct ggaactggga gattctgctc 360
tgtacttctg tgccagcaca catggcagag attctaccga tacccagtac tttggccctg 420
gcacaagact gacagttctg gaggacctga agaacgtgtt ccccccagag gtggccgtgt 480
tcgagcctag cgaggccgag atcagccaca cccagaaagc caccctcgtg tgcctggcca 540
ccggctttta ccccgaccac gtggaactgt cttggtgggt caacggcaaa gaggtgcaca 600
gcggcgtctg caccgacccc cagcccctga aagagcagcc cgccctgaac gacagccggt 660
actgtctgag cagcagactg agagtgtccg ccaccttctg gcagaacccc cggaaccact 720
tcagatgcca ggtgcagttc tacggcctga gcgagaacga cgagtggacc caggaccggg 780
ccaagcccgt gacccagatc gtgtctgctg aggcctgggg cagagccgat tgcggcttca 840
ccagcgagag ctaccagcag ggcgtgctga gcgccaccat cctgtacgag atcctgctgg 900
gcaaggccac cctgtacgcc gtgctggtgt ccgccctggt gctgatggcc atggtcaagc 960
ggaaggacag ccggggcggt tccggagcca cgaacttctc tctgttaaag caagcaggag 1020
acgtggaaga aaaccccggt cccatggaga cactgcttgg cgtatcactg gtgattctgt 1080
ggctgcaact ggctagagtg aactctcagc agggagaaga ggatcctcaa gctctgagca 1140
ttcaggaagg cgaaaatgcc accatgaact gcagctacaa gaccagcatc aacaacctgc 1200
agtggtaccg gcagaatagc ggaagaggac tggttcacct gatcctgatc aggagcaatg 1260
aaagggagaa gcacagcggc agactgagag ttaccctgga taccagcaag aagtctagca 1320
gcctgctgat tacagcctct agagccgccg atacagccag ctacttttgt gccacagatg 1380
aaggaggagg agctgatgga ctgacatttg gaaagggcac acacctgatc atccagccct 1440
acatccagaa tcctgatcct gccgtgtacc agctgcggga cagcaagagc agcgac 1496
<210> 188
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR18_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 188
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcttc agactcttat 60
gctgcgtggc cttttgtctg cttggagctg gacctgtgga ttctggagtt acccagacac 120
ctaaacacct gatcaccgct acaggacaga gagtgaccct gagatgtagc cctagaagcg 180
gagatctgtc tgtgtactgg tatcagcaga gcctggatca aggactgcag ttcctgatcc 240
agtactacaa cggcgaggaa agagccaaag gcaacatcct ggagagattt agcgcccagc 300
agttccctga tctgcattct gagctgaatc tgagcagcct ggaactggga gattctgctc 360
tgtacttctg tgcctctagc gtgacatggg gcccttatga gcagtacttt ggacctggca 420
caagactgac agtgacagag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atggagacac tgcttggcgt atcactggtg attctgtggc 1080
tgcaactggc tagagtgaac tctcagcagg gagaagagga tcctcaagct ctgagcattc 1140
aggaaggcga aaatgccacc atgaactgca gctacaagac cagcatcaac aacctgcagt 1200
ggtaccggca gaatagcgga agaggactgg ttcacctgat cctgatcagg agcaatgaaa 1260
gggagaagca cagcggcaga ctgagagtta ccctggatac cagcaagaag tctagcagcc 1320
tgctgattac agcctctaga gccgccgata cagccagcta cttttgtgcc acagatgaag 1380
gaggaggagc tgatggactg acatttggaa agggcacaca cctgatcatc cagccctaca 1440
tccagaatcc tgatcctgcc gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 189
<211> 1496
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR13_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 189
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgaccatt cgactgctgt 60
gctacatggg cttctacttc ctgggagctg gactgatgga agccgacatt taccaaaccc 120
ccagatacct ggtgatcgga acaggcaaga agatcaccct ggagtgtagc cagacaatgg 180
gacacgacaa gatgtactgg taccagcagg atcctggaat ggaactgcac ctgatccact 240
acagctatgg cgtgaacagc acagagaaag gcgatctgag ctctgagtct acagtgagca 300
gaatcaggac cgagcacttc ccactgacac tggaatctgc tagacctagc cacacaagcc 360
agtacctttg tgcctcttct gaaggcctgt acaacgagca gttctttgga cctggcacca 420
gactgacagt gcttgaagac ctgaagaacg tgttcccccc agaggtggcc gtgttcgagc 480
ctagcgaggc cgagatcagc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
tttaccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cacagcggcg 600
tctgcaccga cccccagccc ctgaaagagc agcccgccct gaacgacagc cggtactgtc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac cgggccaagc 780
ccgtgaccca gatcgtgtct gctgaggcct ggggcagagc cgattgcggc ttcaccagcg 840
agagctacca gcagggcgtg ctgagcgcca ccatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtccgccc tggtgctgat ggccatggtc aagcggaagg 960
acagccgggg cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg atgaagagcc tgcgagtcct cctggtgatt ctgtggttac 1080
agctgtcttg ggtgtggtct cagcagaaag aagtggagca ggatcctgga cctctgtctg 1140
tgcctgaagg agctattgtg agcctgaatt gcacctacag caatagcgcc ttccagtact 1200
tcatgtggta ccggcagtac agcagaaagg gccctgaact gctgatgtac acctactcta 1260
gcggcaataa ggaagatggc cggtttacag ctcaggtgga caagagcagc aagtacatca 1320
gcctgttcat cagggattct cagcctagcg attctgccac ctacctgtgt gccatgtctg 1380
cttctgctgc cggcaataaa ctgacatttg gaggaggcac aagagtgctg gtgaagccca 1440
acatccagaa tcctgatccc gccgtgtacc agctgcggga cagcaagagc agcgac 1496
<210> 190
<211> 1496
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR22_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 190
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgaccatt cgactgctgt 60
gctacatggg cttctacttc ctgggagctg gactgatgga agccgacatt taccaaaccc 120
ccagatacct ggtgatcgga acaggcaaga agatcaccct ggagtgtagc cagacaatgg 180
gacacgacaa gatgtactgg taccagcagg atcctggaat ggaactgcac ctgatccact 240
acagctatgg cgtgaacagc acagagaaag gcgatctgag ctctgagtct acagtgagca 300
gaatcaggac cgagcacttc ccactgacac tggaatctgc tagacctagc cacacaagcc 360
agtacctttg tgcctcttct cagggcctgt acaatgagca gtttttcgga cctggcacca 420
gactgacagt gcttgaagac ctgaagaacg tgttcccccc agaggtggcc gtgttcgagc 480
ctagcgaggc cgagatcagc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
tttaccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cacagcggcg 600
tctgcaccga cccccagccc ctgaaagagc agcccgccct gaacgacagc cggtactgtc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac cgggccaagc 780
ccgtgaccca gatcgtgtct gctgaggcct ggggcagagc cgattgcggc ttcaccagcg 840
agagctacca gcagggcgtg ctgagcgcca ccatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtccgccc tggtgctgat ggccatggtc aagcggaagg 960
acagccgggg cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg atgaagagcc tgcgagtcct cctggtgatt ctgtggttac 1080
agctgtcttg ggtgtggtct cagcagaaag aagtggagca ggatcctgga cctctgtctg 1140
tgcctgaagg agctattgtg agcctgaatt gcacctacag caatagcgcc ttccagtact 1200
tcatgtggta ccggcagtac agcagaaagg gccctgaact gctgatgtac acctactcta 1260
gcggcaataa ggaagatggc cggtttacag ctcaggtgga caagagcagc aagtacatca 1320
gcctgttcat cagggattct cagcctagcg attctgccac ctacctgtgt gccatgtctg 1380
ctggagctgc tggcaataaa ctgacatttg gaggaggcac aagagtgctg gtgaagccca 1440
acatccagaa tcccgatccc gctgtgtacc agctgcggga cagcaagagc agcgac 1496
<210> 191
<211> 1514
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR19_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 191
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggaagc tggacactgt 60
gttgcgttag cctgtgtatc ctggtggcca aacacacaga tgctggagtg attcagagcc 120
ctagacacga ggtgacagag atgggacagg aagtgacact gagatgtaag cccattagcg 180
gacacgacta cctgttctgg tacaggcaga ccatgatgag aggactggaa ctgctgatct 240
acttcaacaa caacgtgccc atcgacgata gcggcatgcc tgaggacaga tttagcgcca 300
agatgcctaa tgccagcttt tctaccctga agatccagcc ctctgagccc agagattctg 360
ccgtgtactt ttgtgcctct agccctacag gaggaggaat gttaggccag tacttcggac 420
ctggaaccag actgacagtg cttgaagacc tgaagaacgt gttcccccca gaggtggccg 480
tgttcgagcc tagcgaggcc gagatcagcc acacccagaa agccaccctc gtgtgcctgg 540
ccaccggctt ttaccccgac cacgtggaac tgtcttggtg ggtcaacggc aaagaggtgc 600
acagcggcgt ctgcaccgac ccccagcccc tgaaagagca gcccgccctg aacgacagcc 660
ggtactgtct gagcagcaga ctgagagtgt ccgccacctt ctggcagaac ccccggaacc 720
acttcagatg ccaggtgcag ttctacggcc tgagcgagaa cgacgagtgg acccaggacc 780
gggccaagcc cgtgacccag atcgtgtctg ctgaggcctg gggcagagcc gattgcggct 840
tcaccagcga gagctaccag cagggcgtgc tgagcgccac catcctgtac gagatcctgc 900
tgggcaaggc caccctgtac gccgtgctgg tgtccgccct ggtgctgatg gccatggtca 960
agcggaagga cagccggggc ggttccggag ccacgaactt ctctctgtta aagcaagcag 1020
gagacgtgga agaaaacccc ggtcccatgg ccatgttact aggagcgagc gtgctgattc 1080
tgtggttaca gcctgattgg gtgaactctc agcagaagaa cgatgatcag caggtgaagc 1140
agaacagccc ctctctgtct gtgcaggaag gcagaatcag catcctgaat tgcgattaca 1200
ccaacagcat gttcgactac ttcctgtggt acaagaagta ccccgccgag ggccctacct 1260
ttctgatcag catctctagc atcaaggaca agaacgaaga tggcagattc accgtgttcc 1320
tgaacaagag cgccaagcac ctgagcctgc acattgtgcc ttctcaacct ggagattctg 1380
ccgtgtactt ttgtgctgcc tctgccaaca acaacgacat gaggtttgga gccggaacca 1440
gactgaccgt gaagcctaat atccagaatc ccgatcctgc tgtgtaccag ctgcgggaca 1500
gcaagagcag cgac 1514
<210> 192
<211> 1487
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR16_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 192
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggaagc tggacactgt 60
gttgcgttag cctgtgtatc ctggtggcca aacacacaga tgctggagtg attcagagcc 120
ctagacacga ggtgacagag atgggacagg aagtgacact gagatgtaag cccattagcg 180
gacacgacta cctgttctgg tacaggcaga ccatgatgag aggactggaa ctgctgatct 240
acttcaacaa caacgtgccc atcgacgata gcggcatgcc tgaggacaga tttagcgcca 300
agatgcctaa tgccagcttt tctaccctga agatccagcc ctctgagccc agagattctg 360
ccgtgtactt ttgtgccagc agcagattag gcccctataa tgagcagttc ttcggccctg 420
gcacaagact gacagttctt gaggacctga agaacgtgtt ccccccagag gtggccgtgt 480
tcgagcctag cgaggccgag atcagccaca cccagaaagc caccctcgtg tgcctggcca 540
ccggctttta ccccgaccac gtggaactgt cttggtgggt caacggcaaa gaggtgcaca 600
gcggcgtctg caccgacccc cagcccctga aagagcagcc cgccctgaac gacagccggt 660
actgtctgag cagcagactg agagtgtccg ccaccttctg gcagaacccc cggaaccact 720
tcagatgcca ggtgcagttc tacggcctga gcgagaacga cgagtggacc caggaccggg 780
ccaagcccgt gacccagatc gtgtctgctg aggcctgggg cagagccgat tgcggcttca 840
ccagcgagag ctaccagcag ggcgtgctga gcgccaccat cctgtacgag atcctgctgg 900
gcaaggccac cctgtacgcc gtgctggtgt ccgccctggt gctgatggcc atggtcaagc 960
ggaaggacag ccggggcggt tccggagcca cgaacttctc tctgttaaag caagcaggag 1020
acgtggaaga aaaccccggt cccatggctc tgcaatctac acttggcgct gtttggcttg 1080
gacttctgct gaactctctg tggaaagtgg ccgagagcaa ggatcaggtt ttccagcctt 1140
ctacagtggc ctcttctgaa ggagctgtgg tggagatctt ctgcaaccac tctgtgtcta 1200
acgcctacaa cttcttctgg tacctgcact tccctggctg tgcccctaga ctgctggtta 1260
agggatctaa gccttctcaa caaggcagat acaacatgac ctacgagcgc ttcagcagca 1320
gcctgctgat cctgcaggtg agagaagctg atgctgctgt gtattattgt gtgctgaaca 1380
gggacgacaa gatcatcttc ggcaagggca ccaggctgca catcctgcct aatatccaga 1440
atcctgatcc tgccgtgtac cagctgcggg acagcaagag cagcgac 1487
<210> 193
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR20_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 193
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca agacttctct 60
gttgggctgc tctttgtctg cttggagctg aactgacaga agctggagtt gcccagtctc 120
ctaggtacaa gatcatcgag aagaggcagt ctgtggcctt ttggtgcaat cccattagcg 180
gacacgccac cctgtactgg tatcagcaaa ttctgggaca aggccctaaa ctgctgatcc 240
agttccagaa caacggcgtg gtggacgatt ctcaactgcc taaggacagg ttttctgccg 300
agagactgaa aggcgtggat agcaccctga agatccaacc agccaaactg gaggattctg 360
ctgtgtacct gtgtgcttct agccctacct ttcctgccgg agatagagac acccagtact 420
ttggacctgg cacaagactg acagttctgg aggacctgaa gaacgtgttc cccccagagg 480
tggccgtgtt cgagcctagc gaggccgaga tcagccacac ccagaaagcc accctcgtgt 540
gcctggccac cggcttttac cccgaccacg tggaactgtc ttggtgggtc aacggcaaag 600
aggtgcacag cggcgtctgc accgaccccc agcccctgaa agagcagccc gccctgaacg 660
acagccggta ctgtctgagc agcagactga gagtgtccgc caccttctgg cagaaccccc 720
ggaaccactt cagatgccag gtgcagttct acggcctgag cgagaacgac gagtggaccc 780
aggaccgggc caagcccgtg acccagatcg tgtctgctga ggcctggggc agagccgatt 840
gcggcttcac cagcgagagc taccagcagg gcgtgctgag cgccaccatc ctgtacgaga 900
tcctgctggg caaggccacc ctgtacgccg tgctggtgtc cgccctggtg ctgatggcca 960
tggtcaagcg gaaggacagc cggggcggtt ccggagccac gaacttctct ctgttaaagc 1020
aagcaggaga cgtggaagaa aaccccggtc ccatgagact ggtggcacgc gtaactgtgt 1080
ttctgacctt tggcaccatc atcgatgcca agacaaccca acctcctagc atggactgtg 1140
ccgagggaag agctgctaat ctgccttgta atcacagcac aatcagcggc aacgagtacg 1200
tgtactggta ccggcagatc cactctcaag gacctcagta catcattcat ggcctgaaga 1260
acaacgagac caacgagatg gccagcctga tcatcaccga ggacaggaag tcttctaccc 1320
tgattctgcc tcatgctaca ctgagagata ccgccgtgta ctactgcatc gtgcggctga 1380
atagcggcaa tacaccactg gtgtttggaa aaggcacaag gctgagcgtg atcgccaata 1440
tccagaaccc tgaccctgct gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 194
<211> 1496
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR21_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 194
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgaccatt cgactgctgt 60
gctacatggg cttctacttc ctgggagctg gactgatgga agccgacatt taccaaaccc 120
ccagatacct ggtgatcgga acaggcaaga agatcaccct ggagtgtagc cagacaatgg 180
gacacgacaa gatgtactgg taccagcagg atcctggaat ggaactgcac ctgatccact 240
acagctatgg cgtgaacagc acagagaaag gcgatctgag ctctgagtct acagtgagca 300
gaatcaggac cgagcacttc ccactgacac tggaatctgc tagacctagc cacacaagcc 360
agtacctttg tgcctcttct gtgggcctgt acaatgagca gtttttcgga cctggcacca 420
gactgacagt gcttgaagac ctgaagaacg tgttcccccc agaggtggcc gtgttcgagc 480
ctagcgaggc cgagatcagc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
tttaccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cacagcggcg 600
tctgcaccga cccccagccc ctgaaagagc agcccgccct gaacgacagc cggtactgtc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac cgggccaagc 780
ccgtgaccca gatcgtgtct gctgaggcct ggggcagagc cgattgcggc ttcaccagcg 840
agagctacca gcagggcgtg ctgagcgcca ccatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtccgccc tggtgctgat ggccatggtc aagcggaagg 960
acagccgggg cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg atgaagagcc tgcgagtcct cctggtgatt ctgtggttac 1080
agctgtcttg ggtgtggtct cagcagaaag aagtggagca ggatcctgga cctctgtctg 1140
tgcctgaagg agctattgtg agcctgaatt gcacctacag caatagcgcc ttccagtact 1200
tcatgtggta ccggcagtac agcagaaagg gccctgaact gctgatgtac acctactcta 1260
gcggcaataa ggaagatggc cggtttacag ctcaggtgga caagagcagc aagtacatca 1320
gcctgttcat cagggattct cagcctagcg attctgccac ctacctgtgt gccatgtctg 1380
gcggaaatgc cggaaatatg ctgacatttg gaggaggcac aaggctgatg gtgaaacccc 1440
acatccagaa ccctgatcct gctgtgtacc agctgcggga cagcaagagc agcgac 1496
<210> 195
<211> 1487
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR24_TCRb-p2a-TCRα seq
(密码子优化,具有Gibson端)
<400> 195
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca tctcttctct 60
gctggatggc tctttgtctg cttggagccg atcatgccga tacaggagtt agccagaacc 120
ctagacacaa gatcaccaag agaggccaga atgtgacctt ccggtgcgat cctattagcg 180
agcacaacag gctgtactgg tacagacaaa cactgggaca aggacctgag ttcctgacct 240
acttccagaa cgaagcccag ctggagaaga gtcgactcct gagcgacaga tttagcgccg 300
agagacctaa aggcagcttt agcaccctgg agatccagag aacagaacag ggcgattctg 360
ccatgtacct gtgtgcttct agccctcctg gatgggaact ggccaagaat atccagtact 420
ttggagccgg cacaagactg tctgttctgg aggacctgaa gaacgtgttc cccccagagg 480
tggccgtgtt cgagcctagc gaggccgaga tcagccacac ccagaaagcc accctcgtgt 540
gcctggccac cggcttttac cccgaccacg tggaactgtc ttggtgggtc aacggcaaag 600
aggtgcacag cggcgtctgc accgaccccc agcccctgaa agagcagccc gccctgaacg 660
acagccggta ctgtctgagc agcagactga gagtgtccgc caccttctgg cagaaccccc 720
ggaaccactt cagatgccag gtgcagttct acggcctgag cgagaacgac gagtggaccc 780
aggaccgggc caagcccgtg acccagatcg tgtctgctga ggcctggggc agagccgatt 840
gcggcttcac cagcgagagc taccagcagg gcgtgctgag cgccaccatc ctgtacgaga 900
tcctgctggg caaggccacc ctgtacgccg tgctggtgtc cgccctggtg ctgatggcca 960
tggtcaagcg gaaggacagc cggggcggtt ccggagccac gaacttctct ctgttaaagc 1020
aagcaggaga cgtggaagaa aaccccggtc ccatgtgggg cgcttttctt ctgtatgtga 1080
gcatgaagat gggcggaaca gctggacagt ctctggaaca gcctagcgag gttacagctg 1140
ttgaaggagc tattgtgcag atcaactgca cctaccagac aagcggcttc tacggcctga 1200
gctggtatca acagcacgat ggaggagctc ctacatttct gagctataat gccctggatg 1260
gcctggagga gacaggcaga tttagcagct tcctgagcag atctgactct tacggatatc 1320
tgctgctgca ggagctgcag atgaaggata gcgccagcta cttttgtgct ggaggagata 1380
gctcttacaa gctgatcttc ggcagcggca caagactgct ggtgagacct gatatccaga 1440
atcctgatcc tgctgtgtac cagctgcggg acagcaagag cagcgac 1487
<210> 196
<211> 1372
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR23_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 196
acacaaaatt accgagacag gaagacaggt gacactggcc tgtcaccaga catggaacca 60
caacaacatg ttctggtaca ggcaggatct gggacatgga ctgcggctga tccactactc 120
ttatggcgtg caggatacca ataaaggcga agtgtctgac ggctacagcg tgagcaggag 180
caataccgaa gatctgcctc tgacactgga atctgctgct tcttctcaga caagcgtgta 240
cttctgcgcc tctagcgagt atgtgggagc ccatgaacag tactttggac ctggcacaag 300
actgacagtg acagaggacc tgaagaacgt gttcccccca gaggtggccg tgttcgagcc 360
tagcgaggcc gagatcagcc acacccagaa agccaccctc gtgtgcctgg ccaccggctt 420
ttaccccgac cacgtggaac tgtcttggtg ggtcaacggc aaagaggtgc acagcggcgt 480
ctgcaccgac ccccagcccc tgaaagagca gcccgccctg aacgacagcc ggtactgtct 540
gagcagcaga ctgagagtgt ccgccacctt ctggcagaac ccccggaacc acttcagatg 600
ccaggtgcag ttctacggcc tgagcgagaa cgacgagtgg acccaggacc gggccaagcc 660
cgtgacccag atcgtgtctg ctgaggcctg gggcagagcc gattgcggct tcaccagcga 720
gagctaccag cagggcgtgc tgagcgccac catcctgtac gagatcctgc tgggcaaggc 780
caccctgtac gccgtgctgg tgtccgccct ggtgctgatg gccatggtca agcggaagga 840
cagccggggc ggttccggag ccacgaactt ctctctgtta aagcaagcag gagacgtgga 900
agaaaacccc ggtcccatgg tgctgaagtt ctctgtctcg atcctgtgga tccagcttgc 960
ttgggtgtct acacagctgc tggaacagtc tcctcagttt ctgagcattc aggaaggcga 1020
gaatctgacc gtgtactgca acagcagcag cgtgtttagc agcttacagt ggtacagaca 1080
ggagcctgga gaaggaccag tgttactggt gacagtggtg acaggaggag aagtgaagaa 1140
gctgaagaga ctgaccttcc agttcggcga tgccagaaag gatagctctc tgcacatcac 1200
agctgctcaa cctggagaca caggcctgta tctgtgtgcc ggagtgagag aagctggagg 1260
aacatcttat ggcaagctga cctttggaca gggcacaatc ctgacagtgc accccaatat 1320
ccagaaccct gatcctgctg tgtaccagct gcgggacagc aagagcagcg ac 1372
<210> 197
<211> 1352
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 TCR15_TCRb-p2a-TCRa seq
(密码子优化,具有Gibson端)
<400> 197
tgcagcctgt gggcagccct ctttctctgg agtgtacagt ggaaggaaca agcaatccca 60
acctttactg gtacagacag gccgccggaa gaggactgca gctgctgttt tactctgtgg 120
gaattggaca gattagctct gaagttcccc agaacctgtc cgcctccaga ccccaggata 180
gacagttcat tctgagctct aagaaacttc tgctgagcga tagcggcttc tacctgtgcg 240
cctggaccct gacaggattt ggacaacctc aacattttgg agatggcaca aggctgagca 300
ttctggagga tctgaacaag gtgttccccc cagaggtggc cgtgttcgag ccttctgagg 360
ccgagatctc ccacacccag aaagccaccc tcgtgtgcct ggccaccggc tttttccccg 420
accacgtgga actgtcttgg tgggtcaacg gcaaagaggt gcactccggc gtgtgcaccg 480
atccccagcc tctgaaagaa cagcccgccc tgaacgacag ccggtactgc ctgagcagca 540
gactgagagt gtccgccacc ttctggcaga acccccggaa ccacttcaga tgccaggtgc 600
agttctacgg cctgagcgag aacgacgagt ggacccagga cagagccaag cccgtgacac 660
agatcgtgtc tgccgaagcc tggggcagag ccgattgcgg ctttacctcc gtgtcctatc 720
agcagggcgt gctgagcgcc acaatcctgt acgagatcct gctgggcaag gccaccctgt 780
acgccgtgct ggtgtctgcc ctggtgctga tggccatggt caagcggaag gacttcggtt 840
ccggagccac gaacttctct ctgttaaagc aagcaggaga cgtggaagaa aaccccggtc 900
ccatgaagag cctgagagtc ctgctggtga ttttgtggct gcagctgtct tgggtttggt 960
ctcagcagaa agaagtggag cagaatagcg gccctctgtc tgttcctgaa ggcgctattg 1020
ctagcctgaa ttgcacatac agcgatagag gatctcagag cttcttctgg taccggcagt 1080
acagcggcaa gagcccagaa ctgatcatgt tcatctacag caatggcgac aaggaggatg 1140
gcaggtttac agcccagctg aacaaggcca gccagtatgt ttctctgctg atcagagata 1200
gccagcctag cgattctgcc acctacctgt gtgccgtgaa cgctagagga aatatgctga 1260
catttggagg cggcacaaga ctgatggtga agccccatat ccagaacccc gatcctgctg 1320
tgtaccagct gcgggacagc aagagcagcg ac 1352
<210> 198
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 KRAS 5-14 G12D
<400> 198
Lys Leu Val Val Val Gly Ala Asp Gly Val
1 5 10
<210> 199
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 KRAS 6-14 G12D
<400> 199
Leu Val Val Val Gly Ala Asp Gly Val
1 5
<210> 200
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 KRAS 5-14 G12V
<400> 200
Lys Leu Val Val Val Gly Ala Val Gly Val
1 5 10
<210> 201
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 KRAS 6-14 G12V
<400> 201
Leu Val Val Val Gly Ala Val Gly Val
1 5
<210> 202
<211> 146
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR17a片段
<400> 202
Met Leu Thr Ala Ser Leu Leu Arg Ala Val Ile Ala Ser Ile Cys Val
1 5 10 15
Val Ser Ser Met Ala Gln Lys Val Thr Gln Ala Gln Thr Glu Ile Ser
20 25 30
Val Val Glu Lys Glu Asp Val Thr Leu Asp Cys Val Tyr Glu Thr Arg
35 40 45
Asp Thr Thr Tyr Tyr Leu Phe Trp Tyr Lys Gln Pro Pro Ser Gly Glu
50 55 60
Leu Val Phe Leu Ile Arg Arg Asn Ser Phe Asp Glu Gln Asn Glu Ile
65 70 75 80
Ser Gly Arg Tyr Ser Trp Asn Phe Gln Lys Ser Thr Ser Ser Phe Asn
85 90 95
Phe Thr Ile Thr Ala Ser Gln Val Val Asp Ser Ala Val Tyr Phe Cys
100 105 110
Ala Leu Ser Glu Val His Ala Ser Gly Gly Ser Tyr Ile Pro Thr Phe
115 120 125
Gly Arg Gly Thr Ser Leu Ile Val His Pro Tyr Ile Gln Asn Pro Asp
130 135 140
Pro Ala
145
<210> 203
<211> 140
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR14a片段
<400> 203
Met Glu Thr Leu Leu Gly Val Ser Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ala Arg Val Asn Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser
20 25 30
Ile Gln Glu Gly Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser
35 40 45
Ile Asn Asn Leu Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val
50 55 60
His Leu Ile Leu Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg
65 70 75 80
Leu Arg Val Thr Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile
85 90 95
Thr Ala Ser Arg Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp
100 105 110
Glu Gly Gly Gly Ala Asp Gly Leu Thr Phe Gly Lys Gly Thr His Leu
115 120 125
Ile Ile Gln Pro Tyr Ile Gln Asn Pro Asp Pro Ala
130 135 140
<210> 204
<211> 140
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR18a片段
<400> 204
Met Glu Thr Leu Leu Gly Val Ser Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ala Arg Val Asn Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser
20 25 30
Ile Gln Glu Gly Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser
35 40 45
Ile Asn Asn Leu Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val
50 55 60
His Leu Ile Leu Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg
65 70 75 80
Leu Arg Val Thr Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile
85 90 95
Thr Ala Ser Arg Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp
100 105 110
Glu Gly Gly Gly Ala Asp Gly Leu Thr Phe Gly Lys Gly Thr His Leu
115 120 125
Ile Ile Gln Pro Tyr Ile Gln Asn Pro Asp Pro Ala
130 135 140
<210> 205
<211> 142
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR13a片段
<400> 205
Met Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ser Trp Val Trp Ser Gln Gln Lys Glu Val Glu Gln Asp Pro Gly Pro
20 25 30
Leu Ser Val Pro Glu Gly Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser
35 40 45
Asn Ser Ala Phe Gln Tyr Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys
50 55 60
Gly Pro Glu Leu Leu Met Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp
65 70 75 80
Gly Arg Phe Thr Ala Gln Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu
85 90 95
Phe Ile Arg Asp Ser Gln Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala
100 105 110
Met Ser Ala Ser Ala Ala Gly Asn Lys Leu Thr Phe Gly Gly Gly Thr
115 120 125
Arg Val Leu Val Lys Pro Asn Ile Gln Asn Pro Asp Pro Ala
130 135 140
<210> 206
<211> 142
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR22a片段
<400> 206
Met Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ser Trp Val Trp Ser Gln Gln Lys Glu Val Glu Gln Asp Pro Gly Pro
20 25 30
Leu Ser Val Pro Glu Gly Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser
35 40 45
Asn Ser Ala Phe Gln Tyr Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys
50 55 60
Gly Pro Glu Leu Leu Met Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp
65 70 75 80
Gly Arg Phe Thr Ala Gln Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu
85 90 95
Phe Ile Arg Asp Ser Gln Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala
100 105 110
Met Ser Ala Gly Ala Ala Gly Asn Lys Leu Thr Phe Gly Gly Gly Thr
115 120 125
Arg Val Leu Val Lys Pro Asn Ile Gln Asn Pro Asp Pro Ala
130 135 140
<210> 207
<211> 145
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR19a片段
<400> 207
Met Ala Met Leu Leu Gly Ala Ser Val Leu Ile Leu Trp Leu Gln Pro
1 5 10 15
Asp Trp Val Asn Ser Gln Gln Lys Asn Asp Asp Gln Gln Val Lys Gln
20 25 30
Asn Ser Pro Ser Leu Ser Val Gln Glu Gly Arg Ile Ser Ile Leu Asn
35 40 45
Cys Asp Tyr Thr Asn Ser Met Phe Asp Tyr Phe Leu Trp Tyr Lys Lys
50 55 60
Tyr Pro Ala Glu Gly Pro Thr Phe Leu Ile Ser Ile Ser Ser Ile Lys
65 70 75 80
Asp Lys Asn Glu Asp Gly Arg Phe Thr Val Phe Leu Asn Lys Ser Ala
85 90 95
Lys His Leu Ser Leu His Ile Val Pro Ser Gln Pro Gly Asp Ser Ala
100 105 110
Val Tyr Phe Cys Ala Ala Ser Ala Asn Asn Asn Asp Met Arg Phe Gly
115 120 125
Ala Gly Thr Arg Leu Thr Val Lys Pro Asn Ile Gln Asn Pro Asp Pro
130 135 140
Ala
145
<210> 208
<211> 137
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR16a片段
<400> 208
Met Ala Leu Gln Ser Thr Leu Gly Ala Val Trp Leu Gly Leu Leu Leu
1 5 10 15
Asn Ser Leu Trp Lys Val Ala Glu Ser Lys Asp Gln Val Phe Gln Pro
20 25 30
Ser Thr Val Ala Ser Ser Glu Gly Ala Val Val Glu Ile Phe Cys Asn
35 40 45
His Ser Val Ser Asn Ala Tyr Asn Phe Phe Trp Tyr Leu His Phe Pro
50 55 60
Gly Cys Ala Pro Arg Leu Leu Val Lys Gly Ser Lys Pro Ser Gln Gln
65 70 75 80
Gly Arg Tyr Asn Met Thr Tyr Glu Arg Phe Ser Ser Ser Leu Leu Ile
85 90 95
Leu Gln Val Arg Glu Ala Asp Ala Ala Val Tyr Tyr Cys Val Leu Asn
100 105 110
Arg Asp Asp Lys Ile Ile Phe Gly Lys Gly Thr Arg Leu His Ile Leu
115 120 125
Pro Asn Ile Gln Asn Pro Asp Pro Ala
130 135
<210> 209
<211> 136
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR20a片段
<400> 209
Met Arg Leu Val Ala Arg Val Thr Val Phe Leu Thr Phe Gly Thr Ile
1 5 10 15
Ile Asp Ala Lys Thr Thr Gln Pro Pro Ser Met Asp Cys Ala Glu Gly
20 25 30
Arg Ala Ala Asn Leu Pro Cys Asn His Ser Thr Ile Ser Gly Asn Glu
35 40 45
Tyr Val Tyr Trp Tyr Arg Gln Ile His Ser Gln Gly Pro Gln Tyr Ile
50 55 60
Ile His Gly Leu Lys Asn Asn Glu Thr Asn Glu Met Ala Ser Leu Ile
65 70 75 80
Ile Thr Glu Asp Arg Lys Ser Ser Thr Leu Ile Leu Pro His Ala Thr
85 90 95
Leu Arg Asp Thr Ala Val Tyr Tyr Cys Ile Val Arg Leu Asn Ser Gly
100 105 110
Asn Thr Pro Leu Val Phe Gly Lys Gly Thr Arg Leu Ser Val Ile Ala
115 120 125
Asn Ile Gln Asn Pro Asp Pro Ala
130 135
<210> 210
<211> 142
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR21a片段
<400> 210
Met Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ser Trp Val Trp Ser Gln Gln Lys Glu Val Glu Gln Asp Pro Gly Pro
20 25 30
Leu Ser Val Pro Glu Gly Ala Ile Val Ser Leu Asn Cys Thr Tyr Ser
35 40 45
Asn Ser Ala Phe Gln Tyr Phe Met Trp Tyr Arg Gln Tyr Ser Arg Lys
50 55 60
Gly Pro Glu Leu Leu Met Tyr Thr Tyr Ser Ser Gly Asn Lys Glu Asp
65 70 75 80
Gly Arg Phe Thr Ala Gln Val Asp Lys Ser Ser Lys Tyr Ile Ser Leu
85 90 95
Phe Ile Arg Asp Ser Gln Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala
100 105 110
Met Ser Gly Gly Asn Ala Gly Asn Met Leu Thr Phe Gly Gly Gly Thr
115 120 125
Arg Leu Met Val Lys Pro His Ile Gln Asn Pro Asp Pro Ala
130 135 140
<210> 211
<211> 134
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR24a片段
<400> 211
Met Trp Gly Ala Phe Leu Leu Tyr Val Ser Met Lys Met Gly Gly Thr
1 5 10 15
Ala Gly Gln Ser Leu Glu Gln Pro Ser Glu Val Thr Ala Val Glu Gly
20 25 30
Ala Ile Val Gln Ile Asn Cys Thr Tyr Gln Thr Ser Gly Phe Tyr Gly
35 40 45
Leu Ser Trp Tyr Gln Gln His Asp Gly Gly Ala Pro Thr Phe Leu Ser
50 55 60
Tyr Asn Ala Leu Asp Gly Leu Glu Glu Thr Gly Arg Phe Ser Ser Phe
65 70 75 80
Leu Ser Arg Ser Asp Ser Tyr Gly Tyr Leu Leu Leu Gln Glu Leu Gln
85 90 95
Met Lys Asp Ser Ala Ser Tyr Phe Cys Ala Gly Gly Asp Ser Ser Tyr
100 105 110
Lys Leu Ile Phe Gly Ser Gly Thr Arg Leu Leu Val Arg Pro Asp Ile
115 120 125
Gln Asn Pro Asp Pro Ala
130
<210> 212
<211> 141
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR23a片段
<400> 212
Met Val Leu Lys Phe Ser Val Ser Ile Leu Trp Ile Gln Leu Ala Trp
1 5 10 15
Val Ser Thr Gln Leu Leu Glu Gln Ser Pro Gln Phe Leu Ser Ile Gln
20 25 30
Glu Gly Glu Asn Leu Thr Val Tyr Cys Asn Ser Ser Ser Val Phe Ser
35 40 45
Ser Leu Gln Trp Tyr Arg Gln Glu Pro Gly Glu Gly Pro Val Leu Leu
50 55 60
Val Thr Val Val Thr Gly Gly Glu Val Lys Lys Leu Lys Arg Leu Thr
65 70 75 80
Phe Gln Phe Gly Asp Ala Arg Lys Asp Ser Ser Leu His Ile Thr Ala
85 90 95
Ala Gln Pro Gly Asp Thr Gly Leu Tyr Leu Cys Ala Gly Val Arg Glu
100 105 110
Ala Gly Gly Thr Ser Tyr Gly Lys Leu Thr Phe Gly Gln Gly Thr Ile
115 120 125
Leu Thr Val His Pro Asn Ile Gln Asn Pro Asp Pro Ala
130 135 140
<210> 213
<211> 139
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 TCR15a片段
<400> 213
Met Lys Ser Leu Arg Val Leu Leu Val Ile Leu Trp Leu Gln Leu Ser
1 5 10 15
Trp Val Trp Ser Gln Gln Lys Glu Val Glu Gln Asn Ser Gly Pro Leu
20 25 30
Ser Val Pro Glu Gly Ala Ile Ala Ser Leu Asn Cys Thr Tyr Ser Asp
35 40 45
Arg Gly Ser Gln Ser Phe Phe Trp Tyr Arg Gln Tyr Ser Gly Lys Ser
50 55 60
Pro Glu Leu Ile Met Phe Ile Tyr Ser Asn Gly Asp Lys Glu Asp Gly
65 70 75 80
Arg Phe Thr Ala Gln Leu Asn Lys Ala Ser Gln Tyr Val Ser Leu Leu
85 90 95
Ile Arg Asp Ser Gln Pro Ser Asp Ser Ala Thr Tyr Leu Cys Ala Val
100 105 110
Asn Ala Arg Gly Asn Met Leu Thr Phe Gly Gly Gly Thr Arg Leu Met
115 120 125
Val Lys Pro His Ile Gln Asn Pro Asp Pro Ala
130 135
<210> 214
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (G-S接头)
<400> 214
Gly Gly Gly Gly Ser
1 5
<210> 215
<211> 20
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (G-S接头)
<220>
<221> 变体
<222> (2)...(10)
<223> 氨基酸 2-10 中的任何一个或全部可以是
存在或不存在
<220>
<221> 变体
<222> (12)...(20)
<223>氨基酸 12-20 中的任何一个或全部可以是
存在或不存在
<400> 215
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Ser Ser Ser Ser Ser
1 5 10 15
Ser Ser Ser Ser
20
<210> 216
<211> 189
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (人HRAS (UniProt P01112))
<400> 216
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1 5 10 15
Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
20 25 30
Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45
Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
50 55 60
Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80
Val Phe Ala Ile Asn Asn Thr Lys Ser Phe Glu Asp Ile His Gln Tyr
85 90 95
Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
100 105 110
Leu Val Gly Asn Lys Cys Asp Leu Ala Ala Arg Thr Val Glu Ser Arg
115 120 125
Gln Ala Gln Asp Leu Ala Arg Ser Tyr Gly Ile Pro Tyr Ile Glu Thr
130 135 140
Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160
Arg Glu Ile Arg Gln His Lys Leu Arg Lys Leu Asn Pro Pro Asp Glu
165 170 175
Ser Gly Pro Gly Cys Met Ser Cys Lys Cys Val Leu Ser
180 185
<210> 217
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - CDRβ1)
<400> 217
Leu Asn His Asn Val
1 5
<210> 218
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - CDRβ2)
<400> 218
Tyr Tyr Asp Lys Asp Phe
1 5
<210> 219
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - CDRβ3)
<400> 219
Cys Ala Thr Ser Ser Leu Gly Gln Gly Tyr Gln Glu Thr Gln Tyr Phe
1 5 10 15
<210> 220
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - CDRα1)
<400> 220
Thr Ser Ile Asn Asn
1 5
<210> 221
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - CDRα2)
<400> 221
Ile Arg Ser Asn Glu Arg Glu
1 5
<210> 222
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - CDRα3)
<400> 222
Cys Ala Thr Asp Asp Asp Tyr Lys Leu Ser Phe
1 5 10
<210> 223
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - CDRβ1)
<400> 223
Ser Gly His Ala Thr
1 5
<210> 224
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - CDRβ2)
<400> 224
Phe Gln Asp Glu Ser Val
1 5
<210> 225
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - CDRβ3)
<400> 225
Cys Ala Ser Ser Pro Thr Gly Glu Gly Glu Gln Tyr Phe
1 5 10
<210> 226
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - CDRα1)
<400> 226
Asp Ser Ser Ser Thr Tyr
1 5
<210> 227
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - CDRα2)
<400> 227
Ile Phe Ser Asn Met Asp Met
1 5
<210> 228
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - CDRα3)
<400> 228
Cys Ala Glu Ile Glu Asp Asn Thr Asp Lys Leu Ile Phe
1 5 10
<210> 229
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - CDRβ1)
<400> 229
Ser Gly His Thr Ala
1 5
<210> 230
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - CDRβ2)
<400> 230
Phe Gln Gly Thr Gly Ala
1 5
<210> 231
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - CDRβ3)
<400> 231
Cys Ala Ser Ser Pro Leu Ala Ala Asn Glu Gln Phe Phe
1 5 10
<210> 232
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - CDRα1)
<400> 232
Asp Ser Ser Ser Thr Tyr
1 5
<210> 233
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - CDRα2)
<400> 233
Ile Phe Ser Asn Met Asp Met
1 5
<210> 234
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - CDRα3)
<400> 234
Cys Ala Glu Arg Thr Asp Thr Asp Lys Leu Ile Phe
1 5 10
<210> 235
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - CDRβ1)
<400> 235
Asp Phe Gln Ala Thr Thr
1 5
<210> 236
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - CDRβ2)
<400> 236
Ser Asn Glu Gly Ser Lys Ala
1 5
<210> 237
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - CDRβ3)
<400> 237
Cys Ser Ala Phe Leu Ser Gly Ser Ala Asp Thr Gln Tyr Phe
1 5 10
<210> 238
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - CDRα1)
<400> 238
Thr Arg Asp Thr Thr Tyr Tyr
1 5
<210> 239
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - CDRα2)
<400> 239
Arg Asn Ser Phe Asp Glu Gln Asn
1 5
<210> 240
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - CDRα3)
<400> 240
Cys Ala Leu Met Asp Ser Ser Tyr Lys Leu Ile Phe
1 5 10
<210> 241
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - CDRβ1)
<400> 241
Met Asp His Glu Asn
1 5
<210> 242
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - CDRβ2)
<400> 242
Ser Tyr Asp Val Lys Met
1 5
<210> 243
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - CDRβ3)
<400> 243
Cys Ala Ser Ala Leu Arg Gly Thr Tyr Glu Gln Tyr Phe
1 5 10
<210> 244
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - CDRα1)
<400> 244
Tyr Gly Ala Thr Pro Tyr
1 5
<210> 245
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - CDRα2)
<400> 245
Tyr Phe Ser Gly Asp Thr Leu Val
1 5
<210> 246
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - CDRα3)
<400> 246
Cys Ala Val Gly Asp Glu Asn Thr Gly Phe Gln Lys Leu Val Phe
1 5 10 15
<210> 247
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - CDRβ1)
<400> 247
Met Asp His Glu Asn
1 5
<210> 248
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - CDRβ2)
<400> 248
Ser Tyr Asp Val Lys Met
1 5
<210> 249
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - CDRβ3)
<400> 249
Cys Ala Ser Ser Leu Gly Asp Arg Ile Tyr Glu Gln Tyr Phe
1 5 10
<210> 250
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - CDRα1)
<400> 250
Asp Ser Ser Ser Thr Tyr
1 5
<210> 251
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - CDRα2)
<400> 251
Ile Phe Ser Asn Met Asp Met
1 5
<210> 252
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - CDRα3)
<400> 252
Cys Ala Glu Ile Asp Gly Thr Asp Lys Leu Ile Phe
1 5 10
<210> 253
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - CDRβ1)
<400> 253
Ser Gly His Ala Thr
1 5
<210> 254
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - CDRβ2)
<400> 254
Phe Gln Asp Glu Ser Val
1 5
<210> 255
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - CDRβ3)
<400> 255
Cys Ala Ser Ser Pro Thr Gly Glu Gly Glu Gln Tyr Phe
1 5 10
<210> 256
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - CDRα1)
<400> 256
Asp Ser Ser Ser Thr Tyr
1 5
<210> 257
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - CDRα2)
<400> 257
Ile Phe Ser Asn Met Asp Met
1 5
<210> 258
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - CDRα3)
<400> 258
Cys Ala Glu Ile Glu Asp Asn Thr Asp Lys Leu Ile Phe
1 5 10
<210> 259
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - CDRβ1)
<400> 259
Met Asp His Glu Asn
1 5
<210> 260
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - CDRβ2)
<400> 260
Ser Tyr Asp Val Lys Met
1 5
<210> 261
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - CDRβ3)
<400> 261
Cys Ala Ile Glu Pro Pro Thr Gly Asn Glu Gln Tyr Phe
1 5 10
<210> 262
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - CDRα1)
<400> 262
Asp Ser Ser Ser Thr Tyr
1 5
<210> 263
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - CDRα2)
<400> 263
Ile Phe Ser Asn Met Asp Met
1 5
<210> 264
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - CDRα3)
<400> 264
Cys Ala Glu Arg Ile Asp Ser Gly Asn Thr Pro Leu Val Phe
1 5 10
<210> 265
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - CDRβ1)
<400> 265
Met Asn His Glu Tyr
1 5
<210> 266
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - CDRβ2)
<400> 266
Ser Met Asn Val Glu Val
1 5
<210> 267
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - CDRβ3)
<400> 267
Cys Ala Ser Ser Gln Ala Gly Leu Gly Asn Glu Gln Phe Phe
1 5 10
<210> 268
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - CDRα1)
<400> 268
Asn Ser Ala Ser Asp Tyr
1 5
<210> 269
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - CDRα2)
<400> 269
Ile Arg Ser Asn Met Asp Lys
1 5
<210> 270
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - CDRα3)
<400> 270
Cys Ala Glu Ile Phe Asn Asp Tyr Lys Leu Ser Phe
1 5 10
<210> 271
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - CDRβ1)
<400> 271
Met Asn His Glu Tyr
1 5
<210> 272
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - CDRβ2)
<400> 272
Ser Val Gly Ala Gly Ile
1 5
<210> 273
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - CDRβ3)
<400> 273
Cys Ala Ser Ser Arg Thr Gly Ala Asp Gly Tyr Thr Phe
1 5 10
<210> 274
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - CDRα1)
<400> 274
Tyr Gly Ala Thr Pro Tyr
1 5
<210> 275
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - CDRα2)
<400> 275
Tyr Phe Ser Gly Asp Thr Leu Val
1 5
<210> 276
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - CDRα3)
<400> 276
Cys Ala Val Gly Ser Asp Ser Asn Tyr Gln Leu Ile Trp
1 5 10
<210> 277
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - CDRβ1)
<400> 277
Met Gly His Arg Ala
1 5
<210> 278
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - CDRβ2)
<400> 278
Tyr Ser Tyr Glu Lys Leu
1 5
<210> 279
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - CDRβ3)
<400> 279
Cys Ala Ser Ser Gln Asp Leu Gly Thr Val Tyr Glu Gln Tyr Phe
1 5 10 15
<210> 280
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - CDRα1)
<400> 280
Asn Ser Met Phe Asp Tyr
1 5
<210> 281
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - CDRα2)
<400> 281
Ile Ser Ser Ile Lys Asp Lys
1 5
<210> 282
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - CDRα3)
<400> 282
Cys Ala Ala Ile Ser Leu Thr Ser Gly Thr Tyr Lys Tyr Ile Phe
1 5 10 15
<210> 283
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - CDRβ1)
<400> 283
Met Asp His Glu Asn
1 5
<210> 284
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - CDRβ2)
<400> 284
Ser Tyr Asp Val Lys Met
1 5
<210> 285
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - CDRβ3)
<400> 285
Cys Ala Ser Ser Leu Gln Val Ser Gly Val Ala Gly Tyr Thr Phe
1 5 10 15
<210> 286
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - CDRα1)
<400> 286
Ser Ser Val Ser Val Tyr
1 5
<210> 287
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - CDRα2)
<400> 287
Tyr Leu Ser Gly Ser Thr Leu Val
1 5
<210> 288
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - CDRα3)
<400> 288
Cys Ala Val Thr Arg Asp Asp Lys Ile Ile Phe
1 5 10
<210> 289
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - CDRβ1)
<400> 289
Ser Gly His Ala Thr
1 5
<210> 290
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - CDRβ2)
<400> 290
Phe Gln Asp Glu Ser Val
1 5
<210> 291
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - CDRβ3)
<400> 291
Cys Ala Ser Ser Pro Thr Gly Glu Gly Glu Gln Tyr Phe
1 5 10
<210> 292
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - CDRα1)
<400> 292
Asp Ser Ser Ser Thr Tyr
1 5
<210> 293
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - CDRα2)
<400> 293
Ile Phe Ser Asn Met Asp Met
1 5
<210> 294
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - CDRα3)
<400> 294
Cys Ala Glu Ile Glu Asp Asn Thr Asp Lys Leu Ile Phe
1 5 10
<210> 295
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - CDRβ1)
<400> 295
Met Gly His Arg Ala
1 5
<210> 296
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - CDRβ2)
<400> 296
Tyr Ser Tyr Glu Lys Leu
1 5
<210> 297
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - CDRβ3)
<400> 297
Cys Ala Ser Ser Gln Asp Leu Gly Thr Val Tyr Glu Gln Tyr Phe
1 5 10 15
<210> 298
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - CDRα1)
<400> 298
Asn Ser Met Phe Asp Tyr
1 5
<210> 299
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - CDRα2)
<400> 299
Ile Ser Ser Ile Lys Asp Lys
1 5
<210> 300
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - CDRα3)
<400> 300
Cys Ala Ala Ile Ser Leu Thr Ser Gly Thr Tyr Lys Tyr Ile Phe
1 5 10 15
<210> 301
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - CDRβ1)
<400> 301
Ser Gly His Ala Thr
1 5
<210> 302
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - CDRβ2)
<400> 302
Phe Gln Asn Asn Gly Val
1 5
<210> 303
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - CDRβ3)
<400> 303
Cys Ala Ser Ser Leu Pro Ser Gly Asn Glu Gln Phe Phe
1 5 10
<210> 304
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - CDRα1)
<400> 304
Asp Ser Ser Ser Thr Tyr
1 5
<210> 305
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - CDRα2)
<400> 305
Ile Phe Ser Asn Met Asp Met
1 5
<210> 306
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - CDRα3)
<400> 306
Cys Ala Glu Met Met Asp Thr Asp Lys Leu Ile Phe
1 5 10
<210> 307
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - CDRβ1)
<400> 307
Lys Gly His Asp Arg
1 5
<210> 308
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - CDRβ2)
<400> 308
Ser Phe Asp Val Lys Asp
1 5
<210> 309
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - CDRβ3)
<400> 309
Cys Ala Thr Ser Gly Gln Gly Gly Asp Glu Gln Phe Phe
1 5 10
<210> 310
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - CDRα1)
<400> 310
Asp Ser Ser Ser Thr Tyr
1 5
<210> 311
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - CDRα2)
<400> 311
Ile Phe Ser Asn Met Asp Met
1 5
<210> 312
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - CDRα3)
<400> 312
Cys Ala Glu Ile Val Asp Asn Gln Gly Gly Lys Leu Ile Phe
1 5 10
<210> 313
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - CDRβ1)
<400> 313
Asp Phe Gln Ala Thr Thr
1 5
<210> 314
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - CDRβ2)
<400> 314
Ser Asn Glu Gly Ser Lys Ala
1 5
<210> 315
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - CDRβ3)
<400> 315
Cys Ser Ala Asp Arg Leu Ala Gly Gly Glu Glu Thr Gln Tyr Phe
1 5 10 15
<210> 316
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - CDRα1)
<400> 316
Ser Val Phe Ser Ser
1 5
<210> 317
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - CDRα2)
<400> 317
Val Val Thr Gly Gly Glu Val
1 5
<210> 318
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - CDRα3)
<400> 318
Cys Ala Gly Ser Asn Asp Tyr Lys Leu Ser Phe
1 5 10
<210> 319
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - CDRbβ1)
<400> 319
Met Asp His Glu Asn
1 5
<210> 320
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - CDRβ2)
<400> 320
Ser Tyr Asp Val Lys Met
1 5
<210> 321
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - CDRβ3)
<400> 321
Cys Ala Ser Arg Gly Leu Ser Thr Asp Thr Gln Tyr Phe
1 5 10
<210> 322
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - CDRα1)
<400> 322
Asp Ser Ser Ser Thr Tyr
1 5
<210> 323
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - CDRα2)
<400> 323
Ile Phe Ser Asn Met Asp Met
1 5
<210> 324
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - CDRα3)
<400> 324
Cys Ala Val Leu Leu Asp Asn Gln Gly Gly Lys Leu Ile Phe
1 5 10
<210> 325
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - CDRβ1)
<400> 325
Leu Asn His Asp Ala
1 5
<210> 326
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - CDRβ2)
<400> 326
Ser Gln Ile Val Asn Asp
1 5
<210> 327
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - CDRβ3)
<400> 327
Cys Ala Ser Arg Ser Asp Arg Asn Glu Gln Phe Phe
1 5 10
<210> 328
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - CDRα1)
<400> 328
Tyr Gly Gly Thr Val Asn
1 5
<210> 329
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - CDRα2)
<400> 329
Tyr Phe Ser Gly Asp Pro Leu Val
1 5
<210> 330
<400> 330
000
<210> 331
<400> 331
000
<210> 332
<400> 332
000
<210> 333
<400> 333
000
<210> 334
<400> 334
000
<210> 335
<400> 335
000
<210> 336
<400> 336
000
<210> 337
<400> 337
000
<210> 338
<400> 338
000
<210> 339
<400> 339
000
<210> 340
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - CDRα3)
<400> 340
Cys Ala Val Asn Asp Pro Ser Asp Tyr Lys Leu Ser Phe
1 5 10
<210> 341
<211> 813
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - TCRα
<400> 341
atggaaactc tcctgggagt gtctttggtg attctatggc ttcaactggc tagggtgaac 60
agtcaacagg gagaagagga tcctcaggcc ttgagcatcc aggagggtga aaatgccacc 120
atgaactgca gttacaaaac tagtataaac aatttacagt ggtatagaca aaattcaggt 180
agaggccttg tccacctaat tttaatacgt tcaaatgaaa gagagaaaca cagtggaaga 240
ttaagagtca cgcttgacac ttccaagaaa agcagttcct tgttgatcac ggcttcccgg 300
gcagcagaca ctgcttctta cttctgtgct acggacgacg actacaagct cagctttgga 360
gccggaacca cagtaactgt aagagcaaat atccagaacc ctgaccctgc cgtgtaccag 420
ctgagagact ctaaatccag tgacaagtct gtctgcctat tcaccgattt tgattctcaa 480
acaaatgtgt cacaaagtaa ggattctgat gtgtatatca cagacaaaac tgtgctagac 540
atgaggtcta tggacttcaa gagcaacagt gctgtggcct ggagcaacaa atctgacttt 600
gcatgtgcaa acgccttcaa caacagcatt attccagaag acaccttctt ccccagccca 660
gaaagttcct gtgatgtcaa gctggtcgag aaaagctttg aaacagatac gaacctaaac 720
tttcaaaacc tgtcagtgat tgggttccga atcctcctcc tgaaagtggc cgggtttaat 780
ctgctcatga cgctgcggct gtggtccagc tga 813
<210> 342
<211> 270
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - TCRα)
<400> 342
Met Glu Thr Leu Leu Gly Val Ser Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ala Arg Val Asn Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser
20 25 30
Ile Gln Glu Gly Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser
35 40 45
Ile Asn Asn Leu Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val
50 55 60
His Leu Ile Leu Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg
65 70 75 80
Leu Arg Val Thr Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile
85 90 95
Thr Ala Ser Arg Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp
100 105 110
Asp Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr Val Arg
115 120 125
Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser
130 135 140
Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln
145 150 155 160
Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys
165 170 175
Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val
180 185 190
Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn
195 200 205
Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys
210 215 220
Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn
225 230 235 240
Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val
245 250 255
Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
260 265 270
<210> 343
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - TCR Vα)
<400> 343
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Asp Asp Tyr Lys
85 90 95
Leu Ser Phe Gly Ala Gly Thr Thr Val Thr Val Arg Ala Asn
100 105 110
<210> 344
<211> 942
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - TCRβ)
<400> 344
atgggtcctg ggcttctcca ctggatggcc ctttgtctcc ttggaacagg tcatggggat 60
gccatggtca tccagaaccc aagataccag gttacccagt ttggaaagcc agtgaccctg 120
agttgttctc agactttgaa ccataacgtc atgtactggt accagcagaa gtcaagtcag 180
gccccaaagc tgctgttcca ctactatgac aaagatttta acaatgaagc agacacccct 240
gataacttcc aatccaggag gccgaacact tctttctgct ttcttgacat ccgctcacca 300
ggcctggggg acgcagccat gtacctgtgt gccaccagca gcctgggaca ggggtaccaa 360
gagacccagt acttcgggcc aggcacgcgg ctcctggtgc tcgaggacct gaaaaacgtg 420
ttcccacccg aggtcgctgt gtttgagcca tcagaagcag agatctccca cacccaaaag 480
gccacactgg tgtgcctggc cacaggcttc taccccgacc acgtggagct gagctggtgg 540
gtgaatggga aggaggtgca cagtggggtc agcacagacc cgcagcccct caaggagcag 600
cccgccctca atgactccag atactgcctg agcagccgcc tgagggtctc ggccaccttc 660
tggcagaacc cccgcaacca cttccgctgt caagtccagt tctacgggct ctcggagaat 720
gacgagtgga cccaggatag ggccaaacct gtcacccaga tcgtcagcgc cgaggcctgg 780
ggtagagcag actgtggctt cacctccgag tcttaccagc aaggggtcct gtctgccacc 840
atcctctatg agatcttgct agggaaggcc accttgtatg ccgtgctggt cagtgccctc 900
gtgctgatgg ccatggtcaa gagaaaggat tccagaggct ag 942
<210> 345
<211> 313
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - TCRβ)
<400> 345
Met Gly Pro Gly Leu Leu His Trp Met Ala Leu Cys Leu Leu Gly Thr
1 5 10 15
Gly His Gly Asp Ala Met Val Ile Gln Asn Pro Arg Tyr Gln Val Thr
20 25 30
Gln Phe Gly Lys Pro Val Thr Leu Ser Cys Ser Gln Thr Leu Asn His
35 40 45
Asn Val Met Tyr Trp Tyr Gln Gln Lys Ser Ser Gln Ala Pro Lys Leu
50 55 60
Leu Phe His Tyr Tyr Asp Lys Asp Phe Asn Asn Glu Ala Asp Thr Pro
65 70 75 80
Asp Asn Phe Gln Ser Arg Arg Pro Asn Thr Ser Phe Cys Phe Leu Asp
85 90 95
Ile Arg Ser Pro Gly Leu Gly Asp Ala Ala Met Tyr Leu Cys Ala Thr
100 105 110
Ser Ser Leu Gly Gln Gly Tyr Gln Glu Thr Gln Tyr Phe Gly Pro Gly
115 120 125
Thr Arg Leu Leu Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu
130 135 140
Val Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys
145 150 155 160
Ala Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu
165 170 175
Leu Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr
180 185 190
Asp Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr
195 200 205
Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro
210 215 220
Arg Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn
225 230 235 240
Asp Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser
245 250 255
Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr
260 265 270
Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly
275 280 285
Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala
290 295 300
Met Val Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 346
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 - TCR Vβ)
<400> 346
Asp Ala Met Val Ile Gln Asn Pro Arg Tyr Gln Val Thr Gln Phe Gly
1 5 10 15
Lys Pro Val Thr Leu Ser Cys Ser Gln Thr Leu Asn His Asn Val Met
20 25 30
Tyr Trp Tyr Gln Gln Lys Ser Ser Gln Ala Pro Lys Leu Leu Phe His
35 40 45
Tyr Tyr Asp Lys Asp Phe Asn Asn Glu Ala Asp Thr Pro Asp Asn Phe
50 55 60
Gln Ser Arg Arg Pro Asn Thr Ser Phe Cys Phe Leu Asp Ile Arg Ser
65 70 75 80
Pro Gly Leu Gly Asp Ala Ala Met Tyr Leu Cys Ala Thr Ser Ser Leu
85 90 95
Gly Gln Gly Tyr Gln Glu Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu
100 105 110
Leu Val Leu
115
<210> 347
<211> 1355
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 -
TCRβ-P2A-TCRα片段)
<400> 347
cccagtttgg caaaccagtg acactgagct gttctcagac cctgaaccac aacgtgatgt 60
actggtacca gcagaagtct tctcaggccc ctaagctgct gttccactac tacgacaagg 120
acttcaacaa cgaggccgat acccctgaca atttccagag caggaggccc aataccagct 180
tctgtttcct ggacattaga agccctggac tgggagatgc tgccatgtac ctgtgtgcca 240
catcttctct gggacaggga tatcaagaaa cccagtactt cggaccaggc accagactgt 300
tagtgctgga ggacctgaag aacgtgttcc ccccagaggt ggccgtgttc gagcctagcg 360
aggccgagat cagccacacc cagaaagcca ccctcgtgtg cctggccacc ggcttttacc 420
ccgaccacgt ggaactgtct tggtgggtca acggcaaaga ggtgcacagc ggcgtctgca 480
ccgaccccca gcccctgaaa gagcagcccg ccctgaacga cagccggtac tgtctgagca 540
gcagactgag agtgtccgcc accttctggc agaacccccg gaaccacttc agatgccagg 600
tgcagttcta cggcctgagc gagaacgacg agtggaccca ggaccgggcc aagcccgtga 660
cccagatcgt gtctgctgag gcctggggca gagccgattg cggcttcacc agcgagagct 720
accagcaggg cgtgctgagc gccaccatcc tgtacgagat cctgctgggc aaggccaccc 780
tgtacgccgt gctggtgtcc gccctggtgc tgatggccat ggtcaagcgg aaggacagcc 840
ggggcggttc cggagccacg aacttctctc tgttaaagca agcaggagac gtggaagaaa 900
accccggtcc catggagaca ctgcttggcg tatcactggt gattctgtgg ctgcaactgg 960
ctagagtgaa ctctcagcag ggagaagagg atcctcaagc tctgagcatt caggaaggcg 1020
aaaatgccac catgaactgc agctacaaga ccagcatcaa caacctgcag tggtaccggc 1080
agaatagcgg aagaggactg gttcacctga tcctgatcag gagcaatgaa agggagaagc 1140
acagcggcag actgagagtt accctggata ccagcaagaa gtctagcagc ctgctgatta 1200
cagcctctag agccgccgat acagccagct acttttgtgc caccgatgat gactacaagc 1260
tgtcttttgg agccggaacc accgtgacag tgagggccaa tatccagaat cctgatcctg 1320
ctgtgtacca gctgcgggac agcaagagca gcgac 1355
<210> 348
<211> 495
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR01 -
TCRβ-P2A-TCRα片段)
<400> 348
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Pro Gly
1 5 10 15
Leu Leu His Trp Met Ala Leu Cys Leu Leu Gly Thr Gly His Gly Asp
20 25 30
Ala Met Val Ile Gln Asn Pro Arg Tyr Gln Val Thr Gln Phe Gly Lys
35 40 45
Pro Val Thr Leu Ser Cys Ser Gln Thr Leu Asn His Asn Val Met Tyr
50 55 60
Trp Tyr Gln Gln Lys Ser Ser Gln Ala Pro Lys Leu Leu Phe His Tyr
65 70 75 80
Tyr Asp Lys Asp Phe Asn Asn Glu Ala Asp Thr Pro Asp Asn Phe Gln
85 90 95
Ser Arg Arg Pro Asn Thr Ser Phe Cys Phe Leu Asp Ile Arg Ser Pro
100 105 110
Gly Leu Gly Asp Ala Ala Met Tyr Leu Cys Ala Thr Ser Ser Leu Gly
115 120 125
Gln Gly Tyr Gln Glu Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Leu
130 135 140
Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe
145 150 155 160
Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val
165 170 175
Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp
180 185 190
Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro
195 200 205
Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser
210 215 220
Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe
225 230 235 240
Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr
245 250 255
Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp
260 265 270
Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val
275 280 285
Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu
290 295 300
Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg
305 310 315 320
Lys Asp Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys
325 330 335
Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Glu Thr Leu Leu
340 345 350
Gly Val Ser Leu Val Ile Leu Trp Leu Gln Leu Ala Arg Val Asn Ser
355 360 365
Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly Glu
370 375 380
Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu Gln
385 390 395 400
Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu Ile
405 410 415
Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr Leu
420 425 430
Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg Ala
435 440 445
Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Asp Asp Tyr Lys Leu
450 455 460
Ser Phe Gly Ala Gly Thr Thr Val Thr Val Arg Ala Asn Ile Gln Asn
465 470 475 480
Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 349
<211> 822
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - TCRα)
<400> 349
atgaagacat ttgctggatt ttcgttcctg tttttgtggc tgcagctgga ctgtatgagt 60
agaggagagg atgtggagca gagtcttttc ctgagtgtcc gagagggaga cagctccgtt 120
ataaactgca cttacacaga cagctcctcc acctacttat actggtataa gcaagaacct 180
ggagcaggtc tccagttgct gacgtatatt ttttcaaata tggacatgaa acaagaccaa 240
agactcactg ttctattgaa taaaaaggat aaacatctgt ctctgcgcat tgcagacacc 300
cagactgggg actcagctat ctacttctgt gcagagatag aggataacac cgacaagctc 360
atctttggga ctgggaccag attacaagtc tttccaaata tccagaaccc tgaccctgcc 420
gtgtaccagc tgagagactc taaatccagt gacaagtctg tctgcctatt caccgatttt 480
gattctcaaa caaatgtgtc acaaagtaag gattctgatg tgtatatcac agacaaaact 540
gtgctagaca tgaggtctat ggacttcaag agcaacagtg ctgtggcctg gagcaacaaa 600
tctgactttg catgtgcaaa cgccttcaac aacagcatta ttccagaaga caccttcttc 660
cccagcccag aaagttcctg tgatgtcaag ctggtcgaga aaagctttga aacagatacg 720
aacctaaact ttcaaaacct gtcagtgatt gggttccgaa tcctcctcct gaaagtggcc 780
gggtttaatc tgctcatgac gctgcggctg tggtccagct ga 822
<210> 350
<211> 273
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - TCRα)
<400> 350
Met Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu
1 5 10 15
Asp Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser
20 25 30
Val Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser
35 40 45
Ser Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu
50 55 60
Gln Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln
65 70 75 80
Arg Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg
85 90 95
Ile Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu
100 105 110
Ile Glu Asp Asn Thr Asp Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu
115 120 125
Gln Val Phe Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu
130 135 140
Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe
145 150 155 160
Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile
165 170 175
Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn
180 185 190
Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala
195 200 205
Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu
210 215 220
Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr
225 230 235 240
Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu
245 250 255
Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser
260 265 270
Ser
<210> 351
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - TCR Vα
<400> 351
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Ile Glu Asp Asn Thr
85 90 95
Asp Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn
100 105 110
<210> 352
<211> 936
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - TCRβ)
<400> 352
atgagcacca ggcttctctg ctggatggcc ctctgtctcc tgggggcaga actctcagaa 60
gctgaagttg cccagtcccc cagatataag attacagaga aaagccaggc tgtggctttt 120
tggtgtgatc ctatttctgg ccatgctacc ctttactggt accggcagat cctgggacag 180
ggcccggagc ttctggttca atttcaggat gagagtgtag tagatgattc acagttgcct 240
aaggatcgat tttctgcaga gaggctcaaa ggagtagact ccactctcaa gatccagcct 300
gcagagcttg gggactcggc catgtatctc tgtgccagca gccccacagg ggaaggcgag 360
cagtacttcg ggccgggcac caggctcacg gtcacagagg acctgaaaaa cgtgttccca 420
cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca 480
ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 540
gggaaggagg tgcacagtgg ggtcagcaca gacccgcagc ccctcaagga gcagcccgcc 600
ctcaatgact ccagatactg cctgagcagc cgcctgaggg tctcggccac cttctggcag 660
aacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag 720
tggacccagg atagggccaa acctgtcacc cagatcgtca gcgccgaggc ctggggtaga 780
gcagactgtg gcttcacctc cgagtcttac cagcaagggg tcctgtctgc caccatcctc 840
tatgagatct tgctagggaa ggccaccttg tatgccgtgc tggtcagtgc cctcgtgctg 900
atggccatgg tcaagagaaa ggattccaga ggctag 936
<210> 353
<211> 311
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - TCRβ)
<400> 353
Met Ser Thr Arg Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala
1 5 10 15
Glu Leu Ser Glu Ala Glu Val Ala Gln Ser Pro Arg Tyr Lys Ile Thr
20 25 30
Glu Lys Ser Gln Ala Val Ala Phe Trp Cys Asp Pro Ile Ser Gly His
35 40 45
Ala Thr Leu Tyr Trp Tyr Arg Gln Ile Leu Gly Gln Gly Pro Glu Leu
50 55 60
Leu Val Gln Phe Gln Asp Glu Ser Val Val Asp Asp Ser Gln Leu Pro
65 70 75 80
Lys Asp Arg Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu
85 90 95
Lys Ile Gln Pro Ala Glu Leu Gly Asp Ser Ala Met Tyr Leu Cys Ala
100 105 110
Ser Ser Pro Thr Gly Glu Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg
115 120 125
Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala
130 135 140
Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr
145 150 155 160
Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser
165 170 175
Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190
Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu
195 200 205
Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn
210 215 220
His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu
225 230 235 240
Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu
245 250 255
Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln
260 265 270
Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala
275 280 285
Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val
290 295 300
Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 354
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 - TCR Vβ)
<400> 354
Glu Ala Glu Val Ala Gln Ser Pro Arg Tyr Lys Ile Thr Glu Lys Ser
1 5 10 15
Gln Ala Val Ala Phe Trp Cys Asp Pro Ile Ser Gly His Ala Thr Leu
20 25 30
Tyr Trp Tyr Arg Gln Ile Leu Gly Gln Gly Pro Glu Leu Leu Val Gln
35 40 45
Phe Gln Asp Glu Ser Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg
50 55 60
Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ala Glu Leu Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Pro
85 90 95
Thr Gly Glu Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr
<210> 355
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 -
TCRβ-P2A-TCRα片段)
<400> 355
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgagcacc agactccttt 60
gctggatggc tttgtgtctg cttggagctg agctgtctga agctgaagtt gcccagtctc 120
ccagatacaa gatcaccgag aaatctcagg ctgtggcctt ctggtgtgac cctatttctg 180
gacacgccac cctgtactgg tataggcaaa ttctgggaca aggccctgaa ctgctggtgc 240
aatttcagga tgagagcgtg gtggacgatt ctcaactgcc taaggacagg ttttctgccg 300
agcggctgaa aggagttgat agcaccctga agatccaacc tgctgaactg ggcgattctg 360
ctatgtacct gtgcgcctct tctcctacag gagagggaga acagtatttt ggacctggca 420
ccagactgac agtgacagag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atgaagacct ttgccggatt ctccttcctg ttcctgtggc 1080
tgcagctgga ttgtatgagc agaggcgaag atgtggaaca gagcctgttt ctgagcgtga 1140
gagagggaga tagcagcgtg atcaattgca cctacaccga ttctagcagc acctacctgt 1200
actggtacaa gcaggaacct ggagccggat tacaactgct gacctacatc ttcagcaaca 1260
tggacatgaa gcaggaccag agactgaccg tgctgctgaa caagaaggac aagcacctga 1320
gcctgagaat tgccgataca cagacaggag atagcgccat ctacttctgt gccgagatcg 1380
aggacaacac cgacaagctg atctttggaa ccggaacaag actgcaggtg ttccccaaca 1440
tccagaatcc cgatcctgcc gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 356
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR02 -
TCRβ-P2A-TCRα片段
<400> 356
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Ser Thr Arg
1 5 10 15
Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala Glu Leu Ser Glu
20 25 30
Ala Glu Val Ala Gln Ser Pro Arg Tyr Lys Ile Thr Glu Lys Ser Gln
35 40 45
Ala Val Ala Phe Trp Cys Asp Pro Ile Ser Gly His Ala Thr Leu Tyr
50 55 60
Trp Tyr Arg Gln Ile Leu Gly Gln Gly Pro Glu Leu Leu Val Gln Phe
65 70 75 80
Gln Asp Glu Ser Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg Phe
85 90 95
Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln Pro
100 105 110
Ala Glu Leu Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Pro Thr
115 120 125
Gly Glu Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Lys Thr Phe Ala Gly Phe
340 345 350
Ser Phe Leu Phe Leu Trp Leu Gln Leu Asp Cys Met Ser Arg Gly Glu
355 360 365
Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp Ser Ser
370 375 380
Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu Tyr Trp
385 390 395 400
Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr Ile Phe
405 410 415
Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu Leu Asn
420 425 430
Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln Thr Gly
435 440 445
Asp Ser Ala Ile Tyr Phe Cys Ala Glu Ile Glu Asp Asn Thr Asp Lys
450 455 460
Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 357
<211> 819
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - TCRα)
<400> 357
atgaagacat ttgctggatt ttcgttcctg tttttgtggc tgcagctgga ctgtatgagt 60
agaggagagg atgtggagca gagtcttttc ctgagtgtcc gagagggaga cagctccgtt 120
ataaactgca cttacacaga cagctcctcc acctacttat actggtataa gcaagaacct 180
ggagcaggtc tccagttgct gacgtatatt ttttcaaata tggacatgaa acaagaccaa 240
agactcactg ttctattgaa taaaaaggat aaacatctgt ctctgcgcat tgcagacacc 300
cagactgggg actcagctat ctacttctgt gcagagagga ccgacaccga caagctcatc 360
tttgggactg ggaccagatt acaagtcttt ccaaatatcc agaaccctga ccctgccgtg 420
taccagctga gagactctaa atccagtgac aagtctgtct gcctattcac cgattttgat 480
tctcaaacaa atgtgtcaca aagtaaggat tctgatgtgt atatcacaga caaaactgtg 540
ctagacatga ggtctatgga cttcaagagc aacagtgctg tggcctggag caacaaatct 600
gactttgcat gtgcaaacgc cttcaacaac agcattattc cagaagacac cttcttcccc 660
agcccagaaa gttcctgtga tgtcaagctg gtcgagaaaa gctttgaaac agatacgaac 720
ctaaactttc aaaacctgtc agtgattggg ttccgaatcc tcctcctgaa agtggccggg 780
tttaatctgc tcatgacgct gcggctgtgg tccagctga 819
<210> 358
<211> 272
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - TCRα)
<400> 358
Met Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu
1 5 10 15
Asp Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser
20 25 30
Val Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser
35 40 45
Ser Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu
50 55 60
Gln Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln
65 70 75 80
Arg Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg
85 90 95
Ile Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu
100 105 110
Arg Thr Asp Thr Asp Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln
115 120 125
Val Phe Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg
130 135 140
Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp
145 150 155 160
Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr
165 170 175
Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser
180 185 190
Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe
195 200 205
Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser
210 215 220
Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn
225 230 235 240
Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu
245 250 255
Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
260 265 270
<210> 359
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - TCR Vα)
<400> 359
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Arg Thr Asp Thr Asp
85 90 95
Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn
100 105 110
<210> 360
<211> 936
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - TCRβ)
<400> 360
atgggcacca ggctcctctg ctgggcagcc ctgtgcctcc tgggggcaga tcacacaggt 60
gctggagtct cccagacccc cagtaacaag gtcacagaga agggaaaata tgtagagctc 120
aggtgtgatc caatttcagg tcatactgcc ctttactggt accgacaaag cctggggcag 180
ggcccagagt ttctaattta cttccaaggc acgggtgcgg cagatgactc agggctgccc 240
aacgatcggt tctttgcagt caggcctgag ggatccgtct ctactctgaa gatccagcgc 300
acagagcggg gggactcagc cgtgtatctc tgtgccagca gccccctagc ggcgaatgag 360
cagttcttcg ggccagggac acggctcacc gtgctagagg acctgaaaaa cgtgttccca 420
cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca 480
ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 540
gggaaggagg tgcacagtgg ggtcagcaca gacccgcagc ccctcaagga gcagcccgcc 600
ctcaatgact ccagatactg cctgagcagc cgcctgaggg tctcggccac cttctggcag 660
aacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag 720
tggacccagg atagggccaa acctgtcacc cagatcgtca gcgccgaggc ctggggtaga 780
gcagactgtg gcttcacctc cgagtcttac cagcaagggg tcctgtctgc caccatcctc 840
tatgagatct tgctagggaa ggccaccttg tatgccgtgc tggtcagtgc cctcgtgctg 900
atggccatgg tcaagagaaa ggattccaga ggctag 936
<210> 361
<211> 311
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - TCRβ)
<400> 361
Met Gly Thr Arg Leu Leu Cys Trp Ala Ala Leu Cys Leu Leu Gly Ala
1 5 10 15
Asp His Thr Gly Ala Gly Val Ser Gln Thr Pro Ser Asn Lys Val Thr
20 25 30
Glu Lys Gly Lys Tyr Val Glu Leu Arg Cys Asp Pro Ile Ser Gly His
35 40 45
Thr Ala Leu Tyr Trp Tyr Arg Gln Ser Leu Gly Gln Gly Pro Glu Phe
50 55 60
Leu Ile Tyr Phe Gln Gly Thr Gly Ala Ala Asp Asp Ser Gly Leu Pro
65 70 75 80
Asn Asp Arg Phe Phe Ala Val Arg Pro Glu Gly Ser Val Ser Thr Leu
85 90 95
Lys Ile Gln Arg Thr Glu Arg Gly Asp Ser Ala Val Tyr Leu Cys Ala
100 105 110
Ser Ser Pro Leu Ala Ala Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg
115 120 125
Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala
130 135 140
Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr
145 150 155 160
Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser
165 170 175
Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190
Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu
195 200 205
Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn
210 215 220
His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu
225 230 235 240
Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu
245 250 255
Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln
260 265 270
Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala
275 280 285
Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val
290 295 300
Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 362
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 - TCR Vβ)
<400> 362
Gly Ala Gly Val Ser Gln Thr Pro Ser Asn Lys Val Thr Glu Lys Gly
1 5 10 15
Lys Tyr Val Glu Leu Arg Cys Asp Pro Ile Ser Gly His Thr Ala Leu
20 25 30
Tyr Trp Tyr Arg Gln Ser Leu Gly Gln Gly Pro Glu Phe Leu Ile Tyr
35 40 45
Phe Gln Gly Thr Gly Ala Ala Asp Asp Ser Gly Leu Pro Asn Asp Arg
50 55 60
Phe Phe Ala Val Arg Pro Glu Gly Ser Val Ser Thr Leu Lys Ile Gln
65 70 75 80
Arg Thr Glu Arg Gly Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Pro
85 90 95
Leu Ala Ala Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Leu
<210> 363
<211> 1490
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 -
TCRβ-P2A-TCRα片段
<400> 363
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca agacttctct 60
gttgggctgc tctttgtctg cttggagccg atcatacagg agctggagtt agccagacac 120
ctagcaataa ggtgaccgaa aagggcaagt acgtggagct gagatgcgac cctatttctg 180
gccatacagc cctgtactgg tacagacaat ctctgggaca aggacccgag ttcctgatct 240
actttcaggg aacaggagcc gccgatgatt ctggacttcc taacgacagg ttcttcgccg 300
tgagaccaga aggatctgtt tctaccctga agatccagag gaccgagaga ggcgattctg 360
ctgtgtacct gtgtgcctct tctcctttag ctgccaatga gcagttcttt ggccctggca 420
caagactgac agtgctggaa gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atgaagacct ttgccggatt ctccttcctg ttcctgtggc 1080
tgcagctgga ttgtatgagc agaggcgaag atgtggaaca gagcctgttt ctgagcgtga 1140
gagagggaga tagcagcgtg atcaattgca cctacaccga ttctagcagc acctacctgt 1200
actggtacaa gcaggaacct ggagccggat tacaactgct gacctacatc ttcagcaaca 1260
tggacatgaa gcaggaccag agactgaccg tgctgctgaa caagaaggac aagcacctga 1320
gcctgagaat tgccgataca cagacaggag atagcgccat ctacttctgt gccgagagaa 1380
ccgacaccga caagctgatc tttggaacag gcacaagact gcaggtgttc cccaatatcc 1440
agaatcccga tcctgccgtg taccagctgc gggacagcaa gagcagcgac 1490
<210> 364
<211> 495
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR03 -
TCRβ-P2A-TCRα片段)
<400> 364
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Thr Arg
1 5 10 15
Leu Leu Cys Trp Ala Ala Leu Cys Leu Leu Gly Ala Asp His Thr Gly
20 25 30
Ala Gly Val Ser Gln Thr Pro Ser Asn Lys Val Thr Glu Lys Gly Lys
35 40 45
Tyr Val Glu Leu Arg Cys Asp Pro Ile Ser Gly His Thr Ala Leu Tyr
50 55 60
Trp Tyr Arg Gln Ser Leu Gly Gln Gly Pro Glu Phe Leu Ile Tyr Phe
65 70 75 80
Gln Gly Thr Gly Ala Ala Asp Asp Ser Gly Leu Pro Asn Asp Arg Phe
85 90 95
Phe Ala Val Arg Pro Glu Gly Ser Val Ser Thr Leu Lys Ile Gln Arg
100 105 110
Thr Glu Arg Gly Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Pro Leu
115 120 125
Ala Ala Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Lys Thr Phe Ala Gly Phe
340 345 350
Ser Phe Leu Phe Leu Trp Leu Gln Leu Asp Cys Met Ser Arg Gly Glu
355 360 365
Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp Ser Ser
370 375 380
Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu Tyr Trp
385 390 395 400
Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr Ile Phe
405 410 415
Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu Leu Asn
420 425 430
Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln Thr Gly
435 440 445
Asp Ser Ala Ile Tyr Phe Cys Ala Glu Arg Thr Asp Thr Asp Lys Leu
450 455 460
Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn Ile Gln Asn
465 470 475 480
Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 365
<211> 825
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - TCRα)
<400> 365
atgctgactg ccagcctgtt gagggcagtc atagcctcca tctgtgttgt atccagcatg 60
gctcagaagg taactcaagc gcagactgaa atttctgtgg tggagaagga ggatgtgacc 120
ttggactgtg tgtatgaaac ccgtgatact acttattact tattctggta caagcaacca 180
ccaagtggag aattggtttt ccttattcgt cggaactctt ttgatgagca aaatgaaata 240
agtggtcggt attcttggaa cttccagaaa tccaccagtt ccttcaactt caccatcaca 300
gcctcacaag tcgtggactc agcagtatac ttctgtgctc tgatggatag cagctataaa 360
ttgatcttcg ggagtgggac cagactgctg gtcaggcctg atatccagaa ccctgaccct 420
gccgtgtacc agctgagaga ctctaaatcc agtgacaagt ctgtctgcct attcaccgat 480
tttgattctc aaacaaatgt gtcacaaagt aaggattctg atgtgtatat cacagacaaa 540
actgtgctag acatgaggtc tatggacttc aagagcaaca gtgctgtggc ctggagcaac 600
aaatctgact ttgcatgtgc aaacgccttc aacaacagca ttattccaga agacaccttc 660
ttccccagcc cagaaagttc ctgtgatgtc aagctggtcg agaaaagctt tgaaacagat 720
acgaacctaa actttcaaaa cctgtcagtg attgggttcc gaatcctcct cctgaaagtg 780
gccgggttta atctgctcat gacgctgcgg ctgtggtcca gctga 825
<210> 366
<211> 274
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - TCRα)
<400> 366
Met Leu Thr Ala Ser Leu Leu Arg Ala Val Ile Ala Ser Ile Cys Val
1 5 10 15
Val Ser Ser Met Ala Gln Lys Val Thr Gln Ala Gln Thr Glu Ile Ser
20 25 30
Val Val Glu Lys Glu Asp Val Thr Leu Asp Cys Val Tyr Glu Thr Arg
35 40 45
Asp Thr Thr Tyr Tyr Leu Phe Trp Tyr Lys Gln Pro Pro Ser Gly Glu
50 55 60
Leu Val Phe Leu Ile Arg Arg Asn Ser Phe Asp Glu Gln Asn Glu Ile
65 70 75 80
Ser Gly Arg Tyr Ser Trp Asn Phe Gln Lys Ser Thr Ser Ser Phe Asn
85 90 95
Phe Thr Ile Thr Ala Ser Gln Val Val Asp Ser Ala Val Tyr Phe Cys
100 105 110
Ala Leu Met Asp Ser Ser Tyr Lys Leu Ile Phe Gly Ser Gly Thr Arg
115 120 125
Leu Leu Val Arg Pro Asp Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln
130 135 140
Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp
145 150 155 160
Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr
165 170 175
Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser
180 185 190
Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn
195 200 205
Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro
210 215 220
Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp
225 230 235 240
Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu
245 250 255
Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp
260 265 270
Ser Ser
<210> 367
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - TCR Vα)
<400> 367
Ala Gln Lys Val Thr Gln Ala Gln Thr Glu Ile Ser Val Val Glu Lys
1 5 10 15
Glu Asp Val Thr Leu Asp Cys Val Tyr Glu Thr Arg Asp Thr Thr Tyr
20 25 30
Tyr Leu Phe Trp Tyr Lys Gln Pro Pro Ser Gly Glu Leu Val Phe Leu
35 40 45
Ile Arg Arg Asn Ser Phe Asp Glu Gln Asn Glu Ile Ser Gly Arg Tyr
50 55 60
Ser Trp Asn Phe Gln Lys Ser Thr Ser Ser Phe Asn Phe Thr Ile Thr
65 70 75 80
Ala Ser Gln Val Val Asp Ser Ala Val Tyr Phe Cys Ala Leu Met Asp
85 90 95
Ser Ser Tyr Lys Leu Ile Phe Gly Ser Gly Thr Arg Leu Leu Val Arg
100 105 110
Pro Asp
<210> 368
<211> 930
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - TCRβ)
<400> 368
atgctgctgc ttctgctgct tctggggcca ggctccgggc ttggtgctgt cgtctctcaa 60
catccgagct gggttatctg taagagtgga acctctgtga agatcgagtg ccgttccctg 120
gactttcagg ccacaactat gttttggtat cgtcagttcc cgaaacagag tctcatgctg 180
atggcaactt ccaatgaggg ctccaaggcc acatacgagc aaggcgtcga gaaggacaag 240
tttctcatca accatgcaag cctgaccttg tccactctga cagtgaccag tgcccatcct 300
gaagacagca gcttctacat ctgcagtgct tttcttagcg gatccgcaga tacgcagtat 360
tttggcccag gcacccggct gacagtgctc gaggacctga aaaacgtgtt cccacccgag 420
gtcgctgtgt ttgagccatc agaagcagag atctcccaca cccaaaaggc cacactggtg 480
tgcctggcca caggcttcta ccccgaccac gtggagctga gctggtgggt gaatgggaag 540
gaggtgcaca gtggggtcag cacagacccg cagcccctca aggagcagcc cgccctcaat 600
gactccagat actgcctgag cagccgcctg agggtctcgg ccaccttctg gcagaacccc 660
cgcaaccact tccgctgtca agtccagttc tacgggctct cggagaatga cgagtggacc 720
caggataggg ccaaacctgt cacccagatc gtcagcgccg aggcctgggg tagagcagac 780
tgtggcttca cctccgagtc ttaccagcaa ggggtcctgt ctgccaccat cctctatgag 840
atcttgctag ggaaggccac cttgtatgcc gtgctggtca gtgccctcgt gctgatggcc 900
atggtcaaga gaaaggattc cagaggctag 930
<210> 369
<211> 309
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - TCRβ)
<400> 369
Met Leu Leu Leu Leu Leu Leu Leu Gly Pro Gly Ser Gly Leu Gly Ala
1 5 10 15
Val Val Ser Gln His Pro Ser Trp Val Ile Cys Lys Ser Gly Thr Ser
20 25 30
Val Lys Ile Glu Cys Arg Ser Leu Asp Phe Gln Ala Thr Thr Met Phe
35 40 45
Trp Tyr Arg Gln Phe Pro Lys Gln Ser Leu Met Leu Met Ala Thr Ser
50 55 60
Asn Glu Gly Ser Lys Ala Thr Tyr Glu Gln Gly Val Glu Lys Asp Lys
65 70 75 80
Phe Leu Ile Asn His Ala Ser Leu Thr Leu Ser Thr Leu Thr Val Thr
85 90 95
Ser Ala His Pro Glu Asp Ser Ser Phe Tyr Ile Cys Ser Ala Phe Leu
100 105 110
Ser Gly Ser Ala Asp Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr
115 120 125
Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe
130 135 140
Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val
145 150 155 160
Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp
165 170 175
Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro
180 185 190
Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser
195 200 205
Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe
210 215 220
Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr
225 230 235 240
Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp
245 250 255
Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val
260 265 270
Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu
275 280 285
Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg
290 295 300
Lys Asp Ser Arg Gly
305
<210> 370
<211> 116
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 - TCR Vβ)
<400> 370
Gly Ala Val Val Ser Gln His Pro Ser Trp Val Ile Cys Lys Ser Gly
1 5 10 15
Thr Ser Val Lys Ile Glu Cys Arg Ser Leu Asp Phe Gln Ala Thr Thr
20 25 30
Met Phe Trp Tyr Arg Gln Phe Pro Lys Gln Ser Leu Met Leu Met Ala
35 40 45
Thr Ser Asn Glu Gly Ser Lys Ala Thr Tyr Glu Gln Gly Val Glu Lys
50 55 60
Asp Lys Phe Leu Ile Asn His Ala Ser Leu Thr Leu Ser Thr Leu Thr
65 70 75 80
Val Thr Ser Ala His Pro Glu Asp Ser Ser Phe Tyr Ile Cys Ser Ala
85 90 95
Phe Leu Ser Gly Ser Ala Asp Thr Gln Tyr Phe Gly Pro Gly Thr Arg
100 105 110
Leu Thr Val Leu
115
<210> 371
<211> 1490
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 -
TCRβ-P2A-TCRα片段)
<400> 371
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgctgctt cttctcctcc 60
ttctcggacc tggatctgga ttaggagctg tggtttctca gcacccttct tgggtgatct 120
gtaaaagcgg cacaagcgtg aagatcgagt gcagaagcct ggactttcag gccacaacca 180
tgttctggta taggcagttc cccaagcagt ctctgatgct gatggccacc tctaatgagg 240
gctctaaggc cacatatgaa cagggagtgg agaaggacaa gttcctgatc aaccacgcct 300
ctctgaccct gtctaccctg acagttacat ctgcccaccc tgaggatagc agcttttaca 360
tctgtagcgc cttcctgtct ggaagcgccg atacacagta ctttggacct ggcaccagac 420
tgacagtgtt agaagacctg aagaacgtgt tccccccaga ggtggccgtg ttcgagccta 480
gcgaggccga gatcagccac acccagaaag ccaccctcgt gtgcctggcc accggctttt 540
accccgacca cgtggaactg tcttggtggg tcaacggcaa agaggtgcac agcggcgtct 600
gcaccgaccc ccagcccctg aaagagcagc ccgccctgaa cgacagccgg tactgtctga 660
gcagcagact gagagtgtcc gccaccttct ggcagaaccc ccggaaccac ttcagatgcc 720
aggtgcagtt ctacggcctg agcgagaacg acgagtggac ccaggaccgg gccaagcccg 780
tgacccagat cgtgtctgct gaggcctggg gcagagccga ttgcggcttc accagcgaga 840
gctaccagca gggcgtgctg agcgccacca tcctgtacga gatcctgctg ggcaaggcca 900
ccctgtacgc cgtgctggtg tccgccctgg tgctgatggc catggtcaag cggaaggaca 960
gccggggcgg ttccggagcc acgaacttct ctctgttaaa gcaagcagga gacgtggaag 1020
aaaaccccgg tcccatgttg accgcttctc tcttacgtgc cgtgattgcc agcatctgtg 1080
tggtgtcttc tatggcccag aaggttacac aggctcagac agagatcagc gttgtggaga 1140
aggaggatgt gaccctggat tgcgtgtacg agacaagaga taccacctac tacctgttct 1200
ggtacaagca gcctccttct ggcgaactgg tgttcctgat ccggagaaac agctttgatg 1260
agcagaacga gattagcggc aggtatagct ggaacttcca gaagagcacc agcagcttca 1320
acttcaccat cacagcctct caggtggtgg attctgccgt gtacttttgt gccctgatgg 1380
acagcagcta caagctgatc tttggaagcg gcaccagact gctggtgaga cctgatatcc 1440
agaatcctga tcctgccgtg taccagctgc gggacagcaa gagcagcgac 1490
<210> 372
<211> 495
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR04 -
TCRβ-P2A-TCRα片段)
<400> 372
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Leu Leu Leu
1 5 10 15
Leu Leu Leu Leu Gly Pro Gly Ser Gly Leu Gly Ala Val Val Ser Gln
20 25 30
His Pro Ser Trp Val Ile Cys Lys Ser Gly Thr Ser Val Lys Ile Glu
35 40 45
Cys Arg Ser Leu Asp Phe Gln Ala Thr Thr Met Phe Trp Tyr Arg Gln
50 55 60
Phe Pro Lys Gln Ser Leu Met Leu Met Ala Thr Ser Asn Glu Gly Ser
65 70 75 80
Lys Ala Thr Tyr Glu Gln Gly Val Glu Lys Asp Lys Phe Leu Ile Asn
85 90 95
His Ala Ser Leu Thr Leu Ser Thr Leu Thr Val Thr Ser Ala His Pro
100 105 110
Glu Asp Ser Ser Phe Tyr Ile Cys Ser Ala Phe Leu Ser Gly Ser Ala
115 120 125
Asp Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Leu Glu Asp
130 135 140
Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser Glu
145 150 155 160
Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala Thr
165 170 175
Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly Lys
180 185 190
Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu Gln
195 200 205
Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg Val
210 215 220
Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln Val
225 230 235 240
Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg Ala
245 250 255
Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala Asp
260 265 270
Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr
275 280 285
Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu
290 295 300
Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Ser Arg
305 310 315 320
Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp
325 330 335
Val Glu Glu Asn Pro Gly Pro Met Leu Thr Ala Ser Leu Leu Arg Ala
340 345 350
Val Ile Ala Ser Ile Cys Val Val Ser Ser Met Ala Gln Lys Val Thr
355 360 365
Gln Ala Gln Thr Glu Ile Ser Val Val Glu Lys Glu Asp Val Thr Leu
370 375 380
Asp Cys Val Tyr Glu Thr Arg Asp Thr Thr Tyr Tyr Leu Phe Trp Tyr
385 390 395 400
Lys Gln Pro Pro Ser Gly Glu Leu Val Phe Leu Ile Arg Arg Asn Ser
405 410 415
Phe Asp Glu Gln Asn Glu Ile Ser Gly Arg Tyr Ser Trp Asn Phe Gln
420 425 430
Lys Ser Thr Ser Ser Phe Asn Phe Thr Ile Thr Ala Ser Gln Val Val
435 440 445
Asp Ser Ala Val Tyr Phe Cys Ala Leu Met Asp Ser Ser Tyr Lys Leu
450 455 460
Ile Phe Gly Ser Gly Thr Arg Leu Leu Val Arg Pro Asp Ile Gln Asn
465 470 475 480
Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 373
<211> 828
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - TCRα)
<400> 373
atgctcctgg agcttatccc actgctgggg atacattttg tcctgagaac tgccagagcc 60
cagtcagtga cccagcctga catccacatc actgtctctg aaggagcctc actggagttg 120
agatgtaact attcctatgg ggcaacacct tatctcttct ggtatgtcca gtcccccggc 180
caaggcctcc agctgctcct gaagtacttt tcaggagaca ctctggttca aggcattaaa 240
ggctttgagg ctgaatttaa gaggagtcaa tcttccttca atctgaggaa accctctgtg 300
cattggagtg atgctgctga gtacttctgt gctgtgggtg atgagaacac aggctttcag 360
aaacttgtat ttggaactgg cacccgactt ctggtcagtc caaatatcca gaaccctgac 420
cctgccgtgt accagctgag agactctaaa tccagtgaca agtctgtctg cctattcacc 480
gattttgatt ctcaaacaaa tgtgtcacaa agtaaggatt ctgatgtgta tatcacagac 540
aaaactgtgc tagacatgag gtctatggac ttcaagagca acagtgctgt ggcctggagc 600
aacaaatctg actttgcatg tgcaaacgcc ttcaacaaca gcattattcc agaagacacc 660
ttcttcccca gcccagaaag ttcctgtgat gtcaagctgg tcgagaaaag ctttgaaaca 720
gatacgaacc taaactttca aaacctgtca gtgattgggt tccgaatcct cctcctgaaa 780
gtggccgggt ttaatctgct catgacgctg cggctgtggt ccagctga 828
<210> 374
<211> 275
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - TCRα)
<400> 374
Met Leu Leu Glu Leu Ile Pro Leu Leu Gly Ile His Phe Val Leu Arg
1 5 10 15
Thr Ala Arg Ala Gln Ser Val Thr Gln Pro Asp Ile His Ile Thr Val
20 25 30
Ser Glu Gly Ala Ser Leu Glu Leu Arg Cys Asn Tyr Ser Tyr Gly Ala
35 40 45
Thr Pro Tyr Leu Phe Trp Tyr Val Gln Ser Pro Gly Gln Gly Leu Gln
50 55 60
Leu Leu Leu Lys Tyr Phe Ser Gly Asp Thr Leu Val Gln Gly Ile Lys
65 70 75 80
Gly Phe Glu Ala Glu Phe Lys Arg Ser Gln Ser Ser Phe Asn Leu Arg
85 90 95
Lys Pro Ser Val His Trp Ser Asp Ala Ala Glu Tyr Phe Cys Ala Val
100 105 110
Gly Asp Glu Asn Thr Gly Phe Gln Lys Leu Val Phe Gly Thr Gly Thr
115 120 125
Arg Leu Leu Val Ser Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr
130 135 140
Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr
145 150 155 160
Asp Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val
165 170 175
Tyr Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys
180 185 190
Ser Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala
195 200 205
Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser
210 215 220
Pro Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr
225 230 235 240
Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile
245 250 255
Leu Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu
260 265 270
Trp Ser Ser
275
<210> 375
<211> 116
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - TCR Vα)
<400> 375
Ala Gln Ser Val Thr Gln Pro Asp Ile His Ile Thr Val Ser Glu Gly
1 5 10 15
Ala Ser Leu Glu Leu Arg Cys Asn Tyr Ser Tyr Gly Ala Thr Pro Tyr
20 25 30
Leu Phe Trp Tyr Val Gln Ser Pro Gly Gln Gly Leu Gln Leu Leu Leu
35 40 45
Lys Tyr Phe Ser Gly Asp Thr Leu Val Gln Gly Ile Lys Gly Phe Glu
50 55 60
Ala Glu Phe Lys Arg Ser Gln Ser Ser Phe Asn Leu Arg Lys Pro Ser
65 70 75 80
Val His Trp Ser Asp Ala Ala Glu Tyr Phe Cys Ala Val Gly Asp Glu
85 90 95
Asn Thr Gly Phe Gln Lys Leu Val Phe Gly Thr Gly Thr Arg Leu Leu
100 105 110
Val Ser Pro Asn
115
<210> 376
<211> 933
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - TCRβ)
<400> 376
atgggaatca ggctcctgtg tcgtgtggcc ttttgtttcc tggctgtagg cctcgtagat 60
gtgaaagtaa cccagagctc gagatatcta gtcaaaagga cgggagagaa agtttttctg 120
gaatgtgtcc aggatatgga ccatgaaaat atgttctggt atcgacaaga cccaggtctg 180
gggctacggc tgatctattt ctcatatgat gttaaaatga aagaaaaagg agatattcct 240
gaggggtaca gtgtctctag agagaagaag gagcgcttct ccctgattct ggagtccgcc 300
agcaccaacc agacatctat gtacctctgt gccagcgccc ttcgggggac ctacgagcag 360
tacttcgggc cgggcaccag gctcacggtc acagaggacc tgaaaaacgt gttcccaccc 420
gaggtcgctg tgtttgagcc atcagaagca gagatctccc acacccaaaa ggccacactg 480
gtgtgcctgg ccacaggctt ctaccccgac cacgtggagc tgagctggtg ggtgaatggg 540
aaggaggtgc acagtggggt cagcacagac ccgcagcccc tcaaggagca gcccgccctc 600
aatgactcca gatactgcct gagcagccgc ctgagggtct cggccacctt ctggcagaac 660
ccccgcaacc acttccgctg tcaagtccag ttctacgggc tctcggagaa tgacgagtgg 720
acccaggata gggccaaacc tgtcacccag atcgtcagcg ccgaggcctg gggtagagca 780
gactgtggct tcacctccga gtcttaccag caaggggtcc tgtctgccac catcctctat 840
gagatcttgc tagggaaggc caccttgtat gccgtgctgg tcagtgccct cgtgctgatg 900
gccatggtca agagaaagga ttccagaggc tag 933
<210> 377
<211> 310
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - TCRβ)
<400> 377
Met Gly Ile Arg Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val
1 5 10 15
Gly Leu Val Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys
20 25 30
Arg Thr Gly Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His
35 40 45
Glu Asn Met Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu
50 55 60
Ile Tyr Phe Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro
65 70 75 80
Glu Gly Tyr Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile
85 90 95
Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser
100 105 110
Ala Leu Arg Gly Thr Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu
115 120 125
Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val
130 135 140
Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu
145 150 155 160
Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp
165 170 175
Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln
180 185 190
Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser
195 200 205
Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His
210 215 220
Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp
225 230 235 240
Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala
245 250 255
Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly
260 265 270
Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr
275 280 285
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys
290 295 300
Arg Lys Asp Ser Arg Gly
305 310
<210> 378
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 - TCR Vβ)
<400> 378
Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly
1 5 10 15
Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe
35 40 45
Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr
50 55 60
Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser
65 70 75 80
Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ala Leu Arg
85 90 95
Gly Thr Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
100 105 110
<210> 379
<211> 1496
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 -
TCRβ-P2A-TCRα)
<400> 379
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcatc agactccttt 60
gcagggtggc cttttgcttt ctggctgtgg gattagtgga cgtgaaggtt acccagagca 120
gcagatatct ggtgaagaga accggcgaga aggtgttcct ggaatgtgtg caggatatgg 180
accacgagaa catgttctgg tacagacagg accctggact gggactgaga ctgatctact 240
tcagctacga cgtgaagatg aaggagaagg gcgatatccc tgagggctac agcgtgagca 300
gagagaaaaa ggagaggttc agcctgattc tggaaagcgc cagcacaaat cagaccagca 360
tgtacctgtg cgcttctgct ctgagaggca catatgagca gtacttcggc cctggaacaa 420
gactgacagt gacagaggac ctgaagaacg tgttcccccc agaggtggcc gtgttcgagc 480
ctagcgaggc cgagatcagc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
tttaccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cacagcggcg 600
tctgcaccga cccccagccc ctgaaagagc agcccgccct gaacgacagc cggtactgtc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac cgggccaagc 780
ccgtgaccca gatcgtgtct gctgaggcct ggggcagagc cgattgcggc ttcaccagcg 840
agagctacca gcagggcgtg ctgagcgcca ccatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtccgccc tggtgctgat ggccatggtc aagcggaagg 960
acagccgggg cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg ctgctggaac tgatacccct actgggcatc cactttgtgc 1080
tgagaacagc tagagcccaa tctgtgacac agcccgatat ccacattacc gtgagcgaag 1140
gagcttctct ggaactgaga tgcaactaca gctatggcgc caccccttac cttttctggt 1200
acgtgcagtc tcctggacag ggattacaac tgctgctgaa gtacttctcc ggcgatacac 1260
tggttcaggg cattaagggc tttgaggccg agttcaagag aagccagagc agctttaacc 1320
tgagaaagcc tagcgtgcac tggtctgatg ctgccgagta cttttgtgct gtgggcgacg 1380
agaataccgg atttcagaaa ctggtgttcg gaacaggcac caggctgtta gttagcccca 1440
acatccagaa ccctgatcct gctgtgtacc agctgcggga cagcaagagc agcgac 1496
<210> 380
<211> 497
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR05 -
TCRβ-P2A-TCRα 片段)
<400> 380
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Ile Arg
1 5 10 15
Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val Gly Leu Val Asp
20 25 30
Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly Glu
35 40 45
Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met Phe
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe Ser
65 70 75 80
Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr Ser
85 90 95
Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser Ala
100 105 110
Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ala Leu Arg Gly
115 120 125
Thr Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr Glu
130 135 140
Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser
145 150 155 160
Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala
165 170 175
Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
180 185 190
Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu
195 200 205
Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg
210 215 220
Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln
225 230 235 240
Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg
245 250 255
Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala
260 265 270
Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser Ala
275 280 285
Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val
290 295 300
Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Ser
305 310 315 320
Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly
325 330 335
Asp Val Glu Glu Asn Pro Gly Pro Met Leu Leu Glu Leu Ile Pro Leu
340 345 350
Leu Gly Ile His Phe Val Leu Arg Thr Ala Arg Ala Gln Ser Val Thr
355 360 365
Gln Pro Asp Ile His Ile Thr Val Ser Glu Gly Ala Ser Leu Glu Leu
370 375 380
Arg Cys Asn Tyr Ser Tyr Gly Ala Thr Pro Tyr Leu Phe Trp Tyr Val
385 390 395 400
Gln Ser Pro Gly Gln Gly Leu Gln Leu Leu Leu Lys Tyr Phe Ser Gly
405 410 415
Asp Thr Leu Val Gln Gly Ile Lys Gly Phe Glu Ala Glu Phe Lys Arg
420 425 430
Ser Gln Ser Ser Phe Asn Leu Arg Lys Pro Ser Val His Trp Ser Asp
435 440 445
Ala Ala Glu Tyr Phe Cys Ala Val Gly Asp Glu Asn Thr Gly Phe Gln
450 455 460
Lys Leu Val Phe Gly Thr Gly Thr Arg Leu Leu Val Ser Pro Asn Ile
465 470 475 480
Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser
485 490 495
Asp
<210> 381
<211> 819
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - TCRα)
<400> 381
atgaagacat ttgctggatt ttcgttcctg tttttgtggc tgcagctgga ctgtatgagt 60
agaggagagg atgtggagca gagtcttttc ctgagtgtcc gagagggaga cagctccgtt 120
ataaactgca cttacacaga cagctcctcc acctacttat actggtataa gcaagaacct 180
ggagcaggtc tccagttgct gacgtatatt ttttcaaata tggacatgaa acaagaccaa 240
agactcactg ttctattgaa taaaaaggat aaacatctgt ctctgcgcat tgcagacacc 300
cagactgggg actcagctat ctacttctgt gcagagatcg atggcaccga caagctcatc 360
tttgggactg ggaccagatt acaagtcttt ccaaatatcc agaaccctga ccctgccgtg 420
taccagctga gagactctaa atccagtgac aagtctgtct gcctattcac cgattttgat 480
tctcaaacaa atgtgtcaca aagtaaggat tctgatgtgt atatcacaga caaaactgtg 540
ctagacatga ggtctatgga cttcaagagc aacagtgctg tggcctggag caacaaatct 600
gactttgcat gtgcaaacgc cttcaacaac agcattattc cagaagacac cttcttcccc 660
agcccagaaa gttcctgtga tgtcaagctg gtcgagaaaa gctttgaaac agatacgaac 720
ctaaactttc aaaacctgtc agtgattggg ttccgaatcc tcctcctgaa agtggccggg 780
tttaatctgc tcatgacgct gcggctgtgg tccagctga 819
<210> 382
<211> 272
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - TCRα)
<400> 382
Met Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu
1 5 10 15
Asp Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser
20 25 30
Val Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser
35 40 45
Ser Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu
50 55 60
Gln Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln
65 70 75 80
Arg Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg
85 90 95
Ile Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu
100 105 110
Ile Asp Gly Thr Asp Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln
115 120 125
Val Phe Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg
130 135 140
Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp
145 150 155 160
Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr
165 170 175
Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser
180 185 190
Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe
195 200 205
Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser
210 215 220
Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn
225 230 235 240
Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu
245 250 255
Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
260 265 270
<210> 383
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - TCR Vα)
<400> 383
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Ile Asp Gly Thr Asp
85 90 95
Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn
100 105 110
<210> 384
<211> 936
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - TCRβ)
<400> 384
atgggaatca ggctcctgtg tcgtgtggcc ttttgtttcc tggctgtagg cctcgtagat 60
gtgaaagtaa cccagagctc gagatatcta gtcaaaagga cgggagagaa agtttttctg 120
gaatgtgtcc aggatatgga ccatgaaaat atgttctggt atcgacaaga cccaggtctg 180
gggctacggc tgatctattt ctcatatgat gttaaaatga aagaaaaagg agatattcct 240
gaggggtaca gtgtctctag agagaagaag gagcgcttct ccctgattct ggagtccgcc 300
agcaccaacc agacatctat gtacctctgt gccagcagtt taggggacag gatatacgag 360
cagtacttcg ggccgggcac caggctcacg gtcacagagg acctgaaaaa cgtgttccca 420
cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca 480
ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 540
gggaaggagg tgcacagtgg ggtcagcaca gacccgcagc ccctcaagga gcagcccgcc 600
ctcaatgact ccagatactg cctgagcagc cgcctgaggg tctcggccac cttctggcag 660
aacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag 720
tggacccagg atagggccaa acctgtcacc cagatcgtca gcgccgaggc ctggggtaga 780
gcagactgtg gcttcacctc cgagtcttac cagcaagggg tcctgtctgc caccatcctc 840
tatgagatct tgctagggaa ggccaccttg tatgccgtgc tggtcagtgc cctcgtgctg 900
atggccatgg tcaagagaaa ggattccaga ggctag 936
<210> 385
<211> 311
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - TCRβ)
<400> 385
Met Gly Ile Arg Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val
1 5 10 15
Gly Leu Val Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys
20 25 30
Arg Thr Gly Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His
35 40 45
Glu Asn Met Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu
50 55 60
Ile Tyr Phe Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro
65 70 75 80
Glu Gly Tyr Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile
85 90 95
Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser
100 105 110
Ser Leu Gly Asp Arg Ile Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg
115 120 125
Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala
130 135 140
Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr
145 150 155 160
Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser
165 170 175
Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190
Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu
195 200 205
Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn
210 215 220
His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu
225 230 235 240
Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu
245 250 255
Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln
260 265 270
Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala
275 280 285
Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val
290 295 300
Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 386
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 - TCR Vβ)
<400> 386
Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly
1 5 10 15
Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe
35 40 45
Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr
50 55 60
Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser
65 70 75 80
Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ser Leu Gly
85 90 95
Asp Arg Ile Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr
<210> 387
<211> 1490
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 -
TCRβ-P2A-TCRα 片段)
<400> 387
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcatc agactccttt 60
gcagggtggc cttttgcttt ctggctgtgg gattagtgga cgtgaaggtt acccagagca 120
gcagatatct ggtgaagaga accggcgaga aggtgttcct ggaatgtgtg caggatatgg 180
accacgagaa catgttctgg tacagacagg accctggact gggactgaga ctgatctact 240
tcagctacga cgtgaagatg aaggagaagg gcgatatccc tgagggctac agcgtgagca 300
gagagaaaaa ggagaggttc agcctgattc tggaaagcgc cagcacaaat cagaccagca 360
tgtacctgtg cgcctcttct ctgggagaca ggatttatga gcagtacttc ggaccaggca 420
caagactgac agtgacagag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atgaagacct ttgccggatt ctccttcctg ttcctgtggc 1080
tgcagctgga ttgtatgagc agaggcgaag atgtggaaca gagcctgttt ctgagcgtga 1140
gagagggaga tagcagcgtg atcaattgca cctacaccga ttctagcagc acctacctgt 1200
actggtacaa gcaggaacct ggagccggat tacaactgct gacctacatc ttcagcaaca 1260
tggacatgaa gcaggaccag agactgaccg tgctgctgaa caagaaggac aagcacctga 1320
gcctgagaat tgccgataca cagacaggag atagcgccat ctacttctgt gccgagatcg 1380
atggcaccga caagctgatc tttggaacag gcacaagact gcaggtgttc cccaatatcc 1440
agaatcccga tcctgccgtg taccagctgc gggacagcaa gagcagcgac 1490
<210> 388
<211> 495
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR06 -
TCRβ-P2A-TCRα 片段)
<400> 388
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Ile Arg
1 5 10 15
Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val Gly Leu Val Asp
20 25 30
Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly Glu
35 40 45
Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met Phe
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe Ser
65 70 75 80
Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr Ser
85 90 95
Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser Ala
100 105 110
Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ser Leu Gly Asp
115 120 125
Arg Ile Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Lys Thr Phe Ala Gly Phe
340 345 350
Ser Phe Leu Phe Leu Trp Leu Gln Leu Asp Cys Met Ser Arg Gly Glu
355 360 365
Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp Ser Ser
370 375 380
Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu Tyr Trp
385 390 395 400
Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr Ile Phe
405 410 415
Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu Leu Asn
420 425 430
Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln Thr Gly
435 440 445
Asp Ser Ala Ile Tyr Phe Cys Ala Glu Ile Asp Gly Thr Asp Lys Leu
450 455 460
Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn Ile Gln Asn
465 470 475 480
Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 389
<211> 822
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - TCRα)
<400> 389
atgaagacat ttgctggatt ttcgttcctg tttttgtggc tgcagctgga ctgtatgagt 60
agaggagagg atgtggagca gagtcttttc ctgagtgtcc gagagggaga cagctccgtt 120
ataaactgca cttacacaga cagctcctcc acctacttat actggtataa gcaagaacct 180
ggagcaggtc tccagttgct gacgtatatt ttttcaaata tggacatgaa acaagaccaa 240
agactcactg ttctattgaa taaaaaggat aaacatctgt ctctgcgcat tgcagacacc 300
cagactgggg actcagctat ctacttctgt gcagagatag aggataacac cgacaagctc 360
atctttggga ctgggaccag attacaagtc tttccaaata tccagaaccc tgaccctgcc 420
gtgtaccagc tgagagactc taaatccagt gacaagtctg tctgcctatt caccgatttt 480
gattctcaaa caaatgtgtc acaaagtaag gattctgatg tgtatatcac agacaaaact 540
gtgctagaca tgaggtctat ggacttcaag agcaacagtg ctgtggcctg gagcaacaaa 600
tctgactttg catgtgcaaa cgccttcaac aacagcatta ttccagaaga caccttcttc 660
cccagcccag aaagttcctg tgatgtcaag ctggtcgaga aaagctttga aacagatacg 720
aacctaaact ttcaaaacct gtcagtgatt gggttccgaa tcctcctcct gaaagtggcc 780
gggtttaatc tgctcatgac gctgcggctg tggtccagct ga 822
<210> 390
<211> 273
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - TCRα)
<400> 390
Met Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu
1 5 10 15
Asp Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser
20 25 30
Val Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser
35 40 45
Ser Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu
50 55 60
Gln Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln
65 70 75 80
Arg Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg
85 90 95
Ile Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu
100 105 110
Ile Glu Asp Asn Thr Asp Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu
115 120 125
Gln Val Phe Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu
130 135 140
Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe
145 150 155 160
Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile
165 170 175
Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn
180 185 190
Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala
195 200 205
Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu
210 215 220
Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr
225 230 235 240
Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu
245 250 255
Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser
260 265 270
Ser
<210> 391
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - TCR Vα)
<400> 391
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Ile Glu Asp Asn Thr
85 90 95
Asp Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn
100 105 110
<210> 392
<211> 936
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - TCRβ)
<400> 392
atgagcacca ggcttctctg ctggatggcc ctctgtctcc tgggggcaga actctcagaa 60
gctgaagttg cccagtcccc cagatataag attacagaga aaagccaggc tgtggctttt 120
tggtgtgatc ctatttctgg ccatgctacc ctttactggt accggcagat cctgggacag 180
ggcccggagc ttctggttca atttcaggat gagagtgtag tagatgattc acagttgcct 240
aaggatcgat tttctgcaga gaggctcaaa ggagtagact ccactctcaa gatccagcct 300
gcagagcttg gggactcggc catgtatctc tgtgccagca gccccacagg ggaaggcgag 360
cagtacttcg ggccgggcac caggctcacg gtcacagagg acctgaaaaa cgtgttccca 420
cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca 480
ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 540
gggaaggagg tgcacagtgg ggtcagcaca gacccgcagc ccctcaagga gcagcccgcc 600
ctcaatgact ccagatactg cctgagcagc cgcctgaggg tctcggccac cttctggcag 660
aacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag 720
tggacccagg atagggccaa acctgtcacc cagatcgtca gcgccgaggc ctggggtaga 780
gcagactgtg gcttcacctc cgagtcttac cagcaagggg tcctgtctgc caccatcctc 840
tatgagatct tgctagggaa ggccaccttg tatgccgtgc tggtcagtgc cctcgtgctg 900
atggccatgg tcaagagaaa ggattccaga ggctag 936
<210> 393
<211> 311
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - TCRβ)
<400> 393
Met Ser Thr Arg Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala
1 5 10 15
Glu Leu Ser Glu Ala Glu Val Ala Gln Ser Pro Arg Tyr Lys Ile Thr
20 25 30
Glu Lys Ser Gln Ala Val Ala Phe Trp Cys Asp Pro Ile Ser Gly His
35 40 45
Ala Thr Leu Tyr Trp Tyr Arg Gln Ile Leu Gly Gln Gly Pro Glu Leu
50 55 60
Leu Val Gln Phe Gln Asp Glu Ser Val Val Asp Asp Ser Gln Leu Pro
65 70 75 80
Lys Asp Arg Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu
85 90 95
Lys Ile Gln Pro Ala Glu Leu Gly Asp Ser Ala Met Tyr Leu Cys Ala
100 105 110
Ser Ser Pro Thr Gly Glu Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg
115 120 125
Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala
130 135 140
Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr
145 150 155 160
Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser
165 170 175
Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190
Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu
195 200 205
Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn
210 215 220
His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu
225 230 235 240
Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu
245 250 255
Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln
260 265 270
Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala
275 280 285
Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val
290 295 300
Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 394
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 - TCR Vβ)
<400> 394
Glu Ala Glu Val Ala Gln Ser Pro Arg Tyr Lys Ile Thr Glu Lys Ser
1 5 10 15
Gln Ala Val Ala Phe Trp Cys Asp Pro Ile Ser Gly His Ala Thr Leu
20 25 30
Tyr Trp Tyr Arg Gln Ile Leu Gly Gln Gly Pro Glu Leu Leu Val Gln
35 40 45
Phe Gln Asp Glu Ser Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg
50 55 60
Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ala Glu Leu Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Pro
85 90 95
Thr Gly Glu Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr
<210> 395
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 -
TCRβ-P2A-TCRα 片段)
<400> 395
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgagcacc agactccttt 60
gctggatggc tttgtgtctg cttggagctg agctgtctga agctgaagtt gcccagtctc 120
ccagatacaa gatcaccgag aaatctcagg ctgtggcctt ctggtgtgac cctatttctg 180
gacacgccac cctgtactgg tataggcaaa ttctgggaca aggccctgaa ctgctggtgc 240
aatttcagga tgagagcgtg gtggacgatt ctcaactgcc taaggacagg ttttctgccg 300
agcggctgaa aggagttgat agcaccctga agatccaacc tgctgaactg ggcgattctg 360
ctatgtacct gtgcgcctct tctcctacag gagagggaga acagtatttt ggacctggca 420
ccagactgac agtgacagag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atgaagacct ttgccggatt ctccttcctg ttcctgtggc 1080
tgcagctgga ttgtatgagc agaggcgaag atgtggaaca gagcctgttt ctgagcgtga 1140
gagagggaga tagcagcgtg atcaattgca cctacaccga ttctagcagc acctacctgt 1200
actggtacaa gcaggaacct ggagccggat tacaactgct gacctacatc ttcagcaaca 1260
tggacatgaa gcaggaccag agactgaccg tgctgctgaa caagaaggac aagcacctga 1320
gcctgagaat tgccgataca cagacaggag atagcgccat ctacttctgt gccgagatcg 1380
aggacaacac cgacaagctg atctttggaa ccggaacaag actgcaggtg ttccccaaca 1440
tccagaatcc cgatcctgcc gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 396
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR07 -
TCRβ-P2A-TCRα 片段)
<400> 396
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Ser Thr Arg
1 5 10 15
Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala Glu Leu Ser Glu
20 25 30
Ala Glu Val Ala Gln Ser Pro Arg Tyr Lys Ile Thr Glu Lys Ser Gln
35 40 45
Ala Val Ala Phe Trp Cys Asp Pro Ile Ser Gly His Ala Thr Leu Tyr
50 55 60
Trp Tyr Arg Gln Ile Leu Gly Gln Gly Pro Glu Leu Leu Val Gln Phe
65 70 75 80
Gln Asp Glu Ser Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg Phe
85 90 95
Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln Pro
100 105 110
Ala Glu Leu Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Pro Thr
115 120 125
Gly Glu Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Lys Thr Phe Ala Gly Phe
340 345 350
Ser Phe Leu Phe Leu Trp Leu Gln Leu Asp Cys Met Ser Arg Gly Glu
355 360 365
Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp Ser Ser
370 375 380
Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu Tyr Trp
385 390 395 400
Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr Ile Phe
405 410 415
Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu Leu Asn
420 425 430
Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln Thr Gly
435 440 445
Asp Ser Ala Ile Tyr Phe Cys Ala Glu Ile Glu Asp Asn Thr Asp Lys
450 455 460
Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 397
<211> 825
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - TCRα)
<400> 397
atgaagacat ttgctggatt ttcgttcctg tttttgtggc tgcagctgga ctgtatgagt 60
agaggagagg atgtggagca gagtcttttc ctgagtgtcc gagagggaga cagctccgtt 120
ataaactgca cttacacaga cagctcctcc acctacttat actggtataa gcaagaacct 180
ggagcaggtc tccagttgct gacgtatatt ttttcaaata tggacatgaa acaagaccaa 240
agactcactg ttctattgaa taaaaaggat aaacatctgt ctctgcgcat tgcagacacc 300
cagactgggg actcagctat ctacttctgt gcagagagaa tagattcagg aaacacacct 360
cttgtctttg gaaagggcac aagactttct gtgattgcaa atatccagaa ccctgaccct 420
gccgtgtacc agctgagaga ctctaaatcc agtgacaagt ctgtctgcct attcaccgat 480
tttgattctc aaacaaatgt gtcacaaagt aaggattctg atgtgtatat cacagacaaa 540
actgtgctag acatgaggtc tatggacttc aagagcaaca gtgctgtggc ctggagcaac 600
aaatctgact ttgcatgtgc aaacgccttc aacaacagca ttattccaga agacaccttc 660
ttccccagcc cagaaagttc ctgtgatgtc aagctggtcg agaaaagctt tgaaacagat 720
acgaacctaa actttcaaaa cctgtcagtg attgggttcc gaatcctcct cctgaaagtg 780
gccgggttta atctgctcat gacgctgcgg ctgtggtcca gctga 825
<210> 398
<211> 274
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - TCRα)
<400> 398
Met Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu
1 5 10 15
Asp Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser
20 25 30
Val Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser
35 40 45
Ser Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu
50 55 60
Gln Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln
65 70 75 80
Arg Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg
85 90 95
Ile Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu
100 105 110
Arg Ile Asp Ser Gly Asn Thr Pro Leu Val Phe Gly Lys Gly Thr Arg
115 120 125
Leu Ser Val Ile Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln
130 135 140
Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp
145 150 155 160
Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr
165 170 175
Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser
180 185 190
Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn
195 200 205
Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro
210 215 220
Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp
225 230 235 240
Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu
245 250 255
Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp
260 265 270
Ser Ser
<210> 399
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - TCR Vα)
<400> 399
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Arg Ile Asp Ser Gly
85 90 95
Asn Thr Pro Leu Val Phe Gly Lys Gly Thr Arg Leu Ser Val Ile Ala
100 105 110
Asn
<210> 400
<211> 933
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - TCRβ)
<400> 400
atgggaatca ggctcctgtg tcgtgtggcc ttttgtttcc tggctgtagg cctcgtagat 60
gtgaaagtaa cccagagctc gagatatcta gtcaaaagga cgggagagaa agtttttctg 120
gaatgtgtcc aggatatgga ccatgaaaat atgttctggt atcgacaaga cccaggtctg 180
gggctacggc tgatctattt ctcatatgat gttaaaatga aagaaaaagg agatattcct 240
gaggggtaca gtgtctctag agagaagaag gagcgcttct ccctgattct ggagtccgcc 300
agcaccaacc agacatctat gtacctctgt gccatcgaac ccccgacagg gaacgagcag 360
tacttcgggc cgggcaccag gctcacggtc acagaggacc tgaaaaacgt gttcccaccc 420
gaggtcgctg tgtttgagcc atcagaagca gagatctccc acacccaaaa ggccacactg 480
gtgtgcctgg ccacaggctt ctaccccgac cacgtggagc tgagctggtg ggtgaatggg 540
aaggaggtgc acagtggggt cagcacagac ccgcagcccc tcaaggagca gcccgccctc 600
aatgactcca gatactgcct gagcagccgc ctgagggtct cggccacctt ctggcagaac 660
ccccgcaacc acttccgctg tcaagtccag ttctacgggc tctcggagaa tgacgagtgg 720
acccaggata gggccaaacc tgtcacccag atcgtcagcg ccgaggcctg gggtagagca 780
gactgtggct tcacctccga gtcttaccag caaggggtcc tgtctgccac catcctctat 840
gagatcttgc tagggaaggc caccttgtat gccgtgctgg tcagtgccct cgtgctgatg 900
gccatggtca agagaaagga ttccagaggc tag 933
<210> 401
<211> 310
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - TCRβ)
<400> 401
Met Gly Ile Arg Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val
1 5 10 15
Gly Leu Val Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys
20 25 30
Arg Thr Gly Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His
35 40 45
Glu Asn Met Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu
50 55 60
Ile Tyr Phe Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro
65 70 75 80
Glu Gly Tyr Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile
85 90 95
Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ile
100 105 110
Glu Pro Pro Thr Gly Asn Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu
115 120 125
Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val
130 135 140
Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu
145 150 155 160
Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp
165 170 175
Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln
180 185 190
Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser
195 200 205
Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His
210 215 220
Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp
225 230 235 240
Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala
245 250 255
Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly
260 265 270
Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr
275 280 285
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys
290 295 300
Arg Lys Asp Ser Arg Gly
305 310
<210> 402
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 - TCR Vβ)
<400> 402
Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly
1 5 10 15
Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe
35 40 45
Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr
50 55 60
Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser
65 70 75 80
Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ile Glu Pro Pro
85 90 95
Thr Gly Asn Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
100 105 110
<210> 403
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 -
TCRβ-P2A-TCRα 片段)
<400> 403
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcatc agactccttt 60
gcagggtggc cttttgcttt ctggctgtgg gattagtgga cgtgaaggtt acccagagca 120
gcagatatct ggtgaagaga accggcgaga aggtgttcct ggaatgtgtg caggatatgg 180
accacgagaa catgttctgg tacagacagg accctggact gggactgaga ctgatctact 240
tcagctacga cgtgaagatg aaggagaagg gcgatatccc tgagggctac agcgtgagca 300
gagagaaaaa ggagaggttc agcctgattc tggaaagcgc cagcacaaat cagaccagca 360
tgtacctgtg cgccattgaa cctcctaccg gcaatgagca gtatttcgga cctggaacaa 420
gactgaccgt gacagaggac ctgaagaacg tgttcccccc agaggtggcc gtgttcgagc 480
ctagcgaggc cgagatcagc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
tttaccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cacagcggcg 600
tctgcaccga cccccagccc ctgaaagagc agcccgccct gaacgacagc cggtactgtc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac cgggccaagc 780
ccgtgaccca gatcgtgtct gctgaggcct ggggcagagc cgattgcggc ttcaccagcg 840
agagctacca gcagggcgtg ctgagcgcca ccatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtccgccc tggtgctgat ggccatggtc aagcggaagg 960
acagccgggg cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg aagacctttg ccggattctc cttcctgttc ctgtggctgc 1080
agctggattg tatgagcaga ggcgaagatg tggaacagag cctgtttctg agcgtgagag 1140
agggagatag cagcgtgatc aattgcacct acaccgattc tagcagcacc tacctgtact 1200
ggtacaagca ggaacctgga gccggattac aactgctgac ctacatcttc agcaacatgg 1260
acatgaagca ggaccagaga ctgaccgtgc tgctgaacaa gaaggacaag cacctgagcc 1320
tgagaattgc cgatacacag acaggagata gcgccatcta cttctgtgcc gagagaatcg 1380
atagcggcaa cacacctctg gtgtttggaa agggcacaag gctgtctgtg attgccaaca 1440
tccagaatcc cgatcctgct gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 404
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR08 -
TCRβ-P2A-TCRα 片段)
<400> 404
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Ile Arg
1 5 10 15
Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val Gly Leu Val Asp
20 25 30
Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly Glu
35 40 45
Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met Phe
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe Ser
65 70 75 80
Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr Ser
85 90 95
Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser Ala
100 105 110
Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ile Glu Pro Pro Thr
115 120 125
Gly Asn Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr Glu
130 135 140
Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser
145 150 155 160
Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala
165 170 175
Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
180 185 190
Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu
195 200 205
Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg
210 215 220
Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln
225 230 235 240
Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg
245 250 255
Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala
260 265 270
Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser Ala
275 280 285
Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val
290 295 300
Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Ser
305 310 315 320
Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly
325 330 335
Asp Val Glu Glu Asn Pro Gly Pro Met Lys Thr Phe Ala Gly Phe Ser
340 345 350
Phe Leu Phe Leu Trp Leu Gln Leu Asp Cys Met Ser Arg Gly Glu Asp
355 360 365
Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp Ser Ser Val
370 375 380
Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu Tyr Trp Tyr
385 390 395 400
Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr Ile Phe Ser
405 410 415
Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu Leu Asn Lys
420 425 430
Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln Thr Gly Asp
435 440 445
Ser Ala Ile Tyr Phe Cys Ala Glu Arg Ile Asp Ser Gly Asn Thr Pro
450 455 460
Leu Val Phe Gly Lys Gly Thr Arg Leu Ser Val Ile Ala Asn Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 405
<211> 819
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - TCRα)
<400> 405
atggcaggca ttcgagcttt atttatgtac ttgtggctgc agctggactg ggtgagcaga 60
ggagagagtg tggggctgca tcttcctacc ctgagtgtcc aggagggtga caactctatt 120
atcaactgtg cttattcaaa cagcgcctca gactacttca tttggtacaa gcaagaatct 180
ggaaaaggtc ctcaattcat tatagacatt cgttcaaata tggacaaaag gcaaggccaa 240
agagtcaccg ttttattgaa taagacagtg aaacatctct ctctgcaaat tgcagctact 300
caacctggag actcagctgt ctacttttgt gcagagattt ttaacgacta caagctcagc 360
tttggagccg gaaccacagt aactgtaaga gcaaatatcc agaaccctga ccctgccgtg 420
taccagctga gagactctaa atccagtgac aagtctgtct gcctattcac cgattttgat 480
tctcaaacaa atgtgtcaca aagtaaggat tctgatgtgt atatcacaga caaaactgtg 540
ctagacatga ggtctatgga cttcaagagc aacagtgctg tggcctggag caacaaatct 600
gactttgcat gtgcaaacgc cttcaacaac agcattattc cagaagacac cttcttcccc 660
agcccagaaa gttcctgtga tgtcaagctg gtcgagaaaa gctttgaaac agatacgaac 720
ctaaactttc aaaacctgtc agtgattggg ttccgaatcc tcctcctgaa agtggccggg 780
tttaatctgc tcatgacgct gcggctgtgg tccagctga 819
<210> 406
<211> 272
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - TCRα)
<400> 406
Met Ala Gly Ile Arg Ala Leu Phe Met Tyr Leu Trp Leu Gln Leu Asp
1 5 10 15
Trp Val Ser Arg Gly Glu Ser Val Gly Leu His Leu Pro Thr Leu Ser
20 25 30
Val Gln Glu Gly Asp Asn Ser Ile Ile Asn Cys Ala Tyr Ser Asn Ser
35 40 45
Ala Ser Asp Tyr Phe Ile Trp Tyr Lys Gln Glu Ser Gly Lys Gly Pro
50 55 60
Gln Phe Ile Ile Asp Ile Arg Ser Asn Met Asp Lys Arg Gln Gly Gln
65 70 75 80
Arg Val Thr Val Leu Leu Asn Lys Thr Val Lys His Leu Ser Leu Gln
85 90 95
Ile Ala Ala Thr Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Glu
100 105 110
Ile Phe Asn Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr
115 120 125
Val Arg Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg
130 135 140
Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp
145 150 155 160
Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr
165 170 175
Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser
180 185 190
Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe
195 200 205
Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser
210 215 220
Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn
225 230 235 240
Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu
245 250 255
Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
260 265 270
<210> 407
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - TCR Vα)
<400> 407
Gly Glu Ser Val Gly Leu His Leu Pro Thr Leu Ser Val Gln Glu Gly
1 5 10 15
Asp Asn Ser Ile Ile Asn Cys Ala Tyr Ser Asn Ser Ala Ser Asp Tyr
20 25 30
Phe Ile Trp Tyr Lys Gln Glu Ser Gly Lys Gly Pro Gln Phe Ile Ile
35 40 45
Asp Ile Arg Ser Asn Met Asp Lys Arg Gln Gly Gln Arg Val Thr Val
50 55 60
Leu Leu Asn Lys Thr Val Lys His Leu Ser Leu Gln Ile Ala Ala Thr
65 70 75 80
Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Glu Ile Phe Asn Asp
85 90 95
Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr Val Arg Ala Asn
100 105 110
<210> 408
<211> 936
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - TCRβ)
<400> 408
atgggccccc agctccttgg ctatgtggtc ctttgccttc taggagcagg ccccctggaa 60
gcccaagtga cccagaaccc aagatacctc atcacagtga ctggaaagaa gttaacagtg 120
acttgttctc agaatatgaa ccatgagtat atgtcctggt atcgacaaga cccagggctg 180
ggcttaaggc agatctacta ttcaatgaat gttgaggtga ctgataaggg agatgttcct 240
gaagggtaca aagtctctcg aaaagagaag aggaatttcc ccctgatcct ggagtcgccc 300
agccccaacc agacctctct gtacttctgt gccagcagtc aagcgggact aggcaatgag 360
cagttcttcg ggccagggac acggctcacc gtgctagagg acctgaaaaa cgtgttccca 420
cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca 480
ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 540
gggaaggagg tgcacagtgg ggtcagcaca gacccgcagc ccctcaagga gcagcccgcc 600
ctcaatgact ccagatactg cctgagcagc cgcctgaggg tctcggccac cttctggcag 660
aacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag 720
tggacccagg atagggccaa acctgtcacc cagatcgtca gcgccgaggc ctggggtaga 780
gcagactgtg gcttcacctc cgagtcttac cagcaagggg tcctgtctgc caccatcctc 840
tatgagatct tgctagggaa ggccaccttg tatgccgtgc tggtcagtgc cctcgtgctg 900
atggccatgg tcaagagaaa ggattccaga ggctag 936
<210> 409
<211> 311
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - TCRβ)
<400> 409
Met Gly Pro Gln Leu Leu Gly Tyr Val Val Leu Cys Leu Leu Gly Ala
1 5 10 15
Gly Pro Leu Glu Ala Gln Val Thr Gln Asn Pro Arg Tyr Leu Ile Thr
20 25 30
Val Thr Gly Lys Lys Leu Thr Val Thr Cys Ser Gln Asn Met Asn His
35 40 45
Glu Tyr Met Ser Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Gln
50 55 60
Ile Tyr Tyr Ser Met Asn Val Glu Val Thr Asp Lys Gly Asp Val Pro
65 70 75 80
Glu Gly Tyr Lys Val Ser Arg Lys Glu Lys Arg Asn Phe Pro Leu Ile
85 90 95
Leu Glu Ser Pro Ser Pro Asn Gln Thr Ser Leu Tyr Phe Cys Ala Ser
100 105 110
Ser Gln Ala Gly Leu Gly Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg
115 120 125
Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala
130 135 140
Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr
145 150 155 160
Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser
165 170 175
Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190
Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu
195 200 205
Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn
210 215 220
His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu
225 230 235 240
Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu
245 250 255
Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln
260 265 270
Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala
275 280 285
Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val
290 295 300
Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 410
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 - TCR Vβ)
<400> 410
Glu Ala Gln Val Thr Gln Asn Pro Arg Tyr Leu Ile Thr Val Thr Gly
1 5 10 15
Lys Lys Leu Thr Val Thr Cys Ser Gln Asn Met Asn His Glu Tyr Met
20 25 30
Ser Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Gln Ile Tyr Tyr
35 40 45
Ser Met Asn Val Glu Val Thr Asp Lys Gly Asp Val Pro Glu Gly Tyr
50 55 60
Lys Val Ser Arg Lys Glu Lys Arg Asn Phe Pro Leu Ile Leu Glu Ser
65 70 75 80
Pro Ser Pro Asn Gln Thr Ser Leu Tyr Phe Cys Ala Ser Ser Gln Ala
85 90 95
Gly Leu Gly Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Leu
<210> 411
<211> 1490
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 -
TCRβ-P2A-TCRα 片段)
<400> 411
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggacct cagcttcttg 60
gatacgttgt gctgtgtctg cttggagctg gacctcttga agctcaggtt acccagaacc 120
ccagatacct gattaccgtg acaggcaaaa agctgaccgt gacatgtagc cagaacatga 180
accacgagta catgagctgg taccggcagg atcctggatt aggcctgaga cagatctact 240
acagcatgaa cgtggaggtg accgataaag gcgacgtgcc tgagggatac aaggtgagca 300
gaaaggagaa gaggaatttc cccctgatcc tggaaagccc aagccccaat cagacaagcc 360
tgtacttttg tgcctcttct caagctggac tgggcaatga gcagttcttc ggccctggca 420
caagactgac agtgttagag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atggccggca ttagagcact cttcatgtac ctgtggctgc 1080
aactggattg ggtgtctaga ggagagtctg tgggcctgca tcttcctaca ctgtctgttc 1140
aggaaggcga caatagcatc atcaattgcg cctacagcaa cagcgccagc gactacttca 1200
tctggtacaa gcaggagagc ggaaaaggac ctcagttcat catcgacatc cggagcaaca 1260
tggacaagag acagggacag agagtgaccg tgctgctgaa caagacagtg aaacatctga 1320
gcctgcagat tgccgctaca caacctggcg attctgccgt gtacttttgt gccgagatct 1380
tcaacgacta caagctgagc tttggagccg gaaccacagt gaccgtgaga gccaatatcc 1440
agaatcctga tcctgctgtg taccagctgc gggacagcaa gagcagcgac 1490
<210> 412
<211> 495
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR09 -
TCRβ-P2A-TCRα 片段)
<400> 412
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Pro Gln
1 5 10 15
Leu Leu Gly Tyr Val Val Leu Cys Leu Leu Gly Ala Gly Pro Leu Glu
20 25 30
Ala Gln Val Thr Gln Asn Pro Arg Tyr Leu Ile Thr Val Thr Gly Lys
35 40 45
Lys Leu Thr Val Thr Cys Ser Gln Asn Met Asn His Glu Tyr Met Ser
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Gln Ile Tyr Tyr Ser
65 70 75 80
Met Asn Val Glu Val Thr Asp Lys Gly Asp Val Pro Glu Gly Tyr Lys
85 90 95
Val Ser Arg Lys Glu Lys Arg Asn Phe Pro Leu Ile Leu Glu Ser Pro
100 105 110
Ser Pro Asn Gln Thr Ser Leu Tyr Phe Cys Ala Ser Ser Gln Ala Gly
115 120 125
Leu Gly Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Ala Gly Ile Arg Ala Leu
340 345 350
Phe Met Tyr Leu Trp Leu Gln Leu Asp Trp Val Ser Arg Gly Glu Ser
355 360 365
Val Gly Leu His Leu Pro Thr Leu Ser Val Gln Glu Gly Asp Asn Ser
370 375 380
Ile Ile Asn Cys Ala Tyr Ser Asn Ser Ala Ser Asp Tyr Phe Ile Trp
385 390 395 400
Tyr Lys Gln Glu Ser Gly Lys Gly Pro Gln Phe Ile Ile Asp Ile Arg
405 410 415
Ser Asn Met Asp Lys Arg Gln Gly Gln Arg Val Thr Val Leu Leu Asn
420 425 430
Lys Thr Val Lys His Leu Ser Leu Gln Ile Ala Ala Thr Gln Pro Gly
435 440 445
Asp Ser Ala Val Tyr Phe Cys Ala Glu Ile Phe Asn Asp Tyr Lys Leu
450 455 460
Ser Phe Gly Ala Gly Thr Thr Val Thr Val Arg Ala Asn Ile Gln Asn
465 470 475 480
Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 413
<211> 822
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - TCRα)
<400> 413
atgctcctgg agcttatccc actgctgggg atacattttg tcctgagaac tgccagagcc 60
cagtcagtga cccagcctga catccacatc actgtctctg aaggagcctc actggagttg 120
agatgtaact attcctatgg ggcaacacct tatctcttct ggtatgtcca gtcccccggc 180
caaggcctcc agctgctcct gaagtacttt tcaggagaca ctctggttca aggcattaaa 240
ggctttgagg ctgaatttaa gaggagtcaa tcttccttca atctgaggaa accctctgtg 300
cattggagtg atgctgctga gtacttctgt gctgtgggtt cggatagcaa ctatcagtta 360
atctggggcg ctgggaccaa gctaattata aagccagata tccagaaccc tgaccctgcc 420
gtgtaccagc tgagagactc taaatccagt gacaagtctg tctgcctatt caccgatttt 480
gattctcaaa caaatgtgtc acaaagtaag gattctgatg tgtatatcac agacaaaact 540
gtgctagaca tgaggtctat ggacttcaag agcaacagtg ctgtggcctg gagcaacaaa 600
tctgactttg catgtgcaaa cgccttcaac aacagcatta ttccagaaga caccttcttc 660
cccagcccag aaagttcctg tgatgtcaag ctggtcgaga aaagctttga aacagatacg 720
aacctaaact ttcaaaacct gtcagtgatt gggttccgaa tcctcctcct gaaagtggcc 780
gggtttaatc tgctcatgac gctgcggctg tggtccagct ga 822
<210> 414
<211> 273
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - TCRα)
<400> 414
Met Leu Leu Glu Leu Ile Pro Leu Leu Gly Ile His Phe Val Leu Arg
1 5 10 15
Thr Ala Arg Ala Gln Ser Val Thr Gln Pro Asp Ile His Ile Thr Val
20 25 30
Ser Glu Gly Ala Ser Leu Glu Leu Arg Cys Asn Tyr Ser Tyr Gly Ala
35 40 45
Thr Pro Tyr Leu Phe Trp Tyr Val Gln Ser Pro Gly Gln Gly Leu Gln
50 55 60
Leu Leu Leu Lys Tyr Phe Ser Gly Asp Thr Leu Val Gln Gly Ile Lys
65 70 75 80
Gly Phe Glu Ala Glu Phe Lys Arg Ser Gln Ser Ser Phe Asn Leu Arg
85 90 95
Lys Pro Ser Val His Trp Ser Asp Ala Ala Glu Tyr Phe Cys Ala Val
100 105 110
Gly Ser Asp Ser Asn Tyr Gln Leu Ile Trp Gly Ala Gly Thr Lys Leu
115 120 125
Ile Ile Lys Pro Asp Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu
130 135 140
Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe
145 150 155 160
Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile
165 170 175
Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn
180 185 190
Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala
195 200 205
Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu
210 215 220
Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr
225 230 235 240
Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu
245 250 255
Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser
260 265 270
Ser
<210> 415
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - TCR Vα)
<400> 415
Ala Gln Ser Val Thr Gln Pro Asp Ile His Ile Thr Val Ser Glu Gly
1 5 10 15
Ala Ser Leu Glu Leu Arg Cys Asn Tyr Ser Tyr Gly Ala Thr Pro Tyr
20 25 30
Leu Phe Trp Tyr Val Gln Ser Pro Gly Gln Gly Leu Gln Leu Leu Leu
35 40 45
Lys Tyr Phe Ser Gly Asp Thr Leu Val Gln Gly Ile Lys Gly Phe Glu
50 55 60
Ala Glu Phe Lys Arg Ser Gln Ser Ser Phe Asn Leu Arg Lys Pro Ser
65 70 75 80
Val His Trp Ser Asp Ala Ala Glu Tyr Phe Cys Ala Val Gly Ser Asp
85 90 95
Ser Asn Tyr Gln Leu Ile Trp Gly Ala Gly Thr Lys Leu Ile Ile Lys
100 105 110
Pro Asp
<210> 416
<211> 927
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - TCRβ)
<400> 416
atgagcatcg gcctcctgtg ctgtgcagcc ttgtctctcc tgtgggcagg tccagtgaat 60
gctggtgtca ctcagacccc aaaattccag gtcctgaaga caggacagag catgacactg 120
cagtgtgccc aggatatgaa ccatgaatac atgtcctggt atcgacaaga cccaggcatg 180
gggctgaggc tgattcatta ctcagttggt gctggtatca ctgaccaagg agaagtcccc 240
aatggctaca atgtctccag atcaaccaca gaggatttcc cgctcaggct gctgtcggct 300
gctccctccc agacatctgt gtacttctgt gccagcagtc ggactggggc tgatggctac 360
accttcggtt cggggaccag gttaaccgtt gtagaggacc tgaacaaggt gttcccaccc 420
gaggtcgctg tgtttgagcc atcagaagca gagatctccc acacccaaaa ggccacactg 480
gtgtgcctgg ccacaggctt cttccccgac cacgtggagc tgagctggtg ggtgaatggg 540
aaggaggtgc acagtggggt cagcacggac ccgcagcccc tcaaggagca gcccgccctc 600
aatgactcca gatactgcct gagcagccgc ctgagggtct cggccacctt ctggcagaac 660
ccccgcaacc acttccgctg tcaagtccag ttctacgggc tctcggagaa tgacgagtgg 720
acccaggata gggccaaacc cgtcacccag atcgtcagcg ccgaggcctg gggtagagca 780
gactgtggct ttacctcggt gtcctaccag caaggggtcc tgtctgccac catcctctat 840
gagatcctgc tagggaaggc caccctgtat gctgtgctgg tcagcgccct tgtgttgatg 900
gccatggtca agagaaagga tttctga 927
<210> 417
<211> 308
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - TCRβ)
<400> 417
Met Ser Ile Gly Leu Leu Cys Cys Ala Ala Leu Ser Leu Leu Trp Ala
1 5 10 15
Gly Pro Val Asn Ala Gly Val Thr Gln Thr Pro Lys Phe Gln Val Leu
20 25 30
Lys Thr Gly Gln Ser Met Thr Leu Gln Cys Ala Gln Asp Met Asn His
35 40 45
Glu Tyr Met Ser Trp Tyr Arg Gln Asp Pro Gly Met Gly Leu Arg Leu
50 55 60
Ile His Tyr Ser Val Gly Ala Gly Ile Thr Asp Gln Gly Glu Val Pro
65 70 75 80
Asn Gly Tyr Asn Val Ser Arg Ser Thr Thr Glu Asp Phe Pro Leu Arg
85 90 95
Leu Leu Ser Ala Ala Pro Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser
100 105 110
Ser Arg Thr Gly Ala Asp Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu
115 120 125
Thr Val Val Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val
130 135 140
Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu
145 150 155 160
Val Cys Leu Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp
165 170 175
Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln
180 185 190
Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser
195 200 205
Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His
210 215 220
Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp
225 230 235 240
Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala
245 250 255
Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly
260 265 270
Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr
275 280 285
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys
290 295 300
Arg Lys Asp Phe
305
<210> 418
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 - TCR Vβ)
<400> 418
Asn Ala Gly Val Thr Gln Thr Pro Lys Phe Gln Val Leu Lys Thr Gly
1 5 10 15
Gln Ser Met Thr Leu Gln Cys Ala Gln Asp Met Asn His Glu Tyr Met
20 25 30
Ser Trp Tyr Arg Gln Asp Pro Gly Met Gly Leu Arg Leu Ile His Tyr
35 40 45
Ser Val Gly Ala Gly Ile Thr Asp Gln Gly Glu Val Pro Asn Gly Tyr
50 55 60
Asn Val Ser Arg Ser Thr Thr Glu Asp Phe Pro Leu Arg Leu Leu Ser
65 70 75 80
Ala Ala Pro Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser Ser Arg Thr
85 90 95
Gly Ala Asp Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val
100 105 110
<210> 419
<211> 1484
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 -
TCRβ-P2A-TCRα 片段)
<400> 419
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgtctatc ggtctgctgt 60
gctgtgctgc tctttctctg ctttgggctg gacctgtgaa tgctggagtt acacaaaccc 120
ccaagttcca agtgctgaag acaggacaga gcatgaccct gcagtgtgct caggacatga 180
atcacgagta catgagctgg tacagacagg atcctggaat gggcctgagg ctgatccact 240
actctgttgg agccggaatt acagatcagg gagaagtgcc aaatggctac aacgtgagca 300
ggagcacaac cgaggacttc cccttaagac tgttgtctgc tgctccatct cagacaagcg 360
tgtacttttg cgccagctcc agaacaggcg ctgatggcta tacatttgga agcggcacaa 420
gactgacagt ggttgaagat ctgaacaagg tgttcccccc agaggtggcc gtgttcgagc 480
cttctgaggc cgagatctcc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
ttttccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cactccggcg 600
tgtgcaccga tccccagcct ctgaaagaac agcccgccct gaacgacagc cggtactgcc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac agagccaagc 780
ccgtgacaca gatcgtgtct gccgaagcct ggggcagagc cgattgcggc tttacctccg 840
tgtcctatca gcagggcgtg ctgagcgcca caatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtctgccc tggtgctgat ggccatggtc aagcggaagg 960
acttcggttc cggagccacg aacttctctc tgttaaagca agcaggagac gtggaagaaa 1020
accccggtcc catgctgctg gaactgatac ccctactggg catccacttt gtgctgagaa 1080
cagctagagc ccaatctgtg acacagcccg atatccacat taccgtgagc gaaggagctt 1140
ctctggaact gagatgcaac tacagctatg gcgccacccc ttaccttttc tggtacgtgc 1200
agtctcctgg acagggatta caactgctgc tgaagtactt ctccggcgat acactggttc 1260
agggcattaa gggctttgag gccgagttca agagaagcca gagcagcttt aacctgagaa 1320
agcctagcgt gcactggtct gatgctgccg agtacttttg tgctgtgggc tccgatagca 1380
attatcagct gatctgggga gccggaacaa agctgatcat caagcctgac atccagaacc 1440
ccgatcctgc tgtgtaccag ctgcgggaca gcaagagcag cgac 1484
<210> 420
<211> 493
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR10 -
TCRβ-P2A-TCRα 片段)
<400> 420
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Ser Ile Gly
1 5 10 15
Leu Leu Cys Cys Ala Ala Leu Ser Leu Leu Trp Ala Gly Pro Val Asn
20 25 30
Ala Gly Val Thr Gln Thr Pro Lys Phe Gln Val Leu Lys Thr Gly Gln
35 40 45
Ser Met Thr Leu Gln Cys Ala Gln Asp Met Asn His Glu Tyr Met Ser
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Met Gly Leu Arg Leu Ile His Tyr Ser
65 70 75 80
Val Gly Ala Gly Ile Thr Asp Gln Gly Glu Val Pro Asn Gly Tyr Asn
85 90 95
Val Ser Arg Ser Thr Thr Glu Asp Phe Pro Leu Arg Leu Leu Ser Ala
100 105 110
Ala Pro Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser Ser Arg Thr Gly
115 120 125
Ala Asp Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val Val Glu
130 135 140
Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser
145 150 155 160
Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala
165 170 175
Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
180 185 190
Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu
195 200 205
Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg
210 215 220
Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln
225 230 235 240
Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg
245 250 255
Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala
260 265 270
Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly Val Leu Ser Ala
275 280 285
Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val
290 295 300
Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Phe
305 310 315 320
Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val
325 330 335
Glu Glu Asn Pro Gly Pro Met Leu Leu Glu Leu Ile Pro Leu Leu Gly
340 345 350
Ile His Phe Val Leu Arg Thr Ala Arg Ala Gln Ser Val Thr Gln Pro
355 360 365
Asp Ile His Ile Thr Val Ser Glu Gly Ala Ser Leu Glu Leu Arg Cys
370 375 380
Asn Tyr Ser Tyr Gly Ala Thr Pro Tyr Leu Phe Trp Tyr Val Gln Ser
385 390 395 400
Pro Gly Gln Gly Leu Gln Leu Leu Leu Lys Tyr Phe Ser Gly Asp Thr
405 410 415
Leu Val Gln Gly Ile Lys Gly Phe Glu Ala Glu Phe Lys Arg Ser Gln
420 425 430
Ser Ser Phe Asn Leu Arg Lys Pro Ser Val His Trp Ser Asp Ala Ala
435 440 445
Glu Tyr Phe Cys Ala Val Gly Ser Asp Ser Asn Tyr Gln Leu Ile Trp
450 455 460
Gly Ala Gly Thr Lys Leu Ile Ile Lys Pro Asp Ile Gln Asn Pro Asp
465 470 475 480
Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490
<210> 421
<211> 846
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - TCRα)
<400> 421
atggccatgc tcctgggggc atcagtgctg attctgtggc ttcagccaga ctgggtaaac 60
agtcaacaga agaatgatga ccagcaagtt aagcaaaatt caccatccct gagcgtccag 120
gaaggaagaa tttctattct gaactgtgac tatactaaca gcatgtttga ttatttccta 180
tggtacaaaa aataccctgc tgaaggtcct acattcctga tatctataag ttccattaag 240
gataaaaatg aagatggaag attcactgtc ttcttaaaca aaagtgccaa gcacctctct 300
ctgcacattg tgccctccca gcctggagac tctgcagtgt acttctgtgc agcaatctcc 360
cttacctcag gaacctacaa atacatcttt ggaacaggca ccaggctgaa ggttttagca 420
aatatccaga accctgaccc tgccgtgtac cagctgagag actctaaatc cagtgacaag 480
tctgtctgcc tattcaccga ttttgattct caaacaaatg tgtcacaaag taaggattct 540
gatgtgtata tcacagacaa aactgtgcta gacatgaggt ctatggactt caagagcaac 600
agtgctgtgg cctggagcaa caaatctgac tttgcatgtg caaacgcctt caacaacagc 660
attattccag aagacacctt cttccccagc ccagaaagtt cctgtgatgt caagctggtc 720
gagaaaagct ttgaaacaga tacgaaccta aactttcaaa acctgtcagt gattgggttc 780
cgaatcctcc tcctgaaagt ggccgggttt aatctgctca tgacgctgcg gctgtggtcc 840
agctga 846
<210> 422
<211> 281
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - TCRα)
<400> 422
Met Ala Met Leu Leu Gly Ala Ser Val Leu Ile Leu Trp Leu Gln Pro
1 5 10 15
Asp Trp Val Asn Ser Gln Gln Lys Asn Asp Asp Gln Gln Val Lys Gln
20 25 30
Asn Ser Pro Ser Leu Ser Val Gln Glu Gly Arg Ile Ser Ile Leu Asn
35 40 45
Cys Asp Tyr Thr Asn Ser Met Phe Asp Tyr Phe Leu Trp Tyr Lys Lys
50 55 60
Tyr Pro Ala Glu Gly Pro Thr Phe Leu Ile Ser Ile Ser Ser Ile Lys
65 70 75 80
Asp Lys Asn Glu Asp Gly Arg Phe Thr Val Phe Leu Asn Lys Ser Ala
85 90 95
Lys His Leu Ser Leu His Ile Val Pro Ser Gln Pro Gly Asp Ser Ala
100 105 110
Val Tyr Phe Cys Ala Ala Ile Ser Leu Thr Ser Gly Thr Tyr Lys Tyr
115 120 125
Ile Phe Gly Thr Gly Thr Arg Leu Lys Val Leu Ala Asn Ile Gln Asn
130 135 140
Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys
145 150 155 160
Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn Val Ser Gln
165 170 175
Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Thr Val Leu Asp Met
180 185 190
Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp Ser Asn Lys
195 200 205
Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu
210 215 220
Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val Lys Leu Val
225 230 235 240
Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser
245 250 255
Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala Gly Phe Asn Leu
260 265 270
Leu Met Thr Leu Arg Leu Trp Ser Ser
275 280
<210> 423
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - TCR Vα)
<400> 423
Asp Gln Gln Val Lys Gln Asn Ser Pro Ser Leu Ser Val Gln Glu Gly
1 5 10 15
Arg Ile Ser Ile Leu Asn Cys Asp Tyr Thr Asn Ser Met Phe Asp Tyr
20 25 30
Phe Leu Trp Tyr Lys Lys Tyr Pro Ala Glu Gly Pro Thr Phe Leu Ile
35 40 45
Ser Ile Ser Ser Ile Lys Asp Lys Asn Glu Asp Gly Arg Phe Thr Val
50 55 60
Phe Leu Asn Lys Ser Ala Lys His Leu Ser Leu His Ile Val Pro Ser
65 70 75 80
Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Ala Ile Ser Leu Thr
85 90 95
Ser Gly Thr Tyr Lys Tyr Ile Phe Gly Thr Gly Thr Arg Leu Lys Val
100 105 110
Leu Ala Asn
115
<210> 424
<211> 939
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - TCRβ)
<400> 424
atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcagt tcccatagac 60
actgaagtta cccagacacc aaaacacctg gtcatgggaa tgacaaataa gaagtctttg 120
aaatgtgaac aacatatggg gcacagggct atgtattggt acaagcagaa agctaagaag 180
ccaccggagc tcatgtttgt ctacagctat gagaaactct ctataaatga aagtgtgcca 240
agtcgcttct cacctgaatg ccccaacagc tctctcttaa accttcacct acacgccctg 300
cagccagaag actcagccct gtatctctgc gccagcagcc aagatctcgg gacagtctac 360
gagcagtact tcgggccggg caccaggctc acggtcacag aggacctgaa aaacgtgttc 420
ccacccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc 480
acactggtgt gcctggccac aggcttctac cccgaccacg tggagctgag ctggtgggtg 540
aatgggaagg aggtgcacag tggggtcagc acagacccgc agcccctcaa ggagcagccc 600
gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660
cagaaccccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac 720
gagtggaccc aggatagggc caaacctgtc acccagatcg tcagcgccga ggcctggggt 780
agagcagact gtggcttcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc 840
ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg 900
ctgatggcca tggtcaagag aaaggattcc agaggctag 939
<210> 425
<211> 312
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - TCRβ
<400> 425
Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala
1 5 10 15
Val Pro Ile Asp Thr Glu Val Thr Gln Thr Pro Lys His Leu Val Met
20 25 30
Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Met Gly His
35 40 45
Arg Ala Met Tyr Trp Tyr Lys Gln Lys Ala Lys Lys Pro Pro Glu Leu
50 55 60
Met Phe Val Tyr Ser Tyr Glu Lys Leu Ser Ile Asn Glu Ser Val Pro
65 70 75 80
Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser Leu Leu Asn Leu His
85 90 95
Leu His Ala Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser
100 105 110
Ser Gln Asp Leu Gly Thr Val Tyr Glu Gln Tyr Phe Gly Pro Gly Thr
115 120 125
Arg Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val
130 135 140
Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala
145 150 155 160
Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu
165 170 175
Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp
180 185 190
Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys
195 200 205
Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg
210 215 220
Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp
225 230 235 240
Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala
245 250 255
Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln
260 265 270
Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys
275 280 285
Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met
290 295 300
Val Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 426
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 - TCR Vβ)
<400> 426
Asp Thr Glu Val Thr Gln Thr Pro Lys His Leu Val Met Gly Met Thr
1 5 10 15
Asn Lys Lys Ser Leu Lys Cys Glu Gln His Met Gly His Arg Ala Met
20 25 30
Tyr Trp Tyr Lys Gln Lys Ala Lys Lys Pro Pro Glu Leu Met Phe Val
35 40 45
Tyr Ser Tyr Glu Lys Leu Ser Ile Asn Glu Ser Val Pro Ser Arg Phe
50 55 60
Ser Pro Glu Cys Pro Asn Ser Ser Leu Leu Asn Leu His Leu His Ala
65 70 75 80
Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser Ser Gln Asp
85 90 95
Leu Gly Thr Val Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr
100 105 110
Val Thr
<210> 427
<211> 1520
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 -
TCRβ-P2A-TCRα 片段)
<400> 427
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggctgt agactgttgt 60
gttgtgctgt gctgtgtctg ttgggagctg tgcctatcga tacagaggtg acccagaccc 120
ctaaacatct ggttatgggc atgaccaaca agaagagcct gaagtgcgag cagcacatgg 180
gccatagggc catgtattgg tataagcaga aggccaagaa acctcctgag ctgatgttcg 240
tgtacagcta cgagaagctg agcatcaacg agagcgtgcc cagcagattt tctcctgagt 300
gccctaattc tagcctgctg aatctgcacc tgcatgctct gcagcctgag gattctgctc 360
tgtacctgtg tgcttcttct caggatcttg gaaccgtgta cgagcagtac tttggccctg 420
gcacaagact gacagtgaca gaggacctga agaacgtgtt ccccccagag gtggccgtgt 480
tcgagcctag cgaggccgag atcagccaca cccagaaagc caccctcgtg tgcctggcca 540
ccggctttta ccccgaccac gtggaactgt cttggtgggt caacggcaaa gaggtgcaca 600
gcggcgtctg caccgacccc cagcccctga aagagcagcc cgccctgaac gacagccggt 660
actgtctgag cagcagactg agagtgtccg ccaccttctg gcagaacccc cggaaccact 720
tcagatgcca ggtgcagttc tacggcctga gcgagaacga cgagtggacc caggaccggg 780
ccaagcccgt gacccagatc gtgtctgctg aggcctgggg cagagccgat tgcggcttca 840
ccagcgagag ctaccagcag ggcgtgctga gcgccaccat cctgtacgag atcctgctgg 900
gcaaggccac cctgtacgcc gtgctggtgt ccgccctggt gctgatggcc atggtcaagc 960
ggaaggacag ccggggcggt tccggagcca cgaacttctc tctgttaaag caagcaggag 1020
acgtggaaga aaaccccggt cccatggcca tgttactagg agcgagcgtg ctgattctgt 1080
ggttacagcc tgattgggtg aactctcagc agaagaacga tgatcagcag gtgaagcaga 1140
acagcccctc tctgtctgtg caggaaggca gaatcagcat cctgaattgc gattacacca 1200
acagcatgtt cgactacttc ctgtggtaca agaagtaccc cgccgagggc cctacctttc 1260
tgatcagcat ctctagcatc aaggacaaga acgaagatgg cagattcacc gtgttcctga 1320
acaagagcgc caagcacctg agcctgcaca ttgtgccttc tcaacctgga gattctgccg 1380
tgtacttttg tgccgccatt agcctgacaa gcggcaccta caagtacatc tttggcacag 1440
gcaccaggct gaaagttctg gccaatatcc agaatcccga tcccgccgtg taccagctgc 1500
gggacagcaa gagcagcgac 1520
<210> 428
<211> 505
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR11 -
TCRβ-P2A-TCRα 片段)
<400> 428
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Cys Arg
1 5 10 15
Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala Val Pro Ile Asp
20 25 30
Thr Glu Val Thr Gln Thr Pro Lys His Leu Val Met Gly Met Thr Asn
35 40 45
Lys Lys Ser Leu Lys Cys Glu Gln His Met Gly His Arg Ala Met Tyr
50 55 60
Trp Tyr Lys Gln Lys Ala Lys Lys Pro Pro Glu Leu Met Phe Val Tyr
65 70 75 80
Ser Tyr Glu Lys Leu Ser Ile Asn Glu Ser Val Pro Ser Arg Phe Ser
85 90 95
Pro Glu Cys Pro Asn Ser Ser Leu Leu Asn Leu His Leu His Ala Leu
100 105 110
Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser Ser Gln Asp Leu
115 120 125
Gly Thr Val Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
130 135 140
Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu
145 150 155 160
Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys
165 170 175
Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val
180 185 190
Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu
195 200 205
Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg
210 215 220
Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg
225 230 235 240
Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln
245 250 255
Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly
260 265 270
Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu
275 280 285
Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr
290 295 300
Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys
305 310 315 320
Asp Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln
325 330 335
Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Ala Met Leu Leu Gly
340 345 350
Ala Ser Val Leu Ile Leu Trp Leu Gln Pro Asp Trp Val Asn Ser Gln
355 360 365
Gln Lys Asn Asp Asp Gln Gln Val Lys Gln Asn Ser Pro Ser Leu Ser
370 375 380
Val Gln Glu Gly Arg Ile Ser Ile Leu Asn Cys Asp Tyr Thr Asn Ser
385 390 395 400
Met Phe Asp Tyr Phe Leu Trp Tyr Lys Lys Tyr Pro Ala Glu Gly Pro
405 410 415
Thr Phe Leu Ile Ser Ile Ser Ser Ile Lys Asp Lys Asn Glu Asp Gly
420 425 430
Arg Phe Thr Val Phe Leu Asn Lys Ser Ala Lys His Leu Ser Leu His
435 440 445
Ile Val Pro Ser Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Ala
450 455 460
Ile Ser Leu Thr Ser Gly Thr Tyr Lys Tyr Ile Phe Gly Thr Gly Thr
465 470 475 480
Arg Leu Lys Val Leu Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr
485 490 495
Gln Leu Arg Asp Ser Lys Ser Ser Asp
500 505
<210> 429
<211> 816
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - TCRα)
<400> 429
atgctcctgc tgctcgtccc agcgttccag gtgattttta ccctgggagg aaccagagcc 60
cagtctgtga cccagcttga cagccaagtc cctgtctttg aagaagcccc tgtggagctg 120
aggtgcaact actcatcgtc tgtttcagtg tatctcttct ggtatgtgca ataccccaac 180
caaggactcc agcttctcct gaagtattta tcaggatcca ccctggttga aagcatcaac 240
ggttttgagg ctgaatttaa caagagtcaa acttccttcc acttgaggaa accctcagtc 300
catataagcg acacggctga gtacttctgt gctgtgacca gggatgacaa gatcatcttt 360
ggaaaaggga cacgacttca tattctcccc aatatccaga accctgaccc tgccgtgtac 420
cagctgagag actctaaatc cagtgacaag tctgtctgcc tattcaccga ttttgattct 480
caaacaaatg tgtcacaaag taaggattct gatgtgtata tcacagacaa aactgtgcta 540
gacatgaggt ctatggactt caagagcaac agtgctgtgg cctggagcaa caaatctgac 600
tttgcatgtg caaacgcctt caacaacagc attattccag aagacacctt cttccccagc 660
ccagaaagtt cctgtgatgt caagctggtc gagaaaagct ttgaaacaga tacgaaccta 720
aactttcaaa acctgtcagt gattgggttc cgaatcctcc tcctgaaagt ggccgggttt 780
aatctgctca tgacgctgcg gctgtggtcc agctga 816
<210> 430
<211> 271
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - TCRα)
<400> 430
Met Leu Leu Leu Leu Val Pro Ala Phe Gln Val Ile Phe Thr Leu Gly
1 5 10 15
Gly Thr Arg Ala Gln Ser Val Thr Gln Leu Asp Ser Gln Val Pro Val
20 25 30
Phe Glu Glu Ala Pro Val Glu Leu Arg Cys Asn Tyr Ser Ser Ser Val
35 40 45
Ser Val Tyr Leu Phe Trp Tyr Val Gln Tyr Pro Asn Gln Gly Leu Gln
50 55 60
Leu Leu Leu Lys Tyr Leu Ser Gly Ser Thr Leu Val Glu Ser Ile Asn
65 70 75 80
Gly Phe Glu Ala Glu Phe Asn Lys Ser Gln Thr Ser Phe His Leu Arg
85 90 95
Lys Pro Ser Val His Ile Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val
100 105 110
Thr Arg Asp Asp Lys Ile Ile Phe Gly Lys Gly Thr Arg Leu His Ile
115 120 125
Leu Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp
130 135 140
Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser
145 150 155 160
Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp
165 170 175
Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala
180 185 190
Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn
195 200 205
Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser
210 215 220
Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu
225 230 235 240
Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys
245 250 255
Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
260 265 270
<210> 431
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - TCR Vα)
<400> 431
Ala Gln Ser Val Thr Gln Leu Asp Ser Gln Val Pro Val Phe Glu Glu
1 5 10 15
Ala Pro Val Glu Leu Arg Cys Asn Tyr Ser Ser Ser Val Ser Val Tyr
20 25 30
Leu Phe Trp Tyr Val Gln Tyr Pro Asn Gln Gly Leu Gln Leu Leu Leu
35 40 45
Lys Tyr Leu Ser Gly Ser Thr Leu Val Glu Ser Ile Asn Gly Phe Glu
50 55 60
Ala Glu Phe Asn Lys Ser Gln Thr Ser Phe His Leu Arg Lys Pro Ser
65 70 75 80
Val His Ile Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val Thr Arg Asp
85 90 95
Asp Lys Ile Ile Phe Gly Lys Gly Thr Arg Leu His Ile Leu Pro Asn
100 105 110
<210> 432
<211> 933
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - TCRβ)
<400> 432
atgggaatca ggctcctgtg tcgtgtggcc ttttgtttcc tggctgtagg cctcgtagat 60
gtgaaagtaa cccagagctc gagatatcta gtcaaaagga cgggagagaa agtttttctg 120
gaatgtgtcc aggatatgga ccatgaaaat atgttctggt atcgacaaga cccaggtctg 180
gggctacggc tgatctattt ctcatatgat gttaaaatga aagaaaaagg agatattcct 240
gaggggtaca gtgtctctag agagaagaag gagcgcttct ccctgattct ggagtccgcc 300
agcaccaacc agacatctat gtacctctgt gccagcagtt tacaggtttc aggggttgct 360
ggctacacct tcggttcggg gaccaggtta accgttgtag aggacctgaa caaggtgttc 420
ccacccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc 480
acactggtgt gcctggccac aggcttcttc cccgaccacg tggagctgag ctggtgggtg 540
aatgggaagg aggtgcacag tggggtcagc acggacccgc agcccctcaa ggagcagccc 600
gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660
cagaaccccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac 720
gagtggaccc aggatagggc caaacccgtc acccagatcg tcagcgccga ggcctggggt 780
agagcagact gtggctttac ctcggtgtcc taccagcaag gggtcctgtc tgccaccatc 840
ctctatgaga tcctgctagg gaaggccacc ctgtatgctg tgctggtcag cgcccttgtg 900
ttgatggcca tggtcaagag aaaggatttc tga 933
<210> 433
<211> 310
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - TCRβ)
<400> 433
Met Gly Ile Arg Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val
1 5 10 15
Gly Leu Val Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys
20 25 30
Arg Thr Gly Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His
35 40 45
Glu Asn Met Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu
50 55 60
Ile Tyr Phe Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro
65 70 75 80
Glu Gly Tyr Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile
85 90 95
Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser
100 105 110
Ser Leu Gln Val Ser Gly Val Ala Gly Tyr Thr Phe Gly Ser Gly Thr
115 120 125
Arg Leu Thr Val Val Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val
130 135 140
Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala
145 150 155 160
Thr Leu Val Cys Leu Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu
165 170 175
Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp
180 185 190
Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys
195 200 205
Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg
210 215 220
Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp
225 230 235 240
Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala
245 250 255
Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln
260 265 270
Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys
275 280 285
Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met
290 295 300
Val Lys Arg Lys Asp Phe
305 310
<210> 434
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 - TCR Vβ)
<400> 434
Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly
1 5 10 15
Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe
35 40 45
Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr
50 55 60
Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser
65 70 75 80
Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ser Leu Gln
85 90 95
Val Ser Gly Val Ala Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr
100 105 110
Val Val
<210> 435
<211> 1484
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 -
TCRβ-P2A-TCRα 片段)
<400> 435
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcatc agactccttt 60
gcagggtggc cttttgcttt ctggctgtgg gattagtgga cgtgaaggtt acccagagca 120
gcagatatct ggtgaagaga accggcgaga aggtgttcct ggaatgtgtg caggatatgg 180
accacgagaa catgttctgg tacagacagg accctggact gggactgaga ctgatctact 240
tcagctacga cgtgaagatg aaggagaagg gcgatatccc tgagggctac agcgtgagca 300
gagagaaaaa ggagaggttc agcctgattc tggaaagcgc cagcacaaat cagaccagca 360
tgtacctgtg cgcctcttct ctgcaagtgt ctggagttgc tggctacacc tttggatctg 420
gcacaagact gacagtggtg gaggatctga acaaggtgtt ccccccagag gtggccgtgt 480
tcgagccttc tgaggccgag atctcccaca cccagaaagc caccctcgtg tgcctggcca 540
ccggcttttt ccccgaccac gtggaactgt cttggtgggt caacggcaaa gaggtgcact 600
ccggcgtgtg caccgatccc cagcctctga aagaacagcc cgccctgaac gacagccggt 660
actgcctgag cagcagactg agagtgtccg ccaccttctg gcagaacccc cggaaccact 720
tcagatgcca ggtgcagttc tacggcctga gcgagaacga cgagtggacc caggacagag 780
ccaagcccgt gacacagatc gtgtctgccg aagcctgggg cagagccgat tgcggcttta 840
cctccgtgtc ctatcagcag ggcgtgctga gcgccacaat cctgtacgag atcctgctgg 900
gcaaggccac cctgtacgcc gtgctggtgt ctgccctggt gctgatggcc atggtcaagc 960
ggaaggactt cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg ctgcttcttc tcgttcctgc ctttcaggtg atcttcacac 1080
tgggcggcac aagagctcag tctgttacac agctggattc tcaggtgcct gtgtttgaag 1140
aagctcctgt ggagctgagg tgcaactact cttctagcgt gagcgtgtac ctgttctggt 1200
atgtgcagta ccccaatcag ggactgcagc tgctgctgaa atatctgtct ggctctaccc 1260
tggtggaaag catcaatggc tttgaagccg agttcaacaa gtcccagacc agctttcacc 1320
tgaggaagcc ctctgtgcac atcagcgata cagccgagta cttttgtgct gtgaccagag 1380
acgacaagat catcttcggc aagggcacca gactgcacat cctgcccaat atccagaatc 1440
ctgatcctgc cgtgtaccag ctgcgggaca gcaagagcag cgac 1484
<210> 436
<211> 493
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR12 -
TCRβ-P2A-TCRα 片段)
<400> 436
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Ile Arg
1 5 10 15
Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val Gly Leu Val Asp
20 25 30
Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly Glu
35 40 45
Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met Phe
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe Ser
65 70 75 80
Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr Ser
85 90 95
Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser Ala
100 105 110
Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ser Leu Gln Val
115 120 125
Ser Gly Val Ala Gly Tyr Thr Phe Gly Ser Gly Thr Arg Leu Thr Val
130 135 140
Val Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe Glu
145 150 155 160
Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys
165 170 175
Leu Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val
180 185 190
Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu
195 200 205
Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg
210 215 220
Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg
225 230 235 240
Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln
245 250 255
Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly
260 265 270
Arg Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly Val Leu
275 280 285
Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr
290 295 300
Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys
305 310 315 320
Asp Phe Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly
325 330 335
Asp Val Glu Glu Asn Pro Gly Pro Met Leu Leu Leu Leu Val Pro Ala
340 345 350
Phe Gln Val Ile Phe Thr Leu Gly Gly Thr Arg Ala Gln Ser Val Thr
355 360 365
Gln Leu Asp Ser Gln Val Pro Val Phe Glu Glu Ala Pro Val Glu Leu
370 375 380
Arg Cys Asn Tyr Ser Ser Ser Val Ser Val Tyr Leu Phe Trp Tyr Val
385 390 395 400
Gln Tyr Pro Asn Gln Gly Leu Gln Leu Leu Leu Lys Tyr Leu Ser Gly
405 410 415
Ser Thr Leu Val Glu Ser Ile Asn Gly Phe Glu Ala Glu Phe Asn Lys
420 425 430
Ser Gln Thr Ser Phe His Leu Arg Lys Pro Ser Val His Ile Ser Asp
435 440 445
Thr Ala Glu Tyr Phe Cys Ala Val Thr Arg Asp Asp Lys Ile Ile Phe
450 455 460
Gly Lys Gly Thr Arg Leu His Ile Leu Pro Asn Ile Gln Asn Pro Asp
465 470 475 480
Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490
<210> 437
<211> 822
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - TCRα)
<400> 437
atgaagacat ttgctggatt ttcgttcctg tttttgtggc tgcagctgga ctgtatgagt 60
agaggagagg atgtggagca gagtcttttc ctgagtgtcc gagagggaga cagctccgtt 120
ataaactgca cttacacaga cagctcctcc acctacttat actggtataa gcaagaacct 180
ggagcaggtc tccagttgct gacgtatatt ttttcaaata tggacatgaa acaagaccaa 240
agactcactg ttctattgaa taaaaaggat aaacatctgt ctctgcgcat tgcagacacc 300
cagactgggg actcagctat ctacttctgt gcagagatag aggataacac cgacaagctc 360
atctttggga ctgggaccag attacaagtc tttccaaata tccagaaccc tgaccctgcc 420
gtgtaccagc tgagagactc taaatccagt gacaagtctg tctgcctatt caccgatttt 480
gattctcaaa caaatgtgtc acaaagtaag gattctgatg tgtatatcac agacaaaact 540
gtgctagaca tgaggtctat ggacttcaag agcaacagtg ctgtggcctg gagcaacaaa 600
tctgactttg catgtgcaaa cgccttcaac aacagcatta ttccagaaga caccttcttc 660
cccagcccag aaagttcctg tgatgtcaag ctggtcgaga aaagctttga aacagatacg 720
aacctaaact ttcaaaacct gtcagtgatt gggttccgaa tcctcctcct gaaagtggcc 780
gggtttaatc tgctcatgac gctgcggctg tggtccagct ga 822
<210> 438
<211> 273
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - TCRα)
<400> 438
Met Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu
1 5 10 15
Asp Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser
20 25 30
Val Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser
35 40 45
Ser Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu
50 55 60
Gln Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln
65 70 75 80
Arg Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg
85 90 95
Ile Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu
100 105 110
Ile Glu Asp Asn Thr Asp Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu
115 120 125
Gln Val Phe Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu
130 135 140
Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe
145 150 155 160
Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile
165 170 175
Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn
180 185 190
Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala
195 200 205
Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu
210 215 220
Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr
225 230 235 240
Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu
245 250 255
Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser
260 265 270
Ser
<210> 439
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - TCR Vα)
<400> 439
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Ile Glu Asp Asn Thr
85 90 95
Asp Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn
100 105 110
<210> 440
<211> 936
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - TCRβ)
<400> 440
atgagcacca ggcttctctg ctggatggcc ctctgtctcc tgggggcaga actctcagaa 60
gctgaagttg cccagtcccc cagatataag attacagaga aaagccaggc tgtggctttt 120
tggtgtgatc ctatttctgg ccatgctacc ctttactggt accggcagat cctgggacag 180
ggcccggagc ttctggttca atttcaggat gagagtgtag tagatgattc acagttgcct 240
aaggatcgat tttctgcaga gaggctcaaa ggagtagact ccactctcaa gatccagcct 300
gcagagcttg gggactcggc catgtatctc tgtgccagca gccccacagg ggaaggcgag 360
cagtacttcg ggccgggcac caggctcacg gtcacagagg acctgaaaaa cgtgttccca 420
cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca 480
ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 540
gggaaggagg tgcacagtgg ggtcagcaca gacccgcagc ccctcaagga gcagcccgcc 600
ctcaatgact ccagatactg cctgagcagc cgcctgaggg tctcggccac cttctggcag 660
aacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag 720
tggacccagg atagggccaa acctgtcacc cagatcgtca gcgccgaggc ctggggtaga 780
gcagactgtg gcttcacctc cgagtcttac cagcaagggg tcctgtctgc caccatcctc 840
tatgagatct tgctagggaa ggccaccttg tatgccgtgc tggtcagtgc cctcgtgctg 900
atggccatgg tcaagagaaa ggattccaga ggctag 936
<210> 441
<211> 311
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - TCRβ)
<400> 441
Met Ser Thr Arg Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala
1 5 10 15
Glu Leu Ser Glu Ala Glu Val Ala Gln Ser Pro Arg Tyr Lys Ile Thr
20 25 30
Glu Lys Ser Gln Ala Val Ala Phe Trp Cys Asp Pro Ile Ser Gly His
35 40 45
Ala Thr Leu Tyr Trp Tyr Arg Gln Ile Leu Gly Gln Gly Pro Glu Leu
50 55 60
Leu Val Gln Phe Gln Asp Glu Ser Val Val Asp Asp Ser Gln Leu Pro
65 70 75 80
Lys Asp Arg Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu
85 90 95
Lys Ile Gln Pro Ala Glu Leu Gly Asp Ser Ala Met Tyr Leu Cys Ala
100 105 110
Ser Ser Pro Thr Gly Glu Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg
115 120 125
Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala
130 135 140
Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr
145 150 155 160
Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser
165 170 175
Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190
Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu
195 200 205
Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn
210 215 220
His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu
225 230 235 240
Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu
245 250 255
Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln
260 265 270
Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala
275 280 285
Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val
290 295 300
Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 442
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 - TCR Vβ)
<400> 442
Glu Ala Glu Val Ala Gln Ser Pro Arg Tyr Lys Ile Thr Glu Lys Ser
1 5 10 15
Gln Ala Val Ala Phe Trp Cys Asp Pro Ile Ser Gly His Ala Thr Leu
20 25 30
Tyr Trp Tyr Arg Gln Ile Leu Gly Gln Gly Pro Glu Leu Leu Val Gln
35 40 45
Phe Gln Asp Glu Ser Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg
50 55 60
Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ala Glu Leu Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Pro
85 90 95
Thr Gly Glu Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr
<210> 443
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 -
TCRβ-P2A-TCRα 片段)
<400> 443
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgagcacc agactccttt 60
gctggatggc tttgtgtctg cttggagctg agctgtctga agctgaagtt gcccagtctc 120
ccagatacaa gatcaccgag aaatctcagg ctgtggcctt ctggtgtgac cctatttctg 180
gacacgccac cctgtactgg tataggcaaa ttctgggaca aggccctgaa ctgctggtgc 240
aatttcagga tgagagcgtg gtggacgatt ctcaactgcc taaggacagg ttttctgccg 300
agcggctgaa aggagttgat agcaccctga agatccaacc tgctgaactg ggcgattctg 360
ctatgtacct gtgcgcctct tctcctacag gagagggaga acagtatttt ggacctggca 420
ccagactgac agtgacagag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atgaagacct ttgccggatt ctccttcctg ttcctgtggc 1080
tgcagctgga ttgtatgagc agaggcgaag atgtggaaca gagcctgttt ctgagcgtga 1140
gagagggaga tagcagcgtg atcaattgca cctacaccga ttctagcagc acctacctgt 1200
actggtacaa gcaggaacct ggagccggat tacaactgct gacctacatc ttcagcaaca 1260
tggacatgaa gcaggaccag agactgaccg tgctgctgaa caagaaggac aagcacctga 1320
gcctgagaat tgccgataca cagacaggag atagcgccat ctacttctgt gccgagatcg 1380
aggacaacac cgacaagctg atctttggaa ccggaacaag actgcaggtg ttccccaaca 1440
tccagaatcc cgatcctgcc gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 444
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR13 -
TCRβ-P2A-TCRα 片段)
<400> 444
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Ser Thr Arg
1 5 10 15
Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala Glu Leu Ser Glu
20 25 30
Ala Glu Val Ala Gln Ser Pro Arg Tyr Lys Ile Thr Glu Lys Ser Gln
35 40 45
Ala Val Ala Phe Trp Cys Asp Pro Ile Ser Gly His Ala Thr Leu Tyr
50 55 60
Trp Tyr Arg Gln Ile Leu Gly Gln Gly Pro Glu Leu Leu Val Gln Phe
65 70 75 80
Gln Asp Glu Ser Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg Phe
85 90 95
Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln Pro
100 105 110
Ala Glu Leu Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Pro Thr
115 120 125
Gly Glu Gly Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Lys Thr Phe Ala Gly Phe
340 345 350
Ser Phe Leu Phe Leu Trp Leu Gln Leu Asp Cys Met Ser Arg Gly Glu
355 360 365
Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp Ser Ser
370 375 380
Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu Tyr Trp
385 390 395 400
Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr Ile Phe
405 410 415
Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu Leu Asn
420 425 430
Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln Thr Gly
435 440 445
Asp Ser Ala Ile Tyr Phe Cys Ala Glu Ile Glu Asp Asn Thr Asp Lys
450 455 460
Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 445
<211> 846
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - TCRα)
<400> 445
atggccatgc tcctgggggc atcagtgctg attctgtggc ttcagccaga ctgggtaaac 60
agtcaacaga agaatgatga ccagcaagtt aagcaaaatt caccatccct gagcgtccag 120
gaaggaagaa tttctattct gaactgtgac tatactaaca gcatgtttga ttatttccta 180
tggtacaaaa aataccctgc tgaaggtcct acattcctga tatctataag ttccattaag 240
gataaaaatg aagatggaag attcactgtc ttcttaaaca aaagtgccaa gcacctctct 300
ctgcacattg tgccctccca gcctggagac tctgcagtgt acttctgtgc agcaatctcc 360
cttacctcag gaacctacaa atacatcttt ggaacaggca ccaggctgaa ggttttagca 420
aatatccaga accctgaccc tgccgtgtac cagctgagag actctaaatc cagtgacaag 480
tctgtctgcc tattcaccga ttttgattct caaacaaatg tgtcacaaag taaggattct 540
gatgtgtata tcacagacaa aactgtgcta gacatgaggt ctatggactt caagagcaac 600
agtgctgtgg cctggagcaa caaatctgac tttgcatgtg caaacgcctt caacaacagc 660
attattccag aagacacctt cttccccagc ccagaaagtt cctgtgatgt caagctggtc 720
gagaaaagct ttgaaacaga tacgaaccta aactttcaaa acctgtcagt gattgggttc 780
cgaatcctcc tcctgaaagt ggccgggttt aatctgctca tgacgctgcg gctgtggtcc 840
agctga 846
<210> 446
<211> 281
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - TCRα)
<400> 446
Met Ala Met Leu Leu Gly Ala Ser Val Leu Ile Leu Trp Leu Gln Pro
1 5 10 15
Asp Trp Val Asn Ser Gln Gln Lys Asn Asp Asp Gln Gln Val Lys Gln
20 25 30
Asn Ser Pro Ser Leu Ser Val Gln Glu Gly Arg Ile Ser Ile Leu Asn
35 40 45
Cys Asp Tyr Thr Asn Ser Met Phe Asp Tyr Phe Leu Trp Tyr Lys Lys
50 55 60
Tyr Pro Ala Glu Gly Pro Thr Phe Leu Ile Ser Ile Ser Ser Ile Lys
65 70 75 80
Asp Lys Asn Glu Asp Gly Arg Phe Thr Val Phe Leu Asn Lys Ser Ala
85 90 95
Lys His Leu Ser Leu His Ile Val Pro Ser Gln Pro Gly Asp Ser Ala
100 105 110
Val Tyr Phe Cys Ala Ala Ile Ser Leu Thr Ser Gly Thr Tyr Lys Tyr
115 120 125
Ile Phe Gly Thr Gly Thr Arg Leu Lys Val Leu Ala Asn Ile Gln Asn
130 135 140
Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys
145 150 155 160
Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn Val Ser Gln
165 170 175
Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Thr Val Leu Asp Met
180 185 190
Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp Ser Asn Lys
195 200 205
Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu
210 215 220
Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val Lys Leu Val
225 230 235 240
Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser
245 250 255
Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala Gly Phe Asn Leu
260 265 270
Leu Met Thr Leu Arg Leu Trp Ser Ser
275 280
<210> 447
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - TCR Vα)
<400> 447
Asp Gln Gln Val Lys Gln Asn Ser Pro Ser Leu Ser Val Gln Glu Gly
1 5 10 15
Arg Ile Ser Ile Leu Asn Cys Asp Tyr Thr Asn Ser Met Phe Asp Tyr
20 25 30
Phe Leu Trp Tyr Lys Lys Tyr Pro Ala Glu Gly Pro Thr Phe Leu Ile
35 40 45
Ser Ile Ser Ser Ile Lys Asp Lys Asn Glu Asp Gly Arg Phe Thr Val
50 55 60
Phe Leu Asn Lys Ser Ala Lys His Leu Ser Leu His Ile Val Pro Ser
65 70 75 80
Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Ala Ile Ser Leu Thr
85 90 95
Ser Gly Thr Tyr Lys Tyr Ile Phe Gly Thr Gly Thr Arg Leu Lys Val
100 105 110
Leu Ala Asn
115
<210> 448
<211> 939
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - TCRβ)
<400> 448
atgggctgca ggctgctctg ctgtgcggtt ctctgtctcc tgggagcagt tcccatagac 60
actgaagtta cccagacacc aaaacacctg gtcatgggaa tgacaaataa gaagtctttg 120
aaatgtgaac aacatatggg gcacagggct atgtattggt acaagcagaa agctaagaag 180
ccaccggagc tcatgtttgt ctacagctat gagaaactct ctataaatga aagtgtgcca 240
agtcgcttct cacctgaatg ccccaacagc tctctcttaa accttcacct acacgccctg 300
cagccagaag actcagccct gtatctctgc gccagcagcc aagatctcgg gacagtctac 360
gagcagtact tcgggccggg caccaggctc acggtcacag aggacctgaa aaacgtgttc 420
ccacccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc 480
acactggtgt gcctggccac aggcttctac cccgaccacg tggagctgag ctggtgggtg 540
aatgggaagg aggtgcacag tggggtcagc acagacccgc agcccctcaa ggagcagccc 600
gccctcaatg actccagata ctgcctgagc agccgcctga gggtctcggc caccttctgg 660
cagaaccccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac 720
gagtggaccc aggatagggc caaacctgtc acccagatcg tcagcgccga ggcctggggt 780
agagcagact gtggcttcac ctccgagtct taccagcaag gggtcctgtc tgccaccatc 840
ctctatgaga tcttgctagg gaaggccacc ttgtatgccg tgctggtcag tgccctcgtg 900
ctgatggcca tggtcaagag aaaggattcc agaggctag 939
<210> 449
<211> 312
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - TCRβ)
<400> 449
Met Gly Cys Arg Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala
1 5 10 15
Val Pro Ile Asp Thr Glu Val Thr Gln Thr Pro Lys His Leu Val Met
20 25 30
Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Met Gly His
35 40 45
Arg Ala Met Tyr Trp Tyr Lys Gln Lys Ala Lys Lys Pro Pro Glu Leu
50 55 60
Met Phe Val Tyr Ser Tyr Glu Lys Leu Ser Ile Asn Glu Ser Val Pro
65 70 75 80
Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser Leu Leu Asn Leu His
85 90 95
Leu His Ala Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser
100 105 110
Ser Gln Asp Leu Gly Thr Val Tyr Glu Gln Tyr Phe Gly Pro Gly Thr
115 120 125
Arg Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val
130 135 140
Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala
145 150 155 160
Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu
165 170 175
Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp
180 185 190
Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys
195 200 205
Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg
210 215 220
Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp
225 230 235 240
Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala
245 250 255
Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln
260 265 270
Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys
275 280 285
Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met
290 295 300
Val Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 450
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 - TCR Vβ)
<400> 450
Asp Thr Glu Val Thr Gln Thr Pro Lys His Leu Val Met Gly Met Thr
1 5 10 15
Asn Lys Lys Ser Leu Lys Cys Glu Gln His Met Gly His Arg Ala Met
20 25 30
Tyr Trp Tyr Lys Gln Lys Ala Lys Lys Pro Pro Glu Leu Met Phe Val
35 40 45
Tyr Ser Tyr Glu Lys Leu Ser Ile Asn Glu Ser Val Pro Ser Arg Phe
50 55 60
Ser Pro Glu Cys Pro Asn Ser Ser Leu Leu Asn Leu His Leu His Ala
65 70 75 80
Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser Ser Gln Asp
85 90 95
Leu Gly Thr Val Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr
100 105 110
Val Thr
<210> 451
<211> 1520
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 -
TCRβ-P2A-TCRα 片段)
<400> 451
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggctgt agactgttgt 60
gttgtgctgt gctgtgtctg ttgggagctg tgcctatcga tacagaggtg acccagaccc 120
ctaaacatct ggttatgggc atgaccaaca agaagagcct gaagtgcgag cagcacatgg 180
gccatagggc catgtattgg tataagcaga aggccaagaa acctcctgag ctgatgttcg 240
tgtacagcta cgagaagctg agcatcaacg agagcgtgcc cagcagattt tctcctgagt 300
gccctaattc tagcctgctg aatctgcacc tgcatgctct gcagcctgag gattctgctc 360
tgtacctgtg tgcttcttct caggatcttg gaaccgtgta cgagcagtac tttggccctg 420
gcacaagact gacagtgaca gaggacctga agaacgtgtt ccccccagag gtggccgtgt 480
tcgagcctag cgaggccgag atcagccaca cccagaaagc caccctcgtg tgcctggcca 540
ccggctttta ccccgaccac gtggaactgt cttggtgggt caacggcaaa gaggtgcaca 600
gcggcgtctg caccgacccc cagcccctga aagagcagcc cgccctgaac gacagccggt 660
actgtctgag cagcagactg agagtgtccg ccaccttctg gcagaacccc cggaaccact 720
tcagatgcca ggtgcagttc tacggcctga gcgagaacga cgagtggacc caggaccggg 780
ccaagcccgt gacccagatc gtgtctgctg aggcctgggg cagagccgat tgcggcttca 840
ccagcgagag ctaccagcag ggcgtgctga gcgccaccat cctgtacgag atcctgctgg 900
gcaaggccac cctgtacgcc gtgctggtgt ccgccctggt gctgatggcc atggtcaagc 960
ggaaggacag ccggggcggt tccggagcca cgaacttctc tctgttaaag caagcaggag 1020
acgtggaaga aaaccccggt cccatggcca tgttactagg agcgagcgtg ctgattctgt 1080
ggttacagcc tgattgggtg aactctcagc agaagaacga tgatcagcag gtgaagcaga 1140
acagcccctc tctgtctgtg caggaaggca gaatcagcat cctgaattgc gattacacca 1200
acagcatgtt cgactacttc ctgtggtaca agaagtaccc cgccgagggc cctacctttc 1260
tgatcagcat ctctagcatc aaggacaaga acgaagatgg cagattcacc gtgttcctga 1320
acaagagcgc caagcacctg agcctgcaca ttgtgccttc tcaacctgga gattctgccg 1380
tgtacttttg tgccgccatt agcctgacaa gcggcaccta caagtacatc tttggcacag 1440
gcaccaggct gaaagttctg gccaatatcc agaatcccga tcccgccgtg taccagctgc 1500
gggacagcaa gagcagcgac 1520
<210> 452
<211> 505
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR14 -
TCRβ-P2A-TCRα 片段)
<400> 452
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Cys Arg
1 5 10 15
Leu Leu Cys Cys Ala Val Leu Cys Leu Leu Gly Ala Val Pro Ile Asp
20 25 30
Thr Glu Val Thr Gln Thr Pro Lys His Leu Val Met Gly Met Thr Asn
35 40 45
Lys Lys Ser Leu Lys Cys Glu Gln His Met Gly His Arg Ala Met Tyr
50 55 60
Trp Tyr Lys Gln Lys Ala Lys Lys Pro Pro Glu Leu Met Phe Val Tyr
65 70 75 80
Ser Tyr Glu Lys Leu Ser Ile Asn Glu Ser Val Pro Ser Arg Phe Ser
85 90 95
Pro Glu Cys Pro Asn Ser Ser Leu Leu Asn Leu His Leu His Ala Leu
100 105 110
Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser Ser Gln Asp Leu
115 120 125
Gly Thr Val Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
130 135 140
Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu
145 150 155 160
Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys
165 170 175
Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val
180 185 190
Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu
195 200 205
Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg
210 215 220
Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg
225 230 235 240
Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln
245 250 255
Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly
260 265 270
Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu
275 280 285
Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr
290 295 300
Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys
305 310 315 320
Asp Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln
325 330 335
Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Ala Met Leu Leu Gly
340 345 350
Ala Ser Val Leu Ile Leu Trp Leu Gln Pro Asp Trp Val Asn Ser Gln
355 360 365
Gln Lys Asn Asp Asp Gln Gln Val Lys Gln Asn Ser Pro Ser Leu Ser
370 375 380
Val Gln Glu Gly Arg Ile Ser Ile Leu Asn Cys Asp Tyr Thr Asn Ser
385 390 395 400
Met Phe Asp Tyr Phe Leu Trp Tyr Lys Lys Tyr Pro Ala Glu Gly Pro
405 410 415
Thr Phe Leu Ile Ser Ile Ser Ser Ile Lys Asp Lys Asn Glu Asp Gly
420 425 430
Arg Phe Thr Val Phe Leu Asn Lys Ser Ala Lys His Leu Ser Leu His
435 440 445
Ile Val Pro Ser Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Ala
450 455 460
Ile Ser Leu Thr Ser Gly Thr Tyr Lys Tyr Ile Phe Gly Thr Gly Thr
465 470 475 480
Arg Leu Lys Val Leu Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr
485 490 495
Gln Leu Arg Asp Ser Lys Ser Ser Asp
500 505
<210> 453
<211> 819
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - TCRα)
<400> 453
atgaagacat ttgctggatt ttcgttcctg tttttgtggc tgcagctgga ctgtatgagt 60
agaggagagg atgtggagca gagtcttttc ctgagtgtcc gagagggaga cagctccgtt 120
ataaactgca cttacacaga cagctcctcc acctacttat actggtataa gcaagaacct 180
ggagcaggtc tccagttgct gacgtatatt ttttcaaata tggacatgaa acaagaccaa 240
agactcactg ttctattgaa taaaaaggat aaacatctgt ctctgcgcat tgcagacacc 300
cagactgggg actcagctat ctacttctgt gcagagatga tggacaccga caagctcatc 360
tttgggactg ggaccagatt acaagtcttt ccaaatatcc agaaccctga ccctgccgtg 420
taccagctga gagactctaa atccagtgac aagtctgtct gcctattcac cgattttgat 480
tctcaaacaa atgtgtcaca aagtaaggat tctgatgtgt atatcacaga caaaactgtg 540
ctagacatga ggtctatgga cttcaagagc aacagtgctg tggcctggag caacaaatct 600
gactttgcat gtgcaaacgc cttcaacaac agcattattc cagaagacac cttcttcccc 660
agcccagaaa gttcctgtga tgtcaagctg gtcgagaaaa gctttgaaac agatacgaac 720
ctaaactttc aaaacctgtc agtgattggg ttccgaatcc tcctcctgaa agtggccggg 780
tttaatctgc tcatgacgct gcggctgtgg tccagctga 819
<210> 454
<211> 272
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - TCRα)
<400> 454
Met Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu
1 5 10 15
Asp Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser
20 25 30
Val Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser
35 40 45
Ser Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu
50 55 60
Gln Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln
65 70 75 80
Arg Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg
85 90 95
Ile Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu
100 105 110
Met Met Asp Thr Asp Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln
115 120 125
Val Phe Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg
130 135 140
Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp
145 150 155 160
Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr
165 170 175
Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser
180 185 190
Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe
195 200 205
Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser
210 215 220
Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn
225 230 235 240
Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu
245 250 255
Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
260 265 270
<210> 455
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - TCR Vα)
<400> 455
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Met Met Asp Thr Asp
85 90 95
Lys Leu Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn
100 105 110
<210> 456
<211> 936
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - TCRβ)
<400> 456
atgggcacca ggctcctctg ctgggcggcc ctctgtctcc tgggagcaga actcacagaa 60
gctggagttg cccagtctcc cagatataag attatagaga aaaggcagag tgtggctttt 120
tggtgcaatc ctatatctgg ccatgctacc ctttactggt accagcagat cctgggacag 180
ggcccaaagc ttctgattca gtttcagaat aacggtgtag tggatgattc acagttgcct 240
aaggatcgat tttctgcaga gaggctcaaa ggagtagact ccactctcaa gatccaacct 300
gcaaagcttg aggactcggc cgtgtatctc tgtgccagca gcttgcctag cgggaatgag 360
cagttcttcg ggccagggac acggctcacc gtgctagagg acctgaaaaa cgtgttccca 420
cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca 480
ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 540
gggaaggagg tgcacagtgg ggtcagcaca gacccgcagc ccctcaagga gcagcccgcc 600
ctcaatgact ccagatactg cctgagcagc cgcctgaggg tctcggccac cttctggcag 660
aacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag 720
tggacccagg atagggccaa acctgtcacc cagatcgtca gcgccgaggc ctggggtaga 780
gcagactgtg gcttcacctc cgagtcttac cagcaagggg tcctgtctgc caccatcctc 840
tatgagatct tgctagggaa ggccaccttg tatgccgtgc tggtcagtgc cctcgtgctg 900
atggccatgg tcaagagaaa ggattccaga ggctag 936
<210> 457
<211> 311
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - TCRβ)
<400> 457
Met Gly Thr Arg Leu Leu Cys Trp Ala Ala Leu Cys Leu Leu Gly Ala
1 5 10 15
Glu Leu Thr Glu Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile Ile
20 25 30
Glu Lys Arg Gln Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly His
35 40 45
Ala Thr Leu Tyr Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys Leu
50 55 60
Leu Ile Gln Phe Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu Pro
65 70 75 80
Lys Asp Arg Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu
85 90 95
Lys Ile Gln Pro Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys Ala
100 105 110
Ser Ser Leu Pro Ser Gly Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg
115 120 125
Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala
130 135 140
Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr
145 150 155 160
Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser
165 170 175
Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190
Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu
195 200 205
Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn
210 215 220
His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu
225 230 235 240
Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu
245 250 255
Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln
260 265 270
Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala
275 280 285
Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val
290 295 300
Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 458
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 - TCR Vβ)
<400> 458
Glu Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile Ile Glu Lys Arg
1 5 10 15
Gln Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly His Ala Thr Leu
20 25 30
Tyr Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys Leu Leu Ile Gln
35 40 45
Phe Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg
50 55 60
Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Leu
85 90 95
Pro Ser Gly Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Leu
<210> 459
<211> 1490
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 -
TCRβ-P2A-TCRα 片段)
<400> 459
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca agacttctct 60
gttgggctgc tctttgtctg cttggagctg aactgacaga agctggagtt gcccagtctc 120
ctaggtacaa gatcatcgag aagaggcagt ctgtggcctt ttggtgcaat cccattagcg 180
gacacgccac cctgtactgg tatcagcaaa ttctgggaca aggccctaaa ctgctgatcc 240
agttccagaa caacggcgtg gtggacgatt ctcaactgcc taaggacagg ttttctgccg 300
agagactgaa aggcgtggat agcaccctga agatccaacc agccaaactg gaggattctg 360
ctgtgtacct gtgtgcttct agcctgccaa gcggcaatga gcagtttttt ggacctggca 420
caagactgac agtgctggaa gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atgaagacct ttgccggatt ctccttcctg ttcctgtggc 1080
tgcagctgga ttgtatgagc agaggcgaag atgtggaaca gagcctgttt ctgagcgtga 1140
gagagggaga tagcagcgtg atcaattgca cctacaccga ttctagcagc acctacctgt 1200
actggtacaa gcaggaacct ggagccggat tacaactgct gacctacatc ttcagcaaca 1260
tggacatgaa gcaggaccag agactgaccg tgctgctgaa caagaaggac aagcacctga 1320
gcctgagaat tgccgataca cagacaggag atagcgccat ctacttctgt gccgagatga 1380
tggacaccga caagctgatc tttggaacag gcaccagact gcaggtgttc cccaatatcc 1440
agaatcctga tcctgccgtg taccagctgc gggacagcaa gagcagcgac 1490
<210> 460
<211> 495
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR15 -
TCRβ-P2A-TCRα 片段)
<400> 460
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Thr Arg
1 5 10 15
Leu Leu Cys Trp Ala Ala Leu Cys Leu Leu Gly Ala Glu Leu Thr Glu
20 25 30
Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile Ile Glu Lys Arg Gln
35 40 45
Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly His Ala Thr Leu Tyr
50 55 60
Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys Leu Leu Ile Gln Phe
65 70 75 80
Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg Phe
85 90 95
Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln Pro
100 105 110
Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Leu Pro
115 120 125
Ser Gly Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Lys Thr Phe Ala Gly Phe
340 345 350
Ser Phe Leu Phe Leu Trp Leu Gln Leu Asp Cys Met Ser Arg Gly Glu
355 360 365
Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp Ser Ser
370 375 380
Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu Tyr Trp
385 390 395 400
Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr Ile Phe
405 410 415
Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu Leu Asn
420 425 430
Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln Thr Gly
435 440 445
Asp Ser Ala Ile Tyr Phe Cys Ala Glu Met Met Asp Thr Asp Lys Leu
450 455 460
Ile Phe Gly Thr Gly Thr Arg Leu Gln Val Phe Pro Asn Ile Gln Asn
465 470 475 480
Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 461
<211> 825
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - TCRα)
<400> 461
atgaagacat ttgctggatt ttcgttcctg tttttgtggc tgcagctgga ctgtatgagt 60
agaggagagg atgtggagca gagtcttttc ctgagtgtcc gagagggaga cagctccgtt 120
ataaactgca cttacacaga cagctcctcc acctacttat actggtataa gcaagaacct 180
ggagcaggtc tccagttgct gacgtatatt ttttcaaata tggacatgaa acaagaccaa 240
agactcactg ttctattgaa taaaaaggat aaacatctgt ctctgcgcat tgcagacacc 300
cagactgggg actcagctat ctacttctgt gcagagatcg tagataacca gggaggaaag 360
cttatcttcg gacagggaac ggagttatct gtgaaaccca atatccagaa ccctgaccct 420
gccgtgtacc agctgagaga ctctaaatcc agtgacaagt ctgtctgcct attcaccgat 480
tttgattctc aaacaaatgt gtcacaaagt aaggattctg atgtgtatat cacagacaaa 540
actgtgctag acatgaggtc tatggacttc aagagcaaca gtgctgtggc ctggagcaac 600
aaatctgact ttgcatgtgc aaacgccttc aacaacagca ttattccaga agacaccttc 660
ttccccagcc cagaaagttc ctgtgatgtc aagctggtcg agaaaagctt tgaaacagat 720
acgaacctaa actttcaaaa cctgtcagtg attgggttcc gaatcctcct cctgaaagtg 780
gccgggttta atctgctcat gacgctgcgg ctgtggtcca gctga 825
<210> 462
<211> 274
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - TCRα)
<400> 462
Met Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu
1 5 10 15
Asp Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser
20 25 30
Val Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser
35 40 45
Ser Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu
50 55 60
Gln Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln
65 70 75 80
Arg Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg
85 90 95
Ile Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu
100 105 110
Ile Val Asp Asn Gln Gly Gly Lys Leu Ile Phe Gly Gln Gly Thr Glu
115 120 125
Leu Ser Val Lys Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln
130 135 140
Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp
145 150 155 160
Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr
165 170 175
Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser
180 185 190
Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn
195 200 205
Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro
210 215 220
Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp
225 230 235 240
Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu
245 250 255
Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp
260 265 270
Ser Ser
<210> 463
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - TCR Vα)
<400> 463
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Ile Val Asp Asn Gln
85 90 95
Gly Gly Lys Leu Ile Phe Gly Gln Gly Thr Glu Leu Ser Val Lys Pro
100 105 110
Asn
<210> 464
<211> 933
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - TCRβ)
<400> 464
atggcctccc tgctcttctt ctgtggggcc ttttatctcc tgggaacagg gtccatggat 60
gctgatgtta cccagacccc aaggaatagg atcacaaaga caggaaagag gattatgctg 120
gaatgttctc agactaaggg tcatgataga atgtactggt atcgacaaga cccaggactg 180
ggcctacggt tgatctatta ctcctttgat gtcaaagata taaacaaagg agagatctct 240
gatggataca gtgtctctcg acaggcacag gctaaattct ccctgtccct agagtctgcc 300
atccccaacc agacagctct ttacttctgt gccaccagtg gacagggggg cgatgagcag 360
ttcttcgggc cagggacacg gctcaccgtg ctagaggacc tgaaaaacgt gttcccaccc 420
gaggtcgctg tgtttgagcc atcagaagca gagatctccc acacccaaaa ggccacactg 480
gtgtgcctgg ccacaggctt ctaccccgac cacgtggagc tgagctggtg ggtgaatggg 540
aaggaggtgc acagtggggt cagcacagac ccgcagcccc tcaaggagca gcccgccctc 600
aatgactcca gatactgcct gagcagccgc ctgagggtct cggccacctt ctggcagaac 660
ccccgcaacc acttccgctg tcaagtccag ttctacgggc tctcggagaa tgacgagtgg 720
acccaggata gggccaaacc tgtcacccag atcgtcagcg ccgaggcctg gggtagagca 780
gactgtggct tcacctccga gtcttaccag caaggggtcc tgtctgccac catcctctat 840
gagatcttgc tagggaaggc caccttgtat gccgtgctgg tcagtgccct cgtgctgatg 900
gccatggtca agagaaagga ttccagaggc tag 933
<210> 465
<211> 310
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - TCRβ)
<400> 465
Met Ala Ser Leu Leu Phe Phe Cys Gly Ala Phe Tyr Leu Leu Gly Thr
1 5 10 15
Gly Ser Met Asp Ala Asp Val Thr Gln Thr Pro Arg Asn Arg Ile Thr
20 25 30
Lys Thr Gly Lys Arg Ile Met Leu Glu Cys Ser Gln Thr Lys Gly His
35 40 45
Asp Arg Met Tyr Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu
50 55 60
Ile Tyr Tyr Ser Phe Asp Val Lys Asp Ile Asn Lys Gly Glu Ile Ser
65 70 75 80
Asp Gly Tyr Ser Val Ser Arg Gln Ala Gln Ala Lys Phe Ser Leu Ser
85 90 95
Leu Glu Ser Ala Ile Pro Asn Gln Thr Ala Leu Tyr Phe Cys Ala Thr
100 105 110
Ser Gly Gln Gly Gly Asp Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu
115 120 125
Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val
130 135 140
Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu
145 150 155 160
Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp
165 170 175
Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln
180 185 190
Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser
195 200 205
Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His
210 215 220
Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp
225 230 235 240
Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala
245 250 255
Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly
260 265 270
Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr
275 280 285
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys
290 295 300
Arg Lys Asp Ser Arg Gly
305 310
<210> 466
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 - TCR Vβ)
<400> 466
Asp Ala Asp Val Thr Gln Thr Pro Arg Asn Arg Ile Thr Lys Thr Gly
1 5 10 15
Lys Arg Ile Met Leu Glu Cys Ser Gln Thr Lys Gly His Asp Arg Met
20 25 30
Tyr Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Tyr
35 40 45
Ser Phe Asp Val Lys Asp Ile Asn Lys Gly Glu Ile Ser Asp Gly Tyr
50 55 60
Ser Val Ser Arg Gln Ala Gln Ala Lys Phe Ser Leu Ser Leu Glu Ser
65 70 75 80
Ala Ile Pro Asn Gln Thr Ala Leu Tyr Phe Cys Ala Thr Ser Gly Gln
85 90 95
Gly Gly Asp Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
<210> 467
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 -
TCRβ-P2A-TCRα 片段)
<400> 467
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catggcttct ctcctgttct 60
tctgtggcgc cttttacctg ctgggaacag gctctatgga tgctgatgtg acacagaccc 120
ccagaaacag aatcaccaag acaggcaagc ggatcatgct ggagtgtagc cagacaaaag 180
gccacgaccg gatgtactgg tatagacaag atcctggact gggactgagg ctgatctact 240
acagcttcga cgtgaaggac atcaacaagg gcgagatctc tgatggctac agcgtgagca 300
gacaggctca ggccaagttt tctctgtctc tggaatctgc catccctaat cagacagccc 360
tgtacttttg cgccacaagc ggccaaggag gagatgagca gttttttgga ccaggaacaa 420
gactgaccgt gttagaggac ctgaagaacg tgttcccccc agaggtggcc gtgttcgagc 480
ctagcgaggc cgagatcagc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
tttaccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cacagcggcg 600
tctgcaccga cccccagccc ctgaaagagc agcccgccct gaacgacagc cggtactgtc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac cgggccaagc 780
ccgtgaccca gatcgtgtct gctgaggcct ggggcagagc cgattgcggc ttcaccagcg 840
agagctacca gcagggcgtg ctgagcgcca ccatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtccgccc tggtgctgat ggccatggtc aagcggaagg 960
acagccgggg cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg aagacctttg ccggattctc cttcctgttc ctgtggctgc 1080
agctggattg tatgagcaga ggcgaagatg tggaacagag cctgtttctg agcgtgagag 1140
agggagatag cagcgtgatc aattgcacct acaccgattc tagcagcacc tacctgtact 1200
ggtacaagca ggaacctgga gccggattac aactgctgac ctacatcttc agcaacatgg 1260
acatgaagca ggaccagaga ctgaccgtgc tgctgaacaa gaaggacaag cacctgagcc 1320
tgagaattgc cgatacacag acaggagata gcgccatcta cttctgtgcc gagatcgtgg 1380
acaatcaggg cggaaagctg atttttggac agggaacaga gctgagcgtg aagcccaaca 1440
tccagaatcc tgatcctgcc gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 468
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR16 -
TCRβ-P2A-TCRα 片段)
<400> 468
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Ala Ser Leu
1 5 10 15
Leu Phe Phe Cys Gly Ala Phe Tyr Leu Leu Gly Thr Gly Ser Met Asp
20 25 30
Ala Asp Val Thr Gln Thr Pro Arg Asn Arg Ile Thr Lys Thr Gly Lys
35 40 45
Arg Ile Met Leu Glu Cys Ser Gln Thr Lys Gly His Asp Arg Met Tyr
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Tyr Ser
65 70 75 80
Phe Asp Val Lys Asp Ile Asn Lys Gly Glu Ile Ser Asp Gly Tyr Ser
85 90 95
Val Ser Arg Gln Ala Gln Ala Lys Phe Ser Leu Ser Leu Glu Ser Ala
100 105 110
Ile Pro Asn Gln Thr Ala Leu Tyr Phe Cys Ala Thr Ser Gly Gln Gly
115 120 125
Gly Asp Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu Glu
130 135 140
Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser
145 150 155 160
Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala
165 170 175
Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
180 185 190
Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu
195 200 205
Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg
210 215 220
Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln
225 230 235 240
Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg
245 250 255
Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala
260 265 270
Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser Ala
275 280 285
Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val
290 295 300
Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Ser
305 310 315 320
Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly
325 330 335
Asp Val Glu Glu Asn Pro Gly Pro Met Lys Thr Phe Ala Gly Phe Ser
340 345 350
Phe Leu Phe Leu Trp Leu Gln Leu Asp Cys Met Ser Arg Gly Glu Asp
355 360 365
Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp Ser Ser Val
370 375 380
Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu Tyr Trp Tyr
385 390 395 400
Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr Ile Phe Ser
405 410 415
Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu Leu Asn Lys
420 425 430
Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln Thr Gly Asp
435 440 445
Ser Ala Ile Tyr Phe Cys Ala Glu Ile Val Asp Asn Gln Gly Gly Lys
450 455 460
Leu Ile Phe Gly Gln Gly Thr Glu Leu Ser Val Lys Pro Asn Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 469
<211> 807
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - TCRα)
<400> 469
atggtcctga aattctccgt gtccattctt tggattcagt tggcatgggt gagcacccag 60
ctgctggagc agagccctca gtttctaagc atccaagagg gagaaaatct cactgtgtac 120
tgcaactcct caagtgtttt ttccagctta caatggtaca gacaggagcc tggggaaggt 180
cctgtcctcc tggtgacagt agttacgggt ggagaagtga agaagctgaa gagactaacc 240
tttcagtttg gtgatgcaag aaaggacagt tctctccaca tcactgcagc ccagcctggt 300
gatacaggcc tctacctctg tgcagggtct aacgactaca agctcagctt tggagccgga 360
accacagtaa ctgtaagagc aaatatccag aaccctgacc ctgccgtgta ccagctgaga 420
gactctaaat ccagtgacaa gtctgtctgc ctattcaccg attttgattc tcaaacaaat 480
gtgtcacaaa gtaaggattc tgatgtgtat atcacagaca aaactgtgct agacatgagg 540
tctatggact tcaagagcaa cagtgctgtg gcctggagca acaaatctga ctttgcatgt 600
gcaaacgcct tcaacaacag cattattcca gaagacacct tcttccccag cccagaaagt 660
tcctgtgatg tcaagctggt cgagaaaagc tttgaaacag atacgaacct aaactttcaa 720
aacctgtcag tgattgggtt ccgaatcctc ctcctgaaag tggccgggtt taatctgctc 780
atgacgctgc ggctgtggtc cagctga 807
<210> 470
<211> 268
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - TCRα)
<400> 470
Met Val Leu Lys Phe Ser Val Ser Ile Leu Trp Ile Gln Leu Ala Trp
1 5 10 15
Val Ser Thr Gln Leu Leu Glu Gln Ser Pro Gln Phe Leu Ser Ile Gln
20 25 30
Glu Gly Glu Asn Leu Thr Val Tyr Cys Asn Ser Ser Ser Val Phe Ser
35 40 45
Ser Leu Gln Trp Tyr Arg Gln Glu Pro Gly Glu Gly Pro Val Leu Leu
50 55 60
Val Thr Val Val Thr Gly Gly Glu Val Lys Lys Leu Lys Arg Leu Thr
65 70 75 80
Phe Gln Phe Gly Asp Ala Arg Lys Asp Ser Ser Leu His Ile Thr Ala
85 90 95
Ala Gln Pro Gly Asp Thr Gly Leu Tyr Leu Cys Ala Gly Ser Asn Asp
100 105 110
Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr Val Arg Ala Asn
115 120 125
Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser
130 135 140
Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr Asn
145 150 155 160
Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Thr Val
165 170 175
Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala Trp
180 185 190
Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser Ile
195 200 205
Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys Asp Val
210 215 220
Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn Phe Gln
225 230 235 240
Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val Ala Gly
245 250 255
Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
260 265
<210> 471
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - TCR Vα)
<400> 471
Thr Gln Leu Leu Glu Gln Ser Pro Gln Phe Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Leu Thr Val Tyr Cys Asn Ser Ser Ser Val Phe Ser Ser Leu
20 25 30
Gln Trp Tyr Arg Gln Glu Pro Gly Glu Gly Pro Val Leu Leu Val Thr
35 40 45
Val Val Thr Gly Gly Glu Val Lys Lys Leu Lys Arg Leu Thr Phe Gln
50 55 60
Phe Gly Asp Ala Arg Lys Asp Ser Ser Leu His Ile Thr Ala Ala Gln
65 70 75 80
Pro Gly Asp Thr Gly Leu Tyr Leu Cys Ala Gly Ser Asn Asp Tyr Lys
85 90 95
Leu Ser Phe Gly Ala Gly Thr Thr Val Thr Val Arg Ala Asn
100 105 110
<210> 472
<211> 936
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - TCRβ)
<400> 472
atgctgctgc ttctgctgct tctggggcca gcaggctccg ggcttggtgc tgtcgtctct 60
caacatccga gcagggttat ctgtaagagt ggaacctctg tgaagatcga gtgccgttcc 120
ctggactttc aggccacaac tatgttttgg tatcgtcagt tcccgaaaaa gagtctcatg 180
ctgatggcaa cttccaatga gggctccaag gccacatacg agcaaggcgt cgagaaggac 240
aagtttctca tcaaccatgc aagcctgacc ttgtccactc tgacagtgac cagtgcccat 300
cctgaagaca gcagcttcta catctgcagt gccgatagac tagcgggagg ggaagagacc 360
cagtacttcg ggccaggcac gcggctcctg gtgctcgagg acctgaaaaa cgtgttccca 420
cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca 480
ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 540
gggaaggagg tgcacagtgg ggtcagcaca gacccgcagc ccctcaagga gcagcccgcc 600
ctcaatgact ccagatactg cctgagcagc cgcctgaggg tctcggccac cttctggcag 660
aacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag 720
tggacccagg atagggccaa acctgtcacc cagatcgtca gcgccgaggc ctggggtaga 780
gcagactgtg gcttcacctc cgagtcttac cagcaagggg tcctgtctgc caccatcctc 840
tatgagatct tgctagggaa ggccaccttg tatgccgtgc tggtcagtgc cctcgtgctg 900
atggccatgg tcaagagaaa ggattccaga ggctag 936
<210> 473
<211> 311
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - TCRβ)
<400> 473
Met Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ser Gly Leu Gly
1 5 10 15
Ala Val Val Ser Gln His Pro Ser Arg Val Ile Cys Lys Ser Gly Thr
20 25 30
Ser Val Lys Ile Glu Cys Arg Ser Leu Asp Phe Gln Ala Thr Thr Met
35 40 45
Phe Trp Tyr Arg Gln Phe Pro Lys Lys Ser Leu Met Leu Met Ala Thr
50 55 60
Ser Asn Glu Gly Ser Lys Ala Thr Tyr Glu Gln Gly Val Glu Lys Asp
65 70 75 80
Lys Phe Leu Ile Asn His Ala Ser Leu Thr Leu Ser Thr Leu Thr Val
85 90 95
Thr Ser Ala His Pro Glu Asp Ser Ser Phe Tyr Ile Cys Ser Ala Asp
100 105 110
Arg Leu Ala Gly Gly Glu Glu Thr Gln Tyr Phe Gly Pro Gly Thr Arg
115 120 125
Leu Leu Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala
130 135 140
Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr
145 150 155 160
Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser
165 170 175
Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190
Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu
195 200 205
Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn
210 215 220
His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu
225 230 235 240
Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu
245 250 255
Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln
260 265 270
Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala
275 280 285
Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val
290 295 300
Lys Arg Lys Asp Ser Arg Gly
305 310
<210> 474
<211> 117
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 - TCRβ)
<400> 474
Gly Ala Val Val Ser Gln His Pro Ser Arg Val Ile Cys Lys Ser Gly
1 5 10 15
Thr Ser Val Lys Ile Glu Cys Arg Ser Leu Asp Phe Gln Ala Thr Thr
20 25 30
Met Phe Trp Tyr Arg Gln Phe Pro Lys Lys Ser Leu Met Leu Met Ala
35 40 45
Thr Ser Asn Glu Gly Ser Lys Ala Thr Tyr Glu Gln Gly Val Glu Lys
50 55 60
Asp Lys Phe Leu Ile Asn His Ala Ser Leu Thr Leu Ser Thr Leu Thr
65 70 75 80
Val Thr Ser Ala His Pro Glu Asp Ser Ser Phe Tyr Ile Cys Ser Ala
85 90 95
Asp Arg Leu Ala Gly Gly Glu Glu Thr Gln Tyr Phe Gly Pro Gly Thr
100 105 110
Arg Leu Leu Val Leu
115
<210> 475
<211> 1478
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 -
TCRβ-P2A-TCRα 片段)
<400> 475
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgctgctt cttctcctcc 60
ttctcggacc tgctggatct ggattaggag ctgttgtgtc tcagcaccct tctagagtga 120
tctgcaaaag cggcaccagc gtgaagatcg agtgtagaag cctggacttt caggccacaa 180
ccatgttctg gtataggcag ttccccaaga agagcctgat gctgatggcc acctctaatg 240
agggcagcaa agccacatat gaacagggag tggagaagga caagttcctg atcaaccacg 300
cctctctgac cctgtctacc ctgacagtta catctgccca ccctgaggat agcagctttt 360
acatctgtag cgccgacaga cttgctggag gagaggaaac acagtacttt ggccctggca 420
ccagactgtt agtgttagag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atggtgctga agttctctgt ctcgatcctg tggatccagc 1080
ttgcttgggt gtctacacag ctgctggaac agtctcctca gtttctgagc attcaggaag 1140
gcgagaatct gaccgtgtac tgcaacagca gcagcgtgtt tagcagctta cagtggtaca 1200
gacaggagcc tggagaagga ccagtgttac tggtgacagt ggtgacagga ggagaagtga 1260
agaagctgaa gagactgacc ttccagttcg gcgatgccag aaaggatagc tctctgcaca 1320
tcacagctgc tcaacctgga gatacaggcc tgtatctgtg tgccggcagc aatgactata 1380
agctgagctt tggagccgga acaaccgtga cagtgagagc caatatccag aaccccgatc 1440
ctgctgtgta ccagctgcgg gacagcaaga gcagcgac 1478
<210> 476
<211> 491
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR17 -
TCRβ-P2A-TCRα 片段)
<400> 476
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Leu Leu Leu
1 5 10 15
Leu Leu Leu Leu Gly Pro Ala Gly Ser Gly Leu Gly Ala Val Val Ser
20 25 30
Gln His Pro Ser Arg Val Ile Cys Lys Ser Gly Thr Ser Val Lys Ile
35 40 45
Glu Cys Arg Ser Leu Asp Phe Gln Ala Thr Thr Met Phe Trp Tyr Arg
50 55 60
Gln Phe Pro Lys Lys Ser Leu Met Leu Met Ala Thr Ser Asn Glu Gly
65 70 75 80
Ser Lys Ala Thr Tyr Glu Gln Gly Val Glu Lys Asp Lys Phe Leu Ile
85 90 95
Asn His Ala Ser Leu Thr Leu Ser Thr Leu Thr Val Thr Ser Ala His
100 105 110
Pro Glu Asp Ser Ser Phe Tyr Ile Cys Ser Ala Asp Arg Leu Ala Gly
115 120 125
Gly Glu Glu Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Leu Val Leu
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Val Leu Lys Phe Ser Val
340 345 350
Ser Ile Leu Trp Ile Gln Leu Ala Trp Val Ser Thr Gln Leu Leu Glu
355 360 365
Gln Ser Pro Gln Phe Leu Ser Ile Gln Glu Gly Glu Asn Leu Thr Val
370 375 380
Tyr Cys Asn Ser Ser Ser Val Phe Ser Ser Leu Gln Trp Tyr Arg Gln
385 390 395 400
Glu Pro Gly Glu Gly Pro Val Leu Leu Val Thr Val Val Thr Gly Gly
405 410 415
Glu Val Lys Lys Leu Lys Arg Leu Thr Phe Gln Phe Gly Asp Ala Arg
420 425 430
Lys Asp Ser Ser Leu His Ile Thr Ala Ala Gln Pro Gly Asp Thr Gly
435 440 445
Leu Tyr Leu Cys Ala Gly Ser Asn Asp Tyr Lys Leu Ser Phe Gly Ala
450 455 460
Gly Thr Thr Val Thr Val Arg Ala Asn Ile Gln Asn Pro Asp Pro Ala
465 470 475 480
Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490
<210> 477
<211> 825
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - TCRα)
<400> 477
atgaagacat ttgctggatt ttcgttcctg tttttgtggc tgcagctgga ctgtatgagt 60
agaggagagg atgtggagca gagtcttttc ctgagtgtcc gagagggaga cagctccgtt 120
ataaactgca cttacacaga cagctcctcc acctacttat actggtataa gcaagaacct 180
ggagcaggtc tccagttgct gacgtatatt ttttcaaata tggacatgaa acaagaccaa 240
agactcactg ttctattgaa taaaaaggat aaacatctgt ctctgcgcat tgcagacacc 300
cagactgggg actcagctat ctacttctgt gcagtacttc tggataacca gggaggaaag 360
cttatcttcg gacagggaac ggagttatct gtgaaaccca atatccagaa ccctgaccct 420
gccgtgtacc agctgagaga ctctaaatcc agtgacaagt ctgtctgcct attcaccgat 480
tttgattctc aaacaaatgt gtcacaaagt aaggattctg atgtgtatat cacagacaaa 540
actgtgctag acatgaggtc tatggacttc aagagcaaca gtgctgtggc ctggagcaac 600
aaatctgact ttgcatgtgc aaacgccttc aacaacagca ttattccaga agacaccttc 660
ttccccagcc cagaaagttc ctgtgatgtc aagctggtcg agaaaagctt tgaaacagat 720
acgaacctaa actttcaaaa cctgtcagtg attgggttcc gaatcctcct cctgaaagtg 780
gccgggttta atctgctcat gacgctgcgg ctgtggtcca gctga 825
<210> 478
<211> 274
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - TCRα)
<400> 478
Met Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu
1 5 10 15
Asp Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser
20 25 30
Val Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser
35 40 45
Ser Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu
50 55 60
Gln Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln
65 70 75 80
Arg Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg
85 90 95
Ile Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Val
100 105 110
Leu Leu Asp Asn Gln Gly Gly Lys Leu Ile Phe Gly Gln Gly Thr Glu
115 120 125
Leu Ser Val Lys Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln
130 135 140
Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp
145 150 155 160
Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr
165 170 175
Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser
180 185 190
Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn
195 200 205
Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro
210 215 220
Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp
225 230 235 240
Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu
245 250 255
Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp
260 265 270
Ser Ser
<210> 479
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - TCR Vα)
<400> 479
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Val Leu Leu Asp Asn Gln
85 90 95
Gly Gly Lys Leu Ile Phe Gly Gln Gly Thr Glu Leu Ser Val Lys Pro
100 105 110
Asn
<210> 480
<211> 933
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - TCRβ)
<400> 480
atgggaatca ggctcctgtg tcgtgtggcc ttttgtttcc tggctgtagg cctcgtagat 60
gtgaaagtaa cccagagctc gagatatcta gtcaaaagga cgggagagaa agtttttctg 120
gaatgtgtcc aggatatgga ccatgaaaat atgttctggt atcgacaaga cccaggtctg 180
gggctacggc tgatctattt ctcatatgat gttaaaatga aagaaaaagg agatattcct 240
gaggggtaca gtgtctctag agagaagaag gagcgcttct ccctgattct ggagtccgcc 300
agcaccaacc agacatctat gtacctctgt gccagcaggg gtctgtccac agatacgcag 360
tattttggcc caggcacccg gctgacagtg ctcgaggacc tgaaaaacgt gttcccaccc 420
gaggtcgctg tgtttgagcc atcagaagca gagatctccc acacccaaaa ggccacactg 480
gtgtgcctgg ccacaggctt ctaccccgac cacgtggagc tgagctggtg ggtgaatggg 540
aaggaggtgc acagtggggt cagcacagac ccgcagcccc tcaaggagca gcccgccctc 600
aatgactcca gatactgcct gagcagccgc ctgagggtct cggccacctt ctggcagaac 660
ccccgcaacc acttccgctg tcaagtccag ttctacgggc tctcggagaa tgacgagtgg 720
acccaggata gggccaaacc tgtcacccag atcgtcagcg ccgaggcctg gggtagagca 780
gactgtggct tcacctccga gtcttaccag caaggggtcc tgtctgccac catcctctat 840
gagatcttgc tagggaaggc caccttgtat gccgtgctgg tcagtgccct cgtgctgatg 900
gccatggtca agagaaagga ttccagaggc tag 933
<210> 481
<211> 310
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - TCRβ)
<400> 481
Met Gly Ile Arg Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val
1 5 10 15
Gly Leu Val Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys
20 25 30
Arg Thr Gly Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His
35 40 45
Glu Asn Met Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu
50 55 60
Ile Tyr Phe Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro
65 70 75 80
Glu Gly Tyr Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile
85 90 95
Leu Glu Ser Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser
100 105 110
Arg Gly Leu Ser Thr Asp Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu
115 120 125
Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val
130 135 140
Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu
145 150 155 160
Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp
165 170 175
Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln
180 185 190
Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser
195 200 205
Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His
210 215 220
Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp
225 230 235 240
Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala
245 250 255
Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly
260 265 270
Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr
275 280 285
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys
290 295 300
Arg Lys Asp Ser Arg Gly
305 310
<210> 482
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 - TCR Vβ)
<400> 482
Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly
1 5 10 15
Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe
35 40 45
Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr
50 55 60
Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser
65 70 75 80
Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Arg Gly Leu
85 90 95
Ser Thr Asp Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
<210> 483
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 -
TCRβ-P2A-TCRα 片段)
<400> 483
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcatc agactccttt 60
gcagggtggc cttttgcttt ctggctgtgg gattagtgga cgtgaaggtt acccagagca 120
gcagatatct ggtgaagaga accggcgaga aggtgttcct ggaatgtgtg caggatatgg 180
accacgagaa catgttctgg tacagacagg accctggact gggactgaga ctgatctact 240
tcagctacga cgtgaagatg aaggagaagg gcgatatccc tgagggctac agcgtgagca 300
gagagaaaaa ggagaggttc agcctgattc tggaaagcgc cagcacaaat cagaccagca 360
tgtacctgtg cgcctctaga ggactgtcta ccgataccca gtatttcgga cctggaacaa 420
gactgacagt gctggaggac ctgaagaacg tgttcccccc agaggtggcc gtgttcgagc 480
ctagcgaggc cgagatcagc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
tttaccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cacagcggcg 600
tctgcaccga cccccagccc ctgaaagagc agcccgccct gaacgacagc cggtactgtc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac cgggccaagc 780
ccgtgaccca gatcgtgtct gctgaggcct ggggcagagc cgattgcggc ttcaccagcg 840
agagctacca gcagggcgtg ctgagcgcca ccatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtccgccc tggtgctgat ggccatggtc aagcggaagg 960
acagccgggg cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg aagacctttg ccggattctc cttcctgttc ctgtggctgc 1080
agctggattg tatgagcaga ggcgaagatg tggaacagag cctgtttctg agcgtgagag 1140
agggagatag cagcgtgatc aattgcacct acaccgattc tagcagcacc tacctgtact 1200
ggtacaagca ggaacctgga gccggattac aactgctgac ctacatcttc agcaacatgg 1260
acatgaagca ggaccagaga ctgaccgtgc tgctgaacaa gaaggacaag cacctgagcc 1320
tgagaattgc cgatacacag acaggagata gcgccatcta cttctgtgct gtgctgctgg 1380
acaatcaggg cggaaagctg atctttggac agggaacaga gctgtctgtg aagcctaaca 1440
tccagaaccc tgatcctgcc gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 484
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR18 -
TCRβ-P2A-TCRα 片段)
<400> 484
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Ile Arg
1 5 10 15
Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val Gly Leu Val Asp
20 25 30
Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly Glu
35 40 45
Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met Phe
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe Ser
65 70 75 80
Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr Ser
85 90 95
Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser Ala
100 105 110
Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Arg Gly Leu Ser
115 120 125
Thr Asp Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Leu Glu
130 135 140
Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser
145 150 155 160
Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala
165 170 175
Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
180 185 190
Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu
195 200 205
Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg
210 215 220
Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln
225 230 235 240
Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg
245 250 255
Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala
260 265 270
Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser Ala
275 280 285
Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val
290 295 300
Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Ser
305 310 315 320
Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly
325 330 335
Asp Val Glu Glu Asn Pro Gly Pro Met Lys Thr Phe Ala Gly Phe Ser
340 345 350
Phe Leu Phe Leu Trp Leu Gln Leu Asp Cys Met Ser Arg Gly Glu Asp
355 360 365
Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp Ser Ser Val
370 375 380
Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu Tyr Trp Tyr
385 390 395 400
Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr Ile Phe Ser
405 410 415
Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu Leu Asn Lys
420 425 430
Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln Thr Gly Asp
435 440 445
Ser Ala Ile Tyr Phe Cys Ala Val Leu Leu Asp Asn Gln Gly Gly Lys
450 455 460
Leu Ile Phe Gly Gln Gly Thr Glu Leu Ser Val Lys Pro Asn Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 485
<211> 822
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - TCRα)
<400> 485
atgctcctgt tgctcatacc agtgctgggg atgatttttg ccctgagaga tgccagagcc 60
cagtctgtga gccagcataa ccaccacgta attctctctg aagcagcctc actggagttg 120
ggatgcaact attcctatgg tggaactgtt aatctcttct ggtatgtcca gtaccctggt 180
caacaccttc agcttctcct caagtacttt tcaggggatc cactggttaa aggcatcaag 240
ggctttgagg ctgaatttat aaagagtaaa ttctccttta atctgaggaa accctctgtg 300
cagtggagtg acacagctga gtacttctgt gccgtgaatg atccaagcga ctacaagctc 360
agctttggag ccggaaccac agtaactgta agagcaaata tccagaaccc tgaccctgcc 420
gtgtaccagc tgagagactc taaatccagt gacaagtctg tctgcctatt caccgatttt 480
gattctcaaa caaatgtgtc acaaagtaag gattctgatg tgtatatcac agacaaaact 540
gtgctagaca tgaggtctat ggacttcaag agcaacagtg ctgtggcctg gagcaacaaa 600
tctgactttg catgtgcaaa cgccttcaac aacagcatta ttccagaaga caccttcttc 660
cccagcccag aaagttcctg tgatgtcaag ctggtcgaga aaagctttga aacagatacg 720
aacctaaact ttcaaaacct gtcagtgatt gggttccgaa tcctcctcct gaaagtggcc 780
gggtttaatc tgctcatgac gctgcggctg tggtccagct ga 822
<210> 486
<211> 273
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - TCRα)
<400> 486
Met Leu Leu Leu Leu Ile Pro Val Leu Gly Met Ile Phe Ala Leu Arg
1 5 10 15
Asp Ala Arg Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu
20 25 30
Ser Glu Ala Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly
35 40 45
Thr Val Asn Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln
50 55 60
Leu Leu Leu Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys
65 70 75 80
Gly Phe Glu Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg
85 90 95
Lys Pro Ser Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val
100 105 110
Asn Asp Pro Ser Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val
115 120 125
Thr Val Arg Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu
130 135 140
Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe
145 150 155 160
Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile
165 170 175
Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn
180 185 190
Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala
195 200 205
Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu
210 215 220
Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr
225 230 235 240
Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu
245 250 255
Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser
260 265 270
Ser
<210> 487
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - TCR Vα)
<400> 487
Ala Gln Ser Val Ser Gln His Asn His His Val Ile Leu Ser Glu Ala
1 5 10 15
Ala Ser Leu Glu Leu Gly Cys Asn Tyr Ser Tyr Gly Gly Thr Val Asn
20 25 30
Leu Phe Trp Tyr Val Gln Tyr Pro Gly Gln His Leu Gln Leu Leu Leu
35 40 45
Lys Tyr Phe Ser Gly Asp Pro Leu Val Lys Gly Ile Lys Gly Phe Glu
50 55 60
Ala Glu Phe Ile Lys Ser Lys Phe Ser Phe Asn Leu Arg Lys Pro Ser
65 70 75 80
Val Gln Trp Ser Asp Thr Ala Glu Tyr Phe Cys Ala Val Asn Asp Pro
85 90 95
Ser Asp Tyr Lys Leu Ser Phe Gly Ala Gly Thr Thr Val Thr Val Arg
100 105 110
Ala Asn
<210> 488
<211> 930
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - TCRβ)
<400> 488
atgagcaacc aggtgctctg ctgtgtggtc ctttgtttcc tgggagcaaa caccgtggat 60
ggtggaatca ctcagtcccc aaagtacctg ttcagaaagg aaggacagaa tgtgaccctg 120
agttgtgaac agaatttgaa ccacgatgcc atgtactggt accgacagga cccagggcaa 180
gggctgagat tgatctacta ctcacagata gtaaatgact ttcagaaagg agatatagct 240
gaagggtaca gcgtctctcg ggagaagaag gaatcctttc ctctcactgt gacatcggcc 300
caaaagaacc cgacagcttt ctatctctgt gccagtagga gcgaccgcaa tgagcagttc 360
ttcgggccag ggacacggct caccgtgcta gaggacctga aaaacgtgtt cccacccgag 420
gtcgctgtgt ttgagccatc agaagcagag atctcccaca cccaaaaggc cacactggtg 480
tgcctggcca caggcttcta ccccgaccac gtggagctga gctggtgggt gaatgggaag 540
gaggtgcaca gtggggtcag cacagacccg cagcccctca aggagcagcc cgccctcaat 600
gactccagat actgcctgag cagccgcctg agggtctcgg ccaccttctg gcagaacccc 660
cgcaaccact tccgctgtca agtccagttc tacgggctct cggagaatga cgagtggacc 720
caggataggg ccaaacctgt cacccagatc gtcagcgccg aggcctgggg tagagcagac 780
tgtggcttca cctccgagtc ttaccagcaa ggggtcctgt ctgccaccat cctctatgag 840
atcttgctag ggaaggccac cttgtatgcc gtgctggtca gtgccctcgt gctgatggcc 900
atggtcaaga gaaaggattc cagaggctag 930
<210> 489
<211> 309
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - TCRβ)
<400> 489
Met Ser Asn Gln Val Leu Cys Cys Val Val Leu Cys Phe Leu Gly Ala
1 5 10 15
Asn Thr Val Asp Gly Gly Ile Thr Gln Ser Pro Lys Tyr Leu Phe Arg
20 25 30
Lys Glu Gly Gln Asn Val Thr Leu Ser Cys Glu Gln Asn Leu Asn His
35 40 45
Asp Ala Met Tyr Trp Tyr Arg Gln Asp Pro Gly Gln Gly Leu Arg Leu
50 55 60
Ile Tyr Tyr Ser Gln Ile Val Asn Asp Phe Gln Lys Gly Asp Ile Ala
65 70 75 80
Glu Gly Tyr Ser Val Ser Arg Glu Lys Lys Glu Ser Phe Pro Leu Thr
85 90 95
Val Thr Ser Ala Gln Lys Asn Pro Thr Ala Phe Tyr Leu Cys Ala Ser
100 105 110
Arg Ser Asp Arg Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr
115 120 125
Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe
130 135 140
Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val
145 150 155 160
Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp
165 170 175
Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro
180 185 190
Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser
195 200 205
Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe
210 215 220
Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr
225 230 235 240
Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp
245 250 255
Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val
260 265 270
Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu
275 280 285
Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg
290 295 300
Lys Asp Ser Arg Gly
305
<210> 490
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 - TCR Vβ)
<400> 490
Asp Gly Gly Ile Thr Gln Ser Pro Lys Tyr Leu Phe Arg Lys Glu Gly
1 5 10 15
Gln Asn Val Thr Leu Ser Cys Glu Gln Asn Leu Asn His Asp Ala Met
20 25 30
Tyr Trp Tyr Arg Gln Asp Pro Gly Gln Gly Leu Arg Leu Ile Tyr Tyr
35 40 45
Ser Gln Ile Val Asn Asp Phe Gln Lys Gly Asp Ile Ala Glu Gly Tyr
50 55 60
Ser Val Ser Arg Glu Lys Lys Glu Ser Phe Pro Leu Thr Val Thr Ser
65 70 75 80
Ala Gln Lys Asn Pro Thr Ala Phe Tyr Leu Cys Ala Ser Arg Ser Asp
85 90 95
Arg Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
<210> 491
<211> 1487
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 -
TCRβ-P2A-TCRα 片段)
<400> 491
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgagcaac caggtcttgt 60
gctgtgtggt gctgtgcttt cttggcgcca atacagtgga tggcggcatt acacaaagcc 120
ccaagtacct gttcaggaaa gagggccaga atgtgacact gagctgtgag cagaacctga 180
atcacgacgc catgtactgg tacagacagg atccaggaca aggactgagg ctgatctact 240
actcccagat cgtgaacgac ttccagaagg gcgatattgc cgagggctat agcgtgagca 300
gagagaagaa agagagcttc ccactgacag tgacatctgc ccagaagaac cctaccgcct 360
tctacctgtg tgcctctaga agcgacagaa atgagcagtt ttttggccct ggcacaagac 420
tgaccgtgct ggaggacctg aagaacgtgt tccccccaga ggtggccgtg ttcgagccta 480
gcgaggccga gatcagccac acccagaaag ccaccctcgt gtgcctggcc accggctttt 540
accccgacca cgtggaactg tcttggtggg tcaacggcaa agaggtgcac agcggcgtct 600
gcaccgaccc ccagcccctg aaagagcagc ccgccctgaa cgacagccgg tactgtctga 660
gcagcagact gagagtgtcc gccaccttct ggcagaaccc ccggaaccac ttcagatgcc 720
aggtgcagtt ctacggcctg agcgagaacg acgagtggac ccaggaccgg gccaagcccg 780
tgacccagat cgtgtctgct gaggcctggg gcagagccga ttgcggcttc accagcgaga 840
gctaccagca gggcgtgctg agcgccacca tcctgtacga gatcctgctg ggcaaggcca 900
ccctgtacgc cgtgctggtg tccgccctgg tgctgatggc catggtcaag cggaaggaca 960
gccggggcgg ttccggagcc acgaacttct ctctgttaaa gcaagcagga gacgtggaag 1020
aaaaccccgg tcccatgctg cttctcctga tccctgttct gggcatgatc tttgccctga 1080
gagatgctag agcccagtct gtttctcagc acaaccatca cgtgatcctg tctgaagctg 1140
cctctctgga actgggctgc aactactctt atggcggaac cgttaacctg ttctggtatg 1200
tgcagtaccc tggacagcat ctgcagctgc tgctgaagta cttctctggc gatcctctgg 1260
tgaaaggcat taagggcttt gaggccgagt tcatcaagtc caagttcagc ttcaacctgc 1320
ggaagccctc tgtgcaatgg agcgatacag ccgagtactt ttgtgccgtg aatgatccta 1380
gcgactacaa gctgagcttt ggagccggca caacagtgac cgtgagagcc aatatccaga 1440
atcctgatcc tgctgtgtac cagctgcggg acagcaagag cagcgac 1487
<210> 492
<211> 494
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A2 KRAS TCR19 -
TCRβ-P2A-TCRα 片段)
<400> 492
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Ser Asn Gln
1 5 10 15
Val Leu Cys Cys Val Val Leu Cys Phe Leu Gly Ala Asn Thr Val Asp
20 25 30
Gly Gly Ile Thr Gln Ser Pro Lys Tyr Leu Phe Arg Lys Glu Gly Gln
35 40 45
Asn Val Thr Leu Ser Cys Glu Gln Asn Leu Asn His Asp Ala Met Tyr
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Gln Gly Leu Arg Leu Ile Tyr Tyr Ser
65 70 75 80
Gln Ile Val Asn Asp Phe Gln Lys Gly Asp Ile Ala Glu Gly Tyr Ser
85 90 95
Val Ser Arg Glu Lys Lys Glu Ser Phe Pro Leu Thr Val Thr Ser Ala
100 105 110
Gln Lys Asn Pro Thr Ala Phe Tyr Leu Cys Ala Ser Arg Ser Asp Arg
115 120 125
Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu Glu Asp
130 135 140
Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser Glu
145 150 155 160
Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala Thr
165 170 175
Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly Lys
180 185 190
Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu Gln
195 200 205
Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg Val
210 215 220
Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln Val
225 230 235 240
Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg Ala
245 250 255
Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala Asp
260 265 270
Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr
275 280 285
Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu
290 295 300
Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Ser Arg
305 310 315 320
Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp
325 330 335
Val Glu Glu Asn Pro Gly Pro Met Leu Leu Leu Leu Ile Pro Val Leu
340 345 350
Gly Met Ile Phe Ala Leu Arg Asp Ala Arg Ala Gln Ser Val Ser Gln
355 360 365
His Asn His His Val Ile Leu Ser Glu Ala Ala Ser Leu Glu Leu Gly
370 375 380
Cys Asn Tyr Ser Tyr Gly Gly Thr Val Asn Leu Phe Trp Tyr Val Gln
385 390 395 400
Tyr Pro Gly Gln His Leu Gln Leu Leu Leu Lys Tyr Phe Ser Gly Asp
405 410 415
Pro Leu Val Lys Gly Ile Lys Gly Phe Glu Ala Glu Phe Ile Lys Ser
420 425 430
Lys Phe Ser Phe Asn Leu Arg Lys Pro Ser Val Gln Trp Ser Asp Thr
435 440 445
Ala Glu Tyr Phe Cys Ala Val Asn Asp Pro Ser Asp Tyr Lys Leu Ser
450 455 460
Phe Gly Ala Gly Thr Thr Val Thr Val Arg Ala Asn Ile Gln Asn Pro
465 470 475 480
Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490
<210> 493
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12 CDR1α)
<400> 493
Ser Ser Tyr Ser Pro Ser
1 5
<210> 494
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12 CDR2α)
<400> 494
Tyr Thr Ser Ala Ala Thr Leu Val
1 5
<210> 495
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12 CDR3α)
<400> 495
Cys Val Val Ser Asp Met Val Ser Gly Tyr Ala Leu Asn Phe
1 5 10
<210> 496
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12 CDR1β)
<400> 496
Met Gly His Asp Lys
1 5
<210> 497
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12 CDR2β)
<400> 497
Ser Tyr Gly Val Asn Ser
1 5
<210> 498
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12 CDR3β)
<400> 498
Cys Ala Ser Ser Glu Ser Leu Tyr Asn Glu Gln Phe Phe
1 5 10
<210> 499
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12
TCRβ-P2A-TCRα 片段)
<400> 499
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgaccatt cgactgctgt 60
gctacatggg cttctacttc ctgggagctg gactgatgga agccgacatt taccaaaccc 120
ccagatacct ggtgatcgga acaggcaaga agatcaccct ggagtgtagc cagacaatgg 180
gacacgacaa gatgtactgg taccagcagg atcctggaat ggaactgcac ctgatccact 240
acagctatgg cgtgaacagc acagagaaag gcgatctgag ctctgagtct acagtgagca 300
gaatcaggac cgagcacttc ccactgacac tggaatctgc tagacctagc cacacaagcc 360
agtacctttg tgcctctagc gagtctctgt acaacgagca gttctttgga cctggcacca 420
gactgacagt gcttgaagac ctgaagaacg tgttcccccc agaggtggcc gtgttcgagc 480
ctagcgaggc cgagatcagc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
tttaccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cacagcggcg 600
tctgcaccga cccccagccc ctgaaagagc agcccgccct gaacgacagc cggtactgtc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac cgggccaagc 780
ccgtgaccca gatcgtgtct gctgaggcct ggggcagagc cgattgcggc ttcaccagcg 840
agagctacca gcagggcgtg ctgagcgcca ccatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtccgccc tggtgctgat ggccatggtc aagcggaagg 960
acagccgggg cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg ctgcttcttc tcgtccctgt cctggaggtg atctttacac 1080
tgggaggcac aagagctcag tctgttacac agctggattc tcacgtgagc gtgtctgagg 1140
gaacacctgt gctgctgaga tgcaactact cttctagcta ctctcctagc ctgttctggt 1200
acgtgcagca ccccaataag ggcctgcaac ttctgctgaa atacacatct gccgctacac 1260
tggtgaaggg catcaacggc tttgaagccg agttcaagaa gagcgagacc tcttttcacc 1320
tgaccaagcc ttctgcccac atgagcgatg ctgccgagta cttttgtgtg gtgagcgata 1380
tggttagcgg atatgccctg aacttcggca agggaacaag cctgctggtt acaccacaca 1440
tccagaatcc tgatcctgct gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 500
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12
TCRβ-P2A-TCRα 片段)
<400> 500
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Thr Ile Arg
1 5 10 15
Leu Leu Cys Tyr Met Gly Phe Tyr Phe Leu Gly Ala Gly Leu Met Glu
20 25 30
Ala Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile Gly Thr Gly Lys
35 40 45
Lys Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His Asp Lys Met Tyr
50 55 60
Trp Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu Ile His Tyr Ser
65 70 75 80
Tyr Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser Ser Glu Ser Thr
85 90 95
Val Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr Leu Glu Ser Ala
100 105 110
Arg Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser Ser Glu Ser Leu
115 120 125
Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu Glu
130 135 140
Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser
145 150 155 160
Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala
165 170 175
Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
180 185 190
Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu
195 200 205
Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg
210 215 220
Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln
225 230 235 240
Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg
245 250 255
Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala
260 265 270
Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser Ala
275 280 285
Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val
290 295 300
Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Ser
305 310 315 320
Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly
325 330 335
Asp Val Glu Glu Asn Pro Gly Pro Met Leu Leu Leu Leu Val Pro Val
340 345 350
Leu Glu Val Ile Phe Thr Leu Gly Gly Thr Arg Ala Gln Ser Val Thr
355 360 365
Gln Leu Asp Ser His Val Ser Val Ser Glu Gly Thr Pro Val Leu Leu
370 375 380
Arg Cys Asn Tyr Ser Ser Ser Tyr Ser Pro Ser Leu Phe Trp Tyr Val
385 390 395 400
Gln His Pro Asn Lys Gly Leu Gln Leu Leu Leu Lys Tyr Thr Ser Ala
405 410 415
Ala Thr Leu Val Lys Gly Ile Asn Gly Phe Glu Ala Glu Phe Lys Lys
420 425 430
Ser Glu Thr Ser Phe His Leu Thr Lys Pro Ser Ala His Met Ser Asp
435 440 445
Ala Ala Glu Tyr Phe Cys Val Val Ser Asp Met Val Ser Gly Tyr Ala
450 455 460
Leu Asn Phe Gly Lys Gly Thr Ser Leu Leu Val Thr Pro His Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 501
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12 Vβ)
<400> 501
Asp Ile Tyr Gln Thr Pro Arg Tyr Leu Val Ile Gly Thr Gly Lys Lys
1 5 10 15
Ile Thr Leu Glu Cys Ser Gln Thr Met Gly His Asp Lys Met Tyr Trp
20 25 30
Tyr Gln Gln Asp Pro Gly Met Glu Leu His Leu Ile His Tyr Ser Tyr
35 40 45
Gly Val Asn Ser Thr Glu Lys Gly Asp Leu Ser Ser Glu Ser Thr Val
50 55 60
Ser Arg Ile Arg Thr Glu His Phe Pro Leu Thr Leu Glu Ser Ala Arg
65 70 75 80
Pro Ser His Thr Ser Gln Tyr Leu Cys Ala Ser Ser Glu Ser Leu Tyr
85 90 95
Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu Thr Val Leu
100 105 110
<210> 502
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_12 Vα)
<400> 502
Ala Gln Ser Val Thr Gln Leu Asp Ser His Val Ser Val Ser Glu Gly
1 5 10 15
Thr Pro Val Leu Leu Arg Cys Asn Tyr Ser Ser Ser Tyr Ser Pro Ser
20 25 30
Leu Phe Trp Tyr Val Gln His Pro Asn Lys Gly Leu Gln Leu Leu Leu
35 40 45
Lys Tyr Thr Ser Ala Ala Thr Leu Val Lys Gly Ile Asn Gly Phe Glu
50 55 60
Ala Glu Phe Lys Lys Ser Glu Thr Ser Phe His Leu Thr Lys Pro Ser
65 70 75 80
Ala His Met Ser Asp Ala Ala Glu Tyr Phe Cys Val Val Ser Asp Met
85 90 95
Val Ser Gly Tyr Ala Leu Asn Phe Gly Lys Gly Thr Ser Leu Leu Val
100 105 110
Thr Pro His
115
<210> 503
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21 CDR1α)
<400> 503
Asp Ser Ser Ser Thr Tyr
1 5
<210> 504
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21 CDR2α)
<400> 504
Ile Phe Ser Asn Met Asp Met
1 5
<210> 505
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21 CDR3α)
<400> 505
Cys Ala Glu Pro Ile Ile Gly Gly Asn Thr Pro Leu Val Phe
1 5 10
<210> 506
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21 CDR1β)
<400> 506
Ser Gly His Val Ser
1 5
<210> 507
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21 CDR2β)
<400> 507
Phe Gln Asn Glu Ala Gln
1 5
<210> 508
<211> 19
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21 CDR3β)
<400> 508
Cys Ala Ser Ser Ser Glu Gly Leu Ala Gly Gly Pro Thr Ala Gly Glu
1 5 10 15
Leu Phe Phe
<210> 509
<211> 1514
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21
TCRβ-P2A-TCRα 片段)
<400> 509
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca agacttctct 60
gctgggtggt gcttggattt ctgggcacag atcatacagg agctggagtt agccagtctc 120
ctaggtacaa agtggccaag agaggacagg atgtggctct gagatgtgac cctattagcg 180
gacatgtgag cctgttttgg taccagcaag ctctgggaca aggacccgag tttctgacct 240
acttccagaa tgaagcccag ctggataaat ctggactgcc tagcgaccgg ttcttcgccg 300
aaagacctga aggatctgtt agcaccctga agattcagag aacacagcag gaggactctg 360
ccgtgtacct gtgtgcctct tcttctgaag gactggctgg aggacctaca gctggagaac 420
tgttttttgg agagggctct aggctgacag ttttggagga cctgaagaac gtgttccccc 480
cagaggtggc cgtgttcgag cctagcgagg ccgagatcag ccacacccag aaagccaccc 540
tcgtgtgcct ggccaccggc ttttaccccg accacgtgga actgtcttgg tgggtcaacg 600
gcaaagaggt gcacagcggc gtctgcaccg acccccagcc cctgaaagag cagcccgccc 660
tgaacgacag ccggtactgt ctgagcagca gactgagagt gtccgccacc ttctggcaga 720
acccccggaa ccacttcaga tgccaggtgc agttctacgg cctgagcgag aacgacgagt 780
ggacccagga ccgggccaag cccgtgaccc agatcgtgtc tgctgaggcc tggggcagag 840
ccgattgcgg cttcaccagc gagagctacc agcagggcgt gctgagcgcc accatcctgt 900
acgagatcct gctgggcaag gccaccctgt acgccgtgct ggtgtccgcc ctggtgctga 960
tggccatggt caagcggaag gacagccggg gcggttccgg agccacgaac ttctctctgt 1020
taaagcaagc aggagacgtg gaagaaaacc ccggtcccat gaagaccttt gccggattct 1080
ccttcctgtt cctgtggctg cagctggatt gtatgagcag aggcgaagat gtggaacaga 1140
gcctgtttct gagcgtgaga gagggagata gcagcgtgat caattgcacc tacaccgatt 1200
ctagcagcac ctacctgtac tggtacaagc aggaacctgg agccggatta caactgctga 1260
cctacatctt cagcaacatg gacatgaagc aggaccagag actgaccgtg ctgctgaaca 1320
agaaggacaa gcacctgagc ctgagaattg ccgatacaca gacaggagat agcgccatct 1380
acttctgtgc cgagcctatc attggcggca atacacctct ggtgtttgga aagggcacaa 1440
ggctgtctgt gattgccaac atccagaatc ccgaccctgc tgtgtaccag ctgcgggaca 1500
gcaagagcag cgac 1514
<210> 510
<211> 503
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21
TCRβ-P2A-TCRα 片段)
<400> 510
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Thr Arg
1 5 10 15
Leu Leu Cys Trp Val Val Leu Gly Phe Leu Gly Thr Asp His Thr Gly
20 25 30
Ala Gly Val Ser Gln Ser Pro Arg Tyr Lys Val Ala Lys Arg Gly Gln
35 40 45
Asp Val Ala Leu Arg Cys Asp Pro Ile Ser Gly His Val Ser Leu Phe
50 55 60
Trp Tyr Gln Gln Ala Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr Phe
65 70 75 80
Gln Asn Glu Ala Gln Leu Asp Lys Ser Gly Leu Pro Ser Asp Arg Phe
85 90 95
Phe Ala Glu Arg Pro Glu Gly Ser Val Ser Thr Leu Lys Ile Gln Arg
100 105 110
Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Ser Glu
115 120 125
Gly Leu Ala Gly Gly Pro Thr Ala Gly Glu Leu Phe Phe Gly Glu Gly
130 135 140
Ser Arg Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu
145 150 155 160
Val Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys
165 170 175
Ala Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu
180 185 190
Leu Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr
195 200 205
Asp Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr
210 215 220
Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro
225 230 235 240
Arg Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn
245 250 255
Asp Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser
260 265 270
Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr
275 280 285
Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly
290 295 300
Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala
305 310 315 320
Met Val Lys Arg Lys Asp Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe
325 330 335
Ser Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met
340 345 350
Lys Thr Phe Ala Gly Phe Ser Phe Leu Phe Leu Trp Leu Gln Leu Asp
355 360 365
Cys Met Ser Arg Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val
370 375 380
Arg Glu Gly Asp Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser
385 390 395 400
Ser Thr Tyr Leu Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln
405 410 415
Leu Leu Thr Tyr Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg
420 425 430
Leu Thr Val Leu Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile
435 440 445
Ala Asp Thr Gln Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Pro
450 455 460
Ile Ile Gly Gly Asn Thr Pro Leu Val Phe Gly Lys Gly Thr Arg Leu
465 470 475 480
Ser Val Ile Ala Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu
485 490 495
Arg Asp Ser Lys Ser Ser Asp
500
<210> 511
<211> 119
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21 Vβ)
<400> 511
Gly Ala Gly Val Ser Gln Ser Pro Arg Tyr Lys Val Ala Lys Arg Gly
1 5 10 15
Gln Asp Val Ala Leu Arg Cys Asp Pro Ile Ser Gly His Val Ser Leu
20 25 30
Phe Trp Tyr Gln Gln Ala Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr
35 40 45
Phe Gln Asn Glu Ala Gln Leu Asp Lys Ser Gly Leu Pro Ser Asp Arg
50 55 60
Phe Phe Ala Glu Arg Pro Glu Gly Ser Val Ser Thr Leu Lys Ile Gln
65 70 75 80
Arg Thr Gln Gln Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Ser
85 90 95
Glu Gly Leu Ala Gly Gly Pro Thr Ala Gly Glu Leu Phe Phe Gly Glu
100 105 110
Gly Ser Arg Leu Thr Val Leu
115
<210> 512
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_220_21 Vα)
<400> 512
Gly Glu Asp Val Glu Gln Ser Leu Phe Leu Ser Val Arg Glu Gly Asp
1 5 10 15
Ser Ser Val Ile Asn Cys Thr Tyr Thr Asp Ser Ser Ser Thr Tyr Leu
20 25 30
Tyr Trp Tyr Lys Gln Glu Pro Gly Ala Gly Leu Gln Leu Leu Thr Tyr
35 40 45
Ile Phe Ser Asn Met Asp Met Lys Gln Asp Gln Arg Leu Thr Val Leu
50 55 60
Leu Asn Lys Lys Asp Lys His Leu Ser Leu Arg Ile Ala Asp Thr Gln
65 70 75 80
Thr Gly Asp Ser Ala Ile Tyr Phe Cys Ala Glu Pro Ile Ile Gly Gly
85 90 95
Asn Thr Pro Leu Val Phe Gly Lys Gly Thr Arg Leu Ser Val Ile Ala
100 105 110
Asn
<210> 513
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2 CDR1α)
<400> 513
Thr Ser Ile Asn Asn
1 5
<210> 514
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2 CDR2α)
<400> 514
Ile Arg Ser Asn Glu Arg Glu
1 5
<210> 515
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2 CDR3α)
<400> 515
Cys Ala Ser Ser Gly Gly Gly Ala Asp Gly Leu Thr Phe
1 5 10
<210> 516
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2 CDR1β)
<400> 516
Ser Gly His Arg Ser
1 5
<210> 517
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2 CDR2β)
<400> 517
Tyr Phe Ser Glu Thr Gln
1 5
<210> 518
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2 CDR3β)
<400> 518
Cys Ala Ser Ser Leu Gly Gly Ala Gly Glu Thr Gln Tyr Phe
1 5 10
<210> 519
<211> 1490
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2
TCRβ-P2A-TCRα 片段)
<400> 519
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggctct agactgttgt 60
gttgggttct gctgtgtctg cttggagctg gacctgtgaa agctggagtt acccagacac 120
ccagatatct gatcaagacc agaggacagc aggtgacact gagctgtagc cctattagcg 180
gccacagatc tgttagctgg tatcagcaaa caccaggaca gggactgcag ttcctgttcg 240
agtacttcag cgagacccag aggaataagg gcaattttcc aggcaggttt agcggcaggc 300
agttcagcaa ctctagaagc gagatgaacg tgagcaccct tgaattgggc gattctgccc 360
tgtacctgtg tgcctcttct ttaggaggag ctggagaaac ccagtacttt ggacctggca 420
caagactgct ggtgcttgag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atggagacac tgcttggcgt atcactggtg attctgtggc 1080
tgcaactggc tagagtgaac tctcagcagg gagaagagga tcctcaagct ctgagcattc 1140
aggaaggcga aaatgccacc atgaactgca gctacaagac cagcatcaac aacctgcagt 1200
ggtaccggca gaatagcgga agaggactgg ttcacctgat cctgatcagg agcaatgaaa 1260
gggagaagca cagcggcaga ctgagagtta ccctggatac cagcaagaag tctagcagcc 1320
tgctgattac agcctctaga gccgccgata cagccagcta cttttgtgcc tcttctggag 1380
gaggagctga tggacttaca tttggaaagg gcacccacct gatcatccag ccttacatcc 1440
agaaccctga tcctgccgtg taccagctgc gggacagcaa gagcagcgac 1490
<210> 520
<211> 495
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2
TCRβ-P2A-TCRα 片段)
<400> 520
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Ser Arg
1 5 10 15
Leu Leu Cys Trp Val Leu Leu Cys Leu Leu Gly Ala Gly Pro Val Lys
20 25 30
Ala Gly Val Thr Gln Thr Pro Arg Tyr Leu Ile Lys Thr Arg Gly Gln
35 40 45
Gln Val Thr Leu Ser Cys Ser Pro Ile Ser Gly His Arg Ser Val Ser
50 55 60
Trp Tyr Gln Gln Thr Pro Gly Gln Gly Leu Gln Phe Leu Phe Glu Tyr
65 70 75 80
Phe Ser Glu Thr Gln Arg Asn Lys Gly Asn Phe Pro Gly Arg Phe Ser
85 90 95
Gly Arg Gln Phe Ser Asn Ser Arg Ser Glu Met Asn Val Ser Thr Leu
100 105 110
Glu Leu Gly Asp Ser Ala Leu Tyr Leu Cys Ala Ser Ser Leu Gly Gly
115 120 125
Ala Gly Glu Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Leu Val Leu
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Glu Thr Leu Leu Gly Val
340 345 350
Ser Leu Val Ile Leu Trp Leu Gln Leu Ala Arg Val Asn Ser Gln Gln
355 360 365
Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly Glu Asn Ala
370 375 380
Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu Gln Trp Tyr
385 390 395 400
Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu Ile Arg Ser
405 410 415
Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr Leu Asp Thr
420 425 430
Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg Ala Ala Asp
435 440 445
Thr Ala Ser Tyr Phe Cys Ala Ser Ser Gly Gly Gly Ala Asp Gly Leu
450 455 460
Thr Phe Gly Lys Gly Thr His Leu Ile Ile Gln Pro Tyr Ile Gln Asn
465 470 475 480
Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 521
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2 Vβ)
<400> 521
Lys Ala Gly Val Thr Gln Thr Pro Arg Tyr Leu Ile Lys Thr Arg Gly
1 5 10 15
Gln Gln Val Thr Leu Ser Cys Ser Pro Ile Ser Gly His Arg Ser Val
20 25 30
Ser Trp Tyr Gln Gln Thr Pro Gly Gln Gly Leu Gln Phe Leu Phe Glu
35 40 45
Tyr Phe Ser Glu Thr Gln Arg Asn Lys Gly Asn Phe Pro Gly Arg Phe
50 55 60
Ser Gly Arg Gln Phe Ser Asn Ser Arg Ser Glu Met Asn Val Ser Thr
65 70 75 80
Leu Glu Leu Gly Asp Ser Ala Leu Tyr Leu Cys Ala Ser Ser Leu Gly
85 90 95
Gly Ala Gly Glu Thr Gln Tyr Phe Gly Pro Gly Thr Arg Leu Leu Val
100 105 110
Leu
<210> 522
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_2 Vα)
<400> 522
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Ser Ser Gly Gly Gly Ala
85 90 95
Asp Gly Leu Thr Phe Gly Lys Gly Thr His Leu Ile Ile Gln Pro Tyr
100 105 110
<210> 523
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3 CDR1α)
<400> 523
Asn Ser Ala Ser Asp Tyr
1 5
<210> 524
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3 CDR2α)
<400> 524
Ile Arg Ser Asn Met Asp Lys
1 5
<210> 525
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3 CDR3α)
<400> 525
Cys Ala Glu Asn Ile Thr Pro Pro Glu Gly Phe Lys Thr Ile Phe
1 5 10 15
<210> 526
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3 CDR1β)
<400> 526
Trp Asn His Asn Asn
1 5
<210> 527
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3 CDR2β)
<400> 527
Ser Tyr Gly Val Gln Asp
1 5
<210> 528
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3 CDR3β)
<400> 528
Cys Ala Ser Ser Gly Arg Gly Glu Thr Gly Glu Leu Phe Phe
1 5 10
<210> 529
<211> 1499
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3
TCRβ-P2A-TCRα 片段)
<400> 529
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca cggctgtttt 60
tctacgttgc cctttgtctg ctttgggctg gccatagaga tgccgagatt acccagagcc 120
ccagacacaa aattaccgag acaggaagac aggtgacact ggcctgtcac cagacatgga 180
accacaacaa catgttctgg tacaggcagg atctgggaca tggactgcgg ctgatccact 240
actcttatgg cgtgcaggat accaataaag gcgaagtgtc tgacggctac agcgtgagca 300
ggagcaatac cgaagatctg cctctgacac tggaatctgc tgcttcttct cagacaagcg 360
tgtacttctg cgcctcttct ggaagaggcg aaacaggaga gctgttcttt ggcgaaggct 420
ctagactgac agttctggag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atggccggca ttagagcact cttcatgtac ctgtggctgc 1080
aactggattg ggtgtctaga ggagagtctg tgggcctgca tcttcctaca ctgtctgttc 1140
aggaaggcga caatagcatc atcaattgcg cctacagcaa cagcgccagc gactacttca 1200
tctggtacaa gcaggagagc ggaaaaggac ctcagttcat catcgacatc cggagcaaca 1260
tggacaagag acagggacag agagtgaccg tgctgctgaa caagacagtg aaacatctga 1320
gcctgcagat tgccgctaca caacctggcg attctgccgt gtacttttgt gccgagaata 1380
tcacacctcc tgagggcttc aagaccatct ttggcgccgg aaccaggctg tttgttaagg 1440
ccaatatcca gaatcctgat cccgccgtgt accagctgcg ggacagcaag agcagcgac 1499
<210> 530
<211> 498
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3
TCRβ-P2A-TCRα 片段)
<400> 530
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Thr Arg
1 5 10 15
Leu Phe Phe Tyr Val Ala Leu Cys Leu Leu Trp Ala Gly His Arg Asp
20 25 30
Ala Glu Ile Thr Gln Ser Pro Arg His Lys Ile Thr Glu Thr Gly Arg
35 40 45
Gln Val Thr Leu Ala Cys His Gln Thr Trp Asn His Asn Asn Met Phe
50 55 60
Trp Tyr Arg Gln Asp Leu Gly His Gly Leu Arg Leu Ile His Tyr Ser
65 70 75 80
Tyr Gly Val Gln Asp Thr Asn Lys Gly Glu Val Ser Asp Gly Tyr Ser
85 90 95
Val Ser Arg Ser Asn Thr Glu Asp Leu Pro Leu Thr Leu Glu Ser Ala
100 105 110
Ala Ser Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser Ser Gly Arg Gly
115 120 125
Glu Thr Gly Glu Leu Phe Phe Gly Glu Gly Ser Arg Leu Thr Val Leu
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Ala Gly Ile Arg Ala Leu
340 345 350
Phe Met Tyr Leu Trp Leu Gln Leu Asp Trp Val Ser Arg Gly Glu Ser
355 360 365
Val Gly Leu His Leu Pro Thr Leu Ser Val Gln Glu Gly Asp Asn Ser
370 375 380
Ile Ile Asn Cys Ala Tyr Ser Asn Ser Ala Ser Asp Tyr Phe Ile Trp
385 390 395 400
Tyr Lys Gln Glu Ser Gly Lys Gly Pro Gln Phe Ile Ile Asp Ile Arg
405 410 415
Ser Asn Met Asp Lys Arg Gln Gly Gln Arg Val Thr Val Leu Leu Asn
420 425 430
Lys Thr Val Lys His Leu Ser Leu Gln Ile Ala Ala Thr Gln Pro Gly
435 440 445
Asp Ser Ala Val Tyr Phe Cys Ala Glu Asn Ile Thr Pro Pro Glu Gly
450 455 460
Phe Lys Thr Ile Phe Gly Ala Gly Thr Arg Leu Phe Val Lys Ala Asn
465 470 475 480
Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser
485 490 495
Ser Asp
<210> 531
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3 Vβ)
<400> 531
Asp Ala Glu Ile Thr Gln Ser Pro Arg His Lys Ile Thr Glu Thr Gly
1 5 10 15
Arg Gln Val Thr Leu Ala Cys His Gln Thr Trp Asn His Asn Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Leu Gly His Gly Leu Arg Leu Ile His Tyr
35 40 45
Ser Tyr Gly Val Gln Asp Thr Asn Lys Gly Glu Val Ser Asp Gly Tyr
50 55 60
Ser Val Ser Arg Ser Asn Thr Glu Asp Leu Pro Leu Thr Leu Glu Ser
65 70 75 80
Ala Ala Ser Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser Ser Gly Arg
85 90 95
Gly Glu Thr Gly Glu Leu Phe Phe Gly Glu Gly Ser Arg Leu Thr Val
100 105 110
Leu
<210> 532
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_3 Vα)
<400> 532
Gly Glu Ser Val Gly Leu His Leu Pro Thr Leu Ser Val Gln Glu Gly
1 5 10 15
Asp Asn Ser Ile Ile Asn Cys Ala Tyr Ser Asn Ser Ala Ser Asp Tyr
20 25 30
Phe Ile Trp Tyr Lys Gln Glu Ser Gly Lys Gly Pro Gln Phe Ile Ile
35 40 45
Asp Ile Arg Ser Asn Met Asp Lys Arg Gln Gly Gln Arg Val Thr Val
50 55 60
Leu Leu Asn Lys Thr Val Lys His Leu Ser Leu Gln Ile Ala Ala Thr
65 70 75 80
Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Glu Asn Ile Thr Pro
85 90 95
Pro Glu Gly Phe Lys Thr Ile Phe Gly Ala Gly Thr Arg Leu Phe Val
100 105 110
Lys Ala Asn
115
<210> 533
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4 CDR1α)
<400> 533
Thr Ser Ile Asn Asn
1 5
<210> 534
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4 CDR2α)
<400> 534
Ile Arg Ser Asn Glu Arg Glu
1 5
<210> 535
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4 CDR3α)
<400> 535
Cys Ser Gly Gly Ser Asn Tyr Lys Leu Thr Phe
1 5 10
<210> 536
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4 CDR1β)
<400> 536
Met Asp His Glu Asn
1 5
<210> 537
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4 CDR2β)
<400> 537
Ser Tyr Asp Val Lys Met
1 5
<210> 538
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4 CDR3β)
<400> 538
Cys Ala Ser Ser Leu Gly Arg Gly Gly Asn Thr Ile Tyr Phe
1 5 10
<210> 539
<211> 1478
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4
TCRβ-P2A-TCRα 片段)
<400> 539
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcatc agactccttt 60
gcagggtggc cttttgcttt ctggctgtgg gattagtgga cgtgaaggtt acccagagca 120
gcagatatct ggtgaagaga accggcgaga aggtgttcct ggaatgtgtg caggatatgg 180
accacgagaa catgttctgg tacagacagg accctggact gggactgaga ctgatctact 240
tcagctacga cgtgaagatg aaggagaagg gcgatatccc tgagggctac agcgtgagca 300
gagagaaaaa ggagaggttc agcctgattc tggaaagcgc cagcacaaat cagaccagca 360
tgtacctgtg cgcctcttct ctgggaagag gaggaaatac catctacttc ggcgaaggat 420
cttggctgac agtggtggag gatctgaaca aggtgttccc cccagaggtg gccgtgttcg 480
agccttctga ggccgagatc tcccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gctttttccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcactccg 600
gcgtgtgcac cgatccccag cctctgaaag aacagcccgc cctgaacgac agccggtact 660
gcctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gacagagcca 780
agcccgtgac acagatcgtg tctgccgaag cctggggcag agccgattgc ggctttacct 840
ccgtgtccta tcagcagggc gtgctgagcg ccacaatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtctg ccctggtgct gatggccatg gtcaagcgga 960
aggacttcgg ttccggagcc acgaacttct ctctgttaaa gcaagcagga gacgtggaag 1020
aaaaccccgg tcccatggag acactgcttg gcgtatcact ggtgattctg tggctgcaac 1080
tggctagagt gaactctcag cagggagaag aggatcctca agctctgagc attcaggaag 1140
gcgaaaatgc caccatgaac tgcagctaca agaccagcat caacaacctg cagtggtacc 1200
ggcagaatag cggaagagga ctggttcacc tgatcctgat caggagcaat gaaagggaga 1260
agcacagcgg cagactgaga gttaccctgg ataccagcaa gaagtctagc agcctgctga 1320
ttacagcctc tagagccgcc gatacagcca gctacttttg ttctggcgga agcaactaca 1380
agctgacatt tggcaaggga accctgctga ccgtgaaccc caatatccag aatcccgatc 1440
ctgctgtgta ccagctgcgg gacagcaaga gcagcgac 1478
<210> 540
<211> 491
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4
TCRβ-P2A-TCRα 片段)
<400> 540
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Ile Arg
1 5 10 15
Leu Leu Cys Arg Val Ala Phe Cys Phe Leu Ala Val Gly Leu Val Asp
20 25 30
Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly Glu
35 40 45
Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met Phe
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe Ser
65 70 75 80
Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr Ser
85 90 95
Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser Ala
100 105 110
Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ser Leu Gly Arg
115 120 125
Gly Gly Asn Thr Ile Tyr Phe Gly Glu Gly Ser Trp Leu Thr Val Val
130 135 140
Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Phe Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp
325 330 335
Val Glu Glu Asn Pro Gly Pro Met Glu Thr Leu Leu Gly Val Ser Leu
340 345 350
Val Ile Leu Trp Leu Gln Leu Ala Arg Val Asn Ser Gln Gln Gly Glu
355 360 365
Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly Glu Asn Ala Thr Met
370 375 380
Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu Gln Trp Tyr Arg Gln
385 390 395 400
Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu Ile Arg Ser Asn Glu
405 410 415
Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr Leu Asp Thr Ser Lys
420 425 430
Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg Ala Ala Asp Thr Ala
435 440 445
Ser Tyr Phe Cys Ser Gly Gly Ser Asn Tyr Lys Leu Thr Phe Gly Lys
450 455 460
Gly Thr Leu Leu Thr Val Asn Pro Asn Ile Gln Asn Pro Asp Pro Ala
465 470 475 480
Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490
<210> 541
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4 Vβ)
<400> 541
Asp Val Lys Val Thr Gln Ser Ser Arg Tyr Leu Val Lys Arg Thr Gly
1 5 10 15
Glu Lys Val Phe Leu Glu Cys Val Gln Asp Met Asp His Glu Asn Met
20 25 30
Phe Trp Tyr Arg Gln Asp Pro Gly Leu Gly Leu Arg Leu Ile Tyr Phe
35 40 45
Ser Tyr Asp Val Lys Met Lys Glu Lys Gly Asp Ile Pro Glu Gly Tyr
50 55 60
Ser Val Ser Arg Glu Lys Lys Glu Arg Phe Ser Leu Ile Leu Glu Ser
65 70 75 80
Ala Ser Thr Asn Gln Thr Ser Met Tyr Leu Cys Ala Ser Ser Leu Gly
85 90 95
Arg Gly Gly Asn Thr Ile Tyr Phe Gly Glu Gly Ser Trp Leu Thr Val
100 105 110
Val
<210> 542
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_4 Vα)
<400> 542
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ser Gly Gly Ser Asn Tyr Lys
85 90 95
Leu Thr Phe Gly Lys Gly Thr Leu Leu Thr Val Asn Pro Asn
100 105 110
<210> 543
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5 CDR1α)
<400> 543
Tyr Gly Ala Thr Pro Tyr
1 5
<210> 544
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5 CDR2α)
<400> 544
Tyr Phe Ser Gly Asp Thr Leu Val
1 5
<210> 545
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5 CDR3α)
<400> 545
Cys Ala Val Gly Ala Ser Gly Thr Tyr Lys Tyr Ile Phe
1 5 10
<210> 546
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5 CDR1β)
<400> 546
Ser Gly His Asn Ser
1 5
<210> 547
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5 CDR2β)
<400> 547
Phe Asn Asn Asn Val Pro
1 5
<210> 548
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5 CDR3β)
<400> 548
Cys Ala Ser Ser Leu Ala Leu Ser Tyr Glu Gln Tyr Phe
1 5 10
<210> 549
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5
TCRβ-P2A-TCRα 片段)
<400> 549
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catggatagc tggaccttct 60
gttgcgtgag cctgtgtatc ctggtggcca aacacacaga tgctggagtg attcagagcc 120
ctagacatga ggtgaccgaa atgggacagg aggtgacact gagatgtaag cccatttctg 180
gccacaacag cctgttctgg tacagacaga ccatgatgag gggactggaa ctgctgatct 240
acttcaacaa caacgtgccc atcgacgata gcggcatgcc tgaggacaga tttagcgcca 300
agatgcctaa tgccagcttt tctaccctga agatccagcc ctctgagccc agagattctg 360
ccgtgtactt ttgtgcctct tctcttgctc tgagctatga gcagtacttc ggacccggca 420
caagactgac cgtgacagaa gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atgctgctgg aactgatacc cctactgggc atccactttg 1080
tgctgagaac agctagagcc caatctgtga cacagcccga tatccacatt accgtgagcg 1140
aaggagcttc tctggaactg agatgcaact acagctatgg cgccacccct taccttttct 1200
ggtacgtgca gtctcctgga cagggattac aactgctgct gaagtacttc tccggcgata 1260
cactggttca gggcattaag ggctttgagg ccgagttcaa gagaagccag agcagcttta 1320
acctgagaaa gcctagcgtg cactggtctg atgctgccga gtacttttgt gctgtgggag 1380
cctctggaac atacaagtac atcttcggaa ccggcacaag gctgaaggtg ctggccaata 1440
tccagaaccc tgatcctgct gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 550
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5
TCRβ-P2A-TCRα 片段)
<400> 550
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Asp Ser Trp
1 5 10 15
Thr Phe Cys Cys Val Ser Leu Cys Ile Leu Val Ala Lys His Thr Asp
20 25 30
Ala Gly Val Ile Gln Ser Pro Arg His Glu Val Thr Glu Met Gly Gln
35 40 45
Glu Val Thr Leu Arg Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe
50 55 60
Trp Tyr Arg Gln Thr Met Met Arg Gly Leu Glu Leu Leu Ile Tyr Phe
65 70 75 80
Asn Asn Asn Val Pro Ile Asp Asp Ser Gly Met Pro Glu Asp Arg Phe
85 90 95
Ser Ala Lys Met Pro Asn Ala Ser Phe Ser Thr Leu Lys Ile Gln Pro
100 105 110
Ser Glu Pro Arg Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu Ala
115 120 125
Leu Ser Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Leu Leu Glu Leu Ile Pro
340 345 350
Leu Leu Gly Ile His Phe Val Leu Arg Thr Ala Arg Ala Gln Ser Val
355 360 365
Thr Gln Pro Asp Ile His Ile Thr Val Ser Glu Gly Ala Ser Leu Glu
370 375 380
Leu Arg Cys Asn Tyr Ser Tyr Gly Ala Thr Pro Tyr Leu Phe Trp Tyr
385 390 395 400
Val Gln Ser Pro Gly Gln Gly Leu Gln Leu Leu Leu Lys Tyr Phe Ser
405 410 415
Gly Asp Thr Leu Val Gln Gly Ile Lys Gly Phe Glu Ala Glu Phe Lys
420 425 430
Arg Ser Gln Ser Ser Phe Asn Leu Arg Lys Pro Ser Val His Trp Ser
435 440 445
Asp Ala Ala Glu Tyr Phe Cys Ala Val Gly Ala Ser Gly Thr Tyr Lys
450 455 460
Tyr Ile Phe Gly Thr Gly Thr Arg Leu Lys Val Leu Ala Asn Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 551
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5 Vβ)
<400> 551
Asp Ala Gly Val Ile Gln Ser Pro Arg His Glu Val Thr Glu Met Gly
1 5 10 15
Gln Glu Val Thr Leu Arg Cys Lys Pro Ile Ser Gly His Asn Ser Leu
20 25 30
Phe Trp Tyr Arg Gln Thr Met Met Arg Gly Leu Glu Leu Leu Ile Tyr
35 40 45
Phe Asn Asn Asn Val Pro Ile Asp Asp Ser Gly Met Pro Glu Asp Arg
50 55 60
Phe Ser Ala Lys Met Pro Asn Ala Ser Phe Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ser Glu Pro Arg Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Leu
85 90 95
Ala Leu Ser Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr
<210> 552
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_5 Vα)
<400> 552
Ala Gln Ser Val Thr Gln Pro Asp Ile His Ile Thr Val Ser Glu Gly
1 5 10 15
Ala Ser Leu Glu Leu Arg Cys Asn Tyr Ser Tyr Gly Ala Thr Pro Tyr
20 25 30
Leu Phe Trp Tyr Val Gln Ser Pro Gly Gln Gly Leu Gln Leu Leu Leu
35 40 45
Lys Tyr Phe Ser Gly Asp Thr Leu Val Gln Gly Ile Lys Gly Phe Glu
50 55 60
Ala Glu Phe Lys Arg Ser Gln Ser Ser Phe Asn Leu Arg Lys Pro Ser
65 70 75 80
Val His Trp Ser Asp Ala Ala Glu Tyr Phe Cys Ala Val Gly Ala Ser
85 90 95
Gly Thr Tyr Lys Tyr Ile Phe Gly Thr Gly Thr Arg Leu Lys Val Leu
100 105 110
Ala Asn
<210> 553
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7 CDR1α)
<400> 553
Thr Ser Ile Asn Asn
1 5
<210> 554
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7 CDR2α)
<400> 554
Ile Arg Ser Asn Glu Arg Glu
1 5
<210> 555
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7 CDR3α)
<400> 555
Cys Ala Thr Asp Ala Leu Ser Trp Gly Ala Gln Lys Leu Val Phe
1 5 10 15
<210> 556
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7 CDR1β)
<400> 556
Ser Gly His Ala Thr
1 5
<210> 557
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7 CDR2β)
<400> 557
Phe Gln Asn Asn Gly Val
1 5
<210> 558
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7 CDR3β)
<400> 558
Cys Ala Ser Ser Arg Gly Ala Asp Tyr Glu Gln Tyr Phe
1 5 10
<210> 559
<211> 1496
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7
TCRβ-P2A-TCRα 片段)
<400> 559
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca agacttctct 60
gttgggctgc tctttgtctg cttggagctg aactgacaga agctggagtt gcccagtctc 120
ctaggtacaa gatcatcgag aagaggcagt ctgtggcctt ttggtgcaat cccattagcg 180
gacacgccac cctgtactgg tatcagcaaa ttctgggaca aggccctaaa ctgctgatcc 240
agttccagaa caacggcgtg gtggacgatt ctcaactgcc taaggacagg ttttctgccg 300
agagactgaa aggcgtggat agcaccctga agatccaacc agccaaactg gaggattctg 360
ctgtgtacct gtgtgctagc tctagaggag ccgactatga gcagtacttt ggacctggca 420
caagactgac agtgacagag gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atggagacac tgcttggcgt atcactggtg attctgtggc 1080
tgcaactggc tagagtgaac tctcagcagg gagaagagga tcctcaagct ctgagcattc 1140
aggaaggcga aaatgccacc atgaactgca gctacaagac cagcatcaac aacctgcagt 1200
ggtaccggca gaatagcgga agaggactgg ttcacctgat cctgatcagg agcaatgaaa 1260
gggagaagca cagcggcaga ctgagagtta ccctggatac cagcaagaag tctagcagcc 1320
tgctgattac agcctctaga gccgccgata cagccagcta cttttgtgcc acagatgctc 1380
tttcttgggg agctcaaaag ctggtgtttg gccagggaac caggctgacc attaacccca 1440
atatccagaa tcctgatcct gccgtgtacc agctgcggga cagcaagagc agcgac 1496
<210> 560
<211> 497
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7
TCRβ-P2A-TCRα 片段)
<400> 560
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Thr Arg
1 5 10 15
Leu Leu Cys Trp Ala Ala Leu Cys Leu Leu Gly Ala Glu Leu Thr Glu
20 25 30
Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile Ile Glu Lys Arg Gln
35 40 45
Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly His Ala Thr Leu Tyr
50 55 60
Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys Leu Leu Ile Gln Phe
65 70 75 80
Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg Phe
85 90 95
Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln Pro
100 105 110
Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Arg Gly
115 120 125
Ala Asp Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Glu Thr Leu Leu Gly Val
340 345 350
Ser Leu Val Ile Leu Trp Leu Gln Leu Ala Arg Val Asn Ser Gln Gln
355 360 365
Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly Glu Asn Ala
370 375 380
Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu Gln Trp Tyr
385 390 395 400
Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu Ile Arg Ser
405 410 415
Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr Leu Asp Thr
420 425 430
Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg Ala Ala Asp
435 440 445
Thr Ala Ser Tyr Phe Cys Ala Thr Asp Ala Leu Ser Trp Gly Ala Gln
450 455 460
Lys Leu Val Phe Gly Gln Gly Thr Arg Leu Thr Ile Asn Pro Asn Ile
465 470 475 480
Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser
485 490 495
Asp
<210> 561
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7 Vβ)
<400> 561
Glu Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile Ile Glu Lys Arg
1 5 10 15
Gln Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly His Ala Thr Leu
20 25 30
Tyr Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys Leu Leu Ile Gln
35 40 45
Phe Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg
50 55 60
Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Arg
85 90 95
Gly Ala Asp Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr
<210> 562
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_7 Vα)
<400> 562
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Ala Leu Ser Trp
85 90 95
Gly Ala Gln Lys Leu Val Phe Gly Gln Gly Thr Arg Leu Thr Ile Asn
100 105 110
Pro Asn
<210> 563
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8 CDR1α)
<400> 563
Asn Ser Met Phe Asp Tyr
1 5
<210> 564
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8 CDR2α)
<400> 564
Ile Ser Ser Ile Lys Asp Lys
1 5
<210> 565
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8 CDR3α)
<400> 565
Cys Ala Ala Asn Thr Asn Ala Gly Lys Ser Thr Phe
1 5 10
<210> 566
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8 CDR1β)
<400> 566
Ser Glu His Asn Arg
1 5
<210> 567
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8 CDR2β)
<400> 567
Phe Gln Asn Glu Ala Gln
1 5
<210> 568
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8 CDR3β)
<400> 568
Cys Ala Ser Ser Thr Gly Thr Ala Glu Gln Tyr Phe
1 5 10
<210> 569
<211> 1505
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8
TCRβ-P2A-TCRα 片段)
<400> 569
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca tctcttctct 60
gctggatggc tctttgtctg cttggagccg atcatgccga tacaggagtt agccaggatc 120
ctagacacaa gatcaccaag agaggccaga atgtgacctt ccggtgcgat cctatctctg 180
agcacaacag gctgtactgg tacagacaaa cactgggaca aggacctgag ttcctgacct 240
acttccagaa cgaagcccag ctggagaagt ctagacttct gagcgacaga tttagcgccg 300
agagacctaa aggcagcttt agcaccctgg agatccagag aacagaacag ggcgattctg 360
ccatgtacct gtgtgctagc tctacaggaa cagccgagca gtactttgga cctggaacca 420
gactgaccgt gacagaagac ctgaagaacg tgttcccccc agaggtggcc gtgttcgagc 480
ctagcgaggc cgagatcagc cacacccaga aagccaccct cgtgtgcctg gccaccggct 540
tttaccccga ccacgtggaa ctgtcttggt gggtcaacgg caaagaggtg cacagcggcg 600
tctgcaccga cccccagccc ctgaaagagc agcccgccct gaacgacagc cggtactgtc 660
tgagcagcag actgagagtg tccgccacct tctggcagaa cccccggaac cacttcagat 720
gccaggtgca gttctacggc ctgagcgaga acgacgagtg gacccaggac cgggccaagc 780
ccgtgaccca gatcgtgtct gctgaggcct ggggcagagc cgattgcggc ttcaccagcg 840
agagctacca gcagggcgtg ctgagcgcca ccatcctgta cgagatcctg ctgggcaagg 900
ccaccctgta cgccgtgctg gtgtccgccc tggtgctgat ggccatggtc aagcggaagg 960
acagccgggg cggttccgga gccacgaact tctctctgtt aaagcaagca ggagacgtgg 1020
aagaaaaccc cggtcccatg gccatgttac taggagcgag cgtgctgatt ctgtggttac 1080
agcctgattg ggtgaactct cagcagaaga acgatgatca gcaggtgaag cagaacagcc 1140
cctctctgtc tgtgcaggaa ggcagaatca gcatcctgaa ttgcgattac accaacagca 1200
tgttcgacta cttcctgtgg tacaagaagt accccgccga gggccctacc tttctgatca 1260
gcatctctag catcaaggac aagaacgaag atggcagatt caccgtgttc ctgaacaaga 1320
gcgccaagca cctgagcctg cacattgtgc cttctcaacc tggagattct gccgtgtact 1380
tttgtgccgc caacacaaat gccggcaaga gcacatttgg cgatggcaca acactgaccg 1440
tgaagcctaa tatccagaac cctgatccag ccgtgtacca gctgcgggac agcaagagca 1500
gcgac 1505
<210> 570
<211> 500
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8
TCRβ-P2A-TCRα 片段)
<400> 570
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Thr Ser
1 5 10 15
Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala Asp His Ala Asp
20 25 30
Thr Gly Val Ser Gln Asp Pro Arg His Lys Ile Thr Lys Arg Gly Gln
35 40 45
Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His Asn Arg Leu Tyr
50 55 60
Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr Phe
65 70 75 80
Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg Phe
85 90 95
Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln Arg
100 105 110
Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Thr Gly
115 120 125
Thr Ala Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr Glu
130 135 140
Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro Ser
145 150 155 160
Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu Ala
165 170 175
Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn Gly
180 185 190
Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys Glu
195 200 205
Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu Arg
210 215 220
Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys Gln
225 230 235 240
Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp Arg
245 250 255
Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg Ala
260 265 270
Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser Ala
275 280 285
Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val
290 295 300
Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp Ser
305 310 315 320
Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly
325 330 335
Asp Val Glu Glu Asn Pro Gly Pro Met Ala Met Leu Leu Gly Ala Ser
340 345 350
Val Leu Ile Leu Trp Leu Gln Pro Asp Trp Val Asn Ser Gln Gln Lys
355 360 365
Asn Asp Asp Gln Gln Val Lys Gln Asn Ser Pro Ser Leu Ser Val Gln
370 375 380
Glu Gly Arg Ile Ser Ile Leu Asn Cys Asp Tyr Thr Asn Ser Met Phe
385 390 395 400
Asp Tyr Phe Leu Trp Tyr Lys Lys Tyr Pro Ala Glu Gly Pro Thr Phe
405 410 415
Leu Ile Ser Ile Ser Ser Ile Lys Asp Lys Asn Glu Asp Gly Arg Phe
420 425 430
Thr Val Phe Leu Asn Lys Ser Ala Lys His Leu Ser Leu His Ile Val
435 440 445
Pro Ser Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Ala Asn Thr
450 455 460
Asn Ala Gly Lys Ser Thr Phe Gly Asp Gly Thr Thr Leu Thr Val Lys
465 470 475 480
Pro Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser
485 490 495
Lys Ser Ser Asp
500
<210> 571
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8 Vβ)
<400> 571
Asp Thr Gly Val Ser Gln Asp Pro Arg His Lys Ile Thr Lys Arg Gly
1 5 10 15
Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His Asn Arg Leu
20 25 30
Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr
35 40 45
Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg
50 55 60
Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln
65 70 75 80
Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Thr
85 90 95
Gly Thr Ala Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
100 105 110
<210> 572
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_129_8 Vα)
<400> 572
Asp Gln Gln Val Lys Gln Asn Ser Pro Ser Leu Ser Val Gln Glu Gly
1 5 10 15
Arg Ile Ser Ile Leu Asn Cys Asp Tyr Thr Asn Ser Met Phe Asp Tyr
20 25 30
Phe Leu Trp Tyr Lys Lys Tyr Pro Ala Glu Gly Pro Thr Phe Leu Ile
35 40 45
Ser Ile Ser Ser Ile Lys Asp Lys Asn Glu Asp Gly Arg Phe Thr Val
50 55 60
Phe Leu Asn Lys Ser Ala Lys His Leu Ser Leu His Ile Val Pro Ser
65 70 75 80
Gln Pro Gly Asp Ser Ala Val Tyr Phe Cys Ala Ala Asn Thr Asn Ala
85 90 95
Gly Lys Ser Thr Phe Gly Asp Gly Thr Thr Leu Thr Val Lys Pro Asn
100 105 110
<210> 573
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1 CDR1α)
<400> 573
Thr Ser Glu Ser Asp Tyr Tyr
1 5
<210> 574
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1 CDR2α)
<400> 574
Gln Glu Ala Tyr Lys Gln Gln Asn
1 5
<210> 575
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1 CDR3α)
<400> 575
Cys Ala Leu Lys Thr Ser Tyr Asp Lys Val Ile Phe
1 5 10
<210> 576
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1 CDR1β)
<400> 576
Met Asn His Glu Tyr
1 5
<210> 577
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1 CDR2β)
<400> 577
Ser Val Gly Ala Gly Ile
1 5
<210> 578
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1 CDR3β)
<400> 578
Cys Ala Ser Ser Leu Gly Ala Gly Glu Trp Lys Ser Pro Leu His Phe
1 5 10 15
<210> 579
<211> 1496
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1
TCRβ-P2A-TCRα 片段)
<400> 579
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgtctatc ggtctgctgt 60
gctgtgctgc tctttctctg ctttgggctg gacctgtgaa tgctggagtt acacaaaccc 120
ccaagttcca agtgctgaag acaggacaga gcatgaccct gcagtgtgct caggacatga 180
atcacgagta catgagctgg tacagacagg atcctggaat gggcctgagg ctgatccact 240
actctgttgg agccggaatt acagatcagg gagaagtgcc aaatggctac aacgtgagca 300
ggagcacaac cgaggacttc cccttaagac tgttgtctgc tgctccatct cagacaagcg 360
tgtacttttg cgcctcttct ctgggagccg gagaatggaa atctcctctg cactttggca 420
atggcaccag attaacagtg accgaggatc tgaacaaggt gttcccccca gaggtggccg 480
tgttcgagcc ttctgaggcc gagatctccc acacccagaa agccaccctc gtgtgcctgg 540
ccaccggctt tttccccgac cacgtggaac tgtcttggtg ggtcaacggc aaagaggtgc 600
actccggcgt gtgcaccgat ccccagcctc tgaaagaaca gcccgccctg aacgacagcc 660
ggtactgcct gagcagcaga ctgagagtgt ccgccacctt ctggcagaac ccccggaacc 720
acttcagatg ccaggtgcag ttctacggcc tgagcgagaa cgacgagtgg acccaggaca 780
gagccaagcc cgtgacacag atcgtgtctg ccgaagcctg gggcagagcc gattgcggct 840
ttacctccgt gtcctatcag cagggcgtgc tgagcgccac aatcctgtac gagatcctgc 900
tgggcaaggc caccctgtac gccgtgctgg tgtctgccct ggtgctgatg gccatggtca 960
agcggaagga cttcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atggcttgtc ctggattctt atgggctctg gtgatcagca 1080
cctgtctgga gttctctatg gcccagacag tgacacagtc tcagcctgaa atgtctgtgc 1140
aggaagccga aaccgtgaca ctgtcttgca cctacgatac aagcgagagc gactactacc 1200
tgttctggta caagcagcct ccctctaggc agatgatcct ggtgattaga caggaggcct 1260
acaaacagca gaatgccacc gagaaccggt ttagcgtgaa cttccagaaa gccgccaaga 1320
gcttcagcct gaaaatctct gacagccagc tgggagatgc tgccatgtac ttttgtgccc 1380
tgaagaccag ctacgacaag gtgatttttg gacctggcac ctctctgagc gtgatcccca 1440
atatccagaa ccccgatcct gctgtgtacc agctgcggga cagcaagagc agcgac 1496
<210> 580
<211> 497
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1
TCRβ-P2A-TCRα 片段)
<400> 580
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Ser Ile Gly
1 5 10 15
Leu Leu Cys Cys Ala Ala Leu Ser Leu Leu Trp Ala Gly Pro Val Asn
20 25 30
Ala Gly Val Thr Gln Thr Pro Lys Phe Gln Val Leu Lys Thr Gly Gln
35 40 45
Ser Met Thr Leu Gln Cys Ala Gln Asp Met Asn His Glu Tyr Met Ser
50 55 60
Trp Tyr Arg Gln Asp Pro Gly Met Gly Leu Arg Leu Ile His Tyr Ser
65 70 75 80
Val Gly Ala Gly Ile Thr Asp Gln Gly Glu Val Pro Asn Gly Tyr Asn
85 90 95
Val Ser Arg Ser Thr Thr Glu Asp Phe Pro Leu Arg Leu Leu Ser Ala
100 105 110
Ala Pro Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser Ser Leu Gly Ala
115 120 125
Gly Glu Trp Lys Ser Pro Leu His Phe Gly Asn Gly Thr Arg Leu Thr
130 135 140
Val Thr Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe
145 150 155 160
Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val
165 170 175
Cys Leu Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp
180 185 190
Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro
195 200 205
Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser
210 215 220
Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe
225 230 235 240
Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr
245 250 255
Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp
260 265 270
Gly Arg Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln Gly Val
275 280 285
Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu
290 295 300
Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg
305 310 315 320
Lys Asp Phe Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Ala Cys Pro Gly Phe Leu
340 345 350
Trp Ala Leu Val Ile Ser Thr Cys Leu Glu Phe Ser Met Ala Gln Thr
355 360 365
Val Thr Gln Ser Gln Pro Glu Met Ser Val Gln Glu Ala Glu Thr Val
370 375 380
Thr Leu Ser Cys Thr Tyr Asp Thr Ser Glu Ser Asp Tyr Tyr Leu Phe
385 390 395 400
Trp Tyr Lys Gln Pro Pro Ser Arg Gln Met Ile Leu Val Ile Arg Gln
405 410 415
Glu Ala Tyr Lys Gln Gln Asn Ala Thr Glu Asn Arg Phe Ser Val Asn
420 425 430
Phe Gln Lys Ala Ala Lys Ser Phe Ser Leu Lys Ile Ser Asp Ser Gln
435 440 445
Leu Gly Asp Ala Ala Met Tyr Phe Cys Ala Leu Lys Thr Ser Tyr Asp
450 455 460
Lys Val Ile Phe Gly Pro Gly Thr Ser Leu Ser Val Ile Pro Asn Ile
465 470 475 480
Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser
485 490 495
Asp
<210> 581
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1 Vβ)
<400> 581
Asn Ala Gly Val Thr Gln Thr Pro Lys Phe Gln Val Leu Lys Thr Gly
1 5 10 15
Gln Ser Met Thr Leu Gln Cys Ala Gln Asp Met Asn His Glu Tyr Met
20 25 30
Ser Trp Tyr Arg Gln Asp Pro Gly Met Gly Leu Arg Leu Ile His Tyr
35 40 45
Ser Val Gly Ala Gly Ile Thr Asp Gln Gly Glu Val Pro Asn Gly Tyr
50 55 60
Asn Val Ser Arg Ser Thr Thr Glu Asp Phe Pro Leu Arg Leu Leu Ser
65 70 75 80
Ala Ala Pro Ser Gln Thr Ser Val Tyr Phe Cys Ala Ser Ser Leu Gly
85 90 95
Ala Gly Glu Trp Lys Ser Pro Leu His Phe Gly Asn Gly Thr Arg Leu
100 105 110
Thr Val Thr
115
<210> 582
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_1 Vα)
<400> 582
Ala Gln Thr Val Thr Gln Ser Gln Pro Glu Met Ser Val Gln Glu Ala
1 5 10 15
Glu Thr Val Thr Leu Ser Cys Thr Tyr Asp Thr Ser Glu Ser Asp Tyr
20 25 30
Tyr Leu Phe Trp Tyr Lys Gln Pro Pro Ser Arg Gln Met Ile Leu Val
35 40 45
Ile Arg Gln Glu Ala Tyr Lys Gln Gln Asn Ala Thr Glu Asn Arg Phe
50 55 60
Ser Val Asn Phe Gln Lys Ala Ala Lys Ser Phe Ser Leu Lys Ile Ser
65 70 75 80
Asp Ser Gln Leu Gly Asp Ala Ala Met Tyr Phe Cys Ala Leu Lys Thr
85 90 95
Ser Tyr Asp Lys Val Ile Phe Gly Pro Gly Thr Ser Leu Ser Val Ile
100 105 110
Pro Asn
<210> 583
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3 CDR1α)
<400> 583
Val Ser Gly Asn Pro Tyr
1 5
<210> 584
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3 CDR2α)
<400> 584
Tyr Ile Thr Gly Asp Asn Leu Val
1 5
<210> 585
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3 CDR3α)
<400> 585
Cys Ala Val Ile Ser Gly Gly Tyr Asn Lys Leu Ile Phe
1 5 10
<210> 586
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3 CDR1β)
<400> 586
Leu Gly His Asp Thr
1 5
<210> 587
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3 CDR2β)
<400> 587
Tyr Asn Asn Lys Glu Leu
1 5
<210> 588
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3 CDR3β)
<400> 588
Cys Ala Ser Ser Ser Ser Gly Ala Arg Gly Pro Tyr Glu Gln Tyr Phe
1 5 10 15
<210> 589
<211> 1499
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3
TCRβ-P2A-TCRα 片段)
<400> 589
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggctgt agactgttgt 60
gttgcgtggt gttttgcctg ctgcaagctg gacctctgga tacagctgtt agccagaccc 120
ctaagtatct ggtgacccaa atgggcaacg ataagagcat caagtgcgag cagaatctgg 180
gccacgacac catgtactgg tacaagcagg acagcaagaa gttcctgaag atcatgttca 240
gctacaacaa caaggagctg atcatcaacg agaccgtgcc caaccggttc agccccaaaa 300
gccctgataa agctcacctg aatctgcaca tcaattctct ggaactgggc gactctgccg 360
tgtacttctg cgcctctagc tcttctggag ctagaggacc ttatgaacag tattttggcc 420
ctggcaccag actgacagtg accgaggacc tgaagaacgt gttcccccca gaggtggccg 480
tgttcgagcc tagcgaggcc gagatcagcc acacccagaa agccaccctc gtgtgcctgg 540
ccaccggctt ttaccccgac cacgtggaac tgtcttggtg ggtcaacggc aaagaggtgc 600
acagcggcgt ctgcaccgac ccccagcccc tgaaagagca gcccgccctg aacgacagcc 660
ggtactgtct gagcagcaga ctgagagtgt ccgccacctt ctggcagaac ccccggaacc 720
acttcagatg ccaggtgcag ttctacggcc tgagcgagaa cgacgagtgg acccaggacc 780
gggccaagcc cgtgacccag atcgtgtctg ctgaggcctg gggcagagcc gattgcggct 840
tcaccagcga gagctaccag cagggcgtgc tgagcgccac catcctgtac gagatcctgc 900
tgggcaaggc caccctgtac gccgtgctgg tgtccgccct ggtgctgatg gccatggtca 960
agcggaagga cagccggggc ggttccggag ccacgaactt ctctctgtta aagcaagcag 1020
gagacgtgga agaaaacccc ggtcccatgg cttcagcacc tatctccatg ctggctatgc 1080
tgttcacact gtctggcctt agagcccagt ctgttgctca acctgaggat caggtgaatg 1140
tggctgaggg aaatccactg accgtgaagt gcacctactc tgtgtctggc aacccttacc 1200
tgttttggta cgtgcagtac cccaatagag gcctgcagtt cctgctgaag tacatcaccg 1260
gcgacaatct ggtgaaagga tcttacggct ttgaagccga gttcaacaag agccagacca 1320
gcttccacct gaagaagcct tctgctctgg tgagcgattc tgccctgtac ttttgtgccg 1380
tgatttctgg cggctacaac aagctgatct ttggagccgg cacaagactg gccgttcatc 1440
cttacatcca gaatcctgac cctgctgtgt accagctgcg ggacagcaag agcagcgac 1499
<210> 590
<211> 498
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3
TCRβ-P2A-TCRα 片段)
<400> 590
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Cys Arg
1 5 10 15
Leu Leu Cys Cys Val Val Phe Cys Leu Leu Gln Ala Gly Pro Leu Asp
20 25 30
Thr Ala Val Ser Gln Thr Pro Lys Tyr Leu Val Thr Gln Met Gly Asn
35 40 45
Asp Lys Ser Ile Lys Cys Glu Gln Asn Leu Gly His Asp Thr Met Tyr
50 55 60
Trp Tyr Lys Gln Asp Ser Lys Lys Phe Leu Lys Ile Met Phe Ser Tyr
65 70 75 80
Asn Asn Lys Glu Leu Ile Ile Asn Glu Thr Val Pro Asn Arg Phe Ser
85 90 95
Pro Lys Ser Pro Asp Lys Ala His Leu Asn Leu His Ile Asn Ser Leu
100 105 110
Glu Leu Gly Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Ser Ser Gly
115 120 125
Ala Arg Gly Pro Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr
130 135 140
Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe
145 150 155 160
Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val
165 170 175
Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp
180 185 190
Val Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro
195 200 205
Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser
210 215 220
Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe
225 230 235 240
Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr
245 250 255
Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp
260 265 270
Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val
275 280 285
Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu
290 295 300
Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg
305 310 315 320
Lys Asp Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys
325 330 335
Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Ala Ser Ala Pro
340 345 350
Ile Ser Met Leu Ala Met Leu Phe Thr Leu Ser Gly Leu Arg Ala Gln
355 360 365
Ser Val Ala Gln Pro Glu Asp Gln Val Asn Val Ala Glu Gly Asn Pro
370 375 380
Leu Thr Val Lys Cys Thr Tyr Ser Val Ser Gly Asn Pro Tyr Leu Phe
385 390 395 400
Trp Tyr Val Gln Tyr Pro Asn Arg Gly Leu Gln Phe Leu Leu Lys Tyr
405 410 415
Ile Thr Gly Asp Asn Leu Val Lys Gly Ser Tyr Gly Phe Glu Ala Glu
420 425 430
Phe Asn Lys Ser Gln Thr Ser Phe His Leu Lys Lys Pro Ser Ala Leu
435 440 445
Val Ser Asp Ser Ala Leu Tyr Phe Cys Ala Val Ile Ser Gly Gly Tyr
450 455 460
Asn Lys Leu Ile Phe Gly Ala Gly Thr Arg Leu Ala Val His Pro Tyr
465 470 475 480
Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser
485 490 495
Ser Asp
<210> 591
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3 Vβ)
<400> 591
Asp Thr Ala Val Ser Gln Thr Pro Lys Tyr Leu Val Thr Gln Met Gly
1 5 10 15
Asn Asp Lys Ser Ile Lys Cys Glu Gln Asn Leu Gly His Asp Thr Met
20 25 30
Tyr Trp Tyr Lys Gln Asp Ser Lys Lys Phe Leu Lys Ile Met Phe Ser
35 40 45
Tyr Asn Asn Lys Glu Leu Ile Ile Asn Glu Thr Val Pro Asn Arg Phe
50 55 60
Ser Pro Lys Ser Pro Asp Lys Ala His Leu Asn Leu His Ile Asn Ser
65 70 75 80
Leu Glu Leu Gly Asp Ser Ala Val Tyr Phe Cys Ala Ser Ser Ser Ser
85 90 95
Gly Ala Arg Gly Pro Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu
100 105 110
Thr Val Thr
115
<210> 592
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_3 Vα)
<400> 592
Ala Gln Ser Val Ala Gln Pro Glu Asp Gln Val Asn Val Ala Glu Gly
1 5 10 15
Asn Pro Leu Thr Val Lys Cys Thr Tyr Ser Val Ser Gly Asn Pro Tyr
20 25 30
Leu Phe Trp Tyr Val Gln Tyr Pro Asn Arg Gly Leu Gln Phe Leu Leu
35 40 45
Lys Tyr Ile Thr Gly Asp Asn Leu Val Lys Gly Ser Tyr Gly Phe Glu
50 55 60
Ala Glu Phe Asn Lys Ser Gln Thr Ser Phe His Leu Lys Lys Pro Ser
65 70 75 80
Ala Leu Val Ser Asp Ser Ala Leu Tyr Phe Cys Ala Val Ile Ser Gly
85 90 95
Gly Tyr Asn Lys Leu Ile Phe Gly Ala Gly Thr Arg Leu Ala Val His
100 105 110
Pro Tyr
<210> 593
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6 CDR1α)
<400> 593
Thr Ser Ile Asn Asn
1 5
<210> 594
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6 CDR2α)
<400> 594
Ile Arg Ser Asn Glu Arg Glu
1 5
<210> 595
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6 CDR3α)
<400> 595
Cys Ala Thr Asp Val Phe Gln Gly Ala Gln Lys Leu Val Phe
1 5 10
<210> 596
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6 CDR1β)
<400> 596
Ser Gly His Ala Thr
1 5
<210> 597
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6 CDR2β)
<400> 597
Phe Gln Asn Asn Gly Val
1 5
<210> 598
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6 CDR3β)
<400> 598
Cys Ala Ser Ser Ile Glu Thr Ser Tyr Glu Gln Tyr Phe
1 5 10
<210> 599
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6
TCRβ-P2A-TCRα 片段)
<400> 599
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca agacttctct 60
gttgggctgc tctttgtctg cttggagctg aactgacaga agctggagtt gcccagtctc 120
ctaggtacaa gatcatcgag aagaggcagt ctgtggcctt ttggtgcaat cccattagcg 180
gacacgccac cctgtactgg tatcagcaaa ttctgggaca aggccctaaa ctgctgatcc 240
agttccagaa caacggcgtg gtggacgatt ctcaactgcc taaggacagg ttttctgccg 300
agagactgaa aggcgtggat agcaccctga agatccaacc agccaaactg gaggattctg 360
ctgtgtacct gtgtgctagc agcatcgaga ccagctatga gcagtacttc ggaccaggca 420
caagactgac agtgacagaa gacctgaaga acgtgttccc cccagaggtg gccgtgttcg 480
agcctagcga ggccgagatc agccacaccc agaaagccac cctcgtgtgc ctggccaccg 540
gcttttaccc cgaccacgtg gaactgtctt ggtgggtcaa cggcaaagag gtgcacagcg 600
gcgtctgcac cgacccccag cccctgaaag agcagcccgc cctgaacgac agccggtact 660
gtctgagcag cagactgaga gtgtccgcca ccttctggca gaacccccgg aaccacttca 720
gatgccaggt gcagttctac ggcctgagcg agaacgacga gtggacccag gaccgggcca 780
agcccgtgac ccagatcgtg tctgctgagg cctggggcag agccgattgc ggcttcacca 840
gcgagagcta ccagcagggc gtgctgagcg ccaccatcct gtacgagatc ctgctgggca 900
aggccaccct gtacgccgtg ctggtgtccg ccctggtgct gatggccatg gtcaagcgga 960
aggacagccg gggcggttcc ggagccacga acttctctct gttaaagcaa gcaggagacg 1020
tggaagaaaa ccccggtccc atggagacac tgcttggcgt atcactggtg attctgtggc 1080
tgcaactggc tagagtgaac tctcagcagg gagaagagga tcctcaagct ctgagcattc 1140
aggaaggcga aaatgccacc atgaactgca gctacaagac cagcatcaac aacctgcagt 1200
ggtaccggca gaatagcgga agaggactgg ttcacctgat cctgatcagg agcaatgaaa 1260
gggagaagca cagcggcaga ctgagagtta ccctggatac cagcaagaag tctagcagcc 1320
tgctgattac agcctctaga gccgccgata cagccagcta cttttgtgcc acagacgttt 1380
ttcagggagc ccaaaaactg gtgtttggac agggcaccag gctgaccatc aatcccaaca 1440
tccagaatcc tgatcctgcc gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 600
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6
TCRβ-P2A-TCRα 片段)
<400> 600
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Thr Arg
1 5 10 15
Leu Leu Cys Trp Ala Ala Leu Cys Leu Leu Gly Ala Glu Leu Thr Glu
20 25 30
Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile Ile Glu Lys Arg Gln
35 40 45
Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly His Ala Thr Leu Tyr
50 55 60
Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys Leu Leu Ile Gln Phe
65 70 75 80
Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg Phe
85 90 95
Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln Pro
100 105 110
Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Ile Glu
115 120 125
Thr Ser Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
130 135 140
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
145 150 155 160
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
165 170 175
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
180 185 190
Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu Lys
195 200 205
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
210 215 220
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
225 230 235 240
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
245 250 255
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
260 265 270
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
275 280 285
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
290 295 300
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
305 310 315 320
Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala
325 330 335
Gly Asp Val Glu Glu Asn Pro Gly Pro Met Glu Thr Leu Leu Gly Val
340 345 350
Ser Leu Val Ile Leu Trp Leu Gln Leu Ala Arg Val Asn Ser Gln Gln
355 360 365
Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly Glu Asn Ala
370 375 380
Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu Gln Trp Tyr
385 390 395 400
Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu Ile Arg Ser
405 410 415
Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr Leu Asp Thr
420 425 430
Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg Ala Ala Asp
435 440 445
Thr Ala Ser Tyr Phe Cys Ala Thr Asp Val Phe Gln Gly Ala Gln Lys
450 455 460
Leu Val Phe Gly Gln Gly Thr Arg Leu Thr Ile Asn Pro Asn Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 601
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6 Vβ)
<400> 601
Glu Ala Gly Val Ala Gln Ser Pro Arg Tyr Lys Ile Ile Glu Lys Arg
1 5 10 15
Gln Ser Val Ala Phe Trp Cys Asn Pro Ile Ser Gly His Ala Thr Leu
20 25 30
Tyr Trp Tyr Gln Gln Ile Leu Gly Gln Gly Pro Lys Leu Leu Ile Gln
35 40 45
Phe Gln Asn Asn Gly Val Val Asp Asp Ser Gln Leu Pro Lys Asp Arg
50 55 60
Phe Ser Ala Glu Arg Leu Lys Gly Val Asp Ser Thr Leu Lys Ile Gln
65 70 75 80
Pro Ala Lys Leu Glu Asp Ser Ala Val Tyr Leu Cys Ala Ser Ser Ile
85 90 95
Glu Thr Ser Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr
<210> 602
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_6 Vα)
<400> 602
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Val Phe Gln Gly
85 90 95
Ala Gln Lys Leu Val Phe Gly Gln Gly Thr Arg Leu Thr Ile Asn Pro
100 105 110
Asn
<210> 603
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7 CDR1α)
<400> 603
Tyr Gly Ala Thr Pro Tyr
1 5
<210> 604
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7 CDR2α)
<400> 604
Tyr Phe Ser Gly Asp Thr Leu Val
1 5
<210> 605
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7CDR3α)
<400> 605
Cys Ala Val Thr Gly Gly Gly Asn Lys Leu Thr Phe
1 5 10
<210> 606
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7 CDR1β)
<400> 606
Ser Glu His Asn Arg
1 5
<210> 607
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7 CDR2β)
<400> 607
Phe Gln Asn Glu Ala Gln
1 5
<210> 608
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7 CDR3β)
<400> 608
Cys Ala Ser Ser Leu Ala Gly Glu Thr Gly Glu Leu Phe Phe
1 5 10
<210> 609
<211> 1493
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7
TCRβ-P2A-TCRα 片段)
<400> 609
ctcaataaaa gagcccacaa cccctcactc ggcgcgccac catgggcaca tctcttctct 60
gctggatggc tctttgtctg cttggagccg atcatgccga tacaggagtt agccaggatc 120
ctagacacaa gatcaccaag agaggccaga atgtgacctt ccggtgcgat cctatctctg 180
agcacaacag gctgtactgg tacagacaaa cactgggaca aggacctgag ttcctgacct 240
acttccagaa cgaagcccag ctggagaagt ctagacttct gagcgacaga tttagcgccg 300
agagacctaa aggcagcttt agcaccctgg agatccagag aacagaacag ggcgattctg 360
ccatgtacct gtgtgcttct tctttggccg gcgaaacagg agagctgttt tttggagagg 420
gctctaggct gacagtgctt gaggacctga agaacgtgtt ccccccagag gtggccgtgt 480
tcgagcctag cgaggccgag atcagccaca cccagaaagc caccctcgtg tgcctggcca 540
ccggctttta ccccgaccac gtggaactgt cttggtgggt caacggcaaa gaggtgcaca 600
gcggcgtctg caccgacccc cagcccctga aagagcagcc cgccctgaac gacagccggt 660
actgtctgag cagcagactg agagtgtccg ccaccttctg gcagaacccc cggaaccact 720
tcagatgcca ggtgcagttc tacggcctga gcgagaacga cgagtggacc caggaccggg 780
ccaagcccgt gacccagatc gtgtctgctg aggcctgggg cagagccgat tgcggcttca 840
ccagcgagag ctaccagcag ggcgtgctga gcgccaccat cctgtacgag atcctgctgg 900
gcaaggccac cctgtacgcc gtgctggtgt ccgccctggt gctgatggcc atggtcaagc 960
ggaaggacag ccggggcggt tccggagcca cgaacttctc tctgttaaag caagcaggag 1020
acgtggaaga aaaccccggt cccatgctgc tggaactgat acccctactg ggcatccact 1080
ttgtgctgag aacagctaga gcccaatctg tgacacagcc cgatatccac attaccgtga 1140
gcgaaggagc ttctctggaa ctgagatgca actacagcta tggcgccacc ccttaccttt 1200
tctggtacgt gcagtctcct ggacagggat tacaactgct gctgaagtac ttctccggcg 1260
atacactggt tcagggcatt aagggctttg aggccgagtt caagagaagc cagagcagct 1320
ttaacctgag aaagcctagc gtgcactggt ctgatgctgc cgagtacttt tgtgccgtga 1380
caggaggagg aaataagctg acatttggca ccggaacaca gctgaaggtg gagctgaata 1440
tccagaaccc tgaccctgct gtgtaccagc tgcgggacag caagagcagc gac 1493
<210> 610
<211> 496
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7
TCRβ-P2A-TCRα 片段)
<400> 610
Gln Lys Ser Pro Gln Pro Leu Thr Arg Arg Ala Thr Met Gly Thr Ser
1 5 10 15
Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala Asp His Ala Asp
20 25 30
Thr Gly Val Ser Gln Asp Pro Arg His Lys Ile Thr Lys Arg Gly Gln
35 40 45
Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His Asn Arg Leu Tyr
50 55 60
Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr Phe
65 70 75 80
Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg Phe
85 90 95
Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln Arg
100 105 110
Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Leu Ala
115 120 125
Gly Glu Thr Gly Glu Leu Phe Phe Gly Glu Gly Ser Arg Leu Thr Val
130 135 140
Leu Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu
145 150 155 160
Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys
165 170 175
Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val
180 185 190
Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu
195 200 205
Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg
210 215 220
Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg
225 230 235 240
Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln
245 250 255
Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly
260 265 270
Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu
275 280 285
Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr
290 295 300
Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys
305 310 315 320
Asp Ser Arg Gly Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln
325 330 335
Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Leu Leu Glu Leu Ile
340 345 350
Pro Leu Leu Gly Ile His Phe Val Leu Arg Thr Ala Arg Ala Gln Ser
355 360 365
Val Thr Gln Pro Asp Ile His Ile Thr Val Ser Glu Gly Ala Ser Leu
370 375 380
Glu Leu Arg Cys Asn Tyr Ser Tyr Gly Ala Thr Pro Tyr Leu Phe Trp
385 390 395 400
Tyr Val Gln Ser Pro Gly Gln Gly Leu Gln Leu Leu Leu Lys Tyr Phe
405 410 415
Ser Gly Asp Thr Leu Val Gln Gly Ile Lys Gly Phe Glu Ala Glu Phe
420 425 430
Lys Arg Ser Gln Ser Ser Phe Asn Leu Arg Lys Pro Ser Val His Trp
435 440 445
Ser Asp Ala Ala Glu Tyr Phe Cys Ala Val Thr Gly Gly Gly Asn Lys
450 455 460
Leu Thr Phe Gly Thr Gly Thr Gln Leu Lys Val Glu Leu Asn Ile Gln
465 470 475 480
Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp
485 490 495
<210> 611
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7 Vβ)
<400> 611
Asp Thr Gly Val Ser Gln Asp Pro Arg His Lys Ile Thr Lys Arg Gly
1 5 10 15
Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His Asn Arg Leu
20 25 30
Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr
35 40 45
Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg
50 55 60
Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln
65 70 75 80
Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Ser Leu
85 90 95
Ala Gly Glu Thr Gly Glu Leu Phe Phe Gly Glu Gly Ser Arg Leu Thr
100 105 110
Val Leu
<210> 612
<211> 113
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (A11 KRAS TCR_141_7 Vα)
<400> 612
Ala Gln Ser Val Thr Gln Pro Asp Ile His Ile Thr Val Ser Glu Gly
1 5 10 15
Ala Ser Leu Glu Leu Arg Cys Asn Tyr Ser Tyr Gly Ala Thr Pro Tyr
20 25 30
Leu Phe Trp Tyr Val Gln Ser Pro Gly Gln Gly Leu Gln Leu Leu Leu
35 40 45
Lys Tyr Phe Ser Gly Asp Thr Leu Val Gln Gly Ile Lys Gly Phe Glu
50 55 60
Ala Glu Phe Lys Arg Ser Gln Ser Ser Phe Asn Leu Arg Lys Pro Ser
65 70 75 80
Val His Trp Ser Asp Ala Ala Glu Tyr Phe Cys Ala Val Thr Gly Gly
85 90 95
Gly Asn Lys Leu Thr Phe Gly Thr Gly Thr Gln Leu Lys Val Glu Leu
100 105 110
Asn
<210> 613
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR17_CDR1b)
<400> 613
Met Asp His Glu Asn
1 5
<210> 614
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR17_ CDR1a)
<400> 614
Thr Arg Asp Thr Thr Tyr Tyr
1 5
<210> 615
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR17_ CDR2b)
<400> 615
Ser Tyr Asp Val Lys Met
1 5
<210> 616
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR17_ CDR2a)
<400> 616
Arg Asn Ser Phe Asp Glu Gln Asn
1 5
<210> 617
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR17_CDR3b-短)
<400> 617
Cys Ala Ser Ser Leu Gly Ala Gly Gln His Asn Ser Pro Leu His
1 5 10 15
<210> 618
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR17_CDR3a-短)
<400> 618
Cys Ala Leu Ser Glu Val His Ala Ser Gly Gly Ser Tyr Ile Pro Thr
1 5 10 15
<210> 619
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR14_CDR1b)
<400> 619
Ser Gly Asp Leu Ser
1 5
<210> 620
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR14_ CDR1a)
<400> 620
Thr Ser Ile Asn Asn
1 5
<210> 621
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR14_ CDR2b)
<400> 621
Tyr Tyr Asn Gly Glu Glu
1 5
<210> 622
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR14_ CDR2a)
<400> 622
Ile Arg Ser Asn Glu Arg Glu
1 5
<210> 623
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR14_ CDR3b-短)
<400> 623
Cys Ala Ser Thr His Gly Arg Asp Ser Thr Asp Thr Gln Tyr
1 5 10
<210> 624
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR14_ CDR3a-短)
<400> 624
Cys Ala Thr Asp Glu Gly Gly Gly Ala Asp Gly Leu Thr
1 5 10
<210> 625
<400> 625
000
<210> 626
<400> 626
000
<210> 627
<400> 627
000
<210> 628
<400> 628
000
<210> 629
<400> 629
000
<210> 630
<400> 630
000
<210> 631
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR13_CDR1b)
<400> 631
Met Gly His Asp Lys
1 5
<210> 632
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR13_ CDR1a)
<400> 632
Asn Ser Ala Phe Gln Tyr
1 5
<210> 633
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR13_ CDR2b)
<400> 633
Ser Tyr Gly Val Asn Ser
1 5
<210> 634
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR13_ CDR2a)
<400> 634
Thr Tyr Ser Ser Gly Asn
1 5
<210> 635
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR13_ CDR3b-短)
<400> 635
Cys Ala Ser Ser Glu Gly Leu Tyr Asn Glu Gln Phe
1 5 10
<210> 636
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR13_ CDR3a-短)
<400> 636
Cys Ala Met Ser Ala Ser Ala Ala Gly Asn Lys Leu Thr
1 5 10
<210> 637
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR22_CDR1b)
<400> 637
Met Gly His Asp Lys
1 5
<210> 638
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR22_ CDR1a)
<400> 638
Asn Ser Ala Phe Gln Tyr
1 5
<210> 639
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR22_ CDR2b)
<400> 639
Ser Tyr Gly Val Asn Ser
1 5
<210> 640
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR22_ CDR2a)
<400> 640
Thr Tyr Ser Ser Gly Asn
1 5
<210> 641
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR22_ CDR3b-短)
<400> 641
Cys Ala Ser Ser Gln Gly Leu Tyr Asn Glu Gln Phe
1 5 10
<210> 642
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR22_ CDR3a-短)
<400> 642
Cys Ala Met Ser Ala Gly Ala Ala Gly Asn Lys Leu Thr
1 5 10
<210> 643
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR19_CDR1b)
<400> 643
Ser Gly His Asp Tyr
1 5
<210> 644
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR19_ CDR1a)
<400> 644
Asn Ser Met Phe Asp Tyr
1 5
<210> 645
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR19_ CDR2b)
<400> 645
Phe Asn Asn Asn Val Pro
1 5
<210> 646
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR19_ CDR2a)
<400> 646
Ile Ser Ser Ile Lys Asp Lys
1 5
<210> 647
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR19_ CDR3b-短)
<400> 647
Cys Ala Ser Ser Pro Thr Gly Gly Gly Met Leu Gly Gln Tyr
1 5 10
<210> 648
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR19_ CDR3a-短)
<400> 648
Cys Ala Ala Ser Ala Asn Asn Asn Asp Met Arg
1 5 10
<210> 649
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR16_CDR1b)
<400> 649
Ser Gly His Asp Tyr
1 5
<210> 650
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR16_ CDR1a)
<400> 650
Val Ser Asn Ala Tyr Asn
1 5
<210> 651
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR16_ CDR2b)
<400> 651
Phe Asn Asn Asn Val Pro
1 5
<210> 652
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR16_ CDR2a)
<400> 652
Gly Ser Lys Pro
1
<210> 653
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR16_ CDR3b-短)
<400> 653
Cys Ala Ser Ser Arg Leu Gly Pro Tyr Asn Glu Gln Phe
1 5 10
<210> 654
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR16_ CDR3a-短)
<400> 654
Cys Val Leu Asn Arg Asp Asp Lys Ile Ile
1 5 10
<210> 655
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR20_CDR1b)
<400> 655
Ser Gly His Ala Thr
1 5
<210> 656
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR20_ CDR1a)
<400> 656
Thr Ile Ser Gly Asn Glu Tyr
1 5
<210> 657
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR20_ CDR2b)
<400> 657
Phe Gln Asn Asn Gly Val
1 5
<210> 658
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR20_ CDR2a)
<400> 658
Gly Leu Lys Asn Asn
1 5
<210> 659
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR20_CDR3b-短)
<400> 659
Cys Ala Ser Ser Pro Thr Phe Pro Ala Gly Asp Arg Asp Thr Gln Tyr
1 5 10 15
<210> 660
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR20_ CDR3a-短)
<400> 660
Cys Ile Val Arg Leu Asn Ser Gly Asn Thr Pro Leu Val
1 5 10
<210> 661
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR21_CDR1b)
<400> 661
Met Gly His Asp Lys
1 5
<210> 662
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR21_ CDR1a)
<400> 662
Asn Ser Ala Phe Gln Tyr
1 5
<210> 663
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR21_ CDR2b)
<400> 663
Ser Tyr Gly Val Asn Ser
1 5
<210> 664
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR21_ CDR2a)
<400> 664
Thr Tyr Ser Ser Gly Asn
1 5
<210> 665
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR21_CDR3b-短)
<400> 665
Cys Ala Ser Ser Val Gly Leu Tyr Asn Glu Gln Phe
1 5 10
<210> 666
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR21_ CDR3a-短)
<400> 666
Cys Ala Met Ser Gly Gly Asn Ala Gly Asn Met Leu Thr
1 5 10
<210> 667
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR24_CDR1b)
<400> 667
Ser Glu His Asn Arg
1 5
<210> 668
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR24_ CDR1a)
<400> 668
Thr Ser Gly Phe Tyr Gly
1 5
<210> 669
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR24_ CDR2b)
<400> 669
Phe Gln Asn Glu Ala Gln
1 5
<210> 670
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR24_ CDR2a)
<400> 670
Asn Ala Leu Asp Gly Leu
1 5
<210> 671
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR24_CDR3b-短)
<400> 671
Cys Ala Ser Ser Pro Pro Gly Trp Glu Leu Ala Lys Asn Ile Gln Tyr
1 5 10 15
<210> 672
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR24_ CDR3a-短)
<400> 672
Cys Ala Gly Gly Asp Ser Ser Tyr Lys Leu Ile
1 5 10
<210> 673
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR23_CDR1b)
<400> 673
Trp Asn His Asn Asn
1 5
<210> 674
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR23_ CDR1a)
<400> 674
Ser Val Phe Ser Ser
1 5
<210> 675
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR23_ CDR2b)
<400> 675
Ser Tyr Gly Val Gln Asp
1 5
<210> 676
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR23_ CDR2a)
<400> 676
Val Val Thr Gly Gly Glu Val
1 5
<210> 677
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR23_CDR3b-短)
<400> 677
Cys Ala Ser Ser Glu Tyr Val Gly Ala His Glu Gln Tyr
1 5 10
<210> 678
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR23_ CDR3a-短)
<400> 678
Cys Ala Gly Val Arg Glu Ala Gly Gly Thr Ser Tyr Gly Lys Leu Thr
1 5 10 15
<210> 679
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR15_CDR1b)
<400> 679
Gly Thr Ser Asn Pro Asn
1 5
<210> 680
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR15_ CDR1a)
<400> 680
Asp Arg Gly Ser Gln Ser
1 5
<210> 681
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR15_ CDR2b)
<400> 681
Ser Val Gly Ile Gly
1 5
<210> 682
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR15_ CDR2a)
<400> 682
Ile Tyr Ser Asn Gly Asp
1 5
<210> 683
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR15_CDR3b-短)
<400> 683
Cys Ala Trp Thr Leu Thr Gly Phe Gly Gln Pro Gln His
1 5 10
<210> 684
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (TCR15_ CDR3a-短)
<400> 684
Cys Ala Val Asn Ala Arg Gly Asn Met Leu Thr
1 5 10
<210> 685
<211> 235
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (CD8 共同受体α链
含信号肽 )
<400> 685
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Ser Gln Phe Arg Val Ser Pro Leu Asp Arg Thr
20 25 30
Trp Asn Leu Gly Glu Thr Val Glu Leu Lys Cys Gln Val Leu Leu Ser
35 40 45
Asn Pro Thr Ser Gly Cys Ser Trp Leu Phe Gln Pro Arg Gly Ala Ala
50 55 60
Ala Ser Pro Thr Phe Leu Leu Tyr Leu Ser Gln Asn Lys Pro Lys Ala
65 70 75 80
Ala Glu Gly Leu Asp Thr Gln Arg Phe Ser Gly Lys Arg Leu Gly Asp
85 90 95
Thr Phe Val Leu Thr Leu Ser Asp Phe Arg Arg Glu Asn Glu Gly Tyr
100 105 110
Tyr Phe Cys Ser Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe
115 120 125
Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg
130 135 140
Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg
145 150 155 160
Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly
165 170 175
Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr
180 185 190
Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His
195 200 205
Arg Asn Arg Arg Arg Val Cys Lys Cys Pro Arg Pro Val Val Lys Ser
210 215 220
Gly Asp Lys Pro Ser Leu Ser Ala Arg Tyr Val
225 230 235
<210> 686
<211> 210
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (CD8 共受体β链
带有信号肽的同种型 1
<400> 686
Met Arg Pro Arg Leu Trp Leu Leu Leu Ala Ala Gln Leu Thr Val Leu
1 5 10 15
His Gly Asn Ser Val Leu Gln Gln Thr Pro Ala Tyr Ile Lys Val Gln
20 25 30
Thr Asn Lys Met Val Met Leu Ser Cys Glu Ala Lys Ile Ser Leu Ser
35 40 45
Asn Met Arg Ile Tyr Trp Leu Arg Gln Arg Gln Ala Pro Ser Ser Asp
50 55 60
Ser His His Glu Phe Leu Ala Leu Trp Asp Ser Ala Lys Gly Thr Ile
65 70 75 80
His Gly Glu Glu Val Glu Gln Glu Lys Ile Ala Val Phe Arg Asp Ala
85 90 95
Ser Arg Phe Ile Leu Asn Leu Thr Ser Val Lys Pro Glu Asp Ser Gly
100 105 110
Ile Tyr Phe Cys Met Ile Val Gly Ser Pro Glu Leu Thr Phe Gly Lys
115 120 125
Gly Thr Gln Leu Ser Val Val Asp Phe Leu Pro Thr Thr Ala Gln Pro
130 135 140
Thr Lys Lys Ser Thr Leu Lys Lys Arg Val Cys Arg Leu Pro Arg Pro
145 150 155 160
Glu Thr Gln Lys Gly Pro Leu Cys Ser Pro Ile Thr Leu Gly Leu Leu
165 170 175
Val Ala Gly Val Leu Val Leu Leu Val Ser Leu Gly Val Ala Ile His
180 185 190
Leu Cys Cys Arg Arg Arg Arg Ala Arg Leu Arg Phe Met Lys Gln Phe
195 200 205
Tyr Lys
210
<210> 687
<211> 221
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (CD8 共受体β链
带有信号肽的同种型 2 )
<400> 687
Met Arg Pro Arg Leu Trp Leu Leu Leu Ala Ala Gln Leu Thr Val Leu
1 5 10 15
His Gly Asn Ser Val Leu Gln Gln Thr Pro Ala Tyr Ile Lys Val Gln
20 25 30
Thr Asn Lys Met Val Met Leu Ser Cys Glu Ala Lys Ile Ser Leu Ser
35 40 45
Asn Met Arg Ile Tyr Trp Leu Arg Gln Arg Gln Ala Pro Ser Ser Asp
50 55 60
Ser His His Glu Phe Leu Ala Leu Trp Asp Ser Ala Lys Gly Thr Ile
65 70 75 80
His Gly Glu Glu Val Glu Gln Glu Lys Ile Ala Val Phe Arg Asp Ala
85 90 95
Ser Arg Phe Ile Leu Asn Leu Thr Ser Val Lys Pro Glu Asp Ser Gly
100 105 110
Ile Tyr Phe Cys Met Ile Val Gly Ser Pro Glu Leu Thr Phe Gly Lys
115 120 125
Gly Thr Gln Leu Ser Val Val Asp Phe Leu Pro Thr Thr Ala Gln Pro
130 135 140
Thr Lys Lys Ser Thr Leu Lys Lys Arg Val Cys Arg Leu Pro Arg Pro
145 150 155 160
Glu Thr Gln Lys Gly Pro Leu Cys Ser Pro Ile Thr Leu Gly Leu Leu
165 170 175
Val Ala Gly Val Leu Val Leu Leu Val Ser Leu Gly Val Ala Ile His
180 185 190
Leu Cys Cys Arg Arg Arg Arg Ala Arg Leu Arg Phe Met Lys Gln Leu
195 200 205
Arg Leu His Pro Leu Glu Lys Cys Ser Arg Met Asp Tyr
210 215 220
<210> 688
<211> 246
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (CD8 共受体β链
带有信号肽的同种型 3 )
<400> 688
Met Arg Pro Arg Leu Trp Leu Leu Leu Ala Ala Gln Leu Thr Val Leu
1 5 10 15
His Gly Asn Ser Val Leu Gln Gln Thr Pro Ala Tyr Ile Lys Val Gln
20 25 30
Thr Asn Lys Met Val Met Leu Ser Cys Glu Ala Lys Ile Ser Leu Ser
35 40 45
Asn Met Arg Ile Tyr Trp Leu Arg Gln Arg Gln Ala Pro Ser Ser Asp
50 55 60
Ser His His Glu Phe Leu Ala Leu Trp Asp Ser Ala Lys Gly Thr Ile
65 70 75 80
His Gly Glu Glu Val Glu Gln Glu Lys Ile Ala Val Phe Arg Asp Ala
85 90 95
Ser Arg Phe Ile Leu Asn Leu Thr Ser Val Lys Pro Glu Asp Ser Gly
100 105 110
Ile Tyr Phe Cys Met Ile Val Gly Ser Pro Glu Leu Thr Phe Gly Lys
115 120 125
Gly Thr Gln Leu Ser Val Val Asp Phe Leu Pro Thr Thr Ala Gln Pro
130 135 140
Thr Lys Lys Ser Thr Leu Lys Lys Arg Val Cys Arg Leu Pro Arg Pro
145 150 155 160
Glu Thr Gln Lys Gly Pro Leu Cys Ser Pro Ile Thr Leu Gly Leu Leu
165 170 175
Val Ala Gly Val Leu Val Leu Leu Val Ser Leu Gly Val Ala Ile His
180 185 190
Leu Cys Cys Arg Arg Arg Arg Ala Arg Leu Arg Phe Met Lys Gln Lys
195 200 205
Phe Asn Ile Val Cys Leu Lys Ile Ser Gly Phe Thr Thr Cys Cys Cys
210 215 220
Phe Gln Ile Leu Gln Ile Ser Arg Glu Tyr Gly Phe Gly Val Leu Leu
225 230 235 240
Gln Lys Asp Ile Gly Gln
245
<210> 689
<211> 246
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (CD8 共受体β链
带有信号肽的同种型 4
<400> 689
Met Arg Pro Arg Leu Trp Leu Leu Leu Ala Ala Gln Leu Thr Val Leu
1 5 10 15
His Gly Asn Ser Val Leu Gln Gln Thr Pro Ala Tyr Ile Lys Val Gln
20 25 30
Thr Asn Lys Met Val Met Leu Ser Cys Glu Ala Lys Ile Ser Leu Ser
35 40 45
Asn Met Arg Ile Tyr Trp Leu Arg Gln Arg Gln Ala Pro Ser Ser Asp
50 55 60
Ser His His Glu Phe Leu Ala Leu Trp Asp Ser Ala Lys Gly Thr Ile
65 70 75 80
His Gly Glu Glu Val Glu Gln Glu Lys Ile Ala Val Phe Arg Asp Ala
85 90 95
Ser Arg Phe Ile Leu Asn Leu Thr Ser Val Lys Pro Glu Asp Ser Gly
100 105 110
Ile Tyr Phe Cys Met Ile Val Gly Ser Pro Glu Leu Thr Phe Gly Lys
115 120 125
Gly Thr Gln Leu Ser Val Val Asp Phe Leu Pro Thr Thr Ala Gln Pro
130 135 140
Thr Lys Lys Ser Thr Leu Lys Lys Arg Val Cys Arg Leu Pro Arg Pro
145 150 155 160
Glu Thr Gln Lys Gly Pro Leu Cys Ser Pro Ile Thr Leu Gly Leu Leu
165 170 175
Val Ala Gly Val Leu Val Leu Leu Val Ser Leu Gly Val Ala Ile His
180 185 190
Leu Cys Cys Arg Arg Arg Arg Ala Arg Leu Arg Phe Met Lys Gln Lys
195 200 205
Phe Asn Ile Val Cys Leu Lys Ile Ser Gly Phe Thr Thr Cys Cys Cys
210 215 220
Phe Gln Ile Leu Gln Ile Ser Arg Glu Tyr Gly Phe Gly Val Leu Leu
225 230 235 240
Gln Lys Asp Ile Gly Gln
245
<210> 690
<211> 243
<212> PRT
<213> 人工序列
<220>
<223> 合成序列 (CD8 共受体β链
带有信号肽的同种型 5
<400> 690
Met Arg Pro Arg Leu Trp Leu Leu Leu Ala Ala Gln Leu Thr Val Leu
1 5 10 15
His Gly Asn Ser Val Leu Gln Gln Thr Pro Ala Tyr Ile Lys Val Gln
20 25 30
Thr Asn Lys Met Val Met Leu Ser Cys Glu Ala Lys Ile Ser Leu Ser
35 40 45
Asn Met Arg Ile Tyr Trp Leu Arg Gln Arg Gln Ala Pro Ser Ser Asp
50 55 60
Ser His His Glu Phe Leu Ala Leu Trp Asp Ser Ala Lys Gly Thr Ile
65 70 75 80
His Gly Glu Glu Val Glu Gln Glu Lys Ile Ala Val Phe Arg Asp Ala
85 90 95
Ser Arg Phe Ile Leu Asn Leu Thr Ser Val Lys Pro Glu Asp Ser Gly
100 105 110
Ile Tyr Phe Cys Met Ile Val Gly Ser Pro Glu Leu Thr Phe Gly Lys
115 120 125
Gly Thr Gln Leu Ser Val Val Asp Phe Leu Pro Thr Thr Ala Gln Pro
130 135 140
Thr Lys Lys Ser Thr Leu Lys Lys Arg Val Cys Arg Leu Pro Arg Pro
145 150 155 160
Glu Thr Gln Lys Gly Pro Leu Cys Ser Pro Ile Thr Leu Gly Leu Leu
165 170 175
Val Ala Gly Val Leu Val Leu Leu Val Ser Leu Gly Val Ala Ile His
180 185 190
Leu Cys Cys Arg Arg Arg Arg Ala Arg Leu Arg Phe Met Lys Gln Pro
195 200 205
Gln Gly Glu Gly Ile Ser Gly Thr Phe Val Pro Gln Cys Leu His Gly
210 215 220
Tyr Tyr Ser Asn Thr Thr Thr Ser Gln Lys Leu Leu Asn Pro Trp Ile
225 230 235 240
Leu Lys Thr
<210> 691
<211> 704
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (编码CD8的多核苷酸
共同受体α链 )
<400> 691
atggctctgc ctgtgacagc tctgctgctg cctctggctc tgcttctgca tgccgctaga 60
cccagccagt tcagagtgtc ccctctggac agaacctgga acctgggcga gacagtggaa 120
ctgaagtgcc aggtgctgct gagcaatcct accagcggct gcagctggct gtttcagcct 180
agaggtgctg ccgcctctcc tacctttctg ctgtacctga gccagaacaa gcccaaggcc 240
gccgaaggac tggacaccca gagattcagc ggcaagagac tgggcgacac cttcgtgctg 300
accctgagcg acttcagaag agagaacgag ggctactact tctgcagcgc cctgagcaac 360
agcatcatgt acttcagcca cttcgtgccc gtgtttctgc ccgccaagcc tacaacaacc 420
cctgctccta gacctcctac accagctcct acaatcgcca gccagcctct gtctctgagg 480
ccagaagctt gtagacctgc tgctggcgga gccgtgcata caagaggact ggatttcgcc 540
tgcgacatct acatctgggc ccctctggct ggaacatgtg gcgtgctgct gctgtccctg 600
gtcatcaccc tgtactgcaa ccaccggaac aggcggagag tgtgcaagtg ccctagacct 660
gtggtcaaga gcggcgacaa gcctagcctg agcgccagat atgt 704
<210> 692
<211> 630
<212> DNA
<213> 人工序列
<220>
<223> 合成序列 (编码CD8的多核苷酸
共受体β链 )
<400> 692
atgaggccta gactgtggct gcttctggct gcccagctga cagtgctgca cggcaattct 60
gtcctgcagc agacccctgc ctacatcaag gtgcagacca acaagatggt catgctgagc 120
tgcgaggcca agatcagcct gtccaacatg cggatctact ggctgcggca gagacaggcc 180
cctagctctg atagccacca cgagtttctg gccctgtggg attctgccaa gggcaccatt 240
cacggcgagg aagtggaaca agagaagatc gccgtgttcc gggacgccag cagattcatc 300
ctgaacctga ccagcgtgaa gcccgaggac agcggcatct atttctgcat gatcgtgggc 360
agccccgagc tgacatttgg caagggaaca cagctgagcg tggtggactt cctgcctact 420
acagcccagc ctaccaagaa gtctaccctg aagaaacgcg tgtgcagact gcccaggcct 480
gagacacaaa agggccctct gtgcagccct atcacactgg gattgctggt ggctggcgtt 540
ctggtcctgc tggtgtctct gggagttgcc atccacctgt gctgtagaag aaggcgggcc 600
agactgcggt tcatgaagca gttctacaaa 630
<210> 693
<211> 1398
<212> DNA
<213> 人工序列
<220>
<223> 合成序列编码CD8的多核苷酸
共受体β链自切割肽-CD8
共同受体α链 )
<400> 693
atggctctgc ctgtgacagc tctgctgctg cctctggctc tgcttctgca tgccgctaga 60
cccagccagt tcagagtgtc ccctctggac agaacctgga acctgggcga gacagtggaa 120
ctgaagtgcc aggtgctgct gagcaatcct accagcggct gcagctggct gtttcagcct 180
agaggtgctg ccgcctctcc tacctttctg ctgtacctga gccagaacaa gcccaaggcc 240
gccgaaggac tggacaccca gagattcagc ggcaagagac tgggcgacac cttcgtgctg 300
accctgagcg acttcagaag agagaacgag ggctactact tctgcagcgc cctgagcaac 360
agcatcatgt acttcagcca cttcgtgccc gtgtttctgc ccgccaagcc tacaacaacc 420
cctgctccta gacctcctac accagctcct acaatcgcca gccagcctct gtctctgagg 480
ccagaagctt gtagacctgc tgctggcgga gccgtgcata caagaggact ggatttcgcc 540
tgcgacatct acatctgggc ccctctggct ggaacatgtg gcgtgctgct gctgtccctg 600
gtcatcaccc tgtactgcaa ccaccggaac aggcggagag tgtgcaagtg ccctagacct 660
gtggtcaaga gcggcgacaa gcctagcctg agcgccagat atgttggcag cggagaaggc 720
agaggctccc tgcttacatg cggcgacgtg gaagagaacc ccggacctat gaggcctaga 780
ctgtggctgc ttctggctgc ccagctgaca gtgctgcacg gcaattctgt cctgcagcag 840
acccctgcct acatcaaggt gcagaccaac aagatggtca tgctgagctg cgaggccaag 900
atcagcctgt ccaacatgcg gatctactgg ctgcggcaga gacaggcccc tagctctgat 960
agccaccacg agtttctggc cctgtgggat tctgccaagg gcaccattca cggcgaggaa 1020
gtggaacaag agaagatcgc cgtgttccgg gacgccagca gattcatcct gaacctgacc 1080
agcgtgaagc ccgaggacag cggcatctat ttctgcatga tcgtgggcag ccccgagctg 1140
acatttggca agggaacaca gctgagcgtg gtggacttcc tgcctactac agcccagcct 1200
accaagaagt ctaccctgaa gaaacgcgtg tgcagactgc ccaggcctga gacacaaaag 1260
ggccctctgt gcagccctat cacactggga ttgctggtgg ctggcgttct ggtcctgctg 1320
gtgtctctgg gagttgccat ccacctgtgc tgtagaagaa ggcgggccag actgcggttc 1380
atgaagcagt tctacaaa 1398
Claims (93)
1.一种结合蛋白,包含T细胞受体(TCR)α链可变(Vα)域和TCRβ链可变(Vβ)域,其中结合蛋白能够结合肽:HLA复合物,其中所述肽包含氨基酸序列KLVVVGAVGV(SEQ ID NO:198)或由其组成,以及其中HLA包括HLA-A*02,任选地HLA-A*02:01。
2.根据权利要求1所述的结合蛋白,其中所述结合蛋白能够由人T细胞异源表达。
3.根据权利要求1或2的结合蛋白,其中Vα结构域和/或Vβ结构域各自独立地是人的、人源化的或嵌合的,并且优选地各自是人。
4.根据权利要求1-3任一项的结合蛋白,其中,当结合蛋白由人T细胞表达时,人T细胞能够特异性杀伤HLA-A*02+肿瘤细胞,其表达包含SEQ ID NO:198中所列氨基酸序列或由其组成的肽。
5.根据权利要求1-4任一项的结合蛋白,其中,当结合蛋白由人T细胞表达时,当存在表达肽的HLA-A*02+肿瘤细胞时,人T细胞具有升高的CD137表达,其中肽包含SEQ ID NO:198中列出的氨基酸序列或由其组成,任选地在进一步存在外源性IFN-γ的情况下,其中CD137表达与以下相比升高:
(i)当参考人T细胞存在肿瘤细胞时,不表达结合蛋白的参考人T细胞表达CD137;和/或
(ii)当不存在肿瘤细胞和/或不存在表达肽:HLA复合物的抗原呈递细胞时,表达结合蛋白的人T细胞表达CD137,其中肽包含SEQ ID NO:198中列出的氨基酸序列或由其组成,并且其中HLA任选地是HLA-A*02:01。
6.根据权利要求1-5任一项的结合蛋白,其中,当结合蛋白由人T细胞表达时,当肽以至少约10-10M、至少约10-9M和/或至少约10-8M的浓度存在时,当存在包含SEQ ID NO.:198所示氨基酸序列或由其组成的肽时,人T细胞产生IFN-γ。
7.根据权利要求1-6中任一项所述的结合蛋白,其中,表达结合蛋白的多个人T细胞的至少约10%、至少约15%、至少约20%或至少约25%的多个人T细胞当存在10-9M肽时产生IFN-γ。
8.根据权利要求6或7所述的结合蛋白,其中,表达结合蛋白的多个人T细胞的至少约25%、至少约30%、或至少约35%的多个人T细胞当存在10-8M肽时产生IFN-γ。
9.根据权利要求4-8中任一项所述的结合蛋白,其中当存在0.1ng/mL或更多肽时,人T细胞或多个人T细胞产生IFN-γ,其中肽包含氨基酸序列KLVVVGAVGV(SEQ ID NO:198)或由其组成,其中任选地,当存在1ng/mL包含氨基酸序列KLVVVGAVGV(SEQ ID NO:198)或由其组成的肽时比存在10,000ng/mL包含SEQ ID NO:1的5-14氨基酸或由其组成的肽时,人T细胞或多个人T细胞产生更多的IFN-γ。
10.根据权利要求1-9中任一项所述的结合蛋白,结合蛋白对于包含SEQ ID NO:198中列出的氨基酸序列或由其组成的肽具有log10EC50,其中,SEQ ID NO:198具有小于-8.0,任选约-8.5或更小,进一步任选约-8.5、约-8.6、约-8.7、约-8.8、约-8.9、约-9、约-9.1或约-9.2。
11.根据权利要求4-10中任一项所述的结合蛋白,其中:
(i)结合蛋白由与人T细胞异源的多核苷酸编码;
(ii)人T细胞包括CD8+T细胞、CD4+T细胞或两者;
(iii)表达包含SEQ ID NO:198所示氨基酸序列或由其组成的肽的肿瘤细胞是HLA-A*02:01+;和/或
(iv)肿瘤细胞包含CFPAC-1细胞。
12.根据权利要求1-11中任一项所述的结合蛋白,其中结合蛋白能够不依赖于或不存在CD8而结合肽:HLA复合物。
13.根据权利要求1-12中任一项所述的结合蛋白,其中:
(i)Vα结构域包含根据Vα氨基酸序列的CDR1α、CDR2α和/或CDR3α氨基酸序列,其中Vα氨基酸序列是以下SEQ ID NO.中任一项:351、343、359、367、375、383、391、399、407、415、423、431、439、447、455、463、471或479;和/或
(ii)Vβ结构域包含根据Vβ氨基酸序列的CDR1β、CDR2β和/或CDR3β氨基酸序列,其中Vβ氨基酸序列是以下的SEQ ID NO.中任一项:354、346、362、370、378、386、394、402、410、418、426、434、442、450、458、466、474、482或490。
14.根据权利要求1-13任一项的结合蛋白,包含Vα和Vβ氨基酸序列的CDR1α、CDR2α、CDR3α和CDR1β、CDR2β和CDR3β氨基酸序列,Vα和Vβ氨基酸序列为如下:
(i)分别为SEQ ID NO:351和354;
(ii)分别为SEQ ID NO:343和346;
(iii)分别为SEQ ID NO:359和362;
(iv)分别为SEQ ID NO:367和370;
(v)分别为SEQ ID NO:375和378;
(vi)分别为SEQ ID NO:383和386;
(vii)分别为SEQ ID NO:391和394;
(viii)分别为SEQ ID NO:399和402;
(ix)分别为SEQ ID NO:407和410;
(x)分别为SEQ ID NO:415和418;
(xi)分别为SEQ ID NO:423和426;
(xii)分别为SEQ ID NO:431和434;
(xiii)分别为SEQ ID NO:439和442;
(xiv)分别为SEQ ID NO:447和450;
(xv)分别为SEQ ID NO:455和458;
(xvi)分别为SEQ ID NO:463和466;
(xvii)分别为SEQ ID NO:471和474;
(xviii)分别为SEQ ID NO:479和482;或
(xix)分别为SEQ ID NO:487和490。
15.根据权利要求1-14任一项的结合蛋白,包括:(i)SEQ ID NO:228、222、234、240、246、252、258、264、270、276、282、288、294、300、306、312、318、324或340或其变体中任一项所列的CDR3α氨基酸序列,其中变体包括一种、二种或三种氨基酸置换;和/或
(ii)SEQ ID NO:225、219、231、237、243、249、255、261、267、273、279、285、291、297、303、309、315、321或327,或其变体中任一项所示的CDR3β氨基酸序列,其中变体包括一种、二种或三种氨基酸置换,和/或
(iii)SEQ ID NO:226、220、232、238、244、250、256、262、268、274、280、286、292、298、304、316、322或328或其变体中任一项所示的CDR1α氨基酸序列,其中变体包含一个、两个或三个氨基酸取代;和/或
(iv)SEQ ID NO:223、217、229、235、241、247、253、259、265、271、277、283、289、295、301、307、313、319或325,或其变体中任一项所示的CDR1β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代;和/或
(v)SEQ ID NO:227、221、233、239、245、251、257、263、269、275、281、287、293、299、305、311、317、323、或329,或其变体中任一项所示的CDR2β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代;和/或
(vi)SEQ ID NO:224、218、230、236、242、248、254、260、266、272、278、284、290、296、302、308、314、320或326,或其变体中任一项所示的CDR2β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代。
16.根据权利要求1-15中任一项所述的结合蛋白,其包含以下所列的CDR1α、CDR2α、CDR3α、CDR1β、CDR2β和CDR3β氨基酸序列:
(i)SEQ ID NO:分别226、227、228、223、224、和225;
(ii)SEQ ID NO:分别220、221、222、217、218、和219;
(iii)SEQ ID NO:分别232、233、234、229、230、和231;
(iv)SEQ ID NO:分别238、239、240、235、236、和237;
(v)SEQ ID NO:分别244、245、246、241、242、和243;
(vi)SEQ ID NO:分别250、251、252、247、248、和249;
(vii)SEQ ID NO:分别256、257、258、253、254、和255;
(viii)SEQ ID NO:分别262、263、264、259、260、和261;
(ix)SEQ ID NO:分别268、269、270、265、266、和267;
(x)SEQ ID NO:分别274、275、276、271、272、和273;
(xi)SEQ ID NO:分别280、281、282、277、278、和279;
(xii)SEQ ID NO:分别286、287、288、283、284、和285;
(viii)SEQ ID NO:分别292、293、294、289、290、和291;
(xiv)SEQ ID NO:分别298、299、300、295、296、和297;
(xv)SEQ ID NO:分别304、305、306、301、302、和303;
(xvi)SEQ ID NO:分别310、311、312、307、308、和309;
(xvii)SEQ ID NO:分别316、317、318、313、314、和315;
(xviii)SEQ ID NO:分别322、323、324、319、320、和321;
(xix)SEQ ID NO:分别328、329、330、325、326、和327。
17.根据权利要求1-16中任一项所述的结合蛋白,其中:
(i)Vα结构域包含氨基酸序列或由其组成,所述氨基酸序列具有与以下任一项至少90%的同一性:SEQ ID NO.:351、343、359、367、375、383、391、399、407、415、423、431、439、447、455、463、471或479;和/或
(ii)Vβ结构域包含氨基酸序列或由其组成,所述氨基酸序列具有与以下任一项至少90%的同一性:SEQ ID NO.:354、346、362、370、378、386、394、402、410、418、426、434、442、450、458、466、474、482或490。
18.根据权利要求1-17中任一项所述的结合蛋白,其中所述Vα结构域和所述Vβ结构域包含以下氨基酸序列或由以下氨基酸序列组成:
(i)分别为SEQ ID NO:351和354;
(ii)分别为SEQ ID NO:343和346;
(iii)分别为SEQ ID NO:359和362;
(iv)分别为SEQ ID NO:367和370;
(v)分别为SEQ ID NO:375和378;
(vi)分别为SEQ ID NO:383和386;
(vii)分别为SEQ ID NO:391和394;
(viii)分别为SEQ ID NO:399和402;
(ix)分别为SEQ ID NO:407和410;
(x)分别为SEQ ID NO:415和418;
(xi)分别为SEQ ID NO:423和426;
(xii)分别为SEQ ID NO:431和434;
(viii)分别为SEQ ID NO:439和442;
(xiv)分别为SEQ ID NO:447和450;
(xv)分别为SEQ ID NO:455和458;
(xvi)分别为SEQ ID NO:463和466;
(xvii)分别为SEQ ID NO:471和474;
(xviii)分别为SEQ ID NO:479和482;或
(xix)分别为SEQ ID NO:487和490。
19.根据权利要求1-18中任一项所述的结合蛋白,进一步包含TCRα链恒定域(Cα)和/或TCRβ链恒定域(Cβ)。
20.根据权利要求19的结合蛋白,其中Cα包含与SEQ ID NO.:85或86中列出的氨基酸序列具有至少90%同一性的氨基酸序列或由其组成。
21.根据权利要求19或20的结合蛋白,其中Cβ包含与SEQ ID NOs.:87-99中任一项所述的氨基酸序列具有至少90%同一性的氨基酸序列或由其组成。
22.根据权利要求1-21任一项的结合蛋白,包含TCRα链和TCRβ链,其中TCRα链和TCRβ链包含与下述氨基酸序列具有至少90%同一性的氨基酸序列或由其组成:
(i)分别为SEQ ID NO:350和353;
(ii)分别为SEQ ID NO:342和345;
(iii)分别为SEQ ID NO:358和361;
(iv)分别为SEQ ID NO:366和369;
(v)分别为SEQ ID NO:374和377;
(vi)分别为SEQ ID NO:382和385;
(vii)分别为SEQ ID NO:390和393;
(viii)分别为SEQ ID NO:398和401;
(ix)分别为SEQ ID NO:406和409;
(x)分别为SEQ ID NO:414和417;
(xi)分别为SEQ ID NO:422和425;
(xii)分别为SEQ ID NO:430和433;
(viii)分别为SEQ ID NO:438和441;
(xiv)分别为SEQ ID NO:446和449;
(xv)分别为SEQ ID NO:454和457;
(xvi)分别为SEQ ID NO:462和465;
(xvii)分别为SEQ ID NO:470和473;
(xviii)分别为SEQ ID NO:478和481;
或(xix)分别为SEQ ID NO:486和489。
23.根据权利要求1-22中任一项所述的结合蛋白,其中所述结合蛋白包括TCR、单链TCR(scTCR)或嵌合抗原受体(CAR)。
24.根据权利要求23所述的结合蛋白,其中所述结合蛋白包含TCR。
25.根据权利要求23所述的结合蛋白,其中所述结合蛋白包含scTCR。
26.根据权利要求23所述的结合蛋白,其中所述结合蛋白包含CAR。
27.一种结合蛋白,包含T细胞受体(TCR)α链可变(Vα)结构域和TCRβ链可变(Vβ)结构域,其中结合蛋白能够结合以下任何一种或多种:
(i)肽:HLA复合物,其中所述肽包含氨基酸序列VVVGAVGVGK(SEQ ID NO:2)或由其组成;
(ii)肽:HLA复合物,其中所述肽包含氨基酸序列VVGAVGVGK(SEQ ID NO:3)或由其组成;
(iii)肽:HLA复合物,其中所述肽包含氨基酸序列VVGADGVGK(SEQ ID NO:4)或由其组成;或者
(iv)肽:HLA复合物,其中所述肽包含氨基酸序列VVVGADGVGK(SEQ ID NO:5)或由其组成,
其中Vα结构域和/或Vβ结构域各自独立地是人的、人源化的或嵌合的,并且优选地各自是人,
并且其中结合蛋白能够由人T细胞异源表达。
28.根据权利要求27所述的结合蛋白,其中所述HLA包含HLA-A*11,任选地HLA-A*11:01。
29.根据权利要求27或28的结合蛋白,其中,当结合蛋白由人T细胞表达时,人T细胞能够特异性杀死HLA-A*11+肿瘤细胞,所述肿瘤细胞在其细胞表面表达或展示包含或由SEQID NO:2-5中的任何一个或多个所列氨基酸序列组成的肽,其中,任选地,表达的结合蛋白由与人T细胞异源的多核苷酸编码。
30.根据权利要求29的结合蛋白,其中肿瘤细胞包括Panc-1细胞、AsPc-1细胞、CFPAC-1细胞、Capan-2细胞、THP-1细胞、GA-10.4细胞或其任何组合。
31.根据权利要求27-30中任一项所述的结合蛋白,其中,当所述结合蛋白由人T细胞表达时,当存在以下情况时,所述人T细胞具有升高的CD137表达:(vi)包含或由SEQ ID NO:4中列出的氨基酸序列组成的肽和包含或由SEQ ID NO:5中列出的氨基酸序列组成的肽,其中当参考人T细胞存在肽时,与不表达结合蛋白的参考人T细胞的CD137表达相比,CD137表达升高,和/或与表达结合蛋白的人T细胞的CD137表达相比,当存在包含SEQ ID NO:2或SEQID NO:3所示氨基酸序列或由其组成的肽时,并且其中(i)-(vi)中任一项的肽任选地在人T细胞存在下由肿瘤细胞表达:
(i)包含SEQ ID NO:2所列氨基酸序列或由其组成的肽;
(ii)包含SEQ ID NO:3所列氨基酸序列或由其组成的肽;
(iii)包含SEQ ID NO:4所列氨基酸序列或由其组成的肽;
(iv)包含SEQ ID NO:5所列氨基酸序列或由其组成的肽;
(v)包含SEQ ID NO:2所列氨基酸序列或由其组成的肽和包含SEQ ID NO:3所列氨基酸序列或由其组成的肽;和/或
(vi)包含SEQ ID NO.:4所列氨基酸序列或由其组成的肽和包含或由SEQ ID NO:5中列出的氨基酸序列组成的肽;
其中当参考人T细胞存在肽时,与不表达结合蛋白的参考人T细胞的CD137表达相比,和/或与表达结合蛋白的人T细胞的CD137表达相比,当存在包含SEQ ID NO.:2或SEQ IDNO:3所示氨基酸序列或由其组成的肽时,CD137表达升高,
并且其中(i)-(vi)中任一项的肽任选地在人T细胞存在下由肿瘤细胞表达。
32.根据权利要求27-31中任一项所述的结合蛋白,其具有:
(i)包含SEQ ID NO.:2或3中列出的氨基酸序列或由其组成的肽的log10EC50小于-6.5,任选地约-7.0、约-7.5或约-8.0或小于-8.0,任选地约-8.0、约-8.1、约-8.2、约-8.3、约-8.4、约-8.5;和/或
(ii)包含SEQ ID NO.:4或5中列出的氨基酸序列或由其组成的肽的log10EC50小于-7.0或小于-8.0,任选地约-7.5、约-7.6、约-7.7、约-7.8、约-8.0、约-8.1、约-8.2、约-8.3、约-8.4、约-8.5、约-8.6、约-8.7、约-8.8,或大约-8.9。
33.根据权利要求27-32中任一项所述的结合蛋白,其中,当所述结合蛋白由人T细胞表达时,当存在以下情况时,所述人T细胞产生IFN-γ:
(i)包含或由SEQ ID NO:2中列出的氨基酸序列组成的肽;和/或
(ii)包含或由SEQ ID NO:3中列出的氨基酸序列组成的肽;和/或
(iii)包含或由SEQ ID NO:4中列出的氨基酸序列组成的肽;和/或
(v)包含或由SEQ ID NO:5中列出的氨基酸序列组成的肽,
当肽以至少约10-11M、至少约10-10M、至少约10-9M和/或至少约10-8M的浓度存在时。
34.根据权利要求33的结合蛋白,其中,在表达结合蛋白的多个人T细胞中,当存在10-8M肽、10-7M肽或10-6M肽时,至少约50%、至少约55%、至少约60%或更多人T细胞产生IFN-γ。
35.根据权利要求33或34中任一项所述的结合蛋白,其中,在表达所述结合蛋白的多个人T细胞中:
(i)当存在10ng/mL包含或由SEQ ID NO:4中列出的氨基酸序列组成的肽时,至少约10%、15%、20%或25%的多个人T细胞产生IFN-γ;
(ii)当存在100ng/mL包含SEQ ID NO:4中列出的氨基酸序列或由其组成的肽时,至少约25%的多个人T细胞产生IFN-γ;
(iii)当存在10ng/mL包含SEQ ID NO:3中列出的氨基酸序列或由其组成的肽时,至少约10%、15%、20%或25%的多个人T细胞产生IFN-γ;和/或
(iii)当存在100ng/mL包含SEQ ID NO:3中列出的氨基酸序列或由其组成的肽时,至少约50%或至少约75%的多个人T细胞产生IFN-γ。
36.根据权利要求1-35中任一项所述的结合蛋白,其中,当结合蛋白由人T细胞表达时,当存在包含SEQ ID NO.:1的氨基酸7-16或8-16或由其组成的肽时,人T细胞基本上不产生IFN-γ。
37.根据权利要求27-36中任一项所述的结合蛋白,其中:
(i)Vα结构域包含根据Vα氨基酸序列的CDR1α、CDR2α和/或CDR3α氨基酸序列,Vα氨基酸序列是以下所示的任一个:SEQ ID NO.:76、62、64、68、70、72、74、78、80、82、84、502、512、522、532、542、552、562、572、582、592、602或612;和/或
(ii)Vβ结构域包含根据Vβ氨基酸序列的CDR1β、CDR2β和/或CDR3β氨基酸序列Vβ氨基酸序列是以下所示中的任一个:SEQ ID NO.:75、61、63、65、67、69、71、73、77、79、81、83、501、511、521、531、541、511、531、541、551、561、571、581、591、601或611。
38.根据权利要求27-37任一项的结合蛋白,包含CDR1α、CDR2α、CDR3α和CDR1β、CDR2β和CDR3β氨基酸序列,根据以下所列的Vα和Vβ氨基酸序列:
(i)分别为SEQ ID NO:76和75;
(ii)分别为SEQ ID NO:62和61;
(iii)分别为SEQ ID NO:64和63;
(iv)分别为SEQ ID NO:66和65;
(v)分别为SEQ ID NO:68和67;
(vi)分别为SEQ ID NO:70和69;
(vii)分别为SEQ ID NO:72和71;
(viii)分别为SEQ ID NO:74和73;
(ix)分别为SEQ ID NO:78和77;
(x)分别为SEQ ID NO:80和79;
(xi)分别为SEQ ID NO:82和81;
(xii)分别为SEQ ID NO:84和83;
(xiii)分别为SEQ ID NO:522和521;
(xiv)分别为SEQ ID NO:532和531;
(xv)分别为SEQ ID NO:542和541;
(xvi)分别为SEQ ID NO:552和551;
(xvii)分别为SEQ ID NO:562和561;
(xviii)分别为SEQ ID NO:572和571;
(xix)分别为SEQ ID NO:582和581;
(xx)分别为SEQ ID NO:592和591;
(xxi)分别为SEQ ID NO:602和601;
(xxii)分别为SEQ ID NO:612和611;
(xxiii)分别为SEQ ID NO:502和501;或
(xxiv)分别为SEQ ID NO:512和511。
39.根据权利要求27-38中任一项所述的结合蛋白,包括:
(i)SEQ ID NO:660、27、10、618、12、624、14、15、630、19、17、636、21、642、23、648、25、654、29、666、31、672、33、678、35、684、495、505、515、525、535、545、555、565、575、585、595或605,或其变体中任一项所列的CDR3α氨基酸序列,其中,变体包含一个、两个或三个氨基酸取代;和/或
(ii)SEQ ID NO:659、26、9、617、11、623、13、629、18、16、635、20、641、22、647、24、653、26、659、28、665、30、671、32、677、498、508、518、528、538、548、558、568、578、588、598或608或其变体中任一项所示的CDR3β氨基酸序列,其中变体包括一个、两个或三个氨基酸取代;和/或
(iii)SEQ ID NO:656、614、620、626、632、638、644、650、656、662、668、674、680、493、503、513、523、533、543、553、563、573、583、或603,或其变体中任一项所示的CDR1α氨基酸序列,其中变体包含一个、两个或三个氨基酸取代;和/或
(iv)SEQ ID NO.:655、613、619、625、631、637、643、649、661、667、673、679、496、506、516、526、536、546、556、566、576、586、596、或606,或其变体中任一项所示的CDR1β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代;和/或
(v)SEQ ID NO.:658、616、622、628、634、640、646、652、664、670、676、682、494、504、514、524、534、544、554、564、574、584、594、或604,或其变体中任一项所示的CDR2α氨基酸序列,其中变体包含一个、两个或三个氨基酸取代;和/或
(vi)SEQ ID NO.:657、615、621、627、633、639、645、651、657、663、669、675、681、497、507、517、527、537、547、557、567、587、597、或607,或其变体中任一项所示的CDR2β氨基酸序列,其中变体包含一个、两个或三个氨基酸取代。
40.根据权利要求27-39中任一项所述的结合蛋白,其包含以下所列的CDR1α、CDR2α、CDR3α、CDR1β、CDR2β和CDR3β氨基酸序列:
(i)SEQ ID NO:分别为656、658、660或27、655、657和659或26;
(ii)SEQ ID NO:分别为614、616、618或10、613、615和617或9;
(iii)SEQ ID NO:分别为620、622、624或12、619、621和629或13;
(iv)SEQ ID NO:分别为626、628、630或14或15、625、627和629或13;
(v)SEQ ID NO:分别为632、634、636或17或19、631、633和635或18或16;
(vi)SEQ ID NO:分别为638、640、642或21或17、637、639和641或20或16;
(vii)SEQ ID NO:分别为644、646、648或23、643、645和647或22;
(viii)SEQ ID NO:分别为650、652、654或25、649、651和653或24;
(ix)SEQ ID NO:分别为662、664、666或29、661、663和665或28;
(x)SEQ ID NO:分别为668、670、672或31、667、669和671或30;
(xi)SEQ ID NO:分别为674、676、678或33、673、675和677或32;
(xii)SEQ ID NO:分别为680、682、684或35、679、681和683或34;
(xii)SEQ ID NO:分别为493-498;
(xiv)SEQ ID NO:分别为503-508;
(xv)SEQ ID NO:分别为513-518;
(xvi)SEQ ID NO:分别为523-528;
(xvii)SEQ ID NO:分别为533-538;
(xviii)SEQ ID NO:分别为543-548;
(xix)SEQ ID NO:分别为553-558;
(xx)SEQ ID NO:分别为563-568;
(xxi)SEQ ID NO:分别为573-578;
(xxii)SEQ ID NO:分别为583-588;
(xxiii)SEQ ID NO:分别为593-598;或
(xxiv)分别为SEQ ID NO:603-608。
41.根据权利要求27-40中任一项所述的结合蛋白,其中:
(i)Vα结构域包含与SEQ ID NO.:76、62、64、68、70、72、74、78、80、82、84、502、512、522、532、542、552、562、572、582、592、602或612中任一项中列出的氨基酸序列具有至少90%同一性的氨基酸序列或由其组成;和/或
(ii)Vβ结构域包含与SEQ ID NOs.:75、61、63、65、67、69、71、73、77、79、81、83、501、511、521、531、541、551、561、571、581、591、601或611中任一项所示的氨基酸序列具有至少90%同一性的氨基酸序列或由其组成。
42.根据权利要求27-41中任一项所述的结合蛋白,其中所述Vα结构域和所述Vβ结构域包含以下氨基酸序列或由其组成:
(i)分别为SEQ ID NO:76和75;
(ii)分别为SEQ ID NO:62和61;
(iii)分别为SEQ ID NO:64和63;
(iv)分别为SEQ ID NO:66和65;
(v)分别为SEQ ID NO:68和67;
(vi)分别为SEQ ID NO:70和69;
(vii)分别为SEQ ID NO:72和71;
(viii)分别为SEQ ID NO:74和73;
(ix)分别为SEQ ID NO:78和77;
(x)分别为SEQ ID NO:80和79;
(xi)分别为SEQ ID NO:82和81;
(xii)分别为SEQ ID NO:84和83;
(xiii)分别为SEQ ID NO:522和521;
(xiv)分别为SEQ ID NO:532和531;
(xv)分别为SEQ ID NO:542和541;
(xvi)分别为SEQ ID NO:552和551;
(xvii)分别为SEQ ID NO:562和561;
(xviii)分别为SEQ ID NO:572和571;
(xix)分别为SEQ ID NO:582和581;
(xx)分别为SEQ ID NO:592和591;
(xxi)分别为SEQ ID NO:602和601;
(xxii)分别为SEQ ID NO:612和611;
(xxiii)分别为SEQ ID NO:502和501;
(xxiv)分别为SEQ ID NO:512和511。
43.根据权利要求27-42中任一项所述的结合蛋白,进一步包含TCRα链恒定域(Cα)和/或TCRβ链恒定域(Cβ)。
44.根据权利要求43的结合蛋白,其中Cα包含与SEQ ID NO.:85或86中列出的氨基酸序列具有至少90%同一性的氨基酸序列或由其组成。
45.根据权利要求43或44的结合蛋白,其中Cβ包含与SEQ ID NO.:87-99中任一项所述的氨基酸序列具有至少90%同一性的氨基酸序列或由其组成。
46.根据权利要求27-45任一项的结合蛋白,包含TCRα链和TCRβ链,其中TCRα链和TCRβ链包含与下述氨基酸序列具有至少90%同一性的氨基酸序列或由其组成:
(i)分别为SEQ ID NO:115和114;
(ii)分别为SEQ ID NO:101和100;
(iii)分别为SEQ ID NO:103和102;
(iv)分别为SEQ ID NO:105和104;
(v)分别为SEQ ID NO:107和106;
(vi)分别为SEQ ID NO:109和108;
(vii)分别为SEQ ID NO:111和110;
(viii)分别为SEQ ID NO:113和112;
(ix)分别为SEQ ID NO:117和116;
(x)分别为SEQ ID NO:119和118;
(xi)分别为SEQ ID NO:121和120;或
(xii)分别为SEQ ID NO:123和122。
47.根据权利要求27-46中任一项所述的结合蛋白,其中所述结合蛋白包括TCR、单链TCR(scTCR)或嵌合抗原受体(CAR)。
48.根据权利要求47所述的结合蛋白,其中所述结合蛋白包含TCR。
49.根据权利要求47所述的结合蛋白,其中所述结合蛋白包含scTCR。
50.根据权利要求47所述的结合蛋白,其中所述结合蛋白包含CAR。
51.一种编码权利要求1-50中任一项的结合蛋白的分离的多核苷酸。
52.根据权利要求51的多核苷酸,包含与以下的任一所述的多核苷酸序列具有至少75%同一性的多核苷酸:SEQ ID NO:349、352、355、341、344、347、357、360、363、364、368、371、373、376、379、381、384、387、389、392、396、397、400、403、405、408、411、413、416、419、421、424、427、429、432、435、437、440、443、445、448、451、453、456、459、461、464、467、469、472、475、477、480、483、485、488、491、139、163、138、162、193、125、149、124、148、186、127、151、126、150、187、129、153、128、152、188、131、155、130、154、189、133、157、132、156、190、135、159、134、158、191、137、161、136、160、192、141、162、140、164、194、143、167、142、166、195、145、169、144、168、196、147、171、146、170、197、499、509、519、529、539、549、559、569、579、589、599、或609、或其任意组合。
53.一种分离的多核苷酸,其编码SEQ ID NO.:356、348、364、372、380、388、396、404、412、420、428、436、444、452、460、468、476、484、492、500、510、520、530、540、550、560、570、580、590、600或610中的任一个氨基酸序列。
54.根据权利要求53的多核苷酸,包含与如下任一所列的多核苷酸序列具有至少75%同一性的多核苷酸序列:SEQ ID NO.:355、347、363、371、379、387、395、403、411、419、427、435、443、451、459、467、475、483、491、186-197、499、509、519、529、539、549、559、569、579、589、599、或609。
55.根据权利要求51-54中任一项所述的多核苷酸,进一步包括:
(i)编码多肽的多核苷酸,该多肽包含CD8共受体α链的胞外部分,其中,任选地,编码的多肽是或包含CD8共受体α链;
(ii)编码多肽的多核苷酸,该多肽包含CD8共受体β链的胞外部分,其中,任选地,编码的多肽是或包含CD8共受体β链;或者
(iii)(i)的多核苷酸和(ii)的多核苷酸。
56.根据权利要求55所述的多核苷酸,包括:
(a)编码多肽的多核苷酸,多肽包含CD8共受体α链的胞外部分;
(b)编码多肽的多核苷酸,多肽包含CD8共受体β链的胞外部分;和
(c)编码自切割肽的多核苷酸,自切割肽位于(a)的多核苷酸和(b)的多核苷酸之间。
57.根据权利要求55或56的多核苷酸,进一步包含编码自切割肽的多核苷酸,并多核苷酸位于如下之间:
(1)编码结合蛋白的多核苷酸和编码包含CD8共受体α链胞外部分的多肽的多核苷酸;和/或
(2)编码结合蛋白的多核苷酸和编码包含CD8共受体β链胞外部分的多肽的多核苷酸。
58.根据权利要求55-57任一项的多核苷酸,包括,在框架内可操作地链接:
(i)(pnCD8α)-(pnSCP1)-(pnCD8β)-(pnSCP2)-(pnBP);
(ii)(pnCD8β)-(pnSCP1)-(pnCD8α)-(pnSCP2)-(pnBP);
(iii)(pnBP)-(pnSCP1)-(pnCD8α)-(pnSCP2)-(pnCD8β);
(iv)(pnBP)-(pnSCP1)-(pnCD8β)-(pnSCP2)-(pnCD8α);
(v)(pnCD8α)-(pnSCP1)-(pnBP)-(pnSCP2)-(pnCD8β);或者
(vi)(pnCD8β)-(pnSCP1)-(pnBP)-(pnSCP2)-(pnCD8α),
其中pnCD8α是编码包含CD8共受体α链的胞外部分的多肽的多核苷酸,
其中pnCD8β是编码包含CD8共受体α链的胞外部分的多肽的多核苷酸,
其中pnBP是编码结合蛋白的多核苷酸,
并且其中pnSCP1和pnSCP2各自独立地是编码自切割肽的多核苷酸,其中多核苷酸和/或编码的自切割肽任选地相同或不同。
59.根据权利要求51-58任一项的多核苷酸,其中编码的结合蛋白包含TCRα链和TCRβ链,其中所述多核苷酸包含编码自切割肽的多核苷酸,所述自切割肽位于编码TCRα链的多核苷酸和编码TCRβ链的多核苷酸之间。
60.根据权利要求59所述的多核苷酸,其包含可操作地框内连接:
(i)(pnCD8α)-(pnSCP1)-(pnCD8β)-(pnSCP2)-(pnTCRβ)-(pnSCP3)-(pnTCRα);
(ii)(pnCD8β)-(pnSCP1)-(pnCD8α)-(pnSCP2)-(pnTCRβ)-(pnSCP3)-(pnTCRα);
(iii)(pnCD8α)-(pnSCP1)-(pnCD8β)-(pnSCP2)-(pnTCRα)-(pnSCP3)-(pnTCRβ);
(iv)(pnCD8β)-(pnSCP1)-(pnCD8α)-(pnSCP2)-(pnTCRα)-(pnSCP3)-(pnTCRβ);
(v)(pnTCRβ)-(pnSCP1)-(pnTCRα)-(pnSCP2)-(pnCD8α)-(pnSCP3)-(pnCD8β);
(vi)(pnTCRβ)-(pnSCP1)-(pnTCRα)-(pnSCP2)-(pnCD8β)-(pnSCP3)-(pnCD8α);
(vii)(pnTCRα)-(pnSCP1)-(pnTCRβ)-(pnSCP2)-(pnCD8α)-(pnSCP3)-(pnCD8β);
(viii)(pnTCRα)-(pnSCP1)-(pnTCRβ)-(pnSCP2)-(pnCD8β)-(pnSCP3)-(pnCD8α);
其中pnCD8α是编码包含CD8共受体α链的胞外部分的多肽的多核苷酸,
其中pnCD8β是编码包含CD8共受体α链的胞外部分的多肽的多核苷酸,
其中pnTCRα是编码TCRα链的多核苷酸,
其中pnTCRβ是编码TCRβ链的多核苷酸,
并且其中pnSCP1、pnSCP2和pnSCP3各自独立地是编码自切割肽的多核苷酸,其中多核苷酸和/或编码的自切割肽任选地相同或不同。
61.根据权利要求51-60任一项的多核苷酸,多核苷酸是或包含密码子优化用于在宿主细胞中表达的多核苷酸序列,其中,任选地,宿主细胞是人免疫系统细胞,并且其中,进一步任选地,是T细胞。
62.一种表达载体,包含与表达控制序列可操作地连接的根据权利要求51-61中任一项的多核苷酸。
63.根据权利要求62所述的表达载体,其中所述载体能够将所述多核苷酸递送至宿主细胞。
64.根据权利要求63所述的表达载体,其中所述宿主细胞为造血祖细胞或人免疫系统细胞。
65.根据权利要求64所述的表达载体,其中所述人免疫系统细胞为CD4+T细胞、CD8+T细胞、CD4-CD8-双阴性T细胞、γδT细胞、自然杀伤细胞、自然杀伤T细胞、巨噬细胞、单核细胞、树突细胞或其任何组合。
66.根据权利要求65所述的表达载体,其中所述T细胞是幼稚T细胞、中央记忆T细胞、效应记忆T细胞或其任意组合。
67.根据权利要求62-66任一项所述的表达载体,其中所述载体为病毒载体。
68.根据权利要求67所述的表达载体,其特征在于,所述病毒载体为慢病毒载体或γ-逆转录病毒载体。
69.一种修饰的宿主细胞,其包含权利要求51-61任一项的多核苷酸和/或权利要求62-68任一项的表达载体和/或表达权利要求1-50任一项的结合蛋白。
70.根据权利要求69所述的修饰宿主细胞,其中所述修饰细胞包括造血祖细胞和/或人免疫细胞。
71.根据权利要求70的修饰的宿主细胞,其中免疫细胞包括T细胞、NK细胞、NK-T细胞、树突细胞、巨噬细胞、单核细胞或其任何组合。
72.根据权利要求71的修饰的宿主细胞,其中免疫细胞包括CD4+T细胞、CD8+T细胞、CD4-CD8-双阴性T细胞、γδT细胞或其任何组合,
其中,任选地,免疫细胞包含CD4+T细胞和CD8+T细胞,其中,进一步任选地,CD4+T细胞、CD8+T细胞或两者包含(i)编码多肽的多核苷酸,所述多肽包含CD8共同受体α链的胞外部分,其中,任选地,所编码的多肽是或包含CD8共同受体α链;(ii)编码多肽的多核苷酸,所述多肽包含CD8共同受体β链的胞外部分,其中,任选地,所编码的多肽是或包含CD8共同受体β链;或者(iii)(i)的多核苷酸和(ii)的多核苷酸。
73.根据权利要求69-72中任一项所述的修饰宿主细胞,其中修饰的细胞包含PD-1基因的染色体基因敲除;LAG3基因;TIM3基因;CTLA4基因;HLA成分基因;TIGIT基因;TCR组分基因、FasL基因或其任何组合。
74.根据权利要求73所述的修饰宿主细胞,其中染色体基因敲除包括敲除选自α1巨球蛋白基因、α2巨球蛋白基因、α3巨球蛋白基因、β1微球蛋白基因或β2微球蛋白基因的HLA成分基因。
75.根据权利要求73或74的修饰的宿主细胞,其中染色体基因敲除包括敲除选自TCRα可变区基因、TCRβ可变区基因、TCR恒定区基因或其组合的TCR组分基因。
76.一种组合物,其包含根据权利要求69-75中任一项的修饰的宿主细胞和药学上可接受的载体、稀释剂或赋形剂。
77.根据权利要求76的组合物剂量,包含至少约30%修饰的CD4+T细胞,以约1:1的比例,与(ii)包含至少约30%的修饰的CD8+T细胞的组合物组合。
78.根据权利要求76或77的组合物,其中组合物基本上不含幼稚T细胞。
79.一种免疫原性多肽,包含SEQ ID NO:198-201中任一项所列的氨基酸序列或由其组成。
80.一种组合物,包括:
(i)权利要求1-50任一项的结合蛋白;
(ii)权利要求51-61任一项的多核苷酸;
(iii)权利要求62-68任一项的表达载体;
(iv)权利要求69-75中任一项的修饰的宿主细胞;和/或
(v)权利要求79的免疫原性多肽,
和药学上可接受的载体、赋形剂或稀释剂。
81.一种用于治疗受试者的与KRAS G12D突变或KRAS G12V或NRASG12D突变或NRASG12V突变或HRAS G12V突变或HRAS G12D突变相关的疾病或病症的方法,该方法包括向受试者施用有效量的:
(i)权利要求1-50中任一项的结合蛋白;
(ii)权利要求51-61中任一项的多核苷酸;
(iii)权利要求62-68任一项的表达载体;
(iv)权利要求69-75中任一项的修饰的宿主细胞,其中,任选地,宿主细胞包括CD8+T细胞、CD4+T细胞或两者,并且其中,任选地,宿主细胞对于受试者是自体的、同种异体的或同基因的;
(v)权利要求76-78中任一项的组合物;和/或
(vi)权利要求79的免疫原性多肽。
82.根据权利要求81所述的方法,其中所述疾病或病症包括癌症,其中所述癌症任选地是实体癌或血液恶性肿瘤。
83.根据权利要求81或82所述的方法,其中所述疾病或病症选自胰腺癌或癌,任选地胰腺导管腺癌(PDAC);结直肠癌或癌;肺癌,任选非小细胞肺癌;胆道癌;子宫内膜癌或癌;宫颈癌;卵巢癌;膀胱癌;肝癌;髓性白血病,可选的髓性白血病,例如急性髓性白血病;骨髓增生异常综合征;淋巴瘤,如非霍奇金淋巴瘤;慢性粒单核细胞白血病;急性淋巴细胞白血病(ALL);泌尿道癌;小肠癌;乳腺癌或癌;黑色素瘤(可选皮肤黑色素瘤、肛门黑色素瘤或粘膜黑色素瘤);胶质瘤;低分化甲状腺癌;神经母细胞瘤;组织细胞和树突细胞肿瘤;1型神经纤维瘤病;横纹肌肉瘤;软组织肉瘤;膀胱癌;肉瘤;胶质母细胞瘤;鳞状细胞肺癌;间变性星形细胞瘤;慢性粒细胞白血病;弥漫性大B细胞淋巴瘤;双重打击淋巴瘤;头颈癌;头颈部鳞状细胞癌;肝细胞癌;恶性周围神经鞘瘤;套细胞淋巴瘤;骨髓增生异常/骨髓增生性肿瘤,无法分类;外周T细胞淋巴瘤;前列腺癌;伴原始细胞过多的难治性贫血-2;肾细胞癌;横纹肌瘤;神经鞘瘤;继发性AML;小细胞肺癌;治疗相关的AML;胸腺癌;甲状腺滤泡癌;恶性甲状腺肿瘤;甲状腺癌;甲状腺腺癌;尿路上皮癌;或甲状腺乳头状癌。
84.根据权利要求81-83中任一项所述的方法,其中所述组合物经肠胃外或静脉内施用于所述受试者。
85.根据权利要求81-84中任一项所述的方法,其中所述方法包括向所述受试者施用多个剂量的(i)-(vi)中的任何一种或多种。
86.根据权利要求85所述的方法,其中以约两周至约四周的施用之间的间隔施用所述多个剂量。
87.根据权利要求81-86中任一项所述的方法,其中组合物包含修饰的宿主细胞,并且其中该方法包括以约104个细胞/kg至约1011个细胞/kg的剂量向受试者施用修饰的宿主细胞。
88.权利要求81-87中任一项所述的方法,包括施用:
(i)一种组合物,其包含修饰的CD8+和/或修饰的CD4+T细胞,其包含编码根据权利要求1-26中任一项所述的结合蛋白的异源多核苷酸,当受试者表达HLA-A*02:01时;和/或
(ii)一种组合物,其包含修饰的CD8+和/或修饰的CD4+T细胞,其包含编码根据权利要求27-50中任一项所述的结合蛋白的异源多核苷酸,当受试者表达出HLA-A*11:01时,
其中如果施用(i)的组合物和(ii)的组合物,则(i)的组合物和(ii)的组合物包含在相同的组合物中或作为单独的组合物施用。
89.根据权利要求81-88中任一项所述的方法,其中所述方法还包括向所述受试者施用细胞因子。
90.根据权利要求89所述的方法,其中所述细胞因子包括IL-2、IL-15或IL-21。
91.根据权利要求81-90中任一项所述的方法,其中受试者已经接受或正在接受免疫检查点抑制剂和/或刺激性免疫检查点试剂的激动剂。
92.根据权利要求1-50任一项的结合蛋白,根据权利要求51-61任一项的多核苷酸,根据权利要求62-68任一项的表达载体,根据权利要求69-75中任一项的修饰的宿主细胞,根据权利要求76-78中任一项的组合物,其中任选地,宿主细胞包含CD8+T细胞、CD4+T细胞或两者;和/或根据权利要求79的免疫原性多肽,用于治疗与受试者的KRAS G12D突变或KRASG12V或NRAS G12D突变或NRAS G12V突变或HRAS G12V突变或HRAS G12D突变相关的疾病或病症的方法,其中,任选地,所述疾病或病症包括癌症,其中,进一步任选地,所述癌症是实体癌或血液恶性肿瘤,并且,其中,任选地,所述疾病或病症选自胰腺癌或癌,任选地胰腺导管腺癌(PDAC);结直肠癌或癌;肺癌,任选非小细胞肺癌;胆道癌;子宫内膜癌或癌;宫颈癌;卵巢癌;膀胱癌;肝癌;髓性白血病,可选的髓性白血病,例如急性髓性白血病;骨髓增生异常综合征;淋巴瘤,如非霍奇金淋巴瘤;慢性粒单核细胞白血病;急性淋巴细胞白血病(ALL);泌尿道癌;小肠癌;乳腺癌或癌;黑色素瘤(可选皮肤黑色素瘤、肛门黑色素瘤或粘膜黑色素瘤);胶质瘤;低分化甲状腺癌;神经母细胞瘤;组织细胞和树突细胞肿瘤;1型神经纤维瘤病;横纹肌肉瘤;软组织肉瘤;膀胱癌;肉瘤;胶质母细胞瘤;鳞状细胞肺癌;间变性星形细胞瘤;慢性粒细胞白血病;弥漫性大B细胞淋巴瘤;双重打击淋巴瘤;头颈癌;头颈部鳞状细胞癌;肝细胞癌;恶性周围神经鞘瘤;套细胞淋巴瘤;骨髓增生异常/骨髓增生性肿瘤,无法分类;外周T细胞淋巴瘤;前列腺癌;伴原始细胞过多的难治性贫血-2;肾细胞癌;横纹肌瘤;神经鞘瘤;继发性AML;小细胞肺癌;治疗相关的AML;胸腺癌;甲状腺滤泡癌;恶性甲状腺肿瘤;甲状腺癌;甲状腺腺癌;尿路上皮癌;或甲状腺乳头状癌。
93.根据权利要求1-50任一项的结合蛋白,根据权利要求51-61任一项的多核苷酸,根据权利要求62-68任一项的表达载体,根据权利要求69-75中任一项的修饰的宿主细胞,根据权利要求76-78中任一项的组合物,其中任选地,宿主细胞包含CD8+T细胞、CD4+T细胞或两者;和/或根据权利要求79的免疫原性多肽,用于制造治疗与受试者的KRAS G12D突变或KRAS G12V或NRAS G12D突变或NRAS G12V突变或HRAS G12V突变或HRAS G12D突变相关的疾病或病症的药剂,其中,任选地,所述疾病或病症包括癌症,其中,进一步任选地,所述癌症是实体癌或血液恶性肿瘤,并且,其中,任选地,所述疾病或病症选自胰腺癌或癌,任选地胰腺导管腺癌(PDAC);结直肠癌或癌;肺癌,任选非小细胞肺癌;胆道癌;子宫内膜癌或癌;宫颈癌;卵巢癌;膀胱癌;肝癌;髓性白血病,可选的髓性白血病,例如急性髓性白血病;骨髓增生异常综合征;淋巴瘤,如非霍奇金淋巴瘤;慢性粒单核细胞白血病;急性淋巴细胞白血病(ALL);泌尿道癌;小肠癌;乳腺癌或癌;黑色素瘤(可选皮肤黑色素瘤、肛门黑色素瘤或粘膜黑色素瘤);胶质瘤;低分化甲状腺癌;神经母细胞瘤;组织细胞和树突细胞肿瘤;1型神经纤维瘤病;横纹肌肉瘤;软组织肉瘤;膀胱癌;肉瘤;胶质母细胞瘤;鳞状细胞肺癌;间变性星形细胞瘤;慢性粒细胞白血病;弥漫性大B细胞淋巴瘤;双重打击淋巴瘤;头颈癌;头颈部鳞状细胞癌;肝细胞癌;恶性周围神经鞘瘤;套细胞淋巴瘤;骨髓增生异常/骨髓增生性肿瘤,无法分类;外周T细胞淋巴瘤;前列腺癌;伴原始细胞过多的难治性贫血-2;肾细胞癌;横纹肌瘤;神经鞘瘤;继发性AML;小细胞肺癌;治疗相关的AML;胸腺癌;甲状腺滤泡癌;恶性甲状腺肿瘤;甲状腺癌;甲状腺腺癌;尿路上皮癌;或甲状腺乳头状癌。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962808248P | 2019-02-20 | 2019-02-20 | |
US62/808,248 | 2019-02-20 | ||
PCT/US2020/018904 WO2020172332A1 (en) | 2019-02-20 | 2020-02-19 | Binding proteins specific for ras neoantigens and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114026116A true CN114026116A (zh) | 2022-02-08 |
Family
ID=69846567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080030201.XA Pending CN114026116A (zh) | 2019-02-20 | 2020-02-19 | Ras新抗原特异性结合蛋白及其用途 |
Country Status (9)
Country | Link |
---|---|
US (3) | US11382954B2 (zh) |
EP (1) | EP3927727A1 (zh) |
JP (1) | JP2022521513A (zh) |
KR (1) | KR20210130189A (zh) |
CN (1) | CN114026116A (zh) |
CA (1) | CA3130618A1 (zh) |
GB (2) | GB2613715B (zh) |
IL (1) | IL285502A (zh) |
WO (1) | WO2020172332A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115772497A (zh) * | 2022-11-11 | 2023-03-10 | 河南尚泰科诺生物科技有限公司 | 一种靶向g12v突变kras的树突状细胞疫苗 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102375218B1 (ko) | 2016-12-08 | 2022-03-17 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
CN113631172A (zh) * | 2019-01-25 | 2021-11-09 | 宾夕法尼亚大学理事会 | 用于靶向突变型ras的组合物和方法 |
WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
MX2022003537A (es) | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Terapias de combinacion. |
JP2023507571A (ja) | 2019-12-20 | 2023-02-24 | ミラティ セラピューティクス, インコーポレイテッド | Sos1阻害剤 |
DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
CN112300269B (zh) * | 2020-09-29 | 2022-12-09 | 中国科学院微生物研究所 | Kras突变特异性t细胞受体筛选及抗肿瘤用途 |
EP4326751A1 (en) * | 2021-04-21 | 2024-02-28 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class i-restricted t cell receptors against ras with q61k mutation |
WO2022244876A1 (ja) * | 2021-05-20 | 2022-11-24 | 慶應義塾 | 抗腫瘍剤 |
WO2023102418A1 (en) * | 2021-12-01 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla-a3-restricted t cell receptors against ras with g12v mutation |
CN114230658B (zh) * | 2022-01-24 | 2024-03-29 | 卡瑞济(北京)生命科技有限公司 | 新型冠状病毒特异性t细胞受体和其用途 |
WO2023175070A1 (en) * | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library |
WO2023175069A1 (en) * | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library for pramevld tcrs |
WO2023220718A1 (en) * | 2022-05-13 | 2023-11-16 | Fred Hutchinson Cancer Center | Binding proteins specific for ras neoantigens and uses thereof |
WO2023230014A1 (en) * | 2022-05-23 | 2023-11-30 | Affini-T Therapeutics, Inc. | Binding proteins and engineered cells specific for neoantigens and uses thereof |
EP4393942A1 (en) * | 2022-12-29 | 2024-07-03 | Keshihua (Nanjing) Biotechnology Co., Ltd | Tcr, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining tcr |
WO2024148181A2 (en) * | 2023-01-04 | 2024-07-11 | Board Of Regents, The University Of Texas System | T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*11:01 in lung cancer |
CN116589557B (zh) * | 2023-03-15 | 2024-04-02 | 北京大学人民医院 | 一种肿瘤新生抗原特异性tcr及其应用 |
CN116640218B (zh) * | 2023-06-01 | 2024-06-04 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | 一种靶向kras g12v单链抗体片段、嵌合抗原受体car及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018026691A1 (en) * | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t cell receptors |
US20180134804A1 (en) * | 2015-03-20 | 2018-05-17 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
CA2479153C (en) | 2002-03-15 | 2015-06-02 | Cellectis | Hybrid and single chain meganucleases and use thereof |
JP4966006B2 (ja) | 2003-01-28 | 2012-07-04 | セレクティス | カスタムメイドメガヌクレアーゼおよびその使用 |
WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
EP2484758B1 (en) | 2005-10-18 | 2013-10-02 | Precision Biosciences | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
KR101319499B1 (ko) | 2008-02-22 | 2013-10-17 | 엘지디스플레이 주식회사 | 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법 |
US8603810B2 (en) * | 2008-05-09 | 2013-12-10 | Agency For Science, Technology And Research | T-cell having a T-cell receptor that recognizes epitope HBC18-27 of hepatitis B viral core antigen |
JP2012501180A (ja) | 2008-08-26 | 2012-01-19 | シティ・オブ・ホープ | T細胞の抗腫瘍エフェクター機能増進のための方法および組成物 |
EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
JP6120848B2 (ja) | 2011-08-15 | 2017-04-26 | メディミューン,エルエルシー | 抗b7−h4抗体およびその使用 |
DE202013012241U1 (de) | 2012-05-25 | 2016-01-18 | Emmanuelle Charpentier | Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription |
RS61345B1 (sr) | 2012-08-20 | 2021-02-26 | Hutchinson Fred Cancer Res | Postupak i kompozicije za ćelijsku imunoterapiju |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
PL2896697T3 (pl) | 2012-12-12 | 2016-01-29 | Broad Inst Inc | Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją |
EP2934575A2 (en) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
ES2804538T3 (es) * | 2013-01-29 | 2021-02-08 | Max Delbrueck Centrum Fuer Molekulare Medizin Mdc Berlin Buch | Moléculas de unión de alta avidez que reconocen MAGE-A1 |
EP3071695A2 (en) | 2013-11-18 | 2016-09-28 | Crispr Therapeutics AG | Crispr-cas system materials and methods |
RU2016127327A (ru) | 2013-12-09 | 2018-01-23 | Тарговакс Аса | Смесь пептидов |
US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
JP6943760B2 (ja) | 2014-09-12 | 2021-10-06 | ジェネンテック, インコーポレイテッド | 抗b7−h4抗体及び免疫複合体 |
RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
WO2016085904A1 (en) * | 2014-11-26 | 2016-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mutated kras t cell receptors |
RU2732042C2 (ru) | 2015-02-19 | 2020-09-10 | Компьюджен Лтд. | Анти-pvrig антитела и способы применения |
CA2980292A1 (en) * | 2015-03-23 | 2016-09-29 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
EP3347374A1 (en) * | 2015-09-09 | 2018-07-18 | Immune Design Corp. | Ny-eso-1 specific tcrs and methods of use thereof |
SG10201913868XA (en) | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
CR20180519A (es) | 2016-03-31 | 2019-03-05 | Neon Therapeutics Inc | Neoantígenos y métodos de su uso |
WO2017192924A1 (en) | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
CN109996868A (zh) | 2016-09-23 | 2019-07-09 | 弗雷德哈钦森癌症研究中心 | 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途 |
US20200232040A1 (en) * | 2017-01-18 | 2020-07-23 | Vinod P. Balachandran | Neoantigens and uses thereof for treating cancer |
US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
US11807662B2 (en) * | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
AU2018378200A1 (en) * | 2017-12-04 | 2020-07-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class I-restricted T cell receptors against mutated RAS |
EP3837279A4 (en) * | 2018-08-16 | 2022-05-11 | BioNTech US Inc. | CONSTRUCTIONS OF T-CELL RECEPTORS AND THEIR USES |
CN113631172A (zh) * | 2019-01-25 | 2021-11-09 | 宾夕法尼亚大学理事会 | 用于靶向突变型ras的组合物和方法 |
AU2020384374A1 (en) | 2019-11-15 | 2022-06-09 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared neoantigens |
-
2020
- 2020-02-19 CA CA3130618A patent/CA3130618A1/en active Pending
- 2020-02-19 GB GB2302285.8A patent/GB2613715B/en active Active
- 2020-02-19 CN CN202080030201.XA patent/CN114026116A/zh active Pending
- 2020-02-19 WO PCT/US2020/018904 patent/WO2020172332A1/en active Search and Examination
- 2020-02-19 EP EP20712746.5A patent/EP3927727A1/en active Pending
- 2020-02-19 JP JP2021548696A patent/JP2022521513A/ja active Pending
- 2020-02-19 GB GB2113386.3A patent/GB2596461B/en active Active
- 2020-02-19 KR KR1020217030168A patent/KR20210130189A/ko not_active Application Discontinuation
-
2021
- 2021-08-10 IL IL285502A patent/IL285502A/en unknown
- 2021-08-20 US US17/408,340 patent/US11382954B2/en active Active
- 2021-12-08 US US17/643,410 patent/US11458191B2/en active Active
-
2022
- 2022-06-03 US US17/832,214 patent/US20230139737A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180134804A1 (en) * | 2015-03-20 | 2018-05-17 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
WO2018026691A1 (en) * | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t cell receptors |
Non-Patent Citations (1)
Title |
---|
QIONG J. WANG: "Identification of T-cell Receptors Targeting KRAS-mutated Human Tumors", CANCER IMMUNOL RES, vol. 4, no. 3, pages 204 - 214, XP055314168, DOI: 10.1158/2326-6066.CIR-15-0188 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115772497A (zh) * | 2022-11-11 | 2023-03-10 | 河南尚泰科诺生物科技有限公司 | 一种靶向g12v突变kras的树突状细胞疫苗 |
Also Published As
Publication number | Publication date |
---|---|
IL285502A (en) | 2021-09-30 |
US20220160832A1 (en) | 2022-05-26 |
GB2596461A (en) | 2021-12-29 |
US20230139737A1 (en) | 2023-05-04 |
GB202302285D0 (en) | 2023-04-05 |
KR20210130189A (ko) | 2021-10-29 |
EP3927727A1 (en) | 2021-12-29 |
US11458191B2 (en) | 2022-10-04 |
GB2613715A (en) | 2023-06-14 |
US11382954B2 (en) | 2022-07-12 |
CA3130618A1 (en) | 2020-08-27 |
US20210379150A1 (en) | 2021-12-09 |
JP2022521513A (ja) | 2022-04-08 |
GB2613715B (en) | 2023-12-06 |
GB2596461B (en) | 2023-09-27 |
WO2020172332A1 (en) | 2020-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114026116A (zh) | Ras新抗原特异性结合蛋白及其用途 | |
KR102375033B1 (ko) | 고친화도 mage-a1-특이적 tcr 및 이의 용도 | |
JP7407701B2 (ja) | strepタグ特異的キメラ受容体およびその使用 | |
US20240165232A1 (en) | Chimeric receptor proteins and uses thereof | |
JP2023105045A (ja) | Braf特異的tcrおよびその使用 | |
TW202317602A (zh) | 嵌合多肽 | |
WO2023230014A1 (en) | Binding proteins and engineered cells specific for neoantigens and uses thereof | |
KR20210138043A (ko) | 고 결합 활성 wt1 t 세포 수용체 및 이의 용도 | |
CN116724053A (zh) | 靶向sox2抗原的免疫治疗 | |
CN113286815B (zh) | 间皮素特异性t细胞受体及其在免疫治疗中的应用 | |
CA3201767A1 (en) | Compositions and methods for cellular immunotherapy | |
CN114555790A (zh) | Wt-1特异性t细胞免疫疗法 | |
TW202400665A (zh) | 對ras新生抗原具有專一性之結合蛋白及其用途 | |
WO2023212507A1 (en) | Compositions and methods for cellular immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Washington State Applicant after: Fred Hutchinson Cancer Center Address before: Washington State Applicant before: Seattle Cancer Care Alliance |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220927 Address after: Washington State Applicant after: Seattle Cancer Care Alliance Address before: Washington State Applicant before: FRED HUTCHINSON CANCER RESEARCH CENTER |